CA2342778A1 - Inhibitors of .alpha.4.beta.1 mediated cell adhesion - Google Patents

Inhibitors of .alpha.4.beta.1 mediated cell adhesion Download PDF

Info

Publication number
CA2342778A1
CA2342778A1 CA002342778A CA2342778A CA2342778A1 CA 2342778 A1 CA2342778 A1 CA 2342778A1 CA 002342778 A CA002342778 A CA 002342778A CA 2342778 A CA2342778 A CA 2342778A CA 2342778 A1 CA2342778 A1 CA 2342778A1
Authority
CA
Canada
Prior art keywords
alkyl
hydrogen
attached
carbon atom
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002342778A
Other languages
French (fr)
Inventor
James R. Blinn
Robert A. Chrusciel
Jed F. Fisher
Steven P. Tanis
Edward William Thomas
Thomas J. Lobl
Bradley R. Teegarden
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanabe Seiyaku Co Ltd
Pharmacia and Upjohn Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2342778A1 publication Critical patent/CA2342778A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D207/28—2-Pyrrolidone-5- carboxylic acids; Functional derivatives thereof, e.g. esters, nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/04—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D263/06—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by oxygen atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D277/06—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/12—1,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/06—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic

Abstract

The present invention relates to compound of formula (I), that are potent inhibitors of .alpha.4.beta.1 mediated adhesion to either VCAM or CS-1 and which could be useful for the treatment of inflammatory diseases. Specifically, the molecules of the present invention can be used for treatin g or preventing .alpha.4.beta.1 adhesion mediated conditions in a mammal such as a human. This method may comprise administering to a mammal or a human patie nt an effective amount of the compound or composition as explained in the prese nt specification.

Description

INHIBITORS OF a4(3, MEDIATED CELL ADHESION
Background of the Invention Field of the Invention The present invention relates to small molecules that are potent inhibitors of a4(3, mediated adhesion to either VCAM or CS-l and which 2ure useful for the treatment of inflammatory diseases.
Description of Related Art The extracellular matrix (ECM) is he major component of connective tissue which provides structural integrity, and promotes cell migration and differentiation. As part of these functions, extracellular matrix molecules such as :fibronectin, collagen, Iaminin, won Willebrand factor, thrombospondin; fibrinogen, and ten<~scin have been shown to support adhesion of cells in vitro. This adhesive interaction is critical for a number of biological processes including hemostasis, thrombosis, wound healing, tumor metastasis, immunity and inflammation.
Fibronectin (FN) is the prototype ECM molecule. The major cell attachment site in the fibronectin molecule has been reproduced synthetically with the amino acid sequence arginine-glycine-aspartic acid, or RGD using single letter nomenclature.
Peptides containing the RGD sequence which either inhibit or promote cell .adhesion have been described (US
Patent Nos. 4,589,881; 4,661,111; 4,SI7,686; 4,683.,291; 4,578,079; 4,614,517;
and 4,792,525}. Changes in the peptide as small as the e:cchange of alanine for glycine or glutamic acid for aspartic acid, which constitute the addition of a single methyl or methylene group to the tripeptide, eliminates these activities (Piersch6acher et al., Proc. Natl. Acad Sci:
USA 81:5985 (1984)). Recently, a second- FN cell binding domain has been identified within the alternatively spliced region of the A chain of the molecule, known as the connecting segment 1 (CS-1). The most active cell-binding site within this alternatively spliced region is composed of 25 amino acids where the carboxy terminus contains the sequence EILDVPST. The amino acid sequence EILDVPST forms a recognition motif on FN for cell surface receptors. (Wayner et al., J. Cell Biol. 109:1321 (1989); Guan et al., Cell 60:53 ( 1990}).
The receptors which recognize these sites on FN belong to a gene superfamily called integrins which consist of heterodimeric complexes of non-covalently associated alpha and beta subunits. A common ~3 subunit combines with unique I subunits to form an adhesion receptor of defined specificity. To date, 8 (3 subunits have been identified which can dimerize with 16 distinct I subunits forming 22 distinct integrins. The (31 subfamily, also known as the VLA family (Very Late Activation Antigen:>), binds to ECM
molecules such as FN, collagen and laminin. For reviews, see, Hynes, Cell 48:549 (1987); Hemier, Annu. Rev.
Immunol. 8:365 (1990). Leukocyte interaction with FN at the two spatially separate binding domains is mediated by twa distinct integrins. The RGI) site is recognized by the integrin ash,, while, EILDV is recognized by aA(i, (Pytela et al., Cell 40:191 (I985);
Wayner et al., J.
Cell Biol. 109:1321 (1989); Guan et al, Cel160:53 (1990)).
Vascular endothelial cells form the interface between blood and tissues and control the passage of leukocytes as well as plasma fluid into tissues. A variety of signals generated at the site of inflammation can activate both endothelial cells as well as circulating leukocytes so that they become more adhesive to onc: another. Following this initial adhesion the leukocytes migrate into the tissues to perform host defense functions. Several adhesion molecules have been identified which are iinvolved in leukocyte-endothelial interactions.
In the Vii, subfamily; in addition to binding to fibronectin, a4(3, interacts with a cytokine inducible protein on endothelial cells termed vascular cell adhesion molecule (VCAM). Further involved in the leukocyte-endothelial adhesion process is the biz integrin subfamily. (32 integrins include CD 11 a/CD 18, CD 11 b/CD I 8, and CD 11 c/CD
18. In addition, the X37 subunit associates with a4 to form a unique x4(37 heterodimer which binds to FN, to VCAM, and to Mucosal Addressin Cell Adhesion lVlolecule-1 (MAdCAM) (Ruegg et al, J. Cell.Biol. 117:179 (1992); Andrew et al., J. Immunol. 153:3847 (I994);
Briskin et al., Nature 363:461 (1993); Shyjan et al, J. Immunol. 156:28:11 (1996)). a4 integrins are widely expressed on different cell types including hematopoietic progenitors, lymphocytes, natural killer cells, monocytes, eosinophils, basaphils, and mast: cells {Hehner, M.
E., Annu. Rev.
Immunol. 8:365 (1990)). Other molecules on endothelial cells which bind to the leukocytes include ICAM-1, ICAM-2, E-selectin and P-selectin ((:arlos and Harlan, Immunol Rev.
114:1 (1990); Osborn, L., Cell 62:3 (1990); Springer T., lJature 346:425 (1990); Geng et- - al., Nature 347:757 (1990); Stoolman, Cell 56:907 {1989)).
A number of in vitro and in vivo studies indicate 'chat a4(3, plays a critical role in the pathogenesis of a variety of diseases. Monoclonal antibodies directed against a4 have been tested in a variety of disease models. Anti-a4 antibodies block adhesion of lymphocytes to synovial endothelial cells; this adhesion plays a potential role in rheumatoid arthritis (van Dinther-Janssen et al, J. Immunol. 147:4207 (1991)). a4 has also been implicated with respect to rheumatoid arthritis in separate studies {Laffon <~t al, J. Clin.
Invest. 88:546 (1991);
Morales-Ducret et al, J. Immunol. 149:1424 (1992)). A significant number of studies have evaluated the role of a4 in allergy and asthma. For example, monoclonal antibodies to a4 block adhesion of basophils and eosinophils to cytokine activated endothelial cells {Walsh et al, J. Immunol. 146:3419 ( 1991 ); Bochner et- aI, J. Exp. Med. 173:1553 ( 1991 )).
Monoclonal antibodies to a4 were also effective in several lung antigen challenge models (Abraham et al, J. Clin. Invest. 93:776 (1994); Weg et ;~1, J. Exp. Med.
177:561 (1993)).
The cotton-top tamarin, which experiences spontaneous clhronic colitis, showed a significant attenuation of their colitis when anti-as antibody was administered (Podolsky et al, J. Clin.
Invest. 92:372 (1993); Bell et al, J. Immunol. 151:4790 (1.993)). In a rat and mouse model, autoimmune encephalomyelitis was blocked by anti-a4 antibody (Yednock et al, Nature 356:63 (1992); Baron et a1, J. Exp. Med. 177:5? (1993)). Anti-a4 monoclonal antibodies also inhibit insulitis and delay the onset of diabetes in the non-obese diabetic mouse (Baron et al, J. Clin. Invest. 93:1700 (1994); Yang et al, Proc. Natl. Acad. Sci. USA
90:10494 (1993); Burkly et al, Diabetes 43:529 {1994)). a4 is also implicated in atherosclerosis due to its endothelial expression during atherogenesis (Cybulsk;~ et al, Science 251:7$8 (1991)).
The migration of leukocytes to an inflammatory site can also be blocked by anti-a,4 antibodies. In addition to the blocking of migration, inhibitors of leukocyte endothelial adhesion may block the costimulatory signals mediated by integrins and thus inhibit overproduction of inflammatory cytokines. In a sepaxate set of experiments not using anti-a4 WO 99/67230 PCT/US99It4233 antibodies, the peptides GRDGSP or EILDV were tested against contact hypersensitivity response. The contact hypersensitivity response was found to be blocked by GRDGSP or EILDV suggesting that both a4(3, and as(3, are involved in this inflammatory response.
Other ailments which may involve a4~i,-mediated conditions include the inflammatory disorders rheumatoid arthritis, allergic disorders, asthma, spontaneous chronic colitis, insulitis, contact hypersensitivity response, atheroselerosis and autoimmune encephalomyelitis. These studies illustrate that small molecules that are potent inhibitors of a4~3, mediated adhesion to either VCAM-1 or CS-I may be used as a form of treatment in numerous inflammatory diseases. However, these inflammatory conditions could be expanded to include adult respiratory distress syndrome, AIDS, cardiovascular diseases, thrombosis or harmful platelet aggregation, reocclusion following thrombolysis, aliograft rejection, reperfusion injury, psoriasis, eczema, contact dermatitis and other skin inflammatory diseases, osteoporosis, osteoarthritis, atherosclerosis, neoplastic diseases including metastasis of neoplastic or cancerous growl;h, wound healing enhancement, treatment of certain eye diseases such as detaching retina, 'Type I diabetes, multiple sclerosis, systemic lupus erythematosus (SLE), inflammatory and immunoinflammatory conditions including ophthalmic inflammatory conditions and inflammatory bowel diseases, ulcerative colitis, regional enteritis and other autoimmune diseases. Accordingly, a compound which could inhibit these conditions is desirable.
Summary of the Invention The present invention particularly provides:
A compound of the formula:
Rz H O
C 1 X W N~
R! _ R4 C I ) v N )m ~ Rs R3-"~y~ n .
o O

WO 99!67230 PCT/US99/14233 In the above formula (I), R; may occur one to four times and each occurrence is independently hydrogen or C,~ alkyl. Also in the above formula (I), RZ is hydrogen, pyridyl, C,_6 alkyl, (C,_6 alkyl)-COZ-R", or -COZ-R". In ;addition, R, and RZ
may be attached to the same carbon atom and form a carbocycIic; ring of 5-8 atoms together with the carbon atom to which they are attached, or they may be attached to the same carbon atom and form a ring of 5-8 atoms of the formula:
~ /(CH2)1~
C NR~~
\(CHz)l together with the carbon atom to which they are attached.
In the above formula (I), R3 is hydrogen, phenyl, C,_6 alkyl, C3_6 alkenyl, C,_"
arylalkyi , (C,_6 alkyl)-COZ-R", (CZ_6 alkenyl)-COZ-R", (C,_6 alkyl)-CO-C,_6 alkyl, (C,.~
alkyl)-O-C,_6 alkyl, (C,~ alkyl)-OH, {C,~ alkyl)-CN, adarnantyl or one of the following:
N~N ~~,, OR~~ ~ /~ \
-(C 1 _ 6 aikyl~ y ~ ~ -(C I -6 a~Y~ ~Z -N Z
~N p 'i--' ~/
H q 9 N
/ / / / ~
COz-R~ t --E~COz-R \
\ ~ ~ ~ \ ~ -COz-R> > '-(C I-6 alkYl~-~
N
N
/ / N\ O /
\ 10(Cy-3a~Y!))~-s COz-Rit \ ~ ~ '~CF3 / N
OH
S \
O NOz I-IN-N \ ~ /
N
N~ v / \
H C~z-R~ i H COz-R" '~ ~COz-R~ t N(C,_3a1kY~2 In addition, RZ and R3-(Y)o may combine with each other at the terminal thereof to form a ring of the following formula together with the carbon atom and the nitrogen atom to which they are attached:

WO 99167230 ' PCT/US99/14233 Z N.:r"
O
In the above formula {I), R4 is -O-R", NH2, NHOH, -O-(C7_,o arylalkyl), or is of the formula:
!°-c"2 ~ .
'N
i In the above formula (I), R5 is a formula of the following:

j Ra-Ri2 In the above, R~ is N or CH, R7 is hydrogen or halogen, R8 is -NH-Y,-, -OCHZ-, or -CONH-, R9 may occur one to three times and is a halogen, C,~ alkoxy, C,_6 alkyl or trifluoromethyl, R,fl is C,~ alkyl, or (C,~ alkyl)-OH, or hydrogen, R" is hydrogen or C,~
alkyl, R,, is C,~ alkyl or the following formula:
Rt3 -{CH2~. R9 and R,3 is N or CH.
In the above formula (I), W is (C,_6 alkyl), X is S, O, or CH2, Y and Y, are independently -CO-, -C(=O)O-, -SOZ-, or -C(=O)N(R,o)- and Z is O, CHz, or N-R".
In theabove,lis 1,2,or3,mis l or2,nis0or l,ois0or l,pis0or l,qis0or l,andris0, l,2or3.
The above formula {I) has the provisos that:
(l) when Y is -C{=O)O-, R3 cannot be hydrogen;
(2) when R4 is equal to O-(C4 alkyl), C4 alkyl is not equal to tent-butyl;
(3) in those pyrrolidine structures (1 is 1; m is. 2; n is 0; o is 0; p is 1;
X is CHZ), W is equal to CH2; and (4) the compound is not H
N
H
In another embodiment of the present invention, RS is a formula of the following:
cl ~~a C J RB
CI
wherein R, is hydrogen or CI.
In another embodiment of the present invention, R Z is hydrogen or C,~ alkyl:
Additionally, R, and Rz may be attached to the same carbon atom and may form a carbocyclic ring of 5-8 atoms together with the carbon atom to which they are attached or be attached to the same carbon atom and form a ring of S-8 atoms of the formula:
~ /(CH2)l~
C NRn ~ ~(CH2)~
together with the carbon atom to which they are attached,. Also, in this embodiment, n is O,mis2andpis0.
In yet another embodiment of the present invention, R, is hydrogen or C,_3 alkyl, and RZ is hydrogen or C,~, alkyl. Additionally, R, and R~ may be attached to the same carbon atom and may form a carbocyclic ring of 5-8 atoms together with the carbon atom to which they are attached or be attached to the same atom and form a ring of 5-8 atoms of the formula:
~ /(CH2)l~
C NRIi ~ ~(CH2)~

WO 9916?230 PCT/US99/14233 -$_ together with the carbon atom to Which they are attached. Also in this embodiment, R3 is hydrogen, C,_6 alkyl, C,_,~ arylalkyl, {C,_b alkyl)-OH, (C,_b alkyl)-CO,-R", (C,_6 alkyl}-CN, adamantyl, phenyl, or one of the following:

~(C 1-6 ~Y~ ~'N _.(C 1-6 alkyl) 'N N
H N
-(CI_6 allcyl)-N Z --N~ Z
(~ (~ w N(CH3)2 Additionally, in this embodiment, R4 is -O-R" , NHZ, N:HOH, ar R4 is of the formula:
-o-cH2 ' %
N , R" is hydrogen or CH3, and X is S or O.
In another embodiment, R, and RZ are hydrogen" and R3 is (CZ~ alkenyl)-COZ-R", (C,.~ alkyl)-O-C,_3 alkyl, (C,_6 alkyl}-COzR", or one of tile following:
N
l -N N
OH
S
O NOZ H~N-N~~
H~COZ-Rtt ' ~ ~COZ-Rat Also, in this embodiment, R4 is O-R,,, R~ is CH, R" is hydrogen, and R7 is hydrogen.
Additionally, X is S, Y is -CO-, and 1 is 1.
In another embodiment of the present invention, R, and RZ are hydrogen, and R3 is C,_6 alkyl, (C,_6 alkyl)-COZ-R", (C,_6 alkenyl}-COz-R", (C,.~ alkyl)-CO-C,_6 alkyl, (C,_6 alkyl}-O-C,_3 alkyl, {C,_6 alkyl)-CN, or one of the following:

WO 99!67230 PCT/US99/14233 / / / / \
\ COz-Rt t \N~COz-Rt t -~--COz-Rt t -(C 1-6 ally \\ O
N
/ / Nw / O
COz-Rt t ~ -~- CF3 \
OCH3 \ / sN

S S p ~~ ORt t NOz HN-N
~ \/ , ~
N' \ ~;~ _...~~ ~.,~
H COz-Ri t H COz-Rt t ~COz-Rt t O
Additionally, R4 is OH, R6 is CH, R" is hydrogen, R, is hydrogen, X is CH2, and Y is -CO- or -C(=O)NH-.
In another embodiment of the present invention, W is (C,~3 alkyl), X is CHz, Y
is -C(=O)O-, R, is hydrogen, RZ is hydrogen, (C,_3 alkyl)-C;Oz-R", or -COZ-R", R3 is hydrogen, C,_,o arylalkyl, C,_6 alkyl, or (C,~ alkyl)-COz-R", R4 is OH, R~ is CH, R" is hydrogen, R, is hydrogen, l is I or 3, and n is 0, In another embodiment of the present invention, W is C,_3 alkyl, X is CH,, R, is hydrogen, RZ is (Ct_4 alkyl)-COZ-R", or COZ-R", R3 is hydrogen, C,_3 alkyl, or CZ_, alkeilyl, R4 is OH, R6 is CH, R" is hydrogen, R, is hydrogen, l is 1, m is l, n is l, o is 0, and p is 1.
In another embodiment, the compound of the preaent invention is represented by the following formula /---S
H O
R3--~Y~ N y W _ Ra p O
\Rs In another embodiment of the,present invention, R, and R~ are hydrogen, and R3 is C,_6 alkyl, {C,~ alkyl)-COZR", (CZ_6 alkenyl)-C02R", (C,_6 alkyl)-O-C,_3 alkyl, or one ofthe following:

N
'N J CO2-Rtt OH
O N~ HlN-N
H~C02-Rtt , ~ ~COz-Rtt Additionally, in this embodiment, R4 is O-R", R6 is CH,, R" is hydrogen or C,_6 alkyl, R, is hydrogen, X is S, Y is -C(=O)O-, and I is 1.
In another embodiment of the present invention, R, is hydrogen or C,_3 alkyl and RZ
is hydrogen or C,~, alkyl. Additionally, R, and R, may be attached to the same carbon atom and may form a carbocyciic ring of 5-8 atoms, or be attached to the same atom and form a ring of S-8 atoms of the formula:
~ /ECH2)1~
C NRIi ~ ~(CH2)~
together with the carbon atom to which they are attached. In this embodiment, R3 is hydrogen, C,_6 alkyl, C7_" arylalkyl, (C,~ alkyl)-OH, (C,..~ alkyl)-COZ-R", (C,_6 alkyl}-CN, adamantyl, phenyl, or one of the following:
~(C ~ _6 alkyn--C ~N -(C ~ _6 ally ~ \ -(C 1-b a~Yn!
N
H N ,N ( (~ \ ~ \ \
~. N
N(C E-3a~Y1)2 H
S
'N IN
H
COzRt, OH C02R> >
Additionally, in this embodiment, R4 is -O-R" , NH2, NHOH, or R4 is of the formula 0 CH \
~N . Also, R" is hydrogen or C,~ alkyl, and X is S or O.
in yet another embodiment, the compound of the present invention is represented by the following formula {I-a):

X ~ N
RI 1 ~ { I-a ) N )m SRS
R3~y'~ n In the above formula (I-a), R, may occur one to :four times and each occurrence is independently hydrogen or C,~ alkyl, and RZ is hydrogen, pyridyl, C,~ alkyl, (C,_6 alkyl)-CO2-Ri,, or -COZ-R". Additionally, R, and RZ may be attached to the same carbon atom and form a carbocyclic ring of 5-8 atoms together with t:he carbon atom to which they are attached, or they may be attached to the same carbon atom and form a ring of 5-8 atoms of the formula:
~ ~(CH2)l~

~ ~(CH2)~
together with the carbon atom to which they are attached. Additionally, in this embodiment, R3 is hydrogen, phenyl, C,~ alkyl, C3_6 alks~nyl, C7_" arylalkyl , (C,~ alkyl)-C02-R", {C2~ alkenyl)-COZ-R", (C,.6 alkyl)-~CO-C,_6 alkyl, (C,_6 alkyl)-O-C,_6 alkyl, (C,.~ alkyl)-OH, (C,_6 alkyl)-CN, adamantyl or onf; of the following:

N''N ~'~',~, ORt t I~ \
-(C I _ 6 alky)~ ~N -(C I -6 a~Y~- ~ -N Z
(~ N
N, O
H
/ /
w / / ~ ~\
\ COz-Rt t \ COz-Rt 1 \ \ --~ COz-Rt t '-(C I -6 alkYlr~
N
N
/ / N ,' O /
\ [O(Ct-3alkyO~t-a COz-Rt i I ~ -~CF3 \ i N
OH
~ O NO~ HN-N \ I /
N' N~ ~ / \
H COz-Rt t H COz-Rt t ~'~ ~COz-Rt t N(C t-aa~Y~z In addition, RZ and R3-(Y)o may combine with each other at the terminal thereof to form a ring of the following formula together with the carbon atom and the nitrogen atom to which they are attached:
Z IV ~, O
Additionally, R4 is -O-Rtt, NH2, NHOH, -O-(C,_to arylalkyl), or is of the formula -o-cH2 ; ~
LH
Also, in this embodiment, RS is a formula of the following:
I R8-'_-RI2 R~
Additionally, in this embodiment, R.6 is N or CH, R, is hydrogen or halogen, Rg is -NH-Y,-; -OCHZ-, or -CONH-, R, may occur one to three times and is a halogen, C,~
alkoxy, C,_6 alkyl or trifluoromethyl, R,a is C,_6 alkyl, or (C,_6 alkyl)-OH, or hydrogen, R"
is hydrogen or C,_6 alkyl, R,2 is C,~ alkyl or the following formula:
Rt 3 -(CH2~. I
R,3 is N or CH, W is (C,_6 alkyl), X is S, O, or CHZ, Y and Y, are independently -CO-, -C(=O)O-, -SOz-, or -C(=O)N(R,o)-, Z is O, CH2, or N-R",1 is I, 2,or3,mislor2,nis0orl,ois0orl,pis0orl,qi:>0orlandris0,i,2or3. This particular embodiment of the present invention has the provisos that { 1 ) when Y is -C(=O)O-, R3 cannot be hydrogen;
(2) when R4 is equal to O-(C4 alkyl), C~ alkyl. is not equal to tent-butyl;
(3) in those pyrralidine structures (I is 1; m is 2; n is 0; o is 0; p is 1; X
is CHZ), W is equal to CH2;
(4) the compound has an IC~o value of less than Sp,M in a Jurkat CS-1 assay and/or an ICso value of less than SOpM in a Jurkat EC assay; and (5) the compound is not O
O COzH
H .,~ ;
N ' N
In yet another embodiment of the compound of formula {I), R, may occur one to four times and each occurrence is independently hydrogen or C,_6 alkyl. Also, RZ is hydrogen, pyridyl, C,_6 alkyl, (C,_6 alkyl)-COZ-R", or -COZ-R". Additionally, R, and RZ
may be attached to the same carbon atom and form a carbocyclic ring of 5-8 atoms together with the carbon atom to which they are attached, or they may be attached to the same carbon atom and form a ring of 5-8 atoms of the formula:

~ ~{CH2)l~
p1 ~(CHZ)~
together with the carbon atom to which they are attachedl. In this embodiment, R3 is hydrogen, phenyl, Ct,b alkyl, C3_6 alkenyl, C,_" arylalkyl , (C,~ alkyl)-COZ-Rtt, (CZ_6 alkenyl)-COZ-R", (Ct_6 alkyl)-CO-C,_6 alkyl, (Ct_6 alkyl}-O-C,~ alkyl, (Ct_6 alkyl)-OH, {C,~
alkyl)-CN, adamantyl or one of the following:
N..N ~'''4,, ORtt -(C 1-6 alkyl N -(C 1-6 alkyl?-. ~ _ ~ \
N.. O ( H a (~q N
/ / /
CO -R ~\
2 t t CO -R
\ ~ z t t \ \ -COz-Rt t '-(C 1-6 alkylp N
N
/ / N' O /
\ 10(Ct-3alkynlt-s COz-Rit ~ __~~CF3 \ / N
OH
S s \
'''~~ O NOz HN-N \ ~ /
N' \ ~ ,..
N~ / \
H COz-Rt t H COz-R" ~~ ~COz-Rt t N(C t-3a~Y~z In addition, RZ and R3-(Y)o may combine with each other at the terminal thereof to form a ring of the following formula together with the carbon atom and the nitrogen atom to which they are attached:
Z N .., O
In this embodiment, R4 is -O-R", NH2, NHOH, -O-(C7_,o arylalkyl), or R4 is of the formula:

L i N
i Alsa, in this embodiment, RS is a formula of the following:

w ~-Riz R~
Additionally, in this embodiment, R.6 is N or CH, R, is hydrogen or halogen, R8 is -NHCO-, R, may occur one to three times and is a halogen, C,_6 alkoxy, C,_b alkyl or trifluoromethyl, R,o is C,~ alkyl, or (C,_6 alkyl)-OH, or hydrogen, R" is hydrogen or C,_6 alkyl, R,2 is C,_6 alkyl or the following formula:
Ri3 -(CHz~. R9 /
R,3 is N or CH, W is (C,_6 al:kyl), X is S, O; or CHz, Y is -CO-, -C(=O)O-, -C(=Q)N(R,a)-, Z is O, CH2, or N-R",1 is 1, :?, or 3, m is 1 or 2, n is 0 or 1, o is 0 or l, p is 0 or 1, q is 0 or 1, and r is 0, 1, 2 or 3. In this embodiment, the following provisos apply:
(1) when Y is -C(=O)O-, R3 cannot be hydrogen;
(2) when R4 is equal to O-(C4 alkyl), C4 alkyl is not equal to tent-butyl; and (3) in those pyrrolidine structures (1 is 1; m is~ 2; n is 0; o is 0; p is l;
X is CHZ), W is equal to CH2.
In yet another embodiment of the campound of formula (I-a), R, may occur one to four times and each occurrence is independently hydrogen or C,~ alkyl, and Rz is hydrogen, pyridyI, C,.~ alkyl, (C,~ alkyl)-COz-R", or -Ci7z-R". Additionally, R, and RZ
may be attached to the same caxbon atom and form a carlbocyclic ring of 5-8 atoms together with the carbon atom to which they are attached, or they may be attached to the same carbon atom and form a ring of 5-8 atoms of the formula:

~ yCH2)l~
C NRtt ~ ~~CHa)~
together with the carbon atom to which they are attached. Additionally, in this embodiment, R3 is hydrogen, phenyl; Ct.b alkyl, C;_6 alkc~nyl, C,_t, arylalkyl , {Ct_6 alkyl)-COz-Rtt, (C2~ alkenyl)-COZ-R", (Ct_6 alkyl)-CO-C,_6 alkyl, (Ct_6 alkyl)-O-C,.~ alkyl, (Ct_6 alkyl)-OH, (C,~ alkyl)-CI\f, adamantyl or one of the following:
ORt t -(CI_6 alkyl \N ~~'~,'' -(CI-6 alkyl}-- ~Z _N~ \
N ~ O (~
H q (~ N
/ / / \
\ COz-Rt t \ CO_rRt i \ \ -COz-Rt i -(C I _( alky'1]I-N N
/ / N :, O '/~
I~(CI-3a~~~1-3 COz-Rtt I y~CF3 \ \ / ~N
OI~f S S \
O NOz HN N \ ~ /
N ~ ~ ,,, ~~v H COz-Rt t H COz-Rt t '''~~ ~COz-Rt z N(C t _3alkylyz In addition, RZ and R3-(Y)o may combine with each other at the terminal thereof to form a ring of the following formula together with the carbon atom and the nitrogen atom to which they are attached:
Z N ,", Additionally, R4 is -O-R", NH2, NHOH, -O-(C7_to arylalkyl), or is of the formula -O-CIi2 ' ~
N
i Also, in this embodiment, RS is a formula of the following:
Rs"-Ri 2 R~
Additionally, in this embodiment, R fi is N or CH, R7 is hydrogen or halogen, R8 is -NHCO-, It9 may occur one to three times and is a halogen, C,_6 alkoxy, C,_6 alkyl or trifluoromethyl, R,o is C,~ alkyl, or (C,_~ alkyl)-OH, or hydrogen, R" is hydrogen or C,_6 a.lkyl,R,2 is C,~ alkyl or the following formula:

R" is N or CH, W is (C,~ alkyl), X is S, O, or CHZ, Y is -CO-, -C(=O)O- or -C(=O)N(R,o)-, Z is O, CH2, or N-R,,, l is I, 2, or 3, m is 1 or 2, n is 0 or 1, o is 0 or I, p is 0 or I, q is 0 or l; and r is 0, 1, 2 or :3. This particular embodiment of the present invention has the provisos that (I) when Y is -C(=O)O-, R3 cannot be hydrogen;
(2) when R4 is equal to O-(C4 alkyl), C4 alkyl is not equal to tent-butyl;
(3) in those pyrrolidine structures (I is 1; m is 2; n is 0; o is 0; p is 1; X
is CHZ), W is equal to CH2; and (4) the compound has an ICso value of less than Sp.M in a Jurkat CS-1 assay and/or an ICso value of less than 50pM in a Jurkat EC assay.
In another embodiment of the compound of formu.'la (I), R, may occur one to four times and each occurrence is independently hydrogen or C,_6 alkyl, R, is hydrogen, pyridyl, C,_b alkyl, (C,_6 alkyl)-COZ-R", or -COZ-R". Additionally, R, and RZ
may be attached to the same carbon atom and form a carbocyclic ring of 5-8 atoms together with the carbon atom to which they are attached, or they may be attached to the same carbon atom and form a ring of 5-8 atoms of the formula:

~C/(CHz)I~NR
/ a ~(CH2)~
together with the carbon atom to which they are attached.. Also, in this embodiment, R3 is hydrogen, phenyl, C,_6 alkyl, C,_6 alkenyl, C,_,7 arylalkyl , (Ct_6 alkyl)-COz-R", (CZ_6 alkenyl)-COZ-R,t, (C,_6 alkyl)-CO-C,_6 alkyl, {C,_6 alkyl)-O-C,_6 alkyl, (Ct_6 alkyl)-OH, (Ct.e alkyl)-CN, adamantyl or one of the following:
N~ ORtt -(C t _6 alkyl-< N ~ -(C t-6 alkylr-- ~Z - ~Z \
,N O
N (~ (~ N
H
/ / / \
\ COz-Rt t \ COz-Rt t --.COz-Rt t '-"(C 1-6 a)kY
N \ \ NJ
/ / N~ ~ ~/
IO(C t-3a~Ynl r-s COz-Rt t ~ --~~CF3 \ \ / ~N/
OHL
S \
~S -~ ~ O ~ NOz HN N \ j /
N' \ _ ~'"'~CO~-R
H COz-Rt t H COz Rt t _ t t N(C t _3alkyi)z In addition, RZ and R3-(Y)o may combine with each other at the terminal thereof to form a ring of the following formula together with the carbon ai:om and the nitrogen atom to which they are attached:
Z N ..., O
In this embodiment, R4 is -O-R", NH,, NHOH, -O-(C7_,~, arylalkyl), or R4 is of the formula:
-o-cH2 l N
s In this embodiment, RS is a formula of the following:
(- / Rs_"Ri2 R~
Also, in this particular embodiment, Rd is N or CH, R, is hydrogen or halogen, R8 is -OCHZ-, R9 may occur one to three times and is a halogen, C,~ alkoxy, C,.~
alkyl or trifluoromethyl, R,o is C,_6 alkyl, (C,_6 alkyl)-OH, or hydrogen, R" is hydrogen or C,_6 alkyl, R,z is C,~ alkyl or the following formula:
Ri3 -(CH2~ R9 R,3 is N or CH, W is (C,.~ alkyl), X is S, O, or CH2, Y is -CO-, -C(=O)O- or -C(=O)N(R,o)-, Z is O, CH2, or N-R", I is 1, 2, or 3, m is 1 or 2, n is 0 or 1; o is 0 or 1, p is 0 or 1, q is 0 or l, and r is 0, 1, 2 or 3. This particular embodiment has the following provisos:
(1) when Y is -C(=O)O-, R3 cannot be hydro3;en;
(2) when R4 is equal to O-(C, alkyl), C4 alkyl is not equal to tert-butyl;
(3) in those pyrrolidine structures (1 is 1; m is. 2; n is 0; o is 0; p is 1;
X is CH,), W is equal to CH2;
(4) when R3 is phenyl, C,_6 alkyl, C,_" arylalk;yl, (C,.~ alkyl)-COZ R", (C,.~ alkyl)-O- C,~ alkyl or (C,_6 alkyl)-OH, o is 0; and {5) the compound is not Cl O ~ /
H O C02H ~ \
N I-N S / Cl H

In yet another embodiment of the compound of formula (I-a), R, may occur one to four times and each occurrence is independently hydrogs~n or Ct_6 alkyl, and Rz is hydrogen, pyridyl, C,.6 alkyl, (C,~ alkyl)-COZ-Rtt, or -COZ-R". Additionally, R, and RZ
may be attached to the same carbon atom and form a carbocyclic ring of 5-8 atoms together with the carbon atom to which they are attached, or they may be attached to the same carbon atom and form a ring of 5-8 atoms of the formula:
~ ~f CH2)l~
C NR~ 1 / ~(CH2)r~
together with the carbon atom to which they are attached. Additionally, in this embodiment, R3 is hydrogen, phenyl, C,_6 alkyl, C3~ alke;nyl, C,_,~ arylalkyl , (C,~ alkyl)-COZ-R", (C2~ alkenyl)-COZ-R", (C,_6 alkyl)-~CO-C,_6 alkyl, {C,~ alkyl)-O-C,_6 alkyl, {C,_6 alkyl)-OH, (C,_6 alkyl)-CN, adamantyl or one of the following:
N'N ~~''~,, ORtt -(C~-6 alkyl}--~ ~~ -(C1-6 alkyl)-- ~Z - ~Z \
,N O
N ~ ~ (~ (~ N
H
,~' / / / \
\ CO~-R" -~CO~-R~ ~ -CO~-R" -(C l_6 alkyl \ \
N N
/ / N :, O /
[O(C,-3alky4lt-s COZ-Rt t W-~~CF3 \ \ / N
OHf S \
S ---~ O NO~ HN~N \ ( /
N ~ I -~' \ ' CO -R
H COZ_Rt t H COZ-Rt t '~ ~ 2 t t N(C t-a~Y~2 In addition, RZ and R3-(I~a may combine with each othE;r at the terminal thereof to form a ring of the following formula together with the carbon atom and the nitrogen atom to which they are attached:

Z N ...."
O
Additionally, R4 is -O-R", NHz, NHOH, -O-(C,_,o arylalk:yl), or is of the formula -O-CHy-',', i N
Also, in this embodiment, RS is a formula of the foilowin.g:
Rg_.Riz Additionally, in this embodiment, R.6 is N or CH, R7 is hydrogen or halogen, Rg is -OCHZ-, R, may occur one to three times and is a halogen, C,~ alk:oxy, C,~ alkyl or trifluoromethyl, R,o is C,~ alkyl, or (C,_6 alkyl)-OH, or hydrogen, R" is hydrogen or C,_6 alkyl, R,z is C,~
alkyl or the following formula:
Ri3 -(CHz}r Rg R,3 is N or CH, W is (C,~ all;yl), X is S, O, or CH,, Y is -CO-, -C(=O)O- or -C(=O)N(R,o}-, Z is O, CHZ, or N-R", l is 1, 2, or 3, m is 1 or 2, n is 0 or 1, o is 0 or 1, p is 0 or l, q is 0 or l, and r is 0, l, 2 or 3. This particular embodiment of the present invention has the provisos that:
(1) when Y is -C(=O)O-, R3 cannot be hydrok;en;
(2) when R4 is equal to O-(C4 alkyl), C4 alkyl is not equal to tent-butyl;
(3} in those pynrolidine structures (1 is 1; m is 2; n is 0; o is 0; p is 1; X
is CHZ), W is equal to CH2;
(4) the compound has an ICSO value of less than Sp,M in a Jurkat CS-1 assay and/or an ICSO value of less than SOp.M in a Jurkat EC assay;
(5) when R3 is phenyl, C,_6 alkyl, C~_" arylalk;yl, (C,_6 alkyl)-COZ-R", (C,_6 alkyl)-O- C,.6 alkyl or (C,~ alkyl)-OH, o is 0; and {6) the compound is not Cl .'w o co2H ~ ~
H '/~ ;
N s ; ~ s / C1 In the above formula (I) the absolute stereochemistry for the bond leading to RS is shown, however the absolute stereochemistry has not been shown for alI
examples which follow. It is understood that all other formulas also follow this type of absolute stereochemistry unless otherwise stated. Additionally, it is to be understood by those of skill in the art that the present invention embodies stereochemical configurations other than those shown. Specifically, the present invention embodies all configurations including the various stereoisomers. Compounds which do not meet the absolute stereochemistry in formula (I) should meet an activity threshold in various assays, to be explained below, which can ensure their efficacy as useful molecules. The present invention includes mixtures, such as racemic mixtures, which contain molecules having the claimed stereochemistry.
The desired compound of the present invention may be clinically used either in a free form or in the form of pharmaceutically acceptable salts thereof.
Pharmaceutically acceptable salts include acid-addition salts with inorganic acid or organic acid (e.g., hydrochloride, sulfate, nitrate, hydrobromide, methanesul#onate, p-toluenesulfonate, acetate), salt with inorganic base, organic base or amino acid (e.g., triethylamine salt, a salt with lysine, an alkali metal salt, an alkali earth metal salt and the like).
The compound may also be formulated into a pharmaceutical composition comprising a therapeutically effective amount of the compound as defined above and a pharmaceutically acceptable carrier or diluent.
The compound can also be used for treating or preventing a4(3, adhesion mediated conditions in a mammal such as a human. This method. may comprise administering to a WO 99!67230 PCT/US99/14233 mammal- or a human patient an effective amount of the compound or composition as explained above.
This method can be used to treat such inflammatory conditions as rheumatoid arthritis, asthma, allergy conditions, adult respiratory distress syndrome, AIDS, cardiovascular diseases, thrombosis or harmful platelet aggregatian, reocclusion following thrombolysis, allograft rejection, reperfusion injury, psori~~sis, eczema, contact dermatitis and other skin inflammatory diseases, osteoporosis, osteoa~.~thritis, atherosclerosis, neoplastic diseases including metastasis of neoplastic or cancerous growth, wound healing enhancement, treatment of certain eye diseases such as detaching retina, Type I diabetes, multiple sclerosis, systemic lupus erythematosus (SLE), inflammatory and immunoinflammatory conditions including ophthalmic inflammatory conditions and inflammatory bowel diseases, ulcerative colitis, atheroscllerosis, regional enteritis and other autoimmune diseases.
As mentioned above, the compounds and compositions containing the compounds according to the present invention are particularly useful in treating or preventing cc4[3, adhesion mediated conditions in a mammal such as a hi.iman. The present inventors have found that the compounds and compositions containing; the compounds according to the present invention are most useful in the treatment of asthma.
The desired compound of the present invention or pharmaceutically acceptable salts thereof may be administered either orally or parenterally, and it may be used as a suitable pharmaceutical preparation, for example, a tablet, a l;ranule, a capsule, a powder, an injection, and an inhalation by a conventional process.
The dose of the desired compound of the present invention or a pharmaceutically acceptable salt thereof varies depending on an administration method, age, body weight, and state of a patient, but, in general, the daily dose is preferably about 0.1 to 100 mg/kg/day, however, 1 to 100 mglkg/day may also be suitable.

Preferred routes of administration for asthma:
It is preferred that the compound of the present invention be administered in the form of an Aerosol. However, other routes of administration include intravenous, oral, intramuscular, and subcutaneous.
S In the case of aerosol administration, compositions containing the compounds of the present invention can be prepared to provide for an excellent means for administering in aerosol form for inhalation therapy. Accordingly, the present invention will provide far self-propelling compositions containing the compounds of the present invention.
Propellants employed should be non-toxic and have a vapor pressure suitable for the conditions under which administration occurs. These ;propellants can be fluorinated or fluorochlorinated lower saturated aliphatic hydrocarbons. The preferred propellants of this type are the halogenated aikanes containing not more than two carbon atoms and at least one fluorine atom. Illustrative of these are trichloromonofluoromethane, dichlorodifluoromethane, monochlorotrifluoromethane, dichloromonofluoromethane and 1S 1,2-dichloro-1,1,2,2-tetrafluoroethane. These compounds are available from E.I. duPont de Nemours and Company under the trade name "Freon". These propellants may be employed singularly or in admixture.
In addition to the propellant, an organic solvent may also be employed. The organic solvent must be non-toxic and without undesirable effects on inhalation in the amount present in the aerosol produced. in addition, the solvent should be substantially anhydrous, completely miscible with the propellant or mixture of propellants employed and have a suitable boiling point. Examples of such solvents included non-toxic aliphatic alcohois such as ethanol; ethers such as ethyl ether and vinyl ether; ketones such as acetone; and suitable halogenated lower alkanes.
2S In addition to the organic solvent, the composition may also optionally contain a non-toxic hygroscopic glycol. The glycol must be suhstantiall3r miscible with the organic solvent and the propellant employed. Satisfactory glycols include propylene glycol, triethylene glycol, glycerol, butylene glycol and hexylene glycol.
The above indicated methods of administration and formulation of aerosol compositions should not be viewed as limiting. The compounds of the present invention can be formulated in anyway deemed suitable to one of ordinary skill in the art so as to obtain the desired effects.
Pharmaceutical Compositions As indicated previously, the compounds of formula {I) can be formulated into pharmaceutical compositions. In determining when a compound of formula (I} is indicated for the treatment of a given disease, the particular disease in question, its severity, as well as the age, sex, weight, and condition of the subject to be treated, must be taken into consideration and this perusal is to be determined by the slkill of the attendant physician.
For medical use, the amount of a compound of formula (I) required to achieve a therapeutic effect will, of course, vary both with the particular compound, the route of administration, the patient under treatment, and the particular disorder or disease being treated. A suitable daily dose of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, for a mammalian subject suffering; from, or likely to suffer from, any 1 S condition as described hereinbefore is 0.1 mg to 100 mg of the compound of formula I, per kilogram body weight of the mammalian subject. In the case of systematic administration, the dose may be in the range of 0.5 to 500 mg of the compound per kilogram body weight, the most preferred dosage being 0.5 to SO mglkg of mammal body weight administered two to three times daily. In the case of topical administration, e.g., to the skin or eye, a suitable dose may be in the range of 0.1 p.g to 100 pg of the compound per kilogram, typically about 0.1 p,glkg.
In the case of oral dosing, a suitable dose of a compound of Formula (I), or a physiologically acceptable salt thereof, may be as specified in the preceding paragraph, but most preferably is from 1 mg to 10 mg of the compound per kilogram, the most preferred dosage being from 1 mg to 5 mglkg of mammal body weight, for example, from 1 to 2 mg/kg. Most preferably, a unit dosage of an orally admitiistrable composition encompassed by the present invention contains less than about 1.0 g of a formula (I) compound.
It is understood that formulation, both for human. and veterinary use, of the present invention may be presented to the mammal by inhalation. To achieve therapeutic effect, the dose may be in the range of 0.5 to 500 rng of the compound, per kg body weight. The most WO 99/67230 PCTlUS99/I4233 preferred -dosage being 0.5 to 50 mglkg of mammal body weight administered two to three times daily.
It is understood that the ordinarily skilled physician or veterinarian will readily determine and prescribe the effective amount of a compound of formula (I) to prevent or arrest the progress of the condition for which treatment is administered. In so proceeding, the physician or veterinarian could employ relatively low doses at first, subsequently increasing the dose until a maximum response is obtained.
The compounds and compositions of the present invention can be administered to patients suffering from a condition listed herein in an amount which is effective to fully or partially alleviate undesired symptoms of the condition. The symptoms may be caused by inappropriate cell adhesion mediated by a4(3, integrins. Such inappropriate cell adhesion would typically be expected to occur as a result of increased VCAM-1 and/or CS-expression on the surface of endothelial cells. Increased VCAM-1 and/or CS-1 expression can be due to a normal inflammation response or due to abnormal inflammatory states. In either case, an effective dose of a compound of the invention may reduce the increased cell adhesion due to increased VCAM-1 expression by endothelial cells. Reducing the adhesion observed in the disease state by 50% can be considered an effective reduction in adhesion.
More preferably, a reduction in adhesion by 90%, is achieved. Most preferably adhesion mediated by VCAM-1/a4(3, and/or CS-1 interaction is abolished by an effective dose.
Clinically. in some instances, effect of the compound can be observed or a decrease in white cell infiltration into tissues or a site of injury. To achieve a therapeutic effect, then, the compounds or compositions of the present invention are administered to provide a dose effective to reduce or eliminate inappropriate cell adhesion or to alleviate undesired symptoms.
While it is possible for an active ingredient to be administered alone, it is preferable to present it as a pharmaceutical formulation comprising a compound of formula (I) and a pharmaceutically acceptable carrier thereof. Such formulations constitute a further feature of the present invention.
The formulations, both for human and veterinary medical use, of the present invention comprise an active ingredient of formula (I), in association with a pharmaceutically acceptable carrier thereof and optionally other therapeutic; ingredient(s), which are generally known to be effective in treating the disease or condition encountered. The carriers) must be "acceptable" in the sense of being compatible v~rith the other ingredients of the formulations and not deleterious to the recipient thereof.
The formulations include those in a form suitable for oral, pulmonary, ophthalmic, rectal, parenteral (including subcutaneous, intramuscular, and intravenous), infra-articular, topical, nasal inhalaxion (e.g., with an aerosol) or buccal administration:
Such formulation are understood to include long-acting formulations known in the art.
The formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art: of pharmacy. All methods may include the step of bringing the active ingredient into association with the earner which constitutes one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing the active ingredient into association with a liquid carrier or a finely divided solid carrier or both; and then, if necessary, shaping the product into the desired form.
Formulations of the present invention suitable for oral administration may be in the form of discrete units such as capsules, cachets, tablets, or lozenges, each containing a predetermined amount of the active ingredient in the form of a powder or granules; in the form of a solution or suspension in an aqueous liquid. Formulations for other uses could involve a nonaqueous liquid; in the form of an oil-in-water emulsion or a water-in-oil _ emulsion; in the form of an aerosol; or in the form of a cream or ointment or impregnated into a transdermal patch for use in administering the a<;tive ingredient transdermally, to a patient in need thereof. The active ingredient of the present inventive compositions may also be administered to a patient in need thereof in the form of a bolus, electuary, or paste.
The practitioner is referred to "Remington: The Science and Practice of Pharmacy,"
19th Edition, - c. 1995 by the Philadelphia College of Pharmacy and Science, as a comprehensive tome on pharmaceutical preparations.

Abbreviations Ac20: Acetic anhydride EtOAc: Ethyl acetate BCECF-AM: 2',T-bis-(2-carboxyethyl)-5-(and 6-) carboxyfluorescein acetoxy-methyl ester BOP-Cl: Bis (2-oxo-3-oxazolidinyl) phosphinic chloride BOP Reagent: Benzotriazol-1-yloxy-tris (dimethylamino)-phosphonium hexafluoro-phosphate DMEM: Dulbecco's Minimal Eagle's Media DMF: Dimethyl formamide DIEA: Diisopropylethylamine EDC: 1-(3-Dimethylaminopropyl)-3-eth;ylcarbodiimide hydrochloride Et: Ethyl EtOH: Ethanol HATU: N [(Dimethylarnino)-1H 1,2,3-txi~~zolo[4,5-b~-pyridin-1-ylmethylene]-N methylmethanaminium hexafluorophosphate N oxide HBSS: Hank's Balanced Salt Solution HBTU: O-Benzotriazol-1-yl-N,N,N',N'-tetxamethyluronium hexafluorophosphate HOBT (HOBt): 1-Hydroxybenzotriazole HSA: Human serum albumin LDA: Lithium diisopropylamide Me: Methyl meq: milliequivalent MeOH: Methanol n-Bu: n-Butyl NMP: 1-Methyl-2-pyrrolidinone PBS: Phosphate buffered saline Pd-C: Palladium on charcoal Ph: Phenyl SPDP: - 3-(2-pyridyldithio}propionic acid N'-hydroxysuccinimide ester t-Bu: t-butyl THF: Tetrahydrofuran TFA: Trifluoroacetic acid DMSO: dimethyl sulfoxide HOAt: 1-hydroxy-7-azabenzotriazole DMAP: 4-dimethylaminopyridine FMOC: 9-fluorenylmethoxycarbonyl Bn: benzyl PyBOP: (benzotriazol-1-yloxy}tripynrolidinophosphonium hexafluoro-phosphate BOC: tert-butoxycarbonyl The representative compounds according to the present invention are prepared as described below. The compounds of the present invention are prepared in a similar manner.

i Scheme A
HS RA-t RA 2 A_1 HZN~'OH
O
RA-~
C ~OH q_2 H O
R-S Rq2 C~OH A-~[O
R3_O~O

H2N ~ w O RA-t RAa S Rp_y O
S Rpz O ~
C NH ~ ---~- Cn~NH pH
O ,~~ ~O~
~O O ~ A-5 Ra-O' O Rs A_9 R3_O R5 RE"~ Rp_t S Rp_2 O S Rqz O
N~NH O~ C , NH
H A~ N ~ OH
O ~ H O A-10 S Rp_2 O
N~NH Oi O ~ A-7 Rp_~
S Rp_2 O
C~NH OH
~y O
R3 s RA_, and RA_2 are defined independently as R,.
Scheme A describes a general method for the preparation of examples of the formula A-5, A-6, A-7, A-B, A-9 and A-10. A commercially available; or readily prepared sulfur containing amino acid of structure A-1 (for the synthesis of ~3,~i-disubstituted cysteine amino acids see: Stanfield, G.F.; Hruby; V.J. Synth. Cornmun.1988, 18, 531 and references therein) is condensed with formaldehyde to afford the thiazolidine-4-carboxylic acid of general formula A-2 (for the condensation of alde;hydes with cysteine or similar sulfur containing amino acids see for example: (a) Ratner, S.; Clark, H.T. .J
Am. Chem.
Soc. 1937, 59, 200. (b) Lewis, N.J.; Inloes, R.L.; Hes, J.; Matthews, R.H.;
Miio, G. J. Med.
IO Chem. 1978, 21, 1070. (c) Oya, M.; Baba, T.; Kato, E.; l~:awashima, Y.;
Watanbe, T.
Chem. Pharm. Bull. 1982, 30, 440.}. Standard protection affords carbamate A-3 which is readily condensed with amino acid derivative A-4 under standard peptide synthesis conditions to provide the psuedodipeptide A-S (for a reviiew of procedures of peptide synthesis see: Bodansky, M.; Bodansky, A. The Practice of Peptide Synthesis;
Springer-Verlag: Berlin, 1984). Deprotection of the carbamate firom A-5 provides the useful intermediate A-6. The amine group may be reacted with a variety of electrophilic reagents such as: ( I ) commercially available or readily prepared sulfonyl chlorides (for the synthesis of sulfonyl chlorides see for examples: (a} Roblin, R.O.; Clapp, J.W. J. Am.
Chem. Soc. 1950, 72, 4890. (b) Gilbert, E.E. in Sulfonation and Related Reactions Olah, G.A., Ed. John Wiley and Sons, New York; 1965. (c} Park, Y.J.; Shin, H.H:;
Kin, Y.H.
Chem Lett. 1992, 1483. (d) Kim, D.; Ko, Y.K.; Kim, S.Ff. Synthesis, 1992, 1203.) to afford sulfonamides of general structure A-7 where Y is SOZ- (preparation S); (2) carbonates or chloroformates to afford carbamates of general structure A-7 where Y is COz (preparations 2, 7, 8}; (3) isocyanates to afford areas of general structure A-7 where Y is CONHR3 (preparation 9); (4} phosgene or a suitable equivalent and an amine to afford areas of general structure A-7 where Y is CON{C,_6 alkyli)R3- (preparation 10, also see for example: Nowick, J.S.; Homes, D.L.; Noronha, G.; Smith, E.M.; Tram, M.N.;
Huang, S.
J. Org. Chem. 1996, 61, 3929.); (5) acid chlorides and c~~rboxylic anhydrides to provide amides of structure A-7 where Y is CO- (preparation 1 I}. Mild base hydrolysis of monoesters of general structure A-7 (preparation 6) or diesters of general structure A-7 (preparation 12) affords the acids' of general structure A-8. Mild base hydrolysis of the ester of general structure A-S provides acid A-9 (preparation 6 or 13) which may be further deprotected to afford the amino acid A-10 (preparation a 4).
Preparation 1 (Scheme A, A-2: where RA_, and RA_z are the same and equal to H and stereochemistry is s-.
~N~OH
H [~O
D-Cysteine hydrochloride monohydrate (A-1, where RA_, and RA_2 are the same and equal to H and stereochemistry is (,S~) (35.04 g, 0.19 mol) was dissolved in formaldehyde (40 wt% solution in water, 38 mL) and the reaction mixture allowed to stir for 18 h at ambient temperature. The mixture was cooled (0-5°C ) and absolute ethanol {93 mL} and pyridine {57 mL) were added. After one hour, the precipitate was collected by filtration, washed with cold absolute ethanol followed by diethyl ether and dried in vacuo to afford the title compound {24.6 g) as a white crystalline solid: mp 181-184 °C (Lit. 194-196 °C; Lewis, N.J.; Tnoles, R.L.; Hes, 3. J. Med. Chem. 1978, 21, 1070.};'H NMR (DMSO-db) 8 4.22 (1 H), 4.04 (1 H), 3.86 {1 H), 3.09 (1 H), 2.24 (1 H); MS (ESI+) for C4H,NOZS
m/z 134.0 (M+H)+.
Preparation 2 (Scheme A, A-3: where RA_, and RA_2 are the same and equal to H, R3 is t-butyl and stereochemistry is (S}) s-.
~OH
I~N
~O~O O
zs A solution of A-2 (Scheme A where RA_, and RA_2 are th.e same and equal to H
and stereochemistry is (f~) (24.6 g, 0.185 mol) and di-t-butyl dicarbonate (44.4 g, 0.2 mol) in THF (1 L) was heated to reflux for 18 h. Volatiles were; removed in vacuo and the residue partitioned between ethyl acetate and 0.1 N NaOH. The aqueous layer was washed with ethyl acetate, made acidic with I .0 N HCl {pH 3-4) and i:hen extracted with ethyl acetate.
The combined organic extracts were washed with brine, dried (Na2S04), filtered and concentrated in vacuo. Crystallization of the white solid. from hexane/methylene chloride provided the title compound (31.8 g) as white crystals: mp 132-134 °C;
[a]ZSD = 117° {c fl.66, ethanol); IR (mull) 3002, 1747, 1635, I421, 1404, 1393, 1310, 1215, 1198, 1166, 1144, 1 I22 , 894, 862, 774 cm'';'H NMR (DMSO-d6) 8 4.57 (2 H), 4.28 {1 H), 3.09 (1 H}, 1.35 (9 H); "C NMR (DMSO-db) 8 171.8, 152.5, 79.8, 60.9, 48.4, 47.7, 33.8, 32.6,27.7;
MS (ESI+) for C9H,SN04S mlz 234.2 (M+H)+; MS (EST-) for C9H,SN04S mlz 232.1 (M-H)' ; Anal. Calcd for C9H,SNO,S: C, 46.34; H, 6.48; N, 6.00. Found: C, 46.27; H, 6.48; N, 6.03.
Preparation 3, Example 1 [S-~R*,R*)]-4-[[[I-[[4-[(2,6--Dichlorobenzoyl)amino]phenyl]methyl]-2-methoxy-2-oxoethyl]amino]carbonyl]-3-thiazolidinecarboxylic acid 3-(I,1-dimethylethyl) ester 1 S (Scheme A, A-5: where RA_, and RA_z are the same and equal to H, R3 is t-butyl, RS is 4-[(2,6-dichlorobenzoyl)amino]phenyl, and stereochemist>iy is {S,S)).
S-. H O
,~ C~'lf N.J~o 0 0° ~ ~ o cl H~I ~
CI
To a cooled (0-5°C ) suspension of A-3 (Scheme A where RA_, and R.A_2 are the same and equal to H, R3 is t-butyl and stereochemistry is (S)) (8.6 i' g, 37.2 mmol) and HOBT (5.69 g, 37.2 mmol) in CHZCIZ (60 mL) was added a solution of EDC (7.12 g, 37.2 mmol) in CHZC12 (I40 mL). After 30 min at 0-5°C , A-4 (where P:5 is 4-[(2,6-dichlorobenzoyl)-amino]phenyl, and stereochemistry is (S)) (10 g, 24.8 mmol) was added followed by 4-methylmorpholine (2.72 mL, 24.8 mmoI). The reaction mixture was gradually warmed to ambient temperature, stirred an additional l8 h and diluted with CHZCl2 and 0.1 N HCI.
The organic layer was separated and washed with 0.1 N HCI, sat. aqueous NaHC03, brine, WO 99/67230 PCT/US99l14233 dried (NaZS04), filtered and concentrated in vacuo. Flash. chromatography of the residue using hexane/ethyl acetate (50%) as eluant afforded the title compound (13.9 g) as a white solid. Recrystallization from acetone/hexane afforded a crystalline solid: mp 222-224°C;
IR (mull) 3282, 3254, 1738, 1714, 1707, 1678, 1662, 1610, I562, 1545, 1431, 1414, 1287, 1256, 784 crri';'H NMR {CDCl3) b 7.57 (2 H), 7.34 (5 H:), 7.14 (2 H}, 4.74 (3 H), 4.30 (1 H), 3.74 {3 H), 3.37 (1 H), 3.15 (3 H), 1.45 {9 H);'3C 1VMR (DMSO-db) 5 172.1, 162.3, 153.2, 137.6, 136.9, 133.2, 131.8, 131.7, 130.1, 128.7, 119.8, 80.4, 62.2, 53.7, 52.4, 36.7, 28.3; MS (ESI+) for CZ6H2~C1zN3O6S m/Z 604.3 (M+Na)+:; Anai. Calcd for CZ6Hz9C13N3O6S:
C, 53.6I ; H, 5.02; N, 7.2I . Found C, 53.82; H, 4.81; N, 7.22.
Preparation 4 (Scheme A, A-6: where RA_, and RA_z are the same and equal to H, RS is 4-[(2,6-dichlorobenzoyl)amino]phenyl, and stereochemistry is (S,S)).
s-. H o CN~N~Oi H ISO
O CI
H/ II
C ~I
To a cooled (5-10°C ) solution of A-5 (Scheme A where RA_, and RA_z are the same and equal to H, R3 is t-butyl, R5 is 4-[(2,6-dichlarobenzoyl)annino]phenyl, and stereochemistry is (S,S)) (3.3 g, 5.67 mmol) in dioxane (34 mL) was added a solution of HCl in dioxane (4 M, 140 mL) in a dropwise manner over 30 min. After an additional 30 min at 0-5°C , the ice bath was removed and the reaction mixture stirred 1 h at ambient temperature. The volatiles were removed in vacuo to afford the title compound (2.94 g) as a light yellow solid: 'H NMR (DMSO-db) 8 10.70 (I H), 9.1 (1 H), 7.52 (5 H), 7.I8 {2 H), 4.64 {1 H}, 4.37 (1 H), 4.2I (2 H), 3.67 (3 H), 3.10 (1 H), 2.89 (1 H)., 2.70 (1 H);'3C
NMR {DMSO-db) b 172.1, 162.3, 153.2, 137.6, 136.9, 133.2, 131.8, 131.7, 130.1, 128.7, 119.8, 80.4, 62.2, 53.7, 52.4, 36.7, 28.3; MS (ESI+) for CZ,HZ,C12N3O'aS m/z 482.I (M+H)+.

Preparation 5 arid Example 2.
4-[(2,6-Dichlorobenzoyl)amino]-N-[ j(4S}-~3-(methyisulfonyl}-4 thiazolidinylJcarbonyl]-L phenylalanine methyl ester (Scheme A, A-7: where RA_, and RA_2 are the same and equal to H, R3 is methyl, Y is SOz, RS is 4-[(2,6-dichlorobenzoyl)amino]phenyl and stereochemistry is (S, S)).

c~.~r "~.~~
i o <:I
H ~~
C ~I
To a cooled (0-5°C ) solution of A-6 (Scheme A, where RA_, and RA_Z are the same and equal to H, RS is 4-[(2,6-dichlorobenzoyl)amino]phenyl and stereochemistry is (S, S)) (2.0 g, 3.86 mmol) in anhydrous THF (50 mL) was added meahanesulfonyl chloride (2.99 mL, 38.6 mrnol} followed by pyridine (6.24 mL, 77.2 mmol}. After 1 h at 0-5°C , the ice bath was removed and the solution stirred at ambient temperature for 2 h then diluted with ethyl acetate and 0.25 N HCI. The layers were separated and the organic layer washed with sat.
aqueous NaHC03, brine, dried (MgS04), filtered and concentrated in vacuo.
Purif canon of the residue by flash chromatography using ethyl acetate/methylene chloride/hexane ( 1:1:1 ) and isopropanol {0.1 %) as eluant afforded the title compound ( 1.99 g) as an amorphous powder: IR {mull) 1742, 1666, 1605, 1562, :1534, 1515, 1432, 1413, 1344, 1327, 1269, 1218, 1195, 1156, 780 cm'; 'H NMR (300 rvlHz, CDC13) b 7.55 (3 H), 7.33 (3 H), 7.12 {3 H}, 4.84 { 1 H), 4.69 ( 1 H), 4.61 ( 1 H), 4.29 ( 1 H), 3.74 (3 H), 3.50 ( 1 H), 3.29 (1 H), 3.14 (2 H), 2.92 (3 H);'3C NMR {75 MHz, C'DC13) 8 171.2, 168.1, 162.4, 136.5, 135.9, 132.3, 132.2, 130.8, 130.0, 128.1, 120.6, 64.9, 53.2, 52.5, 51.8, 37.2, 34.1;
MS {ESI+) for CZZHzsC1zN306S2 mlz 559.8 (M+H)T; HRMS {FAB) calcd for CZZH23CLZN3O6Sz+H, 560.0483, found 560.0504; Anal. (:alcd for CzZHz3CIzNsObSx~
C, 47.15; H, 4.14; N, 7.50. Found: C, 46.88; H, 4.32; N, 7.'16.

Preparation 6 and Example 3.
4-[(2,6-Dichlorobenzoyl)amino]-N-[[{4S}-3--(methylsulfonyl~4-thiazolidinyl]carbonyl]-~-phenylalanine (Scheme A, A-8: where RA_, and RA_Z are the same and equal to H, R3 is methyl, Y is SO2, RS is 4-[(2,6-dichlorobenzoyl)amino]phenyl and stereochemistry is (S, S)).
S-. H O
~N~N v -OH

O (:I
H
CI
To a cooled (0-5°C ) solution of A-7 (Scheme A, where :R,,_, and R,,_2 are the same and equal to H, R3 is methyl, Y is SO2, RS is 4-[(2,6-dichIorobenzoyl)amino]phenyl and stereochemistry is (S, S)) ( 1.75 g, 3 . I 2 mmol) in THF ( 100 mL) and water ( 10 mL) was added an 0.1 N aqueous solution of NaOH (34.3 mL, 3.4.3 mmol) via a syringe pump over 1 h. After an additional 45 min at 0-5°C, the reaction mixture was diluted with ethyl acetate and acidified with 0.25 N HCI to a pH of ca. 3. The organic layer was separated, washed with water and concentrated in vacuo. Purification of the residue by flash chromatography using methylene chloride and methanol (0-5%) as eluant provided a solid which was lyophilized from glacial acetic acid to provide the title compound (1.42g) as an amorphous powder: [a]ZSO = 103°(c 0.97, ethanol); IR (mull} 3291, 1736, 1666, 1605, 1562; 1534, I516, 1432, 1414, 1339, 1270, 1195, 1 I54, '799, 780 cm'. 'H NMR
(300 MHz, CD3OD) b 7.58 (2 H), 7.45 (3 H), 7.25 (2 H},, 4.72 (2 H), 4.37 (1 H), 3.17 (S H), 2.99 (3 H); '3C NMR (75 MHz, CD3OD) 8 174.1, 171.6, 165.2, 138.3, I37.7, 134.8, 133.4, 132.4, 131.2, 129.4, 121.6, 66.2, SS.O, 52.9, 37.9, 37.5, 35.7; MS
(ESI+) for C2lH2EC12N3O6S2 ~z 545.8 (M+H)*; HRMS (FAB) calcd for C,,HZ,CLZN306S2+H, 546.0327, found 546.0358. Anal. Calcd for CZ,HZ,C12N3O6Sz: C, 46.16; H, 3.87;
N, 7.69.
2S Found: C, 46.24; H, 4.04; N, 7.33.

Preparation 7 and Example 4.
[S-(R*,R*)]-4-[[[1-j[4-[{2,6-Dichlorobenzoyl)amino]phenyl]methyl]-2-methoxy-2 oxoethyl]amino]carbonyl]-3-thiazolidinecarboxylic acid 3-ethyl ester (Scheme A, A-7: where RA_, and RA_2 are the same and equal to H, R3 is ethyl, Y is COZ-, RS is 4-[(2,6-dichlorobenzoyl)amino]phenyl and stereoc.hemistry is (S, S)).
S-. H O
~N~ N~Oi /'~O~O O ~ \ ~ C7 N \
H
Cite To a cooled (0-5°C ) solution of A-6 (where RA_, and R,~_Z are the same and equal to H, RS
is 4-[{2,6-dichlorobenzoyl)amino]phenyl and stereochemistry is (S, S)) (1.25 g, 2.40 mmol) in anhydrous THF (30 mL) was added ethyl chloroformate (340 p,L, 3.60 mmol) followed by triethylamine (810 ~L, 5.79 mmoi). After 1 h at 0-5°C , the ice bath was removed and the solution stirred at ambient temperature. for 2 h then diluted with ethyl acetate and 0.25 N HCI. The layers were separated and the organic layer washed with sat.
aqueous NaHC03, brine, dried (MgS04), filtered and concentrated in vacuo.
Purif ration of the residue by flash chromatography using ethyl acet;ate/methylene chloride/hexane ( 1:1:1 ) and isopropanol {0.1 %) as eluant afforded the title compound ( 1.10 g) as an amorphous powder: 'H NMR (300 MHz, CDC13) 8 7.59 (2 H), 7.30 (3 H), 7.10 {2 H), 4.81 (1 H), 4.72 {2 H), 4.38 (I H), 4.11 (2 H), 3.I9 (4 H), 1.25 (3 H);'3C NMR
(75 MHz, CDCl3) 8 171.6, 163.0, 136.9, 136.2, 132.3, I32.1, 130.7, 129.8, 128.0, 120.3, 63.0, 62.8, 57.1, 53.2, 52.5, 37.0, 14.4; MS (ESI+) for C:z4HzsC1aNa06S m/Z
SS4.2 {M+H)+;
MS {FAB) m/z (rel. intensity) 554 (MH+, 99), 557 (29), 556 (76), 555 (45), 554 (99), 349 (35), 245 (27), 175 (35), 173 (52), 160 (93), 88 (38); HFtMS (FAB) calcd for Cz4Hz5CL2N306S +H, 554.0919, found 554.0908. Anal. Calcd for C24HzsClaN306S:
C, 51.99; H, 4.55; N, 7.58.
Found: C, 52.05; H, 4.67; N, 7.44.

_3 8-Preparation 8 and Example S .
[S-(R*,R*)]-4-[[ji-j4-[(2,6-Dichlorophenyl)methoxy]phenyl]methyl]-2-methoxy-2--oxoethyi]amino]carbonyl]-3-thiazolidinecarboxyiic acrid 3-j2-(1-piperidinyi)ethyl] ester (Scheme A, A-7: where R"_, and R"_z are the.same and equal to H, R3 is 2-(1-S piperidinyl)ethyl, Y is COZ-, R5 is 4-((2,6-dichlorophenyl)methoxy]phenyl and stereochemistry is (S, S)).
S- H OI' ~N~N~Oi ~N~'O~O ~ ~ CI
CI
The title compound was prepared by a modification of i:he literature procedure of Ghosh, A.K.; Duong, T.T.; McKee, S.P.; Thompson, W.J. Tetrahedron Lett. 1992, 33, 2781. To a solution of 1-(2-hydroxyethyl)piperidine (S.I1 g, 39.6 rnmol) in CH3CN (220 rnL) at ambient temperature was added N,N-disuccinimidyl carbonate (10.13 g, 39.6 mmol) and triethylamine (16.6 mL, I I8.8 mmol). The solution was stirred at room temperature for 4 1 S h and concentrated in vacuo to give a viscous oil. The oil was dissolved in a minimal amount of methylene chloride (SO mL) and added to a solution of A-b (Scheme A, where RA_, and RA_2 are the same and equal to H, RS is 4-[(2,6-~dichlorophenyl)methoxy]phenyl and stereochemistry is (S, S)) (2.0 g, 3.96 rnmol), trieth~ylamine (0.60 mL) and DMAP (S
mg) in CHZCIZ (10 mL). The solution was stirred overnight and an additional S
equivalents of carbonate in methylene chloride (10 mL) [prepared as described above from N,N-disuccinimidyl carbonate (S.6 g, 19.8 mmol), triethylamine (8.3 mL, 59.4 mmol), and I-(2-hydroxyethyl)piperidine (2.56 g, I9.8 mmol)] were aldded . After 3 h at room temperature, propylamine (30 mL, 0.71 mol) was slowly added (exothermic) and the solution diluted with CHZCIz. The resulting solution w~us stirred vigorously for IS min.
and diluted with water. The organic layer was separated and washed with 0.1 M
HCI, sat.
aqueous NaHC03, dried (MgS04), filtered and concentrated in vacuo.
Purification of the residue by flash chromatography using ethyl acetate/meahylene chloride (3:1 ) as eluant followed by trituration in hexanes afforded the title compound ( 1.54 g, 62%) as an white powder: IR (mull) 1745, 1704, 1660, 1553, 1512, 1435;, 1425, 1397, 1303, L245, 1227, 1212, I 173, 1019, 765 cm -';'H NMR (300 MHz, DMS~D-db) 8 8.42 (I H), 7.54 (2 H), 7.44 (1 H), 7.13 (2 H}, 6.94 {2 H), 5.17 (2 H), 4.59 (2 H}, 4.48 (I H), 4.26 (1 H), 4.02 {2 H), 3.63 (3 H), 3.19 {2 H), 3.19 (I H), 2.82 (3 H), 2.35 (4 H), 1.36 (6 H);
'3C NMR (75 MHz, DMSO-db) 8 172.2; 170.0, 157.7, 153.9, 136.5, 132.2, 132.0, 130.8, 130.1, 129.2, 114.8, 65.3, 63.6, 57.3, 54.6, 53.9, 52.4, 36.4, 26.0, 24.3; MS (ESl+) for Cz9H35CI2N3O6S
m/z 623.9 (M+H}+; Anal. Calcd for C2gH35C12N3O6S: C, :55.77; H; 5.65; N, 6.73.
Found: C, 55.48;H,5.73;N,6.9I.
Preparation 9 and Example 6.
4-[(2,6-Dichlorobenzoyl)amino]-N-[[{4S)--3-[({ 1,1-d.imethylethyl)amino)carbonyl]-4 thiazolidinyl]carbonyl]-1.-phenylalanline methyl ester (Scheme A, A-7: where RA_, and RA_2 are the same and equal to H, R3 is t-butyl, Y is CONH-, RS is 4-[(2,6-dichlorobenzoyl)amino]phenyl and stereochemistry is (S, S)).
S-. H O
~~~ N ~Oi O O ' ~ ~ CI
N
H
CI ~
To a cooled (0-5°C ) solution of A-6 (Scheme A, where RA_, and RA.2 are the same and equal to H, RS is 4-[(2,6-dichlorobenzoyl)amino]phenyl and stereochemistry is (S, S)) (140 mg, 0.27 mmoI) in anhydrous THF (6 mL) was added tent-butyl isocyanate (0.62 mL, 5.4 mmol} followed by 4-dimethylaminopyridine {5 mg, 0.04 mmol). After 0.5 h at 0-5°C, the ice bath was removed and the solution stirred at ambienl: temperature for 16 h. Additional tent-butyl isocyanate (0.62 mL, 5.4 mmol} was added and the solution warmed to 50°C for 4 h. The reaction mixture was cooled to room temperature and diluted with ethyl acetate and 0.25 N HCI. The layers separated and the organic layer washed with sat.
aqueous NaHC03, brine, dried (MgS04), filtered and concentrated in vacuo. Purification of the residue by flash chromatography using ethyl acetate/mel:hylene chloride (1:1:1) and isopropanol (0.1%) as eluant afforded the title compound) {150 mg) as an amorphous powder: 'H NMR (300 MHz, CDC13) 8 7.93 (1 H), 7.54 (2 H}, 7.26 (4 ~I), 7.09 (2 H}, 4.74 (2 H), 4.66 (1 H), 4.41 (1 H), 4.23 (I H), 3.70 (3 H); 3.28 (1 H), 3.09 (3 H), 1.31 (9 H);
'3C NMR (75 MHz, CDCl3) S 171.4, 170.6, 162.4, 155.5,; 136.3, 135.9, 132.5, 132.3, 130.8, 129.9, 128.1, 120.6, 62.7, 53.2, 52.4, 51.5, 49.0, 37.0, 32.9, 29.2; MS
(ESI+) for Cz6H3oCI2N4OsS mlZ 581.0 (M+H}+, 603.0 (M+Na)'; MS (FAB) mlz (rel. intensity) {MH+, 23), 482 (SO), 97 (36}, 88 (36}, 83 (4S), 69 {99), 57 (81), 55 {79), 43 (SO), 43 (69), 41 (50). HRMS (FAB) calcd for CZ6H3oCLzN4O5S +H1 581.1392, found 581.1376.
Preparation 10 and Example 7.
4-[(2,fi-Dichlorobenzoyl)amino]-N-[[(453-[(<iiethylamino)carbonyl]-4-thiazolidinyl]carbonyl]-t,-phenylalaniine methyl ester {Scheme A, A-7: where RA_, and RA_2 are the same and equal to H, R; is ethyl, Y is CON(CHZCH3)-, RS is 4-[(2,6-dichlorobenzoyl)amino]phenyl and stereochemistry is (S, S-. H O'I
~NI~N~Oi ~N~O O l ~ O CI
J ~N
H ~~
CI
The title compound was prepared by a modification of the literature procedure of Majer, P.; Randad, R.S. J. Org. Chem. 1994, S9, 1937. A cooled (0-5°C ) solution of A-6 (Scheme A, where RA_, and RA_2 are the same and equal to H, RS is 4-[{2,6-dichlorobenzoyl)arnino]phenyl and stereochemistry is (S, S)) (200 mg, 0.39 mrnol} and triethylamine (56 p,L, 0.40 mmoI) in anhydrous methylene chloride (10 mL) was added to triphosgene (47 mg; 0. i 6 mmol) followed by additional t:riethylarnine (56 P,L, 0.40 mmol).
After 0.5 h at 0-5°C , the ice bath was removed and the solution stirred at ambient temperature for 2 h. The solution was re-cooled (0-5°C ;E and diethylamine (1.20 mL, 11.70 mmol} and 4-dimethylarninopyridine {S mg, 0.04 mmol} were added. After 0.5 h at 0-S°C , the ice bath was removed and the solution stirred at ambient temperature for 16 h.

WO 99167230 PCTlUS99/14233 The solution was concentrated in vacuo and the residue ;partitioned between ethyl acetate and 0.25 N HCI. The layers were separated and the orgamic layer washed with sat.
aqueous NaHC03, brine, dried (MgS04), filtered and co~;~centrated in vacuo.
Purif cation of the residue by flash chromatography using ethyl acetate/methylene chloride/hexane (1:1:1) and isopropanol (0.1%) as eluant afforded the tithe compound (200 mg) as an amorphous solid: 'H NMR (300 MHz, CDC13} 8 7.86 (1 H), 7.55 (2 H), 7.30 (3 H), 7.03 (2 H), 6.90 (1 H), 5.09 (1 H), 4.83 (1 H), 4.33 (2 H), 3.76 (3 H}, 3.34 (3 H), 3.1 I (5 H), 1.08 {6 H);'3C NMR (CDCl3) 8 171.1, 169.6, 162.3, 162.2, 136.5, 135.9, 132.3, 132.1, 130.9, 129.9, 128.1, 120.3, 64.7, 53.4, 52.7, 52.5, 42.0, :37.0; 32.4, 13.1;
MS (ESI+) for IO CZ6H,°N4OSS m/z 580.9 (M+I-i)+; ~IR1VIS (EI) calcd for C:Z6H3oCL2NøOSS 580.1314, found 580.1297. Anal. Calcd for CZ6H3°C12N4O5S: C, 53.70; H, 5.20; N, 9.63.
Found: C. 53.63;
H, 5.33; N, 9.36.
Preparation 11 and Examl>le 8.
[S-{R*,R*)j~1-[[[ 1-[[4-[(2,6-dichlorobenzoyl)aminajphenyljmethylj-2-methoxy-2-I5 oxoethylJaminojcarbonyl]-y-oxo-3-thiazolidinebutanoic acid 3-methyl ester (Scheme A, A-7: where RA_, and RA.2 are the same and equal to H; R3 is GHZCHZCOzCH3, Y is CO, RS is 4-[(2,6-dichlorobenzoyl}aminojphenyl, and stereochemistry is (S,S)).
S-. H O
N N O~
°~o ° I ~ p ci H I ~
CII
To a cooled (0-5°C ) solution of A-6 (Scheme A, where RA_, and RA_Z are the same and equal to H, RS is 4-[(2,6-dichlorobenzoyl)aminoj phenyl and stereochemistry is (S, S)) (1.03 g, 1.72 mmol) in anhydrous CHZCIz (25 mL) was added triethylamine (460 p,L, 3.27 mmol) followed by methyl succinyl chloride (320 ~L, 2,.5$ mmol). After 1 h at 0-5°C, the ice bath was removed and the solution stirred at ambient temperature for 2 h then diluted with 1 N HCI. The organic layer was separated, washed with sat.
aqueous NaHC03, brine, dried (Na2S04), filtered and concentrated in vacuo.
Crystallization of the w0 99/67230 PCT/US99I14233 yellow solid from ethanol/water provided the title compound (824 mg) as a light yellow solid: mp 221-223 °C; IR (mull) 3275, 1748, 1731, 1687, 1626, 1610, 156I, 1542, 1517, 1430, 1416, 1326 , 1268, 1224, I 193 cm'; 'H NMR (DMSO-db) S 10.64 (1 H), 8.59 (I H), 8:24 (1 H}, 7.50 (5 H), 7.16 (2 H), 4.75 (2 H), 4.51 (2 H;I, 4.23 (1 H); 3.63 (3 H), 3.56 (3 H), 2.87 (5 H); "C NMR (DMSO-db) 8 172.9, 171.6, 169.9, 169.5, 161.9, 137.2, 136.5, 133.0, 132.8, 13I.3, 129.8, 128.3, 119.4, 61.6, 53.6, 52.11, 51.4, 48.6, 36.4, 35.7, 35.2, 33.1, 29.0, 28.9, 28.5; MS (ESI+) for CZ6Hz7C12N307S m,~z 596.0 (M+H}+; MS
(ESI-) for CZ6Hz7C12N3O7S mlZ 593.9 (M-H)'; Anal. Calcd for CZbHz7C1zN3O7S: C, 52.35; H, 4.5d; N, 7.04. Found: C, 52.1 I; H, 4.47; N, 6.96.
Preparation 12 and Example 9.
[S-(R*,R*)j-~--[[[ 1-Carboxy-2-[4-[(2,Ei-dichlorobenzoyl) aminojphenyljethyljaminojcarbonylj-y-oxa-3-thiazolidinebutanoic acid (Scheme A, A-8: where RA_, and R"_2 are the same and equal to H, R3 is CHzCH2COZCOZH, Y is CO, RS is 4-[(2,6-dichiorobenzo~yl)amino)phenyl, and I S stereochemistry is (S,S)).
S, H O
~N~ N ~OH
HO~a IO! I ~ O~ CI
O
H I /
CI
To a cooled (0-5°C ) solution of A-7 (Scheme A where RA_, and RA_z are the same and equal to H, R3 is CHZCHzCOZCH3, Y is CO, RS is 4-[{2,6~-dichlorobenzoyl)aminojphenyl, and stereochemistry is (S,S)) (130 mg, 0.22 mmol) in anhydrous THF (5 mL) and MeOH
( 1 mL) was added an aqueous (2 mL) solution of lithium hydroxide monohydrate {23 mg, 0.55 mmol) via a syringe pump over I h. After an additional 1 h at 0-5°C, the ice bath was removed and the solution stirred 2 h at ambient temperature. The reaction mixture was diluted with ethyl acetate and 0.1 N HCl and the organic layer was separated, washed with water, dried (Na2S04), filtered and concentrated in vacuc~. Lyophilization of the residue from glacial acetic acid afforded the title compound (101. mg) as a white amorphous powder: ~'H NMR (CD3CN) 8 8.87 (1 H), 7.SS (2 H), 7.~E2 (3 H), 7.22 {2 H), 7.I6 (1 H), 4.95 (1 H), 4.52 (3 H), 3.12 (S H), 2.SS (S H);'3C NMR (CD3CN} 8 173.8, 171.7, 171.1, 169.8, 162.5, I36.7, 136.0, 133.5, 131.7, I31.3, 130.1, 129.2, 128.2, 119.7, 62.4, 53.6, 48.8, 36.2, 32.4, 29:1, 28.6; MS (ESI-) for Cz4Hz3C12N30~,S m/z 566.1 (M-H)';
Anal. Calcd S for C24HZSCIaN3O7S: C, 50.31; H, 4.13; N, 7.33. Found: C, 50.13; H, 4.3?; N, 6.93.
Preparation 13 and Example I0.
[S-(R*,R*)]-4-[[[1-Carboxy-2-[4-[(2,6-dichlorobenzoyl)amino]-phenyl)ethyl]aminoJcarbonyl]-3-thiazolidinecarboxylic; acid 3-(1,1-dimethylethyl) ester (Scheme A, A-9: where RA_, and RA_2 are the same and equal to H, R3 is t-butyl, Y is COZ-, RS is 4-[(2,6-dichlorobenzoyl)amino]phenyl, and stereochemistry is (S,S)).
/S-. H O
~~~N~OH
O.~O O ' ~ O CI
H~I ~
CI
To a cooled (0-S°C ) of A-5 (Scheme A where RA., and RA_Z are the same and equal to H, 1S R3 is t-butyl, Y is C02-, RS is 4-[(2,6-dichlorobenzoyl)amino]phenyl, and stereochemistry is (S,S)) (1 SO mg, 0.26 mmol) in anhydrous THF (S mL;l and MeOH (I mL) was added an aqueous (2 mL) solution of lithium hydroxide monohydrate (14 mg, 0.325 mmol) via syringe pump over I h. After an additional i h at 0-S°C , the ice bath was removed and the solution stirred 2 h at ambient temperature. The reaction mixture was diluted with ethyl acetate and 0.1 N HCI, the organic layer separated .and washed with water, dried (Na2S04), filtered and concentrated in vacuo. Lyophilization of the residue from glacial acetic acid afforded the title compound (I42 mg) as an amorphous powder: IR
(mull) 3285, i 735, 1666, 1606, 1562, 1539, 1 S I6, 1432, 1413, 1394, 1326, 1259 , 12I9, 1195, i 161 cm'; 'H NMR (DMF-d7) S 10.71 (1 H), 8.36 (1 H), 7.91 (2 H}, 7.72 (3 H), 7.47 2S (2 H}, 4.88 (3 H), 4.51 (1 H), 3.40 (3 H), 3.22 (2 H), i.S7 (9 H);'3C NMR
(DMF-d7) 8 173.3, 163.1, 162.9, 162.7, 162.3, 154.0, 138.3, 137.5, 1:34.2, 132.3, 131.9, 130.6, 128.9, 120.0, 80.9, 63.1, S4.S, 49.9, 37.4, 28.3; MS {FAB) m/z (:rel. intensity) 568 (MH+, 23), 570 (14}-, 568 (23}, 471 (13), 470 ( 65), 469 (23), 468 (99), 466 (23), 175 {19}, 88 (17), 57 {42); HRMS (FAB) calcd for Cz5Hz7CIzN306S+H, 568.1075, found 568.1071; MS (ESI-) for CZSH27C12N3O6S m/Z 565.8 (M-H)-; Anal. Calcd for CZSH27C1zN3O6S ~ 0.26 HzO: C, 52.38; H, 4.84; N, 7.33. Found: C, 52.07; H, 5.12; N, 7..46; % Water (KF):
0.83.
Preparation 14 and Example i 1.
4-[(2,6-Dichlorobenzoyl)amino]-N-[[(4S}-4-thiazolidinyl]carbonyl]-1,-phenylalanine monohydrochloride salt (Scheme A, A-10: where RA_, and RA_2 are the same and equal to H, RS is 4-[(2,6-dichlorobenzoyl)aminojphenyl, and stereochemistry is (S ,S~).
/S-. H O
_OH
O
O GI
To a cooled (5-10°C ) solution of A-9 (Scheme A where RA_, and RA_Z are the same and equal to H, R3 is t-butyl, Y is COZ-, RS is 4-[(2,6-dichlorobenzoyl)aminojphenyl, and stereochemistry is (S,S)) (193 mg, 0.34 mmol) in dioxane (2 mL) was added a solution of HCl in dioxane (4 M, 8 mL) in a dropwise manner over :30 min. After an additional 3.5 h at 0-5°C, the reaction mixture was concentrated in vacuo.
Lyophilization of the residue from water afforded the title compound {158 mg) as an amorphous powder: IR
(mull) 3248, 3191, 3048, 1731, 1664, 1605, 1577, 1562, 1541, 1516, 1431, 1414, 1327, 1195, 799 cm''; 'H NMR (DMF-d,) 8 9.11 (1 H), 7.76 (2 H), 7.60 (3 H), 7.:35 (2 H), 4.66 (2 H), 4.46 (2 H}, 3.55 (3 H), 3.24 (2 H}, 3.10 {2 H); '3C NMR (DMF-d7) 8 172.8, 167.6, 163.1, 162.9, 162.7, 162.3, 138.5, 137.5, 133.8, 132.3, 131.9, 1:30.6, 128.9, 120.0, 63.8, 54.8, 50.0, 37.3; MS (FAB) mlz (rel. intensity} 468 (MH+, 99), 544 (18), 528 (15), 472 (13), 471 ( 16), 470 (70), 469 (24), 468 (99), 175 (14), 173 (lfi), 88 (18); HRMS
(FAB) calcd for CZOH,9CIzN304S+H, 468.0551, found 468.0556.

Example 12.
(S-(R*,R*)]-4-((( I-Carboxy-=~>_[4-[(2,6-dichlorobenzoyl)amino]phenyl]ethyl]amino]carbonyl]~-3-thiazolidinecarboxylic acid 3-ethyl ester (Scheme A, A-8: where RA_, and RA.Z are the same and equal to H, R3 is ethyl, Y is COZ, RS
is 4-[(2,6-dichlorobenzoyl)amino]phenyl and stereochemistry is (S, S)).
,S-. H O'I
~NI~ N ~OH
~O~O O I ~ ~ CI
N
H i ~ /
CI
Example I2 was prepared from example 4 by the procedure described in preparation 6.
Physical properties as follows: mp 118-121 °C; [cc]ZSD = I06° (c 0.88, ethanol); IR (mull) 3283, 3196, 1665, 1606, 1561, 1539, 1516, 1431, 1414, 1345, 1327, ~ 271, 1219, I 195, 799 crri';'H NMR (300 MHz, CD30D) 8 7.59 (2 H), 7.44 {3 H), 7.22 (2 H), 4.69 (1 H), 4.64 (1 H), 4.41 (1 H); 3.24 (3 H), 2.95 (2 H), 1.26 (3 H);'3C NMR (75 MHz, CDCl3) 8 172.4, 17I .5, i 63.0, 154.8, 136.7, 136.6, 132.4, I32.1, 1130.6, 129.9, 127.9, 120.3, 63.0, 62.7, 53.1; 36.7, 14.3; MS {FAB) mlz (rel. intensity) 540 (MH+, 59}, 544 {12), 543 {17), 542 (53), 540 (59), 160 (32), 123 (15); l I8 (20), 107 (9'9), 95 (11), 23 (2I); HRMS (FAB) calcd for C,3H23CLZN306S +H, 540.0762, found 540.07:30. Anal. Calcd for C23H23C12N3O6"~: C, 51.12; H, 4.29; N, 7.78. Found: C, 50.77; H, 4.43; N, 7.68.
Example 13.
[R-(R*,S * )]-4-([( I-[[4-[(2,b-Dichlorobenzoyi)amino]phenyl]methyl]-2-methoxy-oxoethyi]amino]carbonyl]-3-thiazolidinecarboxylic acid 3-(l,l-dimethylethyl) ester (Scheme A, A-7: where RA_, and RA_z are the same and equal to H, R3 is t-butyl, Y is CO2, RS is 4-((2,6-dichlorobenzoyl)amino]phenyl and stereoc:hemistry is (R, S)}.

N N Oi O~
~~O C ' ~ ~ O CI
_N
H I ~

Example 13 was prepared as described in Scheme A fronn L-cysteine using di-t-butyl dicarbonate to form the requisite carbamate. Physical data as follows: IR
(mull) 1746, S 1666, 1606, 1562, 1538, 1 S 16, 1432, 1413, 1324, 1267, 1260, I2I6, 1195, 1162, 799 cm'';
'H NMR (CDCl3) 8 7.56 (2 H), 7.46 (1 H}, 7.33 (3 H), 7.13 (2 H), 6.94 (1 H), 4.75 (3 H), 4.25 (I H), 3.75 (3 H), 3.39 (I H), 3.14 (3 H), 1.43 (9 H);'3C NMR (DMSO-db} b 171.6, 171.5,170.7, 170.1, 161.7, 152.6, 137.0, 136.9, 136.2,1:32.6, 132.6, 131.2,131.0, 129.3, 128.1, 119.1, 79.7, 78.2, 61.5, 53.4, 53.3, 51.8, 49.3, 49.1, 35.8, 27.6; MS
(ESI+) for C26Hz9C12NsO6S mlz 604 (M+Na)*; MS (ESI-) for Cz6H29'C12N306S mlz 580 (M-H)-;
Anal.
Calcd for Cz6Hz9C12N3O6S ~ 0.17 HzO: C, 53.34; H, 5.05; N, 7. i 8. Found: C, 53.47; H, 5.14; N, 7. I S. % Water (KF): 0.51.
Example 14.
ER-tR* ~ S * )]-4-UL I-Carboxy-2._I~~(2~~
dichlorobenzoyl)amino]phenyl]ethyl]amino]carbonyl]-~3-thiazolidinecarboxylic acid 3-(1,1-dimethylethyl) ester (Scheme A, A-8: where RA., and R,,_Z are the same and equal to H, R3 is t-butyl, Y is COZ, R5 is 4 j{2,6-dichlorobenzoyl)amino]phenyl and stereochemistry is (R, f~).

-~I' H- ~
N N v 'OH
O''~
~O O ~ ~ ~ CI
~N
H ~
CI
Example 14 was prepared from example 13 by the procedure described in preparation 6.
Physical data as follows: IR (mull) 3285, 1665, 1607, 1562, 1538, 1516, 1432, 1413, 1394, 1327, 1259, 1217, 1195, 1162, 799 crri';'H NMR (DMSO-db) 8 12.70 (1 H); 10.67 (1 H), 8.14 (1 H), 7.51 (5 H), 7.20 (2 H); 4.56 (1 H), 4.35 (3 H), 2.98 (3 H), 1.22 {9 H);'3C NMR
(DMSO-db) 8 172.5, 170:1, 169.9, 161.6, 152.6, 136.9, 136.3, 133.0, 131.2, 131.0,129.4, 128.1, 119.1, 79.8, 79.7, 61.6, 53.4, 49.2, 48.3, 35.9, 27.6, 20.9; HRMS (FAB) calcd for CZSH27C12N3O6S+H, 568.1075, found 568.1058; MS (ESI+) for CzSHz,C12N3O6S m/z 567.8 (M+H)+; MS (ESI-) for CZSH27C12N3O6S m/Z 565.8 (M-H)'; Anal. Calcd for ~ 0.24 H20: C, 52.43; H, 4.84; N, 7.34. Found: C, 52.23; H, 4.76; N, 7.24. %
Water (KF):
0.75.
Example 15.
[R-(R*,S*)]~4-[[[1-[[4-[(2,6-Dichlorobenzoyl)amino]phenyl]methyl]-2-methoxy-2-oxoethyl]amino]carbonyl]-3-thiazolidinecarboxylic acid 3-ethyl ester (Scheme A, A-7: where RA_, and RA_2 are the same and equal to H, R3 is ethyl, Y is COz, R5 is 4-[(2,6-dichlorobenzoyl)amino]phenyl and stereochennistry is (R, f)).

N~N~Oi ~ ~O C I ~ ~ CI
'N
Ci Example 15 was prepared as described in Scheme A from L-cysteine using ethyl chloroformate to form the requisite carbamate. Physical data as follows: IR
(mull) 1744, 1666, 1606, 1561, 1538, 1515, 1445, 1431, 1414, 1345, 1325; 1270, 1216, 1194, 1184 cm '; 'H NMR (CDC13) 8 7.55 (2 H), 7.36 {4 H), 7.13 (2 H), 6.95 (1 H), 4.74 (3 H), 4.21 (3 H), 3.75 {3 H), 3.40 (1 H), 3.13 (3 H), 1.26 (3 H); '3C N:MR (CDCl3) 8 171.2, 169.4, 162.3, 136.2, 135.8, 132.4, 132.2, 131.0, 130.3, 130.1, 129.9, 128.2, 128.0, 127.9, 120.2, 62.9, 62.7, 53.2, 52.5, 37.1, 14.5, 14.3; MS (ESI+) for C24H25(..12N3O6S m/z 553.8 (M+H)+; MS
(ESI-) for Cz4H25C12N3~6S ~Z 551.8 {M-H)'; Anal. Calcd for C24H2sC1zN3O6S ~
0.24 H20:
C, 51.59; H, 4.60; N, 7.52. Found: C, 51.89; H, 4.62; N, 7.51. % Water (KF):
0.77.

Example 16.
[R-(R*~S*)]-4-j[L1-Carboxy-2._jq_[(2~6 dichlorobenzoyl)amino]phenyl]ethyl]amino]carbonyl]-3-thiazolidinecarboxylic acid 3 ethyl ester (Scheme A, A-8: where RA_, and RA_2 are the same and equal to H, R3 is ethyl, Y is CO2, RS
is 4-[(2,6-dichlorobenzoyl)amino]phenyl and stereocherra<istry is (R, S}).
S H O
y _OH
~O~O O I ~ O CI

C /'I
1 fl Example 16 was prepared from example 15 by the procedure described in preparation 6.
Physical data as follows: IR {mull) 3287, 1664, 1606, 1561, 1539, 1516, 1445, 1431, 1414, 1346, 1327, 1271, 1217, 1195, 799 crri'; 'H NMR (DMSO-db) 8 12.80 (1 H), 10.69 (1 H), 8.26 (1 H}, 7.51 (5 H), 7.19 {2 H), 4.62 (2 H), 4.37 (2 H), 3.94 (2 H), 2.96 (3 H}, 1.11 {3 H); "C NMR {DMSO-db) 8 i 72.5, 169.6, 161.7, 153.5, 136.9, 136.3, 133.0, 13I.2, 131.0, 129.5, 128.1, 119.1, 61.2, 53.4, 52.5, 35.9, 22.3, 14.3; MS (ESI+) for C23H23C12N3O6S YYllZ 540.0 (M+H)+; MS (ESI-) for Cz3Hz.'C1zN306S mlz 538.0 (M-H)-;
HRMS (FAB) calcd for C23H~3C12N3ObS+HI 540.0762, found 540.0775; Anal. Calcd far C23H23C12N3O6S ~ 0.34 H20: C, 50.54; H, 4.37; N, 7.69. Found: C, 50.53; H, 4.48; N, 7.59.
Water {KF): 1.13.
z0 Example 17.
jR-(R*,S*)]-4-[jj 1-[[4-j{2,6--Dichlorobenzoyl}amino]phenyl]methyl]-2-methoxy-oxoethyl]amino]carbonyl]-5,5-dimethyl-3-thiazolidinecarboxylic acid 3--(l,I
dimethylethyl) ester (Scheme A, A-7: where RA_1 and RA_z are the same and equal to CH3, R3 is t-butyl, Y is CO2, RS is 4-[(2,6-dichlorobenzoyl)amino]phenyl and ste;reochemistry is (R, ,S~).

<s o N~pi O'''~
~O O I ~ ~ CI
~ w ti CI
Example 17 was prepared as described in Scheme A from L-penicillamine using di-t-butyl dicarbonate to form the requisite carbamate. Physical data as follows: IR
(mull) 1747, 1666, 1606, 1562, 1537, 1516, 1432, 1413, 1324, 1268, 1259, 1213, 1195, l 161, 1142 cm' ';'H NMR (CDCl3) 8 7.56 (2 H), 7.34 {4 H), 7.21 (2 H), 6.44 (1 H), 4.94 (1 H), 4.60 (2 H), 4.08 (1 H), 3.70 (3 H), 3.10 (2 H), 1.53 (3 H), 1.42 (9 H:), 1.25 (3 H);'3C
NMR (CDCI,) 8 171.4, 162.3, 136.3, 135.8, 132.6, 132.4, 131.0, 130.2, 130.0, 128.2, 120.5, 120.3, 120.2, 72.7, 63.9, 60.4, 52.9, 52.3, 48.3, 38.0, 30.3; 28.1, 23.9, 21.0, 14.2; MS
(ESI+) for CZ$H33C12N3O6S m/z 630.7 (M+Na)+; Anal. Calcd for CZ8H33CIZN3O6S ~ 0.13 HzO:
C, 54.87; H, 5.47; N, 6.86. Found: C, 54.54; H, 5.55; N, 6.54. % Water (KF):
0.38.
Example 18.
[S--(R*,R*)]-4-[[[1-[[4-[(2,6-Dichiorobenzoyl)amino]phenyl]methyl]-2-methoxy-2-oxoethylJamino]carbonyl]-3 thiazolidinecarboxylic acid 3-[(9H-fluoren-1-yl)methyl]
ester (Scheme A, A-7: where RA_, and RA_2 are the same and equal to H, R, is 9-fluorenylmethyl, Y is CO2, RS is 4-[(2,6-dichlorobenzoyl)amino]phenyl and stereochemistry is (S, S)).
S- : H O
_ CN~N~Oi / O~O ~O ~ ~ O CI
~r~ w Ea I /
cl Example 18 was prepared as described in Scheme A from D-cysteine using 9-fluorenylmethyl chloroformate to form the requisite carlbamate. Physical data as follows:
IR {mull) 3280, 1750, 1692, 1671, 1604, 1560, 1538, 1515, 1441, 1430, 1422, 1346, 1320, 1222, 1118 cm'';'H NMR (DMSO-db) 8 8.59 (1 H), 7.87 (2 H), 7.49 (12 H), 4.65 (3 H), 4.26 (4 H), 3.52 (3 H), 2.96 (3 H); t3C NMR (DMSO-db) b 171.4, 161.8, 143.5, 140.6, 137.0, 136.3, 132.5, 131.2,131.1, 129.5, 128.1, 12;7.6, 127.1, 125.2, 125.1, 120.0, 119.2, 70.6, 70.0, 63.8, 63.2, 53.3, 53.1, 46.4, 36.2, 25.4; MS (ESI+} for C36H3,C12N3O6S
m/z 703.9 (M+H)+; Anal. Calcd for C36H3,C12N3O6S ~ O.I HZO: C,,6I.23; H, 4.:45; N, 5.95.
Found: C, 61.18; H, 4.56; N, 5.89. % Water (KF): 0.22.
Example 19.
[S-(R*,R*)]-4-[[[ I-Carboxy-2--[4-[(2,6-dichlorobenzoyl)amino]phenyl]ethyl]arrZino]carbonyl]-:3-thiazolidinecarboxylic acid 3-[(9H-fluoren-I-yl)methyl] ester (Scheme A, A-8: where RA_, and RA_2 are the same and equal to H, R3 is 9-fluorenylmethyl, Y is CO2, RS is 4-[(2,6-dichlorobenzoyl)amino]phenyl arnd stereochemistry is (S, S)).PNU-/S-.. H O
~N~N~OH
/ O~O O I ~ ~J CI
~N~
H
Gt Example 19 was prepared from example I 8 by the procedure described in preparation 6.
Physical data as follows: IR {mull) 1672, 1606, 1561, 1533, 1517, 1431, 1413, 1347, 1324; 1269, 1218, 1195, 1 i 16, 760, 742 cm'';'H NMR (:DMSO-db) 8 10.71 (1 H), 8.32 (1 H), 7.87 (2 H), 7.47 (13 H), 7.16 (2 H), 4.62 (2 H), 4.15 (5 H), 2.90 (4 H); '3C NMR
(DMSO-d6} S 172.4, 169.2, i 61.8, 143.6, 140.6, 137.0, 136.3, I33.0, 131.3, 131.1, 129.7, 129.6. 128.9, 128.2, 127.7, 127.1, 126.8, 125.2, 121.3, 12O.I, 120.0, 119.2, 53.4, 48.4, 46.4, 36.4, 29.5; 20.0; MS (ESI+) for C35H29CIZN3O6S mlz 690.1 (M+H)+; Anal.
Calcd for C35H29CIZN3O6S ~ 0.4 H20: C, 60.25; H, 4.30; N, 6.02. Found: C, 59.88; H, 4.47; N, 5.75.
Water (KF): 1.02.
Example 20.
[S--(R*,R*)]-4-[[[1-[[4-[(2,6-Dichlorobenzoyl)amino~~phenyl]methyl]-2-methoxy-oxoethyl]amino]carbonyl]-3-thiazolidinecarboxylin acid 3-phenylmethyl ester (Scheme A, A-7: where RA_, and RA_2 are the same and adual to H, R3 is phenylmethyl, Y is CO2, RS is 4-[(2,6-dichlorobenz°yl)amino]phenyl and ste;reochemistry is (S, S)).
s-. w o CN~ N~°i O~O l° ~ % ~> CI
N W
H
CI
Example 20 was prepared as described in Scheme A from D-cysteine using benzyl chloroformate to form the requisite carbamate. Physical data as follows: IR
(mull) 1748, 1694, 1690, 1673, 1610, 1561, iS42, 1517, 1441, 1430, 1408, 1355, 1324, 1269, 1217 cm -'; 1H NMR (CDCl3) 8 7.50 (2 H), 7.33 (9 H), 7.09 (2 H), 6.75 (1 H), S.I9 (2 H), 4.78 (3 H), 4.38 (3 H), 3.73 (3 H), 3.20 (3 H);'3C NMR (DMSO-db) 8 171.4, 162.3, 136.3, 135.9, 135.7, 132.5, 132.4, 131.0, 130.0, 128.7, 128.4, 128.2, 128.1, 120.4, 68.2, 63.3, 53.2, S2.S, 37.2; MS (ESI+) for CZ9H27CIzN3O6S mlz 637.8 (M+Na)+; MS (ESI-) for CZ9Hz7CI,N306S m/z 613.8 (M-H)'; Anal. Calcd for C29Hz7C12N3O6S ~ 0.1 H20: C, 56.39; H, 4.43; N, 6.80. Found: C, 56.31; H; 4.67; N, 6.71. % Water (KF): 0.19.
1 S Example 21.
[S--(R*,R*)]-4-[[[1-Carboxy-2-[4-[(2,6-dichlorobenzoyl)amino]phenyl]ethyl]amino]carbonyl]--3-thiazolidinecarboxylic acid 3-phenylmethyl ester (Scheme A, A-8: where RA_, and RA_z are the same and equal to H, R3 is phenylmethyl, Y is COZ, RS is 4-[(2;6-dichlorobenzoyi)amino phenyl and st<~reochemistry is (S, S)).
s-. H_ o N~OH
0 0 ° ( % p cl n cl Example 2I was prepared from example 20 by the procedure described in preparation 6.
Physical data as follows: IR (mull) 3290, 3034, 1666, 1606, 1562, 1537, 1516, 1431, 1413, 1351, 1326, 1270, 1215, 1195, 799 ciri';'H NMR (DMSO-d6) & 12.85 (1 H), 10.65 ( 1 H), 7.39 { 10 H), 7.18 (2 H), 4.98 (2 H), 4.65 (2 H), 4.5 5 ( 1 H), 4.33 ( 1 H), 3.06 ( I H), 2.83 {2 H); '3C NMR (CD30D) 8 172.6, 163.7, 154.4, 13.6:8, 136.2, 136.1, 131.9, 130.9, 129.6, 128.1, 127.9, 127.8, 127.7, 127.6, 120.0, 67.5, 66.7, 53.4, 36.5; MS
(ESI-) for Cz8H25C12N3O6S mlz 599.7 (M-H)'; MS (FAB) mlz (rel. intensity) 602 (MH+, 99), (37), 604 {74), 603 (33), 602 ( 99), 560 (32), 558 (48), 468 (35),466 (51), 371 (50); 91 (73); HRMS (FAB) calcd for CZgHz5C12N306S+H' 602.0'x19, found 602.0913; Anal.
Calcd for CZBHZSCI,N3O6S ~ 0.23 H20: C, 55.45; H, 4.23; N, 6.x)3. Found: C, SS.S3;
H, 4.46; N, 6.88. % Water {KF): 0.67.
Example 22.
[S-{R*,R*)]-4-[[[I-[[4-[{2,6-Dichlorobenzoyl)amino]phenyl]methyl]-2-methoxy-2-oxoethyl]amino]carbonyl]-3-thiazoIidinecarboxylic acid 3-{tricyclo[3.3.1.13~7]dec-1-yl) ester (Scheme A, A-7: where RA_, and RA_2 are the same and equal to H, R3 is 1-adamantyl, Y is CO2, RS is 4-[(2,6-dichlorabenzoyl)amino]phenyl and st~ereochemistry is (S, S)).
S-. H O
CN~N~Oi ~p~p ~O1 I ~ CJ CI
~N~
H I
GI
Example 22 was prepared as described in Scheme A froam D-cysteine using I-adamantyl fluoroformate to form the requisite carbamate. Physical data as follows: IR
(mull) 3284, 3271, 1747, 1690, 1684, 1666, 1557, 1532, 1436, 1412, 1355, 1298, 1194, 1053, 799 crri ';
'H NMR (DMSO-db) b 10.67 {1 H), 8.41 {1 H}, 7.53 (5 :H), 7.1? (2 H), 4.51 (3 H), 4.23 ( I H), 3.63 (3 H}, 3.22 { 1 H}, 3.04 ( I H), 2.90 { 1 H), 2.75 ( 1 H), 2.01 (9 H), 1.56 (6 H);
'3C NMR (DMSO-db) 8 172.1, 162.3, 152.7, I37.b, 136.9, 133.2, I31.8, 131.6, 130.0, 128.7, 119.8, 53.8, 52.4, 36.7, 36.1, 30.6; MS (ESI+) fo:r C32H35C12N3~6'S ~Z
659.7 (M+H)+;~MS (ESI-) for C32H35C12N3~6's ~Z 657.7 (M-H;I'; MS (FAB) m/z (rel.
intensity) 660 (MH+, 8), d62 (5), 660 (8), 618 (6), 616 (8), 480 (5;1, 173 (7), I36 {11), 135 (99); 123 (14), 93 (8); Anal. Calcd for CgZH35C12N3O6S ~ 0.04 HZO: C, 58.12; H, 5.35; N, 6.35..
Found: C, 58.19; H, 5.62; N, 6.25. % Water (KF): 0.10.
Example 23.
[S-(R*,R*)J-4-[[[ 1-Carboxy-2--[4--[(2,b-dichlorobenzoyl)amino]phenyl]ethyl]amino]carbonyl]-3 thiazolidinecarboxylic acid 3 (tricyclo[3.3.1.137]dec-1-yll) ester (Scheme A, A-8: where RA_, and RA_Z are the same and equal to H, R3 is 1-adamantyl, Y is CO2, RS is 4-[(2,6-dichlorobenzoyl)amino]phenyl and ste:reochemistry is (S, S)).
S-. H O
~~~N~OH
~O O O ! ~ O'i C1 ~N~
H 1 ~
Ci' Example 23 was prepared from example 22 by the procedure described in preparation 6.
Physical data as follows: IR (mull) 3287, 1667, 1606, 1562, 1537, 1516, 1431, 1412, 1353, 1326, 1299, 1274, 1220, 1194, 1049 cm ';'H NMR (DMSO-db) 8 12.70 {1 H), 10.67 (1 H), 8.21 (1 H), 7.58 (5 H), 7.17 (2 H), 4.51 {3 I=t), 4.22 (1 H), 3.20 (1 H), 3.04 (1 H}, 2.88 (1 H}, 2.76 (1 H), 2.07 (9 H), 1.12 (6 H);'3C NMR (DMSO-db} 8 173.1, 162.3, 152.7, 137.5, 136.9, 133.8, 131.8, 131.6, 130.1, 128.7, 119.7, 80.0, 53.8, 36.8, 36.1, 30.6;
MS (ESI+) for C3,H33C12N3O6S m/Z 645.8 (M+H)'; HRIVIS (FAB) calcd for C3,H3,C12N~O6S+H~ 646.1545, found 646.1564; Anal. C;~lcd for C3'H33C12N3ObS ~
0.29 H20: C, 57.13; H, 5.19; N, 6.45. Found: C, 56.82; H, 5.21; N, 6.32. % Water {KF): 0.80.
Example 24.
[S-(R*,R*)]~--[[[1-[[4-[(2,6-Dichlorobenzoyi)amino]phenylJmethyl]-2-methoxy-2-oxoethyi]amino]carbonyl]-3-thiazalidinecarboxylic acid 3-[2--(4-morpholinyl)ethyl]
ester (Scheme-A, A-7: where RA_, and RA_Z are the same and equal to H, R3 is 2-(4-morpholinyl)ethyl, Y is COz-, RS is 4-[(2,6-dichlorobenzoyl)amino]phenyl and stereochemistry is (S, S)).
S-. O
~N~N~Oi ~N~'~Q~p 'O' I ~ O CI
H~ I /
Ca Example 24 was prepared as described in Scheme A from D-cysteine using 4-(2-hydroxyethyl)morpholine to form the requisite carbamat<:. Physical data as follows: IR
(mull) 1745, 1705, 1679, 1605, 1536, 1515, 1431, 1414, 1344, 1323, 1269, 1216, 1194, 1183, 1117 cm' 1H NMR (300 MHz, CDCl3} 8 7.82 (1 H}, 7.56 (2 H), 7.31 (3 H), 7.12 (2 H), 6.95 (1 H}, 4.65 (3 H), 4.39 (3 H), 3.74 (3 H), 3.69 {3 H), 3.34 (1 H), 3.18 (3 H), 2.763 (5 H); "C NMR (7S MHz, CDCl3} $ 171.5, 169.8, 162.9, 154.4, 136.8, 136.1, 132.1, 130.6, 129.7, 127.9, 120.2, 66.3, 62.7, 57.0, 53.4, 53.2, 52.4, 36.7, 29.5; MS {ESI-) for CZ8H32C1zN4O7S mlZ 636.8 {M-H}'; HRMS (FAB) calcd for CZ$H3zCLZN407S +H' 639.1447, found 639.1419. Anal. Calcd for CZ8H32CI,N4O7S: C, 52.58; H, 5.04;
N, 8.76.
Found: C, 52.47; H, 5.17; N, 8.69.
Example 25.
[S-(R*,R* )]4-[[[ 1-Carboxy-2-[4-[{2,6-dichlorobenzoyl)amino]phenyljethyl]amino]carbonyl]-3-thiazolidinecarboxylic acid 3-[2-(4-morpholinyl)ethyI] ester (Scheme A, A-8: where R,~_, and RA_2 are the same and equal to H, R3 is 2-(4-morpholinyl)ethyl, Y is COZ-, Rs is 4-[(2,6-dichiorobenzoyl)amino]phenyl and stereochemistry is (S, S)}.

O
O~ ~N~N~OH
~N~O~° O I ~ p Ci H
~G
Example 2S was prepared from example 24 by the procedure described in preparation 6.
Physical data as follows: IR (mull) 3278, 1667, 1606, 1.562, 1541, 1515, 1431, 1413, 1351, 1326, 1270, 1195, 1 I34, 11 I8, 799 cni';'H NMR {300 MHz, DMSO-db) 8 10.64 ( I H), 8.25 ( 1 H), 7.50 (5 H), 7.16 (2 H), 4.60 (2 H), 4.44 ( 1 H}, 4.27 ( 1 H), 4.06 (2 H), 3.51 (4 H), 3.43 (2 H), 3.29 (4 H), 2.42 (4 H);'3C NMR (75 MHz, DMSO-d6) 8 173.0, 172.4, 169.8, 162.3, 137.5, 136.8, 133.5, 131.7, 130.1, 128.6, 119.7, 66.6, 63.3, 57.0, 53.7, 36.7, 21.5; MS (FAB) m/z (rel. intensity) 625 (MH+, 5:5), 629 (9), 628 (14), 627 (39), 626 (21}, 62S (SS), 308 (7}, 141 (19), I 14 (99), 113 (24), 100 (7); HRMS
(FAB) calcd for C27H3oCLZN407S +H, 625.1290, found 625.1309.
Example 26.
[S-{R*,S*)]-lt-[[[1-[[4-[(2,6-Dichlorobenzoyl)amino]phenyl]methyl]-2-methoxy 2-oxoethyi]aminojcarbonyl]-3-thiazolidinecarboxylic acid 3-{1,1-dimethylethyl) ester (Scheme A, A-7: where RA_, and RA_Z are the same and equal to H, R3 is t-butyl, Y is CO2, RS is 4-[(2,6-dichlorobenzoyl)amino]phenyl and stereochemistry is (S, R)).
s-. ~ o ~~~ N °/
0 0° ~ ~ o ct CI
Example 26 was prepared as described in Scheme A from D-cysteine using di-t-butyl dicarbonate to form the requisite carbamate. Physical data as follows: IR
(mull) 3293, 1746, 1666, 1606, 1562, 1538, 1516, 1432, 1413, 1324, 1260, 1216, I 195, 1162, 799 cm'';
'H NMR (CDCl3) 8 7.55 (2 H), 7.37 {4 H), 7.14 {2 H), 4.89 {1 H), 4.66 (2 H), 4.25 (I H), 3.75 (3 H), 3.39 (1 H), 3.24 (3 H), 1.44 (9 H); '3C NMR {CDCI3) 8 17I .2, 169.8, 162.3, 136.3, 135.8, 132.4, 132.3, 131.0; 130.2, 130.1, 129.9; 128.2, 128.1, 127.9, 120.5, 120.2, 120.1, 82.2, 53.2, 52.5, 37.3, 31.0, 28.4, 28.2; MS (ESI+~) for CZ6Hz9C1zN306S
mlZ 603.9 (M+Na)+; MS {ESI-) for CZ6Ha9C1zN30eS m/Z 580.0 (M-l~)'; HRMS (FAB) calcd for C26HZ9C12N3O6S+H~ 582.1232, found 582:/231. Anal. C'.alcd for CZ6HxgC12N3O6S ~
0.26 HZO: C, 53.18; H, 5.07; N; 7.16. Found: C, 52.78; H, 5.14; N, 6.91. % Water (KF): 0.66.
Example 27.
[s-{R*,s*)]-4-[[[1-c~rboxy-2-[4-[~2,6 dichlorobenzayl)amino]phenyl]ethyl]amino]carbonyl]--3-thiazolidinecarboxylic acid 3 {i,l-dirnethylethyl) ester (Scheme A, A-8: where RA_, and RA_z are the same and e~~ual to H, R, is t-butyl, Y is COZ, RS is 4-[(2,6-dichlorobenzoyl)amino]phenyl and stereochemistry is (S, R)).
H . O
OH
O OO I ~ O CI
H~I /
CI
Example 27 was prepared from example 26 by the procedure described in preparation 6.
Physical data as follows: IR (mull) 3286; 1665, 1606, 1562, 1538, 1516, /432, 1413, 1394, 1326, 1259, 1216, 1195, 1161, 799 cm''; 'H NMR (DMSO-db) 8 12.70 (I H), 10.63 (1 H), 8.13 (1 H), 7.51 (5 H), 7.20 (2 H), 4.45 (4 H), 2.915 (3 H), 1.23 {9 H);'3C NMR
(DMSO-db) 8 173.1,170.5, 162.3, 153.2, 137.5, 136.9, 13 / .8, 131.6,130.0, 128.7, 119.7, 80.4, 62.2, 54.0, 49.8, 36.5, 28.3, 21.5; MS (ESI+) for CZSH27C12N3O6S m/Z
567.9 (M+H)+;
MS (ESI-) for Cz5Hz7C12Ns06S m/z 565.9 (M-H)'; HRMS (EI) calcd for Cz5H27C1zN3O6S
567.0997, found 568.1096. Anal. Calcd for CZSHZ,C12N306S ~ 0.34 HzO: C, 52.82;
H, 4.79; N, 7.39. Found: C, 52.17; H, 4.90; N, 7.25. % Wz~ter (KF): 1.07.
Example 28.
jS-{R*,R*)]-4-[[[1-[[4-[(2,6-Dichlorobenzoyl)amino]phenyl]methyl]-2-rnethoxy-2-oxoethyl]amino]carbonyl]-5,5-dimethyl-3 thiazollidinecarboxylic acid 3-(1,1-dimethylethyl) ester (Scheme-A, A-7: where RA_, and RA_2 are the same and equal to CH3, R3 is t-butyl, Y is CO2, R5 is 4-[(2,6-dichlorobenzoyl)amino]phenyl and stE;reochemistry is (S, S)).
s-l- H o 0 0° ~ ~ o c~
H~I ~

Example 28 was prepared as described in Scheme A from D-penicillamine using di-t-butyl dicarbonate to form the requisite carbamate. Physical data as follows: IR
(mull) 1744, 1707, 1688, 1678, 1657, 1606, 1562, 1541, 1516, 1431, 1414, 1326, 1253,1161, 1140 crn ';'H NMR (CDC13) 8 7.58 (2 H), 7.36 (3 H), 7.14 (2 H), 6.55 (1 H}, 4.87 (I H), 4.56 (2 H), 4.10 (1 H), 3.72 (3 H), 3.08 (2 H), 1.53 (3 H), I.44 {9 H), 1.40 (3 H);'3C NMR
(CDCl3) 8 171.6, 162.3, 153.6, 136.4, 135.8, 132.6, 132.4, 131.0, 1:30.1, 129.9, 129.8, 128.2, 120.7, 120.5, 120.3, 8I.7, 73.0, 52.8, 52.6; 52.4, 48.4, 39.8, 39.5, 37.d, 30.3, 28.3, 28.0,23.5;
MS (ESI-) for CZ$H33C12N3O6S mlz 607.9 (M-H)'; MS (F.AB) mlz (rel. intensity) (MH+, 6), 512 (26), 510 (44), 117 (30), 1 L5 (1 6), 99 (16), 87 {16), 59 (99), 57 {27), 57 {20}, 41 (23); HRMS {FAB) calcd for CZ8H33C12N3O6S+H, 610.1545, found 610.1501;
Anal. Calcd for CZ8H33C12N3O6S ~ 0.07 HzO: C, 54.97; H., 5.46; N, 6.87. Found:
C, 54.92;
H, 5.54; N, 7.11. % Water (KF): 0.2I.
Example 29.
[S--(R*,R*)]-4-[[[1-Carboxy-2--[4-[(2,6-dichlorobenzoyl)amino]phenyl]ethyl]amino]carbonyl]-5,5-dimethyl-3-thiazolidinecarboxylic acid 3--(I,1-dirnethylethyl) ester (Scheme A, A-8: where RA_, and R~_2 are the same and equal to CH3, R3 is t-butyl, Y is CO2, RS is 4-[{2,6-dichlorobenzoyI)amino]phenyl and ste,reochemistry is (S, S}).

S~ H~ O
~N~N~OH
~O~O O ~ ~ O CI
H ~~
Ct Example 29 was prepared from example 28 by the procedure described in preparation 6.
Physical data as follows: IR {mull) 1739, 1666, 1606, 1.'i62, 1535, 1516, 1432, 14I3, S 1394, 1325, 1270, 1260, 1194, 1160, 799 czri';'H NMR (DMSO-db} 8 12.62 (I
H), 10.62 ( 1 H), 8.18 ( 1 H), 7.51 (S H), 7.19 (2 H), 4.50 (3 H), 4.24 ( 1 H), 2.91 (2 H), I .33 { 12 H), 1.04 (3 H); '3C NMR (DMSO-db) 8 172.8, 168.7, 161.9, 153.2, 137.2, 136.5, 133.1, 131.4, 131.3, 129.6, 128.3, I 19.5, 80.0, 70.9, 53.7; 48.5, 37.0, 3Ø7, 28.1, 27.9, 24.6; MS (ESI+) for C27H3'C12N3O6S mlz S9S.9 (M+H}+; MS (ESI-) for C~,,H3,C12N304S mlz 593.8 (M-H)';
MS (FAB} m/z (rel. intensity) 596 (MH+, 19), 672 (17), 596 (19}, 499 (15), 498 { 60}, 497 (26), 496 (99), 494 (3S); 173 (20), 1 I6 (27), 57 (48); An~~l. Calcd for C27H3,CIZN3O6S
0.27 HZO: C, 53.93; H, 5.29; N, 6.99. Found: C, 53.73; '.H, 5.39; N, 7.10. %
Water (KF):
0.80.
Example 30.
1 S [S~R*,R*)]-4-[[[1-[[4-[(2,6-Dichlorobenzoyl)amino]phenyl]methyl]-2-methoxy-oxoethyl]amino]carbonyl]-S,S-dimethyl-3-thiazolidinecarboxylic acid 3-ethyl ester (Scheme A, A-7: where RA_' and RA_Z are the same and equal to CH3, R3 is ethyl, Y is CO2, RS is 4-[(2,6-dichlorobenzoyl}amino]phenyl and stereochemistry is (S, S)).
s--~- H o CN~N~Oi ~O~O ~ ~ ~ O CI
_N
H~I ~
cl Example 30 was prepared as described in Scheme A from D-penicillamine using ethyl chioroformate to form the requisite carbamate. Physical data as follows: IR
(mull} 3292, 1748, 1666, 1606, 1562, 1538, 1516, 1445, 1431, 1414, 1341, 1325, 1271, 1212, 1194 cm '; 'H NMR (CDGl3) 8 7.57 (2 H), 7.37 {4 H), 7.I 1 {2 H), 6.49 (1 H), 4.86 (1 H), 4.59 (2 H), 4. I4 (3 H), 3.75 (3 H), 3.09 (2 H), 1.60 (3 H), 1.54 (3 H), 1.23 (3 H); "C
NMR (CDC13) 8 171.6, 162.3, 154.5, 136.3, 135.8, 132.6, 132.4, 131.1, 1:30.2, 130.1, 129.8, 128.2, 120.5, 120.4, 72.7, 62.5, 52.7, 52.5, 37.3, 30.2, 23.7, I4.6, 14.I:, MS (ESI+) for m/z 581.9 (M+H)+; MS (ESI-) far CZ6H29C1zN3O6S m/Z 5'79.8 (M-H)'; HRMS (EI) calcd for Cz6Hz9ChNa06S SBI.I IS4, found 581.1132; Anal. Calcd fox CZ6Hz9C12N3O6S ~ O.I6 H20:
C, 53.35; H, 5.05; N, 7.18. Found: C, 53.74; H, 5.12; N, 7.12. % Water (KF):
0.49.
Example 31.
(S--(R*,R*)]-4-[[[I--Carboxy-2--[4-[{2,6-I 0 dichlorobenzoyl)amino]phenyl]ethyl]amino]carbonyl]-5,5-dimethyI-3-thiazaiidinecarboxylic acid 3-ethyl ester {Scheme A, A-8: where RA_, and RA_2 are the same and equal to CH3, R3 is ethyl, Y is CO2, RS is 4-[(2,6-dichlorobenzoyl)arnino]phenyl and stereochemistry is (S, S)).
s--L H o ~NI~N~OH
~O~O a I ~ O CI
~N ~
IS H
CI
Example 31 was prepared from example 30 by the procedure described in preparation 6.
Physical data as follows: IR (mull) 3287, 3070, 1666; IEi06, 1562, 1538, 1516, 1431, 1414, 1342, 1328, 1271, 1213, I 194, 799 crri';'H NMR (DMSO-d6) S 12.58 (1 H), 10.63 20 (I H), 8.22 (I H), 7.51 (5 H), 7.20 (2 H), 4.51 {3 H), 3.95 (3 H), 3.04 {I
H), 2.86 (1 H), 1.35 (3 H), 1.16 (6 H);'3C NMR (DMSO-db) 8 223.3, 184.1, I83.9, 172.8, 168.4, I61.7, 136.9, 136.3, 133.1, I3I.2, 131.0, 129.4, 128.1, I I9.2, 70.6, 61.1, 53.6, 53.4, 48.6, 36.2, 30.I, 25.4, 24.3, 21.0, 14.1; MS (ESI+) for CZSHZ~CIZN3O~6S mlZ 568.0 (M+H)+;
MS (ESI-) for CZSH27C12N3O6S mlZ 565.9 (M-H)'; MS (FAB) mlz (rei. intensify) 568 (MH+, 86), 644 25 (18), 571 {19), 570 (61), 569 (30), 568 (86), 335 (16), 188 {99), I73 (19), 141 {S3), 116 (23); HRMS (FAB) calcd for CZSHz7CI2N306S+H, 568.1075, found 568.1096; Anal.
Calcd for C25Hz;C12N3O6S ~ 0.4 HzO: C, 52.16; H, 4.87; N, 7.30. Found: C, 52.46; H, 4.90; N, 7.15. % Water (KF): 1.25.
Example 32.
[S-{R*,R*)]~-[[[1-[4-[(2,6-Dichlorophenyi)methoxy]phenyl]methyl]-2-methoxy-2-oxoethyl]amino]carbonyl]-3-thiazoIidinecarboxylic acid 3-(1,1-dimethylethyl) ester (Scheme A, A-7: where RA_, and RA_2 are the same and equal to H, R3 is t-butyl, Y is C02-, RS is 4-[(2,6-dichlorophenyl)methoxy]phenyl and stereochemistry is (S, S)).
IO
/s-. ~ oIf ~~~N~Oi O O O ~ ~ CI
O~ %
CI
Example 32 was prepared as described in Scheme A from D-cysteine using di-t-butyl dicarbonate to form the requisite carbamate. Physical data as follows: IR
(Iiq.) 1745, 15 1702, 1565, 15I l, 1467, 1439, 1368, 1299, 1241, 1197, 1177, 1162, 1017, 778, 768 cm';
'H NMR (CDCl3} 8 7.36 (2 H), 7.25 {1 H), 7.06 {2 H}, 6.94 (2 H), 5.23 (2 H}, 4.75 (3 H), 4.12 (1 H), 3.72 (3 H), 3.37 (1 H), 3.14 (3 H), 1.45 (9 H); '3C NMR {CDCi3) 8 171.5, 157:9, 136.9, 132.0, 130.3, 128.4, 128.2, 115.0, 81.9, 65.:1, 62.8, 53.2, 52.3, 49.2, 36.9, 28.1, 27.9; MS (ESI+) for CZ6HsoClzNzO6S ~Z 568.9 (M-~-H)+; MS (ESI-} for 20 Cz6HaoC1zNz06S m/z 566.7 (M-H)'; Anal. Calcd for C26H3~,C12NZObS ~ 0.09 H20: C, 54.68;
H, 5.33; N, 4.91. Found: C, 54.62; H, 5.41; N, 4.73. % Water {KF): 0.28.
Example 33.
[S-{R*,R*)]-4-[[[1-Carboxy-2_.[4-[(2,6 dichlorophenyl)methoxy]phenyl]ethyl]amino]carbonyl]-3 thiazolidinecarboxylic acid 3 25 ( 1,1-dimethylethyl) ester (Scheme A, A-8: where RA_, and RA_2 are the same and equal to H, R3 is t-butyl, Y is COZ-, RS is 4-[(2,6-dichlorophenyl}methoxy]phenyl and stereoc:hemistry is (S, S)).

S'~ H O
~~~N~OH
O O O I ~ CI
0~1I w CI~
Example 33 was prepared from example 32 by the procedure described in preparation 6.
Physical data as follows: IR (mull} 1734, 1704, 1676, 1612, 1565, 1511, 1439, 1393, 1300, 1241, 1196, i I78, 1162, 777, 769 crri';'H NMR (DMSO-ds} 8 8.24 (1 H), 7.50 (3 H), 7.13 (2 H); b.93 (2 H), S.I6 (2 H}, 4.52 {3 H), 4.21 (I H}, 2:91 (4 H), I.31 (9 H);
"C NMR (DMSO-db) 8 172.7, 169.7, 157.1, 152.6, 135.9, 131.7, 131.5, 130.2, 129.8, 128.7, 1 I4.2, 79.8, 64.8, 6i.6, 53.2, 49.2, 36.0, 34.8, 27.8, 21.0; MS (ESI+) for C25HZgC12NzO6S mlz 554.9 (M+H)+; MS (ESI-) for CZSHT,8C12NZO6S mlz 552.8 (M-H)';
Anal. Calcd for CZSHZ8C12NZO6S ~ 0.15 H20: C, 53.79; H:, 5.11; N, 5.02. Found:
C, 54.17;
H, 5.17; N, 5.00. % Water {KF): 0.50.
Example 34.
[S-{R*,R* )]-4-[[[ 1-[4-[(2,6-Dichlorophenyi)methox;y]phenyl]methyl]-2-methoxy-IS oxoethyl]amino]carbonyl]-3 thiazolidinecarboxylic acid 3-ethyl ester (Scheme A, A-7: where RA_I and RA_z are the same and equal to H, R3 is ethyl, Y is COz-, RS is 4-[(2,6-dichlorophenyl)methoxy]phenyl and stereochemistry is (S, S)).
/S-. H O
~N~N~Oi ~O~O 'O' I ~ CI
'O~
C'/I .i Example was prepared as described in Scheme A from L)-cysteine using ethyl chloroformate to form the requisite carbamate. Physical data as follows: IR
{mull) 3282, 1742, 1705, 1692, 1664, 1562, 1509, 1436, 1352, 1343, 1236, 1196, 1175, 1015, 786 cm ';
'H NMR (CDCl3) b 7.37 (2 H), 7.25 (1 H), 7.05 (2 H), 6.,94 {2 H}, 6.74 (I H}, 5.23 (2 I-i), WO 9916723b PCTIUS99/14233 4.77 (3 H), 4.34 ( 1 H), 4. I 8 (2 H); 3.74 (3 H), 3.37 ( 1 H;f, 3.13 (3 H), 1.31 (3 H); '3C NMR
(CDCl3) s 171.6, 171.4, 158.0, 137.0, 132.1, 130.5, 130.4, 128.5, 128.2,115.0;
65.2, 63.6, 63.2, 62.7, 53.6, 53.2, 52.4, 36.9, 14.5; MS (ESI+) for C24H26C12N2~6'~ nilz 540.9 (M+H)+;
HRMS (EI) calcd for C24HzeClaNzO6S 540.0889, found 540.0878; Anal. Calcd for Cz4HZ6C12NZO6S ~ 0.26 H20: C, 52.79; H, 4.89; N, 5.13. Found: C, 52.41; H, 4.82; N, 4.96.
Water (KF): 0.85.
Example 3S.
[S-~R*,R*)]-4-~y l-carboxy-2._~4-~(2,6 dichlorophenyl)methoxy]phenyl]ethyl]aminojcarbonyl]-3-thiazolidinecarboxylic acid 3 ethyl ester (Scheme A, A-8: where RA_, and RA_Z are the same and equal to H, R3 is ethyl, Y is CO2-, i5 RS is 4-[(2,6-dichlorophenyl)methoxy]phenyl and stereochemistry is (S, S)).
s-. ~ o ~N~N~OH
~O~O ° I ~ CI
cl Example 35 was prepared from example 34 by the procedure described in preparation 6.
24 Physical data as follows: IR (mull) 1709, 1675, 1612, 1.565, 1511, 1439, 1416, 1346, 1300, 1241, I I96, 1179, 1115, 1018, 768 cm'; IH NMR {CDCI~) S 7.34 (2 H), 7.23 (1 H), 7.12 (2 H), 6.94 (2 H), 6.85 (I H), 5.22 (2 H), 4.77 (4 H), 4.34 (1 H), 4.16 (2 H), 3.33 (4 H), 1.26 (3 H);'3C NMR (CDC13) ~ 174.0, 170.2, 15f,.1, 155.1, 137.0, 132.0, 130.5, I28.5, 128.1, 115.0, 65.2, 63.9, 63.0, 62.9, 53.3, 36.4, 21.9, 14.5; MS (ESI+) for 25 C23H24C12Nz06S mlz 527.0 (M+H)+; MS (ESI-) for Cz3H24C1zN2O6S mlz 524.9 (M-H)';
HRMS {EI) calcd for C23H24C1zNz06S 526.0732, found 526.0726; Anal. Calcd fox WO 991b7230 PCTIUS99I14233 C23H24C12N2~6S ~ 0.20 H20: C, 52.02; H, 4.63; N, 5.27. Found: C, 52.12; H, 4.73; N, 5.34.
Water (KF): 0.69.
Example 36.
[S-{R*,R*)]-4-[[[ 1-[4-[(2,6-Dichlorophenyl)methox;y]phenyl]methyl]-2-methoxy-S oxoethyl]amino]carbonyl]-3 thiazolidinecarboxylic acid 3-[2-(4-morpholinyl)ethyl]
ester (Scheme A, A-7: where RA_, and RA_2 are the same and equal to H, R3 is 2-(4-morpholinyl)ethyl, Y is COZ-, RS is 4-[(2,6-dichlorophenyl)methoxy]phenyl and stereochemistry is (S, S~).
S-- H O
0..~~ CN~.N~Oi ~N~'O~O ~O~ I ~ CI
v 'O
CI
Example 36 was prepared as described in Scheme A from D-cysteine using 4-(2-hydroxyethyl)morpholine to form the requisite carbamat:e. Physical data as follows: mp 1S I38-I40°C;1R (mull) 3286, 1743, 1705, 1660, 1559, 1513, 1435, 1428, 1302, 1245, 1226, 12I S, 1176, 1015, 764 cm ''; 1 H NMR (300 MHz, DMS~O-db) S 8.43 (1 H), 7.48 (3 H), 7.I3 (2 H), 6.94 (2 H), 5.16 {2 H), 4.59 (2 H), 4.48 (1 H;), 4.26 (I H), 4.07 (2 H), 3.63 (3 H), 3.51 {4 H), 3.23 (1 H), 3.01 (1 H), 2.84 (I H), 2.71 (1 H), 2.41 (6 H);'3C NMR (75 MHz, DMSO-db) b I72.2, 157.7, 153.9, 136.5, 132.2, 132.0, 130.8, I30.1, 129.2, 114.8, 66.6, 65.4, 63.4, 57.0, 53.9, 53.8, 52.4, 36.4; MS (ESl+) for CZ$H33C12N3O,S
m/z 625.8 (M+I-I)+; Anal. Calcd for CZgH33CIzN3O,S: C, 53.67; H, :i.3I; N, 6.71. Found:
C, 53.69; H, 5.27; N, 6.69.
Example 37.
[S-{R*,R*)]~-[[[ 1-Carboxy=~;-[4-[(2,6_ dichlorophenyl)methoxy]phenyl]ethyl]amino]carbonyl]~-3-thiazolidinecarboxylic acid 3-[2-(4-morpholinyl)ethyI] ester _(~-(Scheme A, A-8: where RA_, and RA_z are the same and equal to H, R3 is 2-(4-morpholinyl)ethyl, Y is COz-, RS is 4-[{2,6-dichlorophenyl)methoxy]phenyl and stereochemistry is (S, S)).
S-. H O
O~ ~N~N~ON
~N~O~O O ~ \ CI
~O. \
(/
S c,l Example 37 was prepared from example 36 by the procedure described in preparation 6.
Physical data as follows: IR (mull) 1710, 1610, 1S8S, 1565, 1511, 1439, 1408, 1351, 1301, 1240, 1196, 1179, 1116, 1017, 767 cm ''; 1 H NMR (300 MHz, DMSO-db) 8 8.27 ( 1 H), 7. S S (2 H), 7.45 ( 1 H), 7.13 (2 H), 6.94 (2 H), S. I ti (2 H), 4.59 {2 H), 4.40 ( I H), 4.27 (1 H}, 4.04 (2 H), 3.52 (4 H); 3.2I (1 H), 2.86 (3 H), 2.44 (6 H}, '3C
NMR (7S MHz, DMSO-db) 8 173.2, I72.S, 157.6, 136.5, 132.2, 132.0, 130.8, 130.4, 129.2, 114.7, 66.5, 65.3, 63.2, 57.0, 53.9, 53.7, 36.5, 2i.S; MS (ESI+) for C,z,H3,C12N307S m/z 611.9 (M+H);;
Anal. Calcd for CZ,H3,CIZN307S ~ 1.0 CZH402 ~ 0.63 Hz0 ~ 0.28 HCI: C, 50.13;
H, 5.31; N, 1 S 6.03; Cl, 11.59. Found: C, 49.80; H, 5.30; N, 6.OS; CI, 11.20. % Water (KF): 1.58.
Example 38.
[S-(R*,R*)]-4-j[[1-[4-[(2,6--Dichlorophenyl)methoxy]phenyl]methyl]-2-methoxy-2-oxoethyl]amino]carbonyl]-3-thiazolidinecarboxylic acrid 3-[(2-pyridinyl)methyl] ester (Scheme A, A-7: where RA_, and R,,_2 are the same and equal to H, R3 is 2-pyridinylmethyl, Y is COZ-, RS is 4-[(2,6-dichlorophenyl)methoxy]phenyl and stereochemistry is (S, S}).
s-. H o CN~ N~Oi I Nw O~O ~Ot ~ ~ Cf /
CI

Example 38 was prepared as described in Scheme A from D-cysteine using 2-pyridinemet:hanol to form the requisite carbamate. Physical data as follows:
mp 123-125°C; IR (muil) 3334, 1728, 1709; I668, 1531, 1511, 1441, 1405. 1345, 1294, 1286, 1236, 1228, 1015, 762 cm ''; ~H NMR (300 MHz, DMSO-db) 8 8.57 (2 H), 7.79 (1 H), 7.54 (2 H}, 7.42 (1 H), 7.27 (2 H), 7.12 (2 H), 6.92 (2 H.), 5.13(4 H), 4.69 (2 H), 4.49 ( 1 H), 4.34 ( 1 H), 3.59 (3 H), 3.24 ( 1 H), 2.89 (3 H); '3C; NMR (75 MHz, L7MS0-db 8 172.2, 169.9, 157.7, 156.5, 153.6, 137.3, 136.5, 132.2, ',132.0, 130.8, 130:1, 129.2, I23.2, 121.0, I I4.8, 67.7, 65.3, 62.0, 54.0, 52.4, 50.3, 36.3, 35.3; HRMS (EI} calcd for C~8Hz7C1,N306S 603.0997. found 603.0992; Anal. Calc<i for C,gH,7ChN306S: C, 55.63; H, 4.50; N, 6.95. Found: C, 55:56; H, 4.59; N, 6.93.
Example 39.
[S-(R*,R*)]-4-[[[1-[4-[(2,6-Dichlorophenyi)methoxy]phenyl]methyl]-2-methoxy-2-oxoethyl]amino]carbonyl]-3-thiazolidinecarboxylic acid 3-j2-(I-pyrrolidinyl)ethyl] ester (Scheme A, A-7: where RA_, and RA_Z are the same and equal to H, R3 is 2-(1-pyrrolidinyl}ethyl, Y is COz-, RS is 4-[(2,6-dichlorophenyl)methoxy]phenyl and stereochemistry is (S, S)).
/S-. H OII
~N~N~,Oi ° I ~ ci ~o I~
ci Example 39 was prepared as described in Scheme A from D-cysteine using I-{2-hydroxyethyl)pyrrolidine to form the requisite carbamat:e. Physical data as follows: mp 130-I32°C; IR (mull) 1745, 1702. 1661, 1556, 1513, 1435, 1426, 1303, 1245, 1226, 1214, I 176, 1017, 825, 7b5 cm ~~y'H NMR (300 MHz, DMSC>-db) 8 8.42 (1 H), 7.48 (3 H}, 7.I3 (2 H), 6.94 (2 H), 5.16 (2 H), 4.59 (2 H), 4.48 ( I H), 4.27 ( 1 H), 3.99 (2 H), 3.63 (3 H), 3.24 (1 H), 2.68 {9 H), 1.62 (4 H); "C NMR (75 MHz, I7MS0-d~) cS 172.2, 170.0, 157.7, 136.5, I32.2, 132.0, 130.8, I30.1, 129.2, I 14.8, 65.3, 65.I, 54.4, 53.9.
52.42, 36.35, 23.6;

MS (ESI+) for C,gH33C12N306S m/z 609.8 (M+H)'; Anal. Calcd for CzgH33CI2N,O6S:
C, 55.08; H. 5.45; N, 6.88. Found: C, 54.72; H, 5.58; N, 6.60.
Example 40.
[R-(R*;S*)J-4-[[[1-[4-[(2,6-Dichlorophenyl)methoxyJphenyl]methyl)-2-methoxy-2-oxoethyl]amino]carbonylJ-3-thiazolidinecarboxylic acid 31,1--dimethylethyl}
ester (Scheme A, A-7: where RA., and RA_Z are the same and equal to H, R3 is t-butyl, Y is C02-, R5 is 4-[(2,6-dichlorophenyl)methoxy]phenyl and stereochemistry is {R, ,S~).
~s o H ~~
N~ N ~Oi 0''~
O 0 I ~ CI
O~
i CI
Example 40 was prepared as described in Scheme A frorn L-cysteine using di-t-butyl dicarbonate to form the requisite carbamate. Physical data as follows: IR
(mull) 1746, 1702, 1611. 1565, 1511, 1439,1299, 1241, 1197, 1177, i 162, 1118, 1016, 777, 768 cm'';
'H NMR (CDCl3} b 7.39 (2 H), 7.25 (1 H), 6.93 (2 H), 6.93 (2 H), 5.24 (2 H), 4.72 (3 H), 4.20 ( 1 H), 3.74 (3 H), 3.35 ( 1 H), 3.12 (3 H}, 1.44 (9 H); "C NMR (CDC13) 8 171.7, 170.0, 169.5, 158.3, 137.3, 132.4, 130.7, 130.6, 128.8, 128.5, I 15.2, 115.1, 82.4. 65.5, 53.5, 52.6. 50.3. 37.3, 28.4; MS (ESI+) for C,~H3oCI,N,C>6S m/z 554.9 (M+I-I)'; MS (ESI-) for C,6H~oCI~N,O6S m/z 552.8 (M-H)'; Anal. Calcd for C,bH3oCIZNZO6S ~ 0.1 H,O:
C, 54.65; H, 5.33; N, 4.90. Found: C, 54.59; H, 5.30; N, 4.88. % Water (KF):
0.33.
Example 41.
[R-(R*,S*}J-4--[[[ 1-Carbox~J-2__[q-[{2,6-.
dichlorophenyl)methoxyjphenylJethyljaminoJcarbonyl]--3-thiazoiidinecarboxylic acid 3-( 1,1-dimethyIethyl) ester (Scheme A. A-8: where R"_, and RA.2 are the same and equal to H, R3 is t-butyl, Y is CO,-, RS is 4-[(2,6-dichlorophenyl)methoxy]phenyl and stereoc;hemistry is (R, S~).

H
<S~ ~ ~°
N Nv 'oH
O
~o ° ~ ~ ct ~ o Gt Example 4I was prepared from example 40 by the procedure described in preparation 6.
Physical data as follows: IR (mull) 1737, 1705, 1679, Ifil2, 1565, 1512, 1439, 1300, 1241, I 196, 1178, 1 i63, 1117, 777, 769 crri';'H NMR (DMSO-db) 8 8.07 (1 H), 7.54 {2 H), 7.44 (1 H), 7.16(2 H), 6.93 (2 H), 5.16 (2 H), 4.5Ei (1 EI), 4.39 (3 H), 3.56 (I H), 2.84 (3 H), 1.23 (9 H);
"C NMR (DMSO-db) 8 I72.7, 169.9, 157.0, 152.6, 135.9, I3I.6, 131.4, I30.1, I29.9, 129.8, I28.7, 114.1, 79.8, 66.9, 64.7, 61.7, 53.5, 49.3, 35.6, 34.8, 27.9, 27.6; MS (ESI+) for CZSH,gC12N206S mlz 554.9 (M+H)+; MS (ESI-) for CZSHZgCI,N,ObS mlz 552.8 (M-H)';
Anal. Calcd for CzSHzgCI,N,O6S ~ 0.27 HZO: C, 53.59: H., 5.13; N, 5.00. Found:
C, 53.97;
H, 5.14; N, 4.96. % Water (KF): 0.86.
Example 42.
4-[(2,6-Dichlorobenzoyl)amino]-N-[[(4S~-3--(ethylsulfonyl~4-thiazolidinyl]carbonyl]-~-phenyialanine methyl ester (Scheme A, A-7: where R"_, and RA_2 are the same and equal to H, R, is ethyl, Y is SO2, RS
is 4-[(2,6-dichlorobenzoyl)amino]phenyl and stereocherrtistry is (S, S)).
S. H O
~N~N~Oi O=5=OIOI y O C:I
Et H
..O Gt Example 42 was prepared as described in Scheme A from D-cysteine using ethanesulfonyl chloride to form the requisite sulfonamide. Physical data as follows: IR
(mull) 1743, 1666; 1605, 1561, 1535, 1515. 1432, 1413, 1328, 1269, 1219. 1195, I I46, 799, 782 cm -';

'H NMR (CDCI3) 8 7.58 (2 H), 7.46 (I H), 7.32 (3 H), '1.17 (2 H), 7.07 (I H), 4.85 (I H), 4.73 (2 H), 4.28 ( I H), 3.76 (3 H), 3.54 ( 1 H), 3.26 ( 1 Hf), 3.05 (4 H), I
.40 (3 H); "C NMR
(CDCl3) b 171.3, 168.2, 162.4, 136.4, 135.8, 132.4, 13f..3, 131.0, 130.1, 128.2. 120.6, 64.9, 53.2, 52.6, 51.5, 45.8, 37.1, 34.2, 31.0, 29.3, 7.7; IVIS (ESI+) for C,3H~SCI~N306S2 m/z 573.9 {M+H)+; MS (ESI-) for Cz3H25C1,N;O6S2 m/z 571..7 {M-H)'; HRMS (FAB) calcd for C~3HzsC1,N3O6S2+H, 574.0640, found 574.0634; Anal. Calcd for Cz3H,5CI,N3O6Sz ~
0.1 H20: C, 47.97; H, 4.40; N, 7.30. Found: C, 48.36; H, 4.59; N, 6.80.
Example 43.
4-[{2,b--Dichlorobenzoyl)amino]-N-[[(453-(ethylsu.lfonyl)-4--thiazolidinyl]carbonyl]-~-phenylalanine (Scheme A, A-8: where RA_, and R,,_2 are the same and equal to H, R~ is ethyl, Y is SOz, RS
is 4-[(2,6-dichlorobenzoyl)amino]phenyl and stereochemistry is (S, S)).
S-. H OII
CN~N~ON
O=S=O 4 w O CI
Et IS
cl Example 43 was prepared from example 42 by the procedure described in preparation 6..
Physical data as follows: IR (mull) 1734, I 664, 1605, 1562, I 536, I S I6, 1432, 1414, 1330, I272, 1234, I I95, I 146, 799, 78I cm''; IH NMR (DMSO-db) 8 12.91 {I H), 10.65 ( 1 H), 8.15 ( 1 H), 7.51 (5 H), 7. I 7 (2 H), 4.77 {2 H), 4.43 { 1 H), 4.29 ( 1 H), 3.94 (6 H), 1.20 (3 H); 13C NMR (DMSO-db) 8 172.5, 168.9, 161.9, 137.1, I3d.5, I33.2, 131.4, I3I.3, 129.8, 128.3, 1 I9.3, 63.7, 53.6, S 1.4, 45.3, 36.1, 34.7; NIS (ESI+) for C"H,,CI,N3O6Sz m/z 559.9 (M+H)'; MS (ESI-) for C,~H,3C1,N~O6S, m/z 557.8 (M-H)-; HRMS {FAB) calcd for C"H,~CI,N;O6S2+H, 560.0483, found 560.0488; Anal. C;alcd for C,~H,3Cl,NzO6S2 ~
0.72 H,O: C, 46.08: H, 4.30; N, 7.33. Found: C, 46.42; H. 4.37; N, 7.01. % Water (KF): 2.26.

Example 44.
4-[(2,6-Dichlorobenzoyl)amino]-N-[[{4S~3--[[5--(trifluoromethyl}-2-pyridinyl]sulfonyl]-4-thiazolidinyI]carbonyl]-~--phenylalanine methyl ester (Scheme A, A-7: where R"_, and RA_Z are the same and e~quaI to H, R3 is 2-(5-triflouromethylpyridyl}, Y is SO~, RS is 4-[(2,6-dichlorobenzoyl)amino]phenyl and stereochemistry is (S, S)).
S-. H 0 CN~N~Oi 0=S=O O
O C!
i N
w I H
CI

Example 44 was prepared as described in Scheme A from D-cysteine using 2-(5-triflouromethyipyridyl)sulfonyl chloride to form the requisite sulfonamide.
Physical data as follows: IR (mull) 1745, 1668, 1603; 1535, 1515, 14:32, 1413, 1327, 1219, 1179, 1142, 1108, 1073, 1016, 616 cm ' '; 'H NMR (CDCI3) 8 8.76 ( i H), 8.17 (2 H}, 7.90 ( 1 H), 7.51 (2 H), 7.32 (4 H}, 7.17 (2 H), 5.18 (1 H), 4.96 (1 H), 4.66 (1 H), 4.31 (1 H), 3.78 (3 H), 1 S 3.52 {1 H}, 3.15 (3 H); "C NMR (CDCI,) 8 171.3, 168.4, 162.2, 147.2, 136.2, 136.0, 132.4, 131.0, 130.3. 128.2, 123.0, 120.4, 120.3, 65.7, 53.6. 52.5, 51.4, 37.3, 34.0; MS
(ESI+) for CZ,H,aCl,F3N~O6S2 mlz d90.8 (M+H)+; MS (ESI+} for C27H23C12F3N4O6Sz mlz 712.9 {M+Na)+; Anal. Caled for C27HZ3C12F3N4O6S~ ~ 0.2 HBO: C, 46.68; H, 3.39;
N, 8.06.
Found: C, 46.60; H, 3.52; N, 7.92. % Water (KF): 0.47.
Example 45.
4-[(2,6-Dichlorobenzoyl)amino]-N-[[(4S~3--[[5--(trifluoromethyl)-2-pyr~idinyl]sulfonyi]-4-thiazolidinyl]carbonyl]=L-phenylalanine (Scheme A, A-8: where RA_, and RA_z are the same and equal to H, R3 is 2-(5-triflouromethylpyridyl), Y is SO,, RS is 4-[(2,6-dichlorobenzoyl)amino]phenyl and stereochemistry is (S, S)}.

S~ H- O.
~N~N~OH
O=S=O O ~ O (:I
N ~ i N w H
CI

Example 45 was prepared from example 44 by the procedure described in preparation 6.
Physical data as follows: IR {mull) 1740, 1666, 1602, 1:>62, 1533, 1517, 1432, 1354, 1327, I 179, 1 I43, 1108, 1074, 1016. 613 cni';'H NMR (DMSO-dh) 8 10.63 (I H), 9.24 ( 1 H), 8.54 ( 1 H), 8.46 ( 1 H), 8.18 ( 1 H), 7.50 (5 H), 7. I '~ (2 H), 5 .00 { 1 H), 4:74 { 1 H);
4.42 (2 H), 3.04 (2 H), 2.90 ( 1 H), 2.78 ( 1 H); '3C NMR (DMS4-db) ~ 172.8, 168.9, 162.3, 159.0, 147.8, 137.5, 137.4, 136.9, 133.5, 131.8, 131.7, 1:30.2, 128.7, 123.8, 119.7, 64.7, 53.9, 52.3, 36.7, 35.1; MS (ESI+) for C~6HZ,C12F,N406SZ mlz 676.5 (M+H)*; MS
(ESI-) for IO C_sH,,Cl,F3N4O6S2 m/z 674.5 (M-H)'; Anal. Calcd for CZ6Hz,C12F3N4O6Sz ~
0.33: C, 45.69;
H, 3.20; N, 8.20. Found: C, 45.81; H, 3.38; N, 8.13. % Water (KF): 0.88.
Example 46.
4-[(2,6-Dichlorobenzoyl)amino]-N-[[(4S}-3-(phenylsulfonyl}-4-thiazolidinyl]carbonyl]-L-phenylalan:ine methyl ester (Scheme A, A-7: where RA_, and R;,_z are the same and e(lual to H, Rj is phenyl, Y is SO2, RS is 4-[(2,6-dichlorobenzoyl)amino]phenyl and stereochemistry is (S, S)).
S-. H O
CN~N~Oi O-S-O CIO
O C;i I~
H IW

Example 46 was prepared as described in Scheme A fronn D-cysteine using benzenesulfonyl chloride to form the requisite sulfonamide. Physical data as follows: IR
(mull) 1744, 1668, 1604, 1531, 1515. 1432, 1413, 1355, 1324, 1268, 1220. 1195.
1167, 1090, 730 em -';'H NMR (CDCI,) S 7.84 (2 H), 7.65 (5 lH), 7.45 (I H}, 7.30 (6 H), 4.90 (1 H), 4.63 (2 H), 4.37 (I H}, 3.75 (3 H), 3.32 (1 H), 3.1 '_> (2 H), 2.53 (I
H); "C NMR

(CDC13) 8 171.2, 168.2, 162.4, 136.4, 136.3. 134.1. 132.4, 131.0, 130.2, 129.6. 128.2, 128.1, 127.9, 120.6. 65.3, 53.3, 52.6, 51.8, 37.4. 33.3: M.S (ESI+) far C,7HZSChN3ObS2 m/z 621.8 (M+H)'; MS (ESI-) for C,,HzsCIzN,O6S, rrrlz 619.8 (M-H)'; Anal. Calcd for C27H23C1zN;O6S~ ~ 0.2 H20: C, 51.84; H, 4.18; N, 6.72. lFound: C, 51.72; H, 4.18; N, 6.52.
% Water (KF): 0.48.
Example 47.
4-[(2,6-Dichlorobenzoyl)amino]-N-[[(4S}-3-(phenylsulfonyl}-4-thiazolidinyl]carbonyl]-t -phen.ylalanine (Scheme A, A-8: where RA., and R,,_Z are the same and edual to H, R3 is phenyl, Y is S02, I0 RS is 4-[(2,6-dichlorobenzoyl)aminoJphenyl and stereocl~emistry is (S, S)).
S-. H ~O[I
CN~N~OH
O=S=O 0 O C:I
~ 1 I ~ N w H I ,, Ct Example 47 was prepared from example 46 by the procedure described in preparation 6.
Physical data as follows: IR (mull) 1735, 1666, 1605, 1:162, 1533, 1516, 1432, 1414, 1352, 1328, 1195. 1180, 1167, 1090, 731 crri';'H NMR (CDC13) 8 8.11 (1 H), 7.82 (2 H), 7.66 (3 H), 7.56 (2 H), 7.23 (6 H), 4.91 ( 1 H), 4.66 ( 1 H), 4.60 ( 1 H), 4.35 ( 1 H), 3.30 (I H), 3.19 (2 H), 2.59 (1 H);'3C NMR (DMSO-db) 8 I72.2, 168.2, 161.7, 137.0, 136.9, 136.3, 133.6, 133.0, 131.2, 131.1; 129.6, 129.3, 128.1, 1;27.6, 119.2, 63.9, 53.4, 51.5, 48.4, 36.0, 33.8; MS (ESI+) far CZ6H23C12N3~6S2 ~z 607.9 (1V1+H)+; MS (FAB) m/z (rel.
intensity} 608 (MH+, g5}, 6I0 (67), 608 (85), 466 (30}, >i71 ( 41), 228 (38), 193 (38), 149 (30), 129 (31), 118 (99), 63 (35}; HRMS (FAB) calcd fo:r CzbH,3C12N3O6Sz+H~
608.0483, found 608.0491: Anal. Calcd for C,6Hz3ChN3O6S~~ 0.27 I-i,0: C, 50.9I; H, 3.87;
N. 6.85.
Found: C, 50.68; H, 4.05; N, 6.65. % Water (KF): 0.79.
Example 48.
4-[(2,6-Dichlorobenzoyl)amino] N-[[(453-~[[5-(dirnethylamino}-1 naphthalenyl]sulfonyl]--0-thiazolidinyl]carbonyl]-mphenylalanine methyl ester (Scheme A, A-7: where RA_, and R~.2 are the same and equal to H, R3 is 5-dimethylamino-1-naphthyl, Y is SO,, RS is 4-[(2,6-dichlorobenzoyl)aminoJphenyl and stereochemistry is (S~ ~)~
/S-. H OI' ~N~N~Oi O=S=O O
CI
I w I ~ i N
w ~ . ~ i CI
N
Fi C~ ,Chi Example 48 was prepared as described in Scheme A from D-cysteine using 5-dimethylamino-1-napthalenesuifonyl chloride to form the requisite sulfonamide.
Physical data as follows: 1R (rnulI) 1744, 1684, 1605, 1562, 153:3, 1515. 1431, 1412, 1350, 1324, 1231, 1202, 1163, I 145, 798 cm -'; 'H NMR (CDCl3) 8 8.64 ( 1 H), 8.34 (2 H), 7.53 {5 H), 7.29 (4 H), 6.87 (3 H), 4.93 ( 1 H), 4.75 (1 H), 4.64 ( 1 H}, 4.31 ( I H), 3.69 (3 H), 3.47 (1 H), 2.84 {8 H), 2.46 (1 H); "C NMR (CDCl3) S 171.2., 167.7, 162.5, 136.3, 135.9, 132.4, 132.3, 131.9, 131.5, 131.0, 130.1, 129.7, 129.2, 128.2, 124.4, 120.4, 65.1, 53.3, 52.5, 50.1, 45.9; 37.1, 33.3; MS (ESI+) for C3~H32C1ZN4t~6Sz m/z 736.8 (M+Na)+; Anal.
Calcd for C33H32C12N4~6S2 ' 0.17 H,O: C, 55.15; H, 4.54: N, 7.79. Found: C, 55.20; H, 4.73; N, 7.49. % Water (KF}: 0.43.
Example 49.
4--[(2,6--Dichlorobenzoyl)amino]-N-[[(4S}-3--[[5-(dimethylamino)-1-naphthalenyl]suIfonyl]~--thiazolidinyl]carbonyl]-L-phenylalanine (Scheme A, A-8: where RA., and RA_z are the same and equal to H, R; is 5-dimethylamino-1-naphthyl, Y is S4~, RS is 4-[(2,6-dichlorobenzoyl)aminoJphenyl and stereochemistry is S- H O
CN~N~OH
O=S=O O
CI
I ~~ ~ ~ ~ N w iw H !~
cr N
H3c 'cH3 Example 49 was prepared from example 48 by the proce;dare described in preparation 6.
Physical data as follows: IR (mull) 1666,1605, 1587, 1577, 1562, 1532, 1516, 1431, 1412, 1395, 1325, 1163, 114S, 798, 631 cm -';'H NMR (DMSO-db) 8 10.60 (1 H), 8.54 ( 1 H), 8.28 (2 H), 7.54 (8 H), 7.25 ( 1 H), 6.93 (2 H), 4.95 ( 1 H), 4.84 ( 1 H), 4.39 ( 1 H), 4. I 7 ( 1 H), 2.95 (2 H), 2.80 (7 H), 2.54 ( 1 H); ' lC NMR (DMSO-db) b 167.2; 161.7, I 51.4, 136.6, 136.3, 133.6, 133.1, 131.1, 130.8, 130.3, 129.5, 129.3, 129.0, 128.8, 128.1, 123.6, 118.9, 118.3, 115.3, 63.6, 54.2, 50.3, 44.9, 36.7, 33.9, 2:l .0; MS (ESI+) for lO C3zH3oC1,N4ObS2 m~Z 700.8 (M+H)+; HRMS (FAB) calcd for C3iH,oChN,O6Sz+H, 701.1062, found 701.1039 Example 50.
U--[(2,6-Dichlorophenyl)methyl]-N-[[(4S~3-{rnethylsulfonyl}-4-thiazolidinyljcarbonylj-1,-tyrosine. methyl ester (Scheme A. A-7: where RA_~ and RA_2 are the same and equal to H, R3 is methyl, Y is SO2, RS is 4-[(2,6-dichlorophenyl)methoxy]phenyl and stereochemistry is (S, S)).
S-. H O
CN N O~
O S OO ~ cl O~ i C ~I
Example 50 was prepared as described in Scheme A from D-cysteine using methanesulfonyl chloride to form the requisite sulfonamide. Physical data as follows: IR
(mull) 1742, 1680, 1611, 1564, 15 i 0, 1439, 1345, 1299, 1240, 1179, 1158, 1016, 976, 779, 768 cm~';'H NMR (CDCl3) 8 7.36 (2 H), 7.24 (1 H), 7.08 (3 H), 6.97 {2 H), 5.25 (2 H), 4.77 (3 H), 4.29 ( 1 H), 3.74 (3 H). 3.43 ( 1 H), 3.5:3 ( 1 H), 3.1 ~
(2 H), 2.93 (3 H);

'3C NMR (CDCI,) 8 171.4, 168.0; 158.2, .137.0, 132.1, 1.30.3, 128.5, 127.9, 115.3, 65.2, 65.0, 59.4, 53.5, 53.3, 52.5. 5I.9, 42.2, 37.3, 36.9, 34.2; MS (ESI+) for CZZH~4C12NZO6Sz mlz 546.8 (M+H)'; MS (ESi+) for C~ZH24C12NZO6S2 mlz 568.8 (M+H)'; HRMS (EI) calcd for CZZH,,C12N2O6Sz 546.0453, found 546.0448; Anal. C'.alcd for C"H24C1,N,O6Sz ~ 0.07 H,O: C, 48.15; H, 4.43; N, 5.10. Found: C, 48.17; H, 4.51; N, 5.02. % Water (KF): 0.24.
Example 51.
O-[(2,6-Dichlorophenyl)methylJ-N-([(4S)--3-(methylsulfonyl)--4-thiazolidinyl]carbonyl]-t.-tyrosine (Scheme A, A-8: where R,,_, and RA_Z are the same and equal to H, R, is methyl, Y is SO2, RS is 4-[(2,6-dichlorophenyl)methoxy]phenyl and stereochemistry is (S, S)).
S- H O
~N~N~OH
O CH~ O ~ CI
O ~ w CI
Example 5I was prepared from example 50 by the procedure described in preparation 6.
Physical data as follows: IR {mull) 1737, 1675, 161 I, 1:565, 1511, 1439, 1345, 1300, 1241, 1197, 1179, 1 I57, 1016, 778, 769 crn''; 'H NMR (CDC1,) b 7.34 (2 H), 7.16 (5 H), 6.99 (2 H), 5.23 (2 H), 4.85 ( 1 H), 4.68 (2 H), 4.27 (1 H); 3.51 ( 1 H), 3.32 { 1 H), 3. I 5 (2 H), 2.93 (3 H);'3C NMR (CDCl3) b 174.8, 168.7, 158.3, 137.0, 132.1, 130.5, 130.4, 128.5, I27.6, 1 I5.4, 115.2, 65.2, 64.9, 53.1, 52.0, 37.1. ?~6.4, 34.3; MS
{ESI+) for CZ,Hz,ChN,O6S, mlz 532.8 (M+H)'; MS {ESI-) for C~,H,~CI,N,O6S2 mlz 530.7 (M-H)';
HRMS (FAB) calcd for C~,H,~Cl,N206Sz+H, 533.0374, iPound 533.0386; Anal. Calcd for C,,H~ZC1,N,06S, ~ 0.06 HBO: C, 47.19; H, 4.17; N, 5.24. Found: C, 47.58; H, 4.35; N, 5.10. % Water (KF): 0.20.
Example 52.
4-[(2,6-Dichlorobenzoyl)aminoJ-N-[((4S)~3-[[(I,l~li,methyiethyl)amino]carbonylJ-4-thiazolidinyl]carbonyl]-t,-phenylalanine (Scheme A, A-8: where RA_, and R~_~ are the same and equal to I-I, R, is t-butyl, Y is CONH-, R5 is 4-((2,6-dichlorobenzoyl)amino]phenyl and stereochemistry is (S, S)).
5-.. H O
C~~N~OH
0 0 l ~ O CI
H
C ~'I
Example 52 was prepared from example 6 by the procedure described in preparation 6.
Physical properties as follows: IR (mull) 3289. 1728, 1664, 1607, I 580, 1561, 1536, I432, 1414, 1394, 1326, 1270, 1242, 1213, I 195 cm'IH: NMR (300 MHz, CD30D) b 7.47 (2 H), 7.24 (3 H), 7.04 (2 H), 4.63 (2 H), 4.37(1 H)., 4.17 (I H), 3.09 (4 H), 1.22 (9 H);'3C NMR (75 MHz, CDCl3) 8 176.9, 174.8, 167.2, 159.9, 140.5, 144.0, 136.4, I36.I, I34.6, 133.8, 131.8, 124.5, 66.6, 57.I, 55.3, 53.0, 40.1, 37.I, 32.9;
MS (ESI+) for CzSH,gCl,N405S mlz 566.9 (M+I-i)', Sgg.9 M+Na)+; MS (:ESI+) for C,sHzgC1,N405S
mlz 566.9 (M+H)+; HRMS (FAB) calcd for C,SHZBCL,N405S +HI 567.1235, found 567.1253.
Example 53.
1 S 4-[{2,6-Dichiorobenzoyl)amino]-N-([{4S}--3-[(dliethylamino)carbonyl)-4-thiazolidinyl]carbonyl]-L-phenylalanine (Scheme A, A-8: where RA., and RA_, are the same and equal to H, R, is ethyl, Y is CON(CH,CH3)-, R5 is 4-[(2,6-dichlorobenzoyl)amino] phenyl and stereochemistry is (S, S-. H O
~N~N~OH
~N~O O I ~ 0 CI
J ~N
H ~~
CI
Example S3 was prepared from example 7 by the procedure described in preparation 6.
Physical properties as follows: IR (mull) 3269, 1734, 16fi3, 1607. 1562. 1535, 15I5, 1431, 1415, 1348, 1325, 1269, 1213, 1195, 799 cm-';'I-1 NMR (300 MHz, CD30D) 8 7.57 {2 H), 7.35 (3 H), 7.09 {2 H), 5.09 (1 H), 4.76 (1 H), 4.?~8 (2 H), 3.31 (3 H), 3.13 (5 H), 1.05 (6 H); '3C NMR (75 MHz, CD30D) b 176.6, 173.9, 167.1, 166.3, 140.7, 140.1, 136.1, 134.6, 133.8, 131.8, 124.1, 68.5, 57.4, 56:6, 45.9. 40.4, 36.6, 16.8; MS
(ESI+) for CZSHZ8C12N~O5S m/z 567.1 (M+H)+; Anal. Calcd for C,S:H~gCI2N405S: C, 52.91; H, 4.97; N, 9.87.
Found: C, 52.60; H, 5.13; N, 9.47.
Example 54.
4-((2,6-Dichlorobenzoyi)amino]-N-[[{4S}-3-[[methyl [2-{2-pyridinyl)ethyl]amino]carbonyl]-4-thiazolidinyl]carbonyl]-E.-phenylalanine methyl ester (Scheme A, A-7: where RA_, and RA_Z are the same and equal to H, R3 is 2-(2-pyridyl}ethyl, Y is CONCH;)-, Rs is 4-((2,6-dichlorobenzoyl)amino]phenyl and stereochemistry is (S, S-- H OI( CN : N~Oi ~N ~ N~O O I ~ O CI
I
~NI ''.
HI ~ , CI
Example 54 was prepared as described in Scheme A from D-cysteine using 2-{2-methylaminoethyl)pyridine to form the requisite urea. Physical data as follows: mp 80-90°C (dec); IR (mull) 1743, 1665, 1606, 1561, 1538, 15~14, 1489, 1432, 1413, 1395, 1323, 1268, 1216. 1195, 799 cm''; IH NMR (300 MHz, DMSO-d6} 8 8.44 (I H), 8.34 (1 H), 7.66 ( 1 H), 7.5 I {5 H), 7.19 (4 H), 4.72 ( 1 H), 4.48 ( 1 H); 4.40 ( 1 H), 4.20 ( 1 H), 3.58 {4 H), 3.42 { I H), 3.89 ( I0 H); '3C NMR (75 MHz: DMISO-db) S 172.1, 170.3, 162.3, 161.8, 159.4, 149.4, 137.6, 137.0, 136.8, 133.3, 131.8, 1131.7, 130.0; 128.7, 123.8, 122.0, 119.8, 64.58. 53.8, 52.7, 52.5, 49.7, 36.5, 36.2, 35.7. 33.4; MS (ESI+) for C3oH3,ChNSOSS
m/z 643.9(M+H)'; Anal. Calcd for C3oH~,C1zN50sS: C. :>5.90; H, 4.85; N; 10.86.
Found:
C, 55.52; H, 5.09; N, I0.b4 Example SS.
4-[(2,6-Dichlorobenzoyl)amino]-N-[[(4S}-3-[[methyl[2-{2-pyridinyl)ethyl]amino]carbonyl]-4-thiazolidinyl]carbonyl]-L-phenylalanine S (Scheme A, A-8: where R~_, and RA_2 are the same and equal to H. R, is 2-(2-pyridyl)ethyl, Y is CON(CH3)-, R5 is 4-[(2,6-dichiorobenzoyl)amino]phenyl and stereochemistry is (S, ~)~
S-. H O'I
w ( ~~~N~Oi-!
N N O I ~ O Cl I
H I/
Ct Example SS was prepared from example S4 by the procedure described in preparation 6.
Physical data as follows: IR (mull) 1682, 1656, 1606, 1561, 1540, 1 S 13, 1432, 1413, 1398, 1323, 1268, 1242, 1195, 799, 780 cm ''; 'H NMR (300 MHz, DMSO-db) S
10.66 ( 1 H), 8.45 ( 1 H), 8.09 ( 1 H), 7.66 ( 1 H), 7.S 1 (S H), 7.f.0 (4 H), 4.72 ( 1 H), 4.40 (2 H), IS 4.23 (1 H), 3.61 (1 H), 3.40 (1 H), 3.04 (7 H), 2.79 (3 H); MS (ESI+) for C,9H29C1zN505S
m/z 629.9 (M+I-i)~; Anal. Calcd for C,9H29C12NSOSS ~ 0.~6I H,O: C. 54:29; H, 4.75; N, 10.92. Found: C, 54.29; H, 5.00; N, 10.32. % Water (k;F): 1.72.
Example S6.
4-[(2,6-Dichlorobenzoyl)amino]-N-[[(453-(4--morpholinylcarbonyl~4--thiazolidinyl]carbonyl]-t,--phenylalanine methyl ester (Scheme A, A-7: where RA_, and RA_Z are the same and equal to H, R~ and Y
together form CO-morpholino, R5 is 4-[(2,6-dichlorobenzoyl)amino]p:henyl and stereochemistry is (S, ~).

S.,. H O
~N N °i M ,r Example 56 was prepared as described in Scheme A from D-cysteine using morpholine to form the requisite urea. Physical data as follows: mp 223-225°C; I H
NMR (300 MHz, DMSO-db) 8 10.66 ( I H), 8.25 ( 1 H), 7.5 I (5 H}, 7.16 (2 H), 4.81 ( l H), 4.60 ( 1 H), 4.50 (1 H), 4.28 (1 H), 3.64 (3 H), 3.53 (4 H), 3.09 (8 H}; "C NMR (75 MHz, DMSO-d6) 172.1, 170.3, 162.3, 161.4, 137.6, 136.8, 133.3, 131.8, 131.7, 130.0, 128.7, 119.8, 66.2, 64.3, 53.8, 52.8, 52.5, 46.8, 36.1, 33.7; HRMS (FAB) cz~lcd for C,6H2gCL,N406S+H, 595.1185, found 595.1189; Anal. Calcd for C26HZ$CI,N,~D6S: C, 52.44; H, 4.74;
N, 9.41.
Found: C, 52.42; H, 4.96; N, 9:23.
Example 5 7.
N-[[(4S~3-[[Bis(2-hydroxyethyl)aminojcarbonylj-4--thiazolidiny ljcarbonyl]-4-[(2,1r dichlorobenzoyl)amino]-~-phenylalanine methyl ester (Scheme A, A-7: where RA_, and RA_Z are the same arid equal to H, R3 is 2-hydroxyethyl and Y is CON{CH,CH,OH), RS is 4-[(2,6-dichlorobenzoyl)amino]phenyl and stereochemistry is (S, S)).
5-.. H O
CN~ N~Oi HO~N~° I° ! ~ ~ G
HoJ ~N
i Example 57 was prepared as described in Scheme A from D-cysteine using diethanolamine to form the requisite urea. Physical data as follows: mp I05-107°C; IR
(mull) 3284. 1743, 1662, 1608, 156I, 1539, 1516, 1432, 1414, 1355, 1326, 1270, 1217, 1 I96, 799 cm ~'; ~H NMR (300 MHz, DMSO-d~) 8 10.69 (l H), 8.28 (1 H), 7.56 (4 H), 7.47 ( I H}, 7.16 (2 H), 4.87 (3 H),~ 4.66 { I H}, 4:47 ( 1 H}, 4.25 ( I H), 3.63 (3 H), 3.47 (6 H), 3.02 (6 H); MS (ESI+) for Cz6H3oCIZN4O7S m/z 612.9 (M+H)*; Anal. Calcd for C26H30C1?N4O7S ~ 0.47 H,O: C, 50.21; H, 5.01: N, 9.Oi. :Found: C, 50.02; H, 5.00; N, 8.93.
Water (KF): 1.36.
Example 58.
N-[[(4S}-3-[[Bis(2-hydroxyethyl)amino]carbonyl]-4-thiazolidinyl]carbonyl]-4-[(2,6 dichlorobenzoyl)amino]-L-phenylalanine (Scheme A, A-8: where RA_, and R~_z are the same and equal to H, R, is 2-hydroxyethyl and Y is CON(CH,CH,OH), RS is 4-[(2,6-dichiorobenzoyl)amino]phenyl and stereochemistry is (S, S)).
S. H~ O
~N~N~OH
HO~N~O O I ~ ~ CI
HOJ ~N
H
cl-Example 58 was prepared from example 57 by the procedure described in preparation 6.
Physical data as follows: IR (mull} 3281, 3196, 1724, 1660, 1608, 1580, 1561, 1542, 1515, 1431, 1415, 1354, 1328, 1271, 1196 cm ~'; 'H NMR (300 MHz, DMSO-db) 8 10.65 (1 H), 8.13 (1 H), 7.55 (4 H), 7.47 (1 H), 7.16 {2 H), 4.85 (2 H}, 4.66 (1 H), 4.40 (i H), 4.27 ( 1 H), 3.48 {6 H), 3.01 (6 H); MS (ESI+) for CZSHz$(:1,N~07S mlz 598.9 (M+H}+;
Anal. Calcd for Cz5H~8C1~N,~O,S ~ 1.04 HBO: C, 58.58; H, 4.90; N, 9.06. Found:
C, 48.88;
H, 5.05; N, 8.79. % Water (KF): 3.02.
Example 59.
[S-(R*,R*)]-4-jj[ 1-[j4-[(2,6--dichlorobenzoyl)amino]phenyl]methyl]-2-methoxy-oxoethyl]amino]carbonyl]-S-oxo-3-thiazolidinepe~ntanoic acid 3-methyl ester {Scheme A, A-'7: where RA_, and RA_, are the same and equal to H, R~ is CH~CH,CH,CO~CH3, Y is CO, R$ is 4-[(2,6-dichioroben2:oyl)amino]phenyl, and stereochemistry is (S,S)}.

_80_ S-. H OI' O ~N~N~Oi ~O~O O l ~ O CI
N' w h~ l /
iCl Example 59 was prepared as described in Scheme A from D-cysteine using methyl glutaryl chloride to form the requisite amide. Physical dlata as follows: IR
(mull) 3266, I741, 1734, 1685, 1678, 1630, 1610. 1560, 1545, 1441, 1435, 1414, 1327, 1268, 1227 cm' ' ; IH NMR (DMSO-db} 8 10.65 (1 H), 8.43 (I H), 7.50 (5 H}, 7.15 (2 H), 4.72 (2 H), 4.44 (2 H), 3.63 (3 H), 3.56 (3 H), 3.10 (4 H), 2.15 (4 H), 1. i'0 (2 H}; "C NMR
(CDC13) 8 171.6, 170.6, 170.1, 169.9, I69.6, 161.9, 137.2, 136.5, 132.9, 131.3, 129.7, 128.3, 119.4, 61.4, 53.7, 53.5, 52.0, 51.3, 48.7, 36.4, 35.8, 35.1, 33.I, 32.8, 32.5, 25.4, 19.8; MS (ESI+) for C,7HZ9N3O7SC12 mlz 610.0 (M+H)'; MS (ESI-) for C,7Hz9N30,SCh mlz 608.0 (M-H)';
Anai. Calcd fox C,7H29C12N30,S: C, 53.12; H, 4.79; N, 6.88. Found: C, 52.81;
H, 4.90; N, 6.88 Example 60.
[S-(R *,R* )]--4-[[[ I -Carboxy-2-[4-[(2,6-dichlorobenzoyl)amino]phenylJethyl]amino]carbonyl]-b--oxo-3-thiazolidinepentanoic acid (Scheme A, A-8: where RA_, and RA_z are the same and equal to H, R3 is CHZCH~CH,COZH, Y is CO, RS is 4-[(2,6-dichlorobenzo~yl}amino]phenyl, and stereochemistry is (S,S)}.
S-. H OI' ~N~OH
HO O O l ~ O CI
H~ I /
C;i Example 60 was prepared from example 59 by the procedure described in preparation 12.
Physical data as follows: IR (mull} 3271, 3193, 3124, 1'.125, 1661, 1607, I56I. 1539, 1516, 1432, 1414, 1327, 1271, i 195, 799 cm -';'H NMR (DMSO-db) S 12.40 (1 H), 10.63 ( l H), 8.31 ( 1 H). 7.50 (5 H), 7.16 (2 H), 4.75 (2 H), 4:34 {2 H), 2.95 {4 H), 2.15 {4 H), 1.66 (2 H); "C NMR (CD~CN) 8 175.0, i 72.7, 172.6, 17I Ø 163.5, 137.8, 137.0, 134.4, 132.7, 132.3, 131.1, 130.9, 129.1, 120.7, 63.2, 54.5, 49.9, 37.2, 34.1, 33.3, 20.7; MS
(ESi+) for C,SH~sCI,N30,S mlz 582.0 (M+H)+; MS fESI~-) far C,SHz5C12N30,S mlz 579.9 (M-H)-; Anal. Calcd for CZSH2sChN30,S ~ H20: C. 50.01. ; H, 4.53; N, 7.00.
Found: C, 49.61; H, 4.38; N. 6.61.
Example 61.
N-[[(4S~3-Acetyl-thiazolidinyl]carbonyl]-~i--[{f.,6-dichlorobenzoyl)amino]-~-i 0 phenylalanine methyl ester (Scheme A, A-7: where R.4:1 and RA.z are the same and equal to H, R3 is CH3, Y
is CO, RS
is 4-[(2,6-dichlorobenzoyl)amino]phenyl, and stereochelmistry is (S,S)).
S-. H t7 O t:l H II , C ~I
Example 61 was prepared as described in Scheme A from D-cysteine using acetyl chloride to form the requisite amide. Physical data as follows: l:R (mull) 3260, 3067, 1748, 1686, 1623, 1608, 156 I , 1542, I' S 1 S, 1445, 1429, 1419, 1324, 1267, 1221 cm '';
' H NMR
(DMSO-db) 8 8.44 ( 1 H), 7.52 (5 H), 7.17 (2 H), 4.78 (2 H), 4.37 (2 H), 3.63 (3 H), 3.06 (4 H), 1.94 (3 H); "C NMR (DMF-d,) b 172.4, 170.6, 1:38.4, 137.5, 133.8, 132.3. 131.9, 130.6, 128.9, 120.0, 70.9, 63.6, 62.4, 54.7, 52.3, 50.2, 4!x.8, 49.2, 37.2, 36.6, 22.7; MS
(ESI+) for C,3H,3C1zN~O5S mlz 523.9 (M+H)+; MS (ESI+) for Cz3Hz3C12N30sS mlZ
545.8 (M+Na)'; HRMS (FAB) calcd for Cz3H,,C12N305S+H, 524.0814, found 524.0812;
Anal.
Calcd for C,3H,3Cl,N~OSS ~ 0.1 H,O: C, 52.46; H, 4.45; N, 7.98. Found: C, 52.85; H, 4.42; N, 8.00. % Water (KF): 0.24.

-8z-Example 62.
N-[[(4S}-3-Acetyl-4-thiazolidinyl]carbonyl]-~-[(2;6-dichlorobenzoyl)amino]-t,-phenylalanine (Scheme A, A-8: where R"_, and RA_Z are the same and equal to H. R, is CH3, Y
is CO, RS
is 4-[(2,6-dichlorobenzoyl)amino]phenyl, and stereochemistry is (S,S)).
S-. H O
'OH
Q O f ~ O CI
H
CI
Example 62 was prepared from example 61 by the procecture described in preparation 6.
Physical data as follows: IR (mull) 3070, 1747, 1682, 1663, 1625, 1608, 1580, 1561, 1548, 1514, 1443, 1431, 1416, 1278, 1220 cm'';'H NMR (DMSO-d~) 8 12.48 (1 H), 10.63 (I H), 8.29 (1 H}, 7.50 (5 H), 4.73 (2 H), 4.34 (2 H;), 2.97 (4 H), 1.93 (3 H);
'3C NMR (DMSO-db) 8 172.4, 169.6, 169.2, 168.5, 168.0, 161.7, 136.9, 136.3, 133.2, 133.0, 131.2, 129.6, 128.1, I 19.2, 62.2, 61.0, 53.5, 53.3, 49.3, 48.4, 36.3, 35.7; 35.0, 33.1, 22.4, 20.9; MS (ESI-) for C"H2,C12N305S m/z 507.9 (M-l~)'; Anal. Calcd for C~~H~,C1,N305S ~ 0.1 HZO: C, 51.57; H, 4.18; N, 8.20. Found: C, ~ 1.49: H, 4.36; N, 8.07.
°,% Water (KF): 0.40.
Example 63.
[S-(R*,R*)]-4-CCCI-carboxy-2_.[4-C(2,6-dichlorobenzoyl)amino]phenyl]ethyl]amino]carbonyl]-5,5-dimethyl-$-oxo-3-thiazolidinebutanoic acici (Scheme A, A-8: where RA_, and RA_z are the same and equal to CH3, R, is CH,CHZCOZH, Y is C0, RS is 4-[(2,6-dichlorobenzoyl)amino]phenyl, and stereochemistry is (S,S)).

WO 99/6?230 PCT/US99114233 /Sy H~ O
~PI~N =' OH
HO~O O I ~ ~ CI
~0 i H I~
Ct' Example 63 was prepared as described in Scheme A from D-penicillamine using methyl succinyl chloride to form the requisite amide. Physical data as follows: IR
(mull) 3264, S 3198, 3071, 1721, 1660, 1608, 1562, 1541, 1516, 1432, 1415, 1327, 1270, 1195, 799 cm'';
'H NMR (DMSO-db) 8 10.62 (I H), 8.1 S (i H), 7.52 (5 H), 7.18 (2 H), 4.72 (2 H), 4.43 (3 H), 2.91 {4 H}, 2.17 (2 H), 1.36 (3 H), 1.07 (3 H);'3C NMR (DMSO-db) 8 173.5, 172.6, 170.2, 169.7, 168.4, 168.1, 161:7, 136.9, 136.3, 133.3, 1:31.1, 129.6, 129.4, 128.1, 119.2, 70.6, 53.8, 53.5, 51.6, 48.4, 47.7, 35.9, 30.7, 30.5, 28.9, :?8.6, 24.1; MS
(ESI+) for CZ6Hz7ChN307S mlz 596.0 (M+H)+; MS (ESI+) for C,6H~,~C12N30,S mlz 6I7.9 (M+Na)+.
MS (ESI-) for C~6Hz7C1,N30,S mla 593.8 (M-H)'; MS (FAB) mlz (rel. intensity) (MH+, 20), S98 (1S), S96 (20), 331 (1 I), 193 ( 13), 141 (IS), 139 (99), 116 (16), 107 (13), 105 (S0), 89 (2S); HRMS {FAB) calcd for Cz6H27C1,N30.,S+H, 596.1025, found 596.1036.
Example 64.
1 S [S-{R*,R* )]-4-[[[ 1-Carboxy-2--[4-[(2,6-dichlorophenyi)methoxy]phenyl]ethyl]amino]carbonyl] y-oxo-3-thiazolidinebutanoic acid (Scheme A, A-$: where RA_, and RA_2 are the same and equal to H, R3 is CHZCH~COzH, Y
is CO, RS is 4-[(2,6-dichlorophenyl)methoxy]phenyl, and stereochemistry is (S,S)).
z0 S-: H O
~N~N~OH
HO~O O I ~ CI
[O~ - i O~
CI
Example 64 was prepared as described in Scheme A from D-cysteine using methyl succinyl chloride to form the requisite amide. Physical data as follows: IR
(rnull) 3073, 3031, 1725, 1640, 1612, 1585, 1565, 1535, 1511, 1439, 1300, 1241, 1196, 1179, 768 cm';
'H NMR (DMSO-db) 8 8.26 (I H), 7.53 (2 H), 7.44 (I H), 7.I2 (2 H), 6.93 (2 H), 5.16 (2 H), 4.75 (2 H), 4.40 (2 H), 4.20 (I H), 2.81 (4 H), 2.3:2 (2 H), 2,07 (1 H);'3C NMR
(DMSO-db) 8 173.8, 172.6. 170.0, 169.3,157.I, 136.0; 131.5, 130.4, 130.0, 129.8, 128.7, 114.2, 64.8, 61.5, 53.6, 48.5, 36.I, 35.5, 35.0, 33.1, 28.9, 28.6, 21.0; MS
(ESI+) for C24H24C12N2~7S ~Z 554.8 (M+H)~; MS (ESI-) for Cz4HzaC1zN,07S m/z 552.7 (M-H)';
HRMS (FAB) calcd for Cz4Hz4C1zN20,S+Ht 555.0759, found 555.0750.
Example 65.
N-[[(4S}-3-Acetyl-4--thiazolidinyl]carbonyl]-O-[(?.,6-dichlorophenyl)methyl]-1.-I0 tyrosine methyl ester (Scheme A, A-7: where R~_, and R,,_z are the same and equal to H, R, is CH3, Y
is CO, RS
is 4-[(2,6-dichlorophenyl)methoxyJphenyl, and stereochemistry is (S,S~).
s--.. ~ oI, CN~N~Oi H3C~0 C ~ ~ Ct 'O
Ct IS
Example 65 was prepared as described in Scheme A frorn D-cysteine using acetyl chloride to form the requisite amide. Physical data as follows: I1z (mull) 1744, 1657, 1612, 1585, 1564, 1511, 1438, 1405, 1352, 1299, I240, 1197, 1 I79, 1016, 768 cm'; 'H NMR
{CDCl3) b 7.36 (2 H), 7.24 ( 1 H), 6.97 (5 H), 5.24 (2 H), 5.04 ( 1 H), 4.78 ( 1 H), 4.50 (2 H), 3.74 20 (3 H}, 3.45 ( 1 H), 3. I 7 (3 H), 2.02 (3 H); '3C NMR (CDC:1,) 8 172.7, 171.6, 171.4, 169.8, 168.9, 168.7, 157.8, 136.9, I3I.9, 130.3, 129.9, 128.6, 128.4, 114.9, 65.1, 61.6, 56.0, 53.6, 53.3, 49.6, 36.7, 3 I.7, 22.5; MS (ESI+) for Cz3H24C:IzN,OSS m/z 532.9 (M+Na)+; MS
(Ei) mlz (rel. intensity) 510 (M+, I), 338 (42), 337 (I2), 336 (63), 267 (12 ), 265 (18), 163 (10), 161 (63), 159 (99), 130 (9), 88 (43); Anal. Calcd for Cz3HzaCIzN,OSS~0.19 H,O: C, 25 53.66; H, 4.77; N, 5.44. Found: C. 53.81; H, 4.75; N, 5.:33. % Water (KF):
0.66.

Example 66.
N-[[(4S}-3-Acetyl-4-thiazolidinyl]carbonyl]-0-[(~!,6-dichlorophenyl)methyi]-~-tyrosine (Scheme A, A-8: where R,,_, and RA_2 are the same and equal to H, R3 is CH,, Y
is CO, R, is 4-[(2,6-dichlorophenyl)methoxy]phenyl, and stereochemistry is (S,S)). .
S-. H O
~~~ N ~OH
O
H3C O I ~ Ct Example 66 was prepared from example 65 by the procedure described in preparation 6.
Physical data as follows: IR (mull) 1730, 1646, T6I2, 1585, 1565, 151 I, 1439, 14I4, 1299, 1240, 1196, 1179, 1016, 779, 768 cm''; ' H NMR (DMSO-db) 8 8.26 ( 1 H), 7.54 (2 H), 7.44 ( 1 H), 7.13 (2 H), 6.92 (2 H), 5. i 6 (2 H), 4.7:? (2 H), 4.31 (2 H), 2.91 (5 H), 1.92 (3 H);'3C NMR (DMSO-db) 8 172.6, 169.2, 168.0, 157.1, 136.0, 131.7, 131.5, 130.3, 128.7, 114.2, 64.$, 62.2, 6I.0, 53.7, 49.4, 48.5, 36.1, 35..5, 35.1, 33.2, 22.4, 21.0; MS
(ESI+) for CZZH~ZC12NZOSS mlz 496.9 (M+H)+; MS (ESI-) for C~HZZCIzN,OSS mlz 494.8 (M-H)'; MS (FAB) m/z (reI. intensity} 497 (MH+, 99), 6I7 (29), 573 (12), 539 (25), 500 11 ), 499 (78), 498 (38), 497 (99), 496 ( 11 ), 225 (62}, 130 ( 14); HRMS
{FAB} calcd for C,~H"CI,NZOSS+H, 497.0705, found 497.0713; Anal. Calcd for CZ,H~,C1,N,05S ~
0.41 H20: C, 52.35; H, 4.56; N, 5.55. Found: C, 52.65; H, 4.51; N, 5.50. % Water (KF): 1.46.
Example 67.
[R-(R*,S*)]-4-[[[ I-Carboxy-2.-[4-[(2,6-dichlorobenzoyl)amino]phenyl]ethyl]amino]carbonyl]-y-oxo-3-thiazolidinebutanoic acid (Scheme A, A-8: where RA_~ and R4_2 are the same and equal to H, Ra is CH,CH,CO,H, Y
is CO, RS is 4-[{2,6-dichlorobenzoyl)amino]phenyl, and stereochemistry is {R,S)).

~s~ o .~~~,H- ~
'OH
O-0 O I ~ ~) Ci HO
H I ~
CI
Example 67 was prepared as described in Scheme A from L-cysteine using methyl succinyl chloride to form the requisite amide. Physical data as follows: ' H
NMR
(CD3CN) 8 8.86 ( 1 H), 7.55 (2 H), 7.42 (3 H}, 7.24 {2 H), 7.11 ( 1 H), 4.90 ( 1 H}, 4.65 (2 H), 4.33 (I H), 3.14 {3 H), 2.47 (6 H), 1.80 (1 H); "C NMR (CD3CN) 8 174.7, 172.6, 172.3, 170.7, 163.4, 137.7, 137.0, 134.4, 132.7, 132.2, 130.9, 129.1, 63.2, 60.9, 54.4, 49.7, 37.1, 36.7, 32.7, 30.6, 30.0, 29.5, 21.1, 14.4; MS (FAB} m/Z (rel. intensity) S68 {MH+, 99), 646 (11); 644 (16), 572 (13), 571 { 12), 570 (73}, 5Ei9 (38), 568 (99), 567 (15), 216 (22), 88 (27); Anal. Calcd for C,4H23CIzN307S ~ 0.5 H,O: C, 49.92; H, 4.19; N, 7.23.
Found: C, 50.01; H, 4.54; N, 7.05.
Example 68.
[R-{R*,S*)]-4-[[[1-Carboxy-2-[4-[(2,6-dichlorobenzoyl)amino]phenyl]ethyl]amino]carbonyl]-8-oxo-3-thiazolidinepentanoic acid (Scheme A, A-8: where R.4_, and R,~_z are the same and equal to H, R3 is CHZCH~CH~CO,H, Y is CO, RS is 4-[(2,6-dichlorobenzoyi)amino]phenyl, and stereochemistry is {R,S~).
H_ J~
~s~ o 'ON
O O I ~ O CI
HO-O N' w ~ I ~
cl Example 67 was prepared as described in Scheme A from L-cysteine using methyl glutaryl chloride to form the requisite amide. Physical data as follows: 'H NMR (CD3CN) 8 8.85 (1 H), 7.55 (2 H), 7.44 (3 H), 7.17 (3 H), 4.86 (1 H), 4.64 {2 H), 4.34 (1 H), 3.64 (1 H), _87-3.13 (3 H), 2.27 (4 H}, 1.79 (4 H):; '3C NMR (CD3CN) 8 175.0, 172.9. 172.7, 170.6, 163.4, I37.7, 137.0, 134.2, 132.7, 132.2, 131.0, 129.1, 120.7, 68.2, 63.1, 54.2, 49.8, 37.1, 36.9, 34.0, 33.2, 32.6, 26.2, 20.6; MS (FAB) m/z (rel. intensity) 582 {MH+, 99), 585 (12), 584 {68}, 583 (35), 582 ( 99), 581 (11), 88 (23}, 69 {8), 57 (9;1, 55 (11), 43 (11); Anal. Calcd for C,SH,SC1~N~O,S ~ 0.2 HZO: C, 51.24; H, 4.37; N, 7.17. Found: C, 51.25; H, 4.68; N, 6.92.
Example 69.
N-[[{4R}-3-Acetyl-4.-thiazolidinyl]carbonyl]-~-[(2,6-dichlorobenzoyi)amino]-~.-phenylalanine methyl ester (Scheme A, A-7: where RA_, and RA_Z are the same and equal to H, R~ is CH3; Y
is CO, RS
is 4-[(2,6-dichlorobenzoyl)amino]phenyl, and stereochernistry is (R,S~).

H I' N~N~Oi H3C~0 ~ I ~ O CI
~N
H~N
CI
Example 69 was prepared as described in Scheme A from L-cysteine using acetyl chloride to form the requisite amide. Physical data as follows: IR. (mull) 3268, 1743, 1662, 1607, 1561, 1538, 1515, 1431, 1413, 1354, 1324, 1270, I217, 1195, 799 crri ';'H NMR
(CDC13) 8 7.56 (3 H), 7.31 (4 H}, 7.14 (2 H), 4.92 (2 H), 4.49 ( 1 H), 4.29 ( 1 H), 3.77 (3 H), 3.54 (1 H), 3.26 {1 H}, 3.00 (2 H), 2.11 (3 H);'~C NMR (CDC13) b 171.5, 170.3, 168.9, 152.5, 135.9, 135.7, 132.9, 132.3, 131.0, 130.1, 129.9, 128.2, 1:28.0, 127.9, 120.4, 63.9, 61.4, 53.1, 52.5, 49.7, 37.0, 3 i.2, 22.6; MS {ESI+) for Cz3Hz3C=1,N305S mlz 523.8 (M+H)+.
Example 70.
N-[[(4R)-3 Acetyl-4-thiazolidinyl]carbonyl]-4-[(2,6-dichlorobenzoyl)amino]-~-phenylalanine {Scheme A, A-8: where RA_, and RA_2 are the same and equal to H, R~ is CH,, Y
is CD, RS
is 4-[(2,6-dichlorobenzoyl)amino]phenyl, and stereochemistry is {R,,S~).

S H O
C ~ N~OH
HgC~O O 1 ~ O CI
H ' CI
Examp1e70 was prepared from example 69 by the procedure described in preparation 6.
Physical data as follows: IR (mull) 3276, 3068, 1727, 1661, 1607, 1561, 1540, 1516, 1444, 1431, 1414, 1327, 1271, 1218, 1 I95 cm '; 'H NMR (DMSO-db) 8 12.78 (1 H), 10.67 (1 H), 8.27 (1 H), 7.49 (4 H), 7.19 {2 H), 4.75 {2 H), 4.415 (3 H), 3.01 (3 H), I.96 (3 H);
'3C NMR {DMSO-db) b 172:6, 172.3, 169.4, 168.6, 168.:2, 161.7, 136.9, 136.3, 133.3, 132.8, 131.1, 129.6, 128.1, 119.1, 62.2, 60.9, 53.4, 49.3, 48.7, 35.9, 35.1, 32.7, 22.4; MS
(ESI+) fox C,zH2,Cl~N305S mlz 509.8 (M+H)+; MS (ESI-.) for CZZHZIC1,N305S mlz 507.$
(M-H)'; HRMS (FAB) calcd for CzzH21C12N305S+HI 5It1.0657, found 510.0667;
Example 7I .
4-[(2,6-Dichiorobenzoyl)amino]-N-[[(4R}-4-thiazolidinyI]carbonyl]-L-phenylalanine monohydrochloride salt (Scheme A, A-10: where RA_, and RA_2 are the same and equal to H, RS is 4-[(2,6-i S dichlorobenzoyl)amino]phenyl, and stereochemistry is (n,.S'~).
<s~ a H_ ~
N N v 'OH
H
O I ~ O CI
CI
Example 7I was prepared as described in Scheme A from L-cysteine. Physical data as follows: IR (mull) 3249, 3190, 3036, 1729. 1662, 1605, 1578, 1562, 1541, 1516, 1432, 1414, 1328, 1271, 1195 crri';'H NMR (DMSO-db) 8 10.71 (1 H), 8.83 (1 H), 7.56 (5 H), 7.24 (2 H), 4.50 ( 1 H), 4.25 ( I H), 4.2I (2 H), 3.62 ( 1 H), 3.01 (4 H); '3C
NMR (DMSO-db) 8 172.0, 166.8, 161.8, 137.7, 132.7, 131.3, 131Ø 12SL5, 128.1, I 19.4, 72.0, 70.4, 62.3, 53.8, 49.0, 35.7, 33.4; MS (ESI+) for C,oH,9Cl,N;O,S rrva 468.1 (M+H)';

Scheme B
HS R9.1 Re z 8-1 HZN~OH.
nO
O

R8 ~Re~
Rg_~
Rg~ Re-2 ~OH 8.3 Rs~ H O
RB_~
RB~~' R8.2 B-4 ~OH
[[[[N
RB~a y O
R~

rR5 !3-5 Hy ' ~N
RB_~
O
RB.3 S Re_2 O
R Res 0 ~ 8-8 RB_~
Rea S Rs_2 O
R ~NH OH
O ~ B-7 Re_~
Rss S RB 2 O
~NH OH &8 Rep H 0 WO 99!67230 PCTIUS99/14233 where RB_,, RR_,, RH_,, and RBA are defined as R, and in addition RB_, and Rep may be attached to the same carbon atom and form a cyclic ring of 5-8 atoms of the formula:
~(CH~)l~
C NR~~
~ ~(CHZ)t/
together with the carbon atom to which they are attached; Rs_5 is defined as OH or O-(C,~
alkyl) Scheme B describes a general method for the preparation of thiazolidine-4-carboxylic acid derivatives of general structure B-6, B-7 and B-8 which are disubstituted at the 2 position (i.e., RB_3 and RBA are not equal to H). VVithin this class of structures, the nitrogen is derivatized immediately after forming the heterocyclic ring.
Accordingly, a I O commercially available or readily prepared sulfur-containing amino acid of structure B-I
(which is the same structure as A-1) is condensed with a commercially available or readily prepared ketone to afford the thiazolidine-4-carboxylic acid of general formula B-3 (preparation 15) (for a general discussion of the condensation of aldehydes and ketones with cysteine or similar sulfur containing amino acids see: Coppola, G.M.;
Schuster, H.F.
I 5 Asymmetric Synthesis: Construction of Chiral Molecules Using Amino Acids;
.Iahn Wiley:
New York, 1987; Chapter 6, I7I.). The amine group may be reacted with a variety of electrophilic reagents such as sulfonyl chlorides, carbonates, chlaroformates.
isocyanates, phosgene (or a suitable equivalent) and an amine, acid chilorides, and carboxylic acid anhydrides as described in Scheme A far the reaction of A-6. Preparation 16 is provided 20 as a specific example of the synthesis of a compound of l;eneral structure B-4.
Condensation of B-4 with amino acid derivative B-5 under standard peptide synthesis conditions provides the compound of general structure B-6 (preparation 17).
Mild base hydrolysis of the methyl ester of general structure B-6 (where RB_5 is OCH3) may be effected as described and exemplified in Scheme A (preparation 6 or i3) to afford 25 compounds of the general structure B-7. Alternatively, in those cases where RB_5 is O-t-Bu, mild acidolysis can also provide compounds of the general structure B-7 (by the procedure described in preparation 4 of Scheme A). In the case of t-butoxycarbonyl derivatised analogs of general structure B-7 (i.e. where R, is t-butyl and Y
is CO,), mild acidolysis affords compounds of general structure B-8 (by the procedure described in preparation 4 of Scheme A).
Preparation 15.
(Scheme B, B-3: where Rg_, and RB_2 are the same and c;qual to H, RB_~ and R~~
are the S same and equal to CH,. and stereochemistry is (R)).
H3G,,./S
H3C/~H~OH
O
A suspension of L-cysteine hydrochloride monohydrate (Scheme B. B-1: where R,~_, and RB_Z are the same and equal to H and stereochemistry is (R)) {20 g, 0.11 mol) in acetone (Scheme B, B-2: where RB_3 and Rg~ are equal to CH3) (800 mL) was heated to reflux for 8 h. Cooling to room temperature resulted in precipitation of a solid which was collected by filtration, washed with acetone and dried in vacuo to afford the title compound (17.46 g) as a white solid: mp 165-167°C; (Lit. 165-I68°C: Sheehan, 3.C.; Yang, D-D.H. J. Am.
Chem. Soc. 1957, 80, i 1 S 8) ~ H NMR (DSO) 8 4.75 ( 1 H), 3.59 ( 1 H), 3.44 ( 1 H), 1.73 (3 H), 1.71 (3 H); MS (ESi-) for C6H"NOZS m/z 159.9 (:M-H)'.
Preparation 16.
(Scheme B, B-4: where Ra_, and Ra_z are the same and equal to H. RB_3 and RB~
are the same and equal to CH,, Y is COz, R3 is t-butyl and stereochemistry is (R)).
H3G,~S
H3C N~OH
O~ ''O
O
To a solution of B-3 (Scheme B where Rs:, and RB_2 are the same and equal to H, RB_3 and RB~ are the same and equal to CH3, and stereochemistry is (R)) ( 17.46 g, 0.11 mol) in acetonitrile (250 mL) at ambient temperature was added di-t-butyl dicarbonate (25.64 g, 0.117 mol) followed by N,N-diisopropylethylamine (16.9 mL, 0.097 mol). The reaction mixture was stirred for ? days and volatiles remove in vcrcuo. The residue was slurried in diethyl ether and filtered through a pad of celite. The filtrate was washed with 0.1 N HCI, water, brine, dried (Na2S04), filtered and concentrated ir! vacuo:
Crystallization of the clear oil from hexane provided the title compound (3.85 g) as a white solid:
mp 125-126°C; {Lit. 114°C: Woodward, R.B.; Heusler, K.; Go:>teli, J.;
Naegeli, P.; Oppolzer, W.;
Ramage, R.; Ranganathan, S.; Vorbruggen, H. J. Am. Cliem. Soc. 1966, 88, 8S2)'H NMR
(CDCI~) & 8.70 (1 H), 4.89 (1 H), 3.27 (2 H), 1.81 (6 H); MS (ESI-) for CI
IH,9N04S m/z 260.1 (M-H)-.
Preparation 17 and Example 72.
IO [R-(R*,S*)]-4-[[[1-[[4-[(2,6-Dichlorobenzoyl)amino]phenyl]methyl]-2-methoxy-oxo-ethyl]amino]carbonyl]-2.2-dimethyl-3-thiazolidinecarboxylic acid 3-{1;1-dimethyiethyl)ester (Scheme B, B-6: where RB_, and Re_2 are the same and Equal to H, RB_~ and RBA
are the same and equal to CH3, Y is COz, R, is t-butyl, RB_5 is OCH3, RS is 4-[(2,6-dichlorobenzoyl)amino]phenyl and stereochemistry is (R, S)).
H3CH.. S Q
H3~~~N~Oi O
~O O ~ ~ ~ CI
CI' To a cooled (0-5°C) suspension of B-4 {Scheme B where Rs_, and RB_2 are the same and equal to H, RB_3 and Re~, are the same and equal to CH3, Y is CO2, R~ is t-butyl and stereochemistry is (R)) (1.0 g, 3.83 mmol) and HOBt (6a8 mg, 4.17 mmol) in CH,CIz (20 mL) was added a solution of EDC (799 mg, 4.17 mmol) in CI-IZCI~ (20 mL). After 30 min at 0-5°C, B-5 (Scheme B where RB_5 is OCH3, RS is 4-[(2,6-dichlorobenzoyl)amino]phenyl and stereochemistry is (S)) ( 1.93 g, 4.77 mmol) was added followed by 4-methyimorpholine (520 p.L, 4.77 mmol). The reaction mixture was gradually warmed to room temperature, stirred an additional 18 h and diluted with CH,CI,. The organic layer was separated and washed with 0.1 N HCi, sat. aqueous NaHCO;, brine. dried (Na,SO,), filtered and concentrated in vacuo: Flash chromatography of the residue using CHZCl2lacetone (3%) as eluant afforded the title compowzd (2.05 g) as a white solid: IR
(mull) 1746, 1666, 1606, 1562, I53?, 1515, 1432, 1413, 1347, 1325, 1259, I2I4, I 195, 1169, 799 cni';'H NMR (CDCl3) b 7.54 (2 H}, 7.32 (4 hf), 7.20 (2 H), 6.90 (1 H), 4.78 (2 H), 3.74 (3 H), 3.17 (4 H), 1.74 (3 H), 1:43 (9 H); "C NMR (CDCl3) 8 171.6, 136.7, 136.2, 135.9, 132.7, 132.4, 132.3, 131.0, 130.6, 130:4, 1~f0.0, 129.9, 128.2, 127.9, 120.5, 120.2, 120.1, 67.3, 53.4, 52.4, 42.8, 37.3, 36:9, 34.9, 30.9, 28.3; MS (ESI+) for Cz$H33C12N3O6S mlz 610 {M+H)+; MS (ESI-) for CzgH33C:I2N3O6S mlz 607.9 (M-H)';
Anal.
Calcd for CZgH3~Cl,N3O6S ~ 0.13 HZO: C, 54.88; H, 5.47; N, 6.86. Found: C, 54.66; H, I0 5.57; N, 6.73. % Water (KF): 0.37.
Example 73:
[R--{R*,S*)]-4-[[[I-car6oxy-2--[4-[(2,6 dichlorobenzoyI)amino]phenyl]ethyl]amino]carbonyl]-2,2-dimethyl-3 thiazolidinecarboxylic acid 3-(I,1-dirnethylethyl}ester (Scheme B, B-7: where RB_, and RB_2 are the same and equal to H, RB_3 and RB~, are the same and equal to CH3, Y is CO2, R3 is t-butyl, RS is 4-[(2,6-dichlorobenzoyl)amino]phenyl and stereochemistry is (R, ,f~).
HgCv~s H O
H3C~/~N~ N ~OH
~O~O O ~ ~ O CI
w H~I
2~ CI
Example 73 was prepared from example 72 by the procedure described in preparation 6.
Fhysicai data as follows: IR (mull) 1738, 1'665, 1606, 1562, 1535, 1516, 1432, 1413, 1347, i2S9, 1213, 1194, 1167, 799, 777 crri';'H NMR (CD,CN) b 8.89 (I H), 7.54 (2 H), 7.41 2S {3 H), 7.25 (2 H), 4.66 (2 H), 3.I5 (4 H), 1.72 (3 H), 1.7CI (3 I-I), I.35 (9 H); "C NMR
(CD3CN) 8 177.3. 171.8, 163.4, /37.9, I37.I, 133.9, 132.7, 132.3, 131.3, 129.1, 120.7, 8I.2, 79.3, 68.0, 54.5. 37.4, 28.4; MS (ESI-) for C"H"CI,N,O6S m/z 593.9 (M-H)'; Anal.

Calcd for C27H3,CIZN3O6S ~ 0.5 H,O: C, 53.56; H, 5.33; N, 6.94. Found: C, 53.77; H, 5.39; N, 6.70.
Example 74.
4-[(2,6-Dichlorobenzoyl)amino]-N-[[(4R~2,2-dimethyl-4-thiazolidinyl]carbonyl]-L-phenylalanine (Scheme B, B-8: where Ra_, and RB_2 are the same and equal to H, R~_3 and RB.~
are the same and equal to CH3, RS is 4-[(2,6-dichlorobenzoyl)amino]phenyl and stereochemistry is (R, ~).
' HgC~~s O
/~ ~H
H3C H~N~~H
O CI
w H ~~

Example 74 was prepared from example 73 by the procedure described in preparation 4.
Physical data as follows: IR (mull) 3244, 3192, 3049, 1720, 1664, 1605, 1578, 1562, 1541, 1516, 1432, 1414, 1327, 1195, 799 cni l;'H NMR (DMSO-db) 8 13.00 (1 H), 10.69 ( 1 H), 7.52 (6 H), 7.24 (2 H), 4.52 (2 H), 3.12 (2 H), 2.93 ( 1 H), 1.62 (9 H); 13C NMR
(CD,OD) & 166.9, 136.8, 136.0, 133.5, 131.8, 130.9, 129..5, 129.4, 127.9, 120.4, 120.2, 120.1, 60.8, 54:3, 54.0, 36.2, 36.0, 25.1; MS (ESI+) for CZZH23CI,N3O~S rnlz 496.2 (M+H)+; MS (ESI-) for C,zH,3CI,N304S m/z 494.2 (M-H)-; Anal. Calcd for Cz,H23C1zN3O,S
~ HCI ~ 0.50 H20: C, 48.76; H, 4.65; N, 7:75. Found: C, 48.56; H. 4.72; N, 7.49.
Example 75.
[S-(R*,R*)]-4-[[[I-[[4-[(2,6-Dichlorobenzoyl)amino]phenyl]methyl]-2-methoxy-2-oxo-ethyl]amino]carbonyl]-2,2-dimethyl-3-thiazol.idinecarboxylic acid 3-( 1,1-dimethylethyl)ester (Scheme B, B-6: where RB_, and R$_Z are the same and equal to H, Rg_3 and R~~
are the same and equal to CH,, Y is CO,, R, is t-butyl, RS is 4-[(~!,6-dichlorobenzoyl)amino]phenyl and stereochemistry is (S, S~).

S_ H O.
N N Oi ~O~O O I ~ 0 CI
H
CI
Example 75 was prepared as described in Scheme B froml D-cysteine and acetone using di-t-butyl dicarbonate to form the requisite carbamate. Physical data as follows:
IR (mull) 1745, 1686, 1666, 1605, 1537, 1515, 1432, 1413, 1349, 1325, 1259, 1213, 1206.
I I95, 1169 cni';'H NMR (CDCl3) 8 7.56 (2 H), 7.32 (3 H), 7.16 (2 H), 6.92 (I H), 4.83 (2 H);
3.73 (3 H), 3.20 (4 H), 1.78 (6 H), 1.45,(9 H);'3C NMR (CDCl3) 8 171.6, 170.0, 136.2, 132.6, 132.4, 131.0, 130.9, 130.1, 129.9, /28.2, 120.5, 12Ø4, 67.3, 53.3, 52.5, 52.4,37.4, 28.4; MS (ESI+) for C~gH33CI,N3O6S m/z 610.0 (M+H)'; :MS (ESI-) for C,8H33C1,N3O6S
m/z 607.9 (M-H)'; Anal. Calcd for Cz$H33C1zN3O6S: C, 55.08; H, 5.45; N, 6.88;
Cl, 1 i.61;
S, 5.25. Found: C, 54.87; H, 5.47; N, 6.78 Example 76.
(S-(R*,R*)j-~4-[[[ 1-Carboxy-2-~(4-[(2,6-dichlorobenzoyI)aminojphenyl]ethyljaminojcarbonylj-2,2--dimethyl--3-thiazolidinecarboxylic acid 3-( 1,1--dim~ethyiethyl) ester (Scheme B, B-7: where RB_, and RB_Z are the same and equal to H, Rr,_3 and RB~
are the same and equal to CH3, Y is CO2, R3 is t-butyl, RS is 4-[(2l,6-dichlorobenzoyl)aminojphenyl and stereochemistry is (S, S)).
S~ H~ O
H~~~OH
~O~O 0 ~ ~ O CI
H
CI

Example 76 was prepared from example 75 by the procedure described in preparation 6.
Physical data as follows: IR {mull) 3280, 1739, 1665, 1fi06, 1562, 1535, 1516, 1432, I4I3, 1348, 1272, 1259. 1195, 1167, 799 crri';'H NMR (CD3CN) 8 8.83 (I H), 7.55 (2 H), 7.43 (3 H), 7.22 (2 H), 6.83 (1 H), 4.68 (2 H), 3.07 (5 H), I.73 (6 H), 1.40 (9 H);
S '3C NMR (CD3CN) b 172.6, 163.3, 137.9, 133.4, 133.3, 132.7, 132.1, 131.1, 130.2, 130.1, 129.1, 128.1, 128.0, 120.6, 119.5, 54.1, 37.4, 29.4, 28.5, 27.6; MS (ESI+) for C~,H3,C12N3O6S m/z 595.9 (M+H)'; MS (ESI-) for CZ,H3,CIZN~O6S »~/z 593.7 (M-H)'; MS
(FAB) m/z {rel. intensity) 596 (MH+, 16), 598 (12), 596 ( 16), 500 ( 16), 499 ( 19), 498 (7I ), 497 {32), 496 (99), 173 ( 16), 1 I6 { 19), 57 {51 }; HRMS (FAB) calcd for C27H3,CI,N306S+H, 596.1389, found 596.1364; Anal. Calcd for C,7H3,CIZN306S ~
0.5 H20: C, 53.56; H, 5.33; N, 6.94. Found: C, 53.86; H, 5.35; N, 6.90.
Example 77.
[S-(R*,R*)]-3-[[[ 1-[ [4-[(2,6-Dichlorobenzoyl)amino] phenyl]methyl]-2-methoxy-oxoethyl]amino]carbonyl] -1-thia~-azaspiro[4.4Jnonane-4-carboxylic acid 4-ethyl ester I S (Scheme B, B-b: where RB., and Rg_Z are the same and equal to H, RB.3 and Ray together form a carbocyclic ring of 5 atoms, Y is CO2, R3 is ethyl, RS is 4-[(2,6-dichlorobenzoyl)amino]phenyl and stereochemistry is (S, S)).
5-.. H O
~N~N~°~
~o'~o ° f ~ o ci H
Ct Example 77 was prepared as described in Scheme B from D-cysteine and cyclopentanone using ethyl chloroformate to form the requisite carbamate. Physical data as follows: IR
(mull) 1760, 1739, 1694, 1656, 1607, 1560, 1543, 1517, 1445. 1429, 1411, 1334, 1273, 1253, I 1I6 crri';'H NMR (CDCIz) b 7.56 (2 H), 7.44 {1 H), 7.34 (3 H}, 7.11 (2 H), 6.70 ( 1 H), 4.84 (2 H), 4.14 (2 H), 3.74 (3 H), 3.12 (4 H), 2.6 i' ( 1 H), 2.51 ( 1 H), 1.73 (6 H), 1.25 (3 H); '3C NMR (CDCI~) 8171.4, 170.7, 162.3, 136.3. 135.8, 132.5, 132.4, 131.0, 130.1, 128.2, 120.2, 66.4, 62.1. 53.1, 52.5, 37.3, 32.3. 31.9, 25.1, 24.6, 14.5, 14.1; MS

(ESI+) for CzgH3~CI2N3ObS m/Z 630.0 (M+Na)'; HRMS (EI) calcd for C,gH~,C1~N306S
607.1310, found 607.131 S; Anal. Calcd for C,$H3,C1~N3(J6S ~ 0.75 H20: C, 54.06; H, 5.27;
N, 6.90. Found: C, 53.98; H, 5.16; N, 6.72.
Example 78.
S [S-(R*,R* ) j-3-[ [[ 1-Carboxy-2-[4--[(2,6-dichlorobenzoyl)amino]phenyl)ethyl]amino]carbonyl]-I-this-4-azaspiro[4.4]nonane-4-carboxylic acid 4-ethyl ester (Scheme B, B-7: where Rs_, and RH_2 are the same and equal to H, RB_3 and RH-0 together form a carbocyclic ring of S atoms, Y is CO~, R3 is ethyl., RS is 4-[(2,6-dichlorobenzoyI)amino]phenyl and stereochemistry is {S', f~).
S-- H O
C~N~N " OH
~O~O O I ~ O Ci H~I ~
Ct Example 78 was prepared from example 77 by the procedure described in preparation 6.
Physical data as follows: IR (mull) 3276, 1664, 1606, 1.'i62, 1537, 1 S 1 S, 1445, 1432, 1413, 1335, 1273, 1239, 1195, 1116, 799 cni';'H NMR (CDC13) 88.08 (1 H), 7.62 {2 H), 7.24 (3 H), 7.14 (2 H), 6.72 (1, H), 4.85 (2 H), 4.13 (2 H), 3.21 (4 H), 2.53 (2 H), 1.75 {6 H), 1.22 (3 H); '3C NMR (CDCl3) b 175.2, 171.2, 162.6, 136.7, 135.7, 132.3, 132.0, 130.7, 130.2, 127.9, 120.2, 66.3, 62.2, 53.2, 37.3, 36.6, 32.3, 25.2, 24.6, 20.5. 14.5; MS
{ESI+) for C,7H29C1zN3O6S mlz 593.8 (M+H)+; MS {ESI-) for Cz,H,gChN3O~S mlZ
591.8 (M-H)-; HRMS (FAB) caicd for C27H~~C1,N306S+H~ 594.1232, found 594.1226; Anal.
Calcd for C,7Hz9CIzN3O6S ~ 0.37 H,O: C, S3.9S; H, 4.99; N, 6.99. Found: C.
54.28; H, 5.10; N, 7.03. % Water (KF): 1.10.
Example 79.
2S [S-{R*,R*)]-3-[[[1-[[4-[{2,6-Dichlorobenzoyl)amino~]phenyljmethylj-2-methoxy-2-oxoethyl]amino]carbonylj-1-thia-4-azaspiro[4.S]decan;e-4-carboxylic acid 4-ethyl ester _98-(Scheme B, B-6: where R8_, and RB_Z are the same and equal to H, RB_3 and RBA
together form a carbocyclic ring of 6 atoms, Y is CO2, R3 is ethyl, RS is 4-[{2,6-dichlorobenzoyl)amino]phenyl and stereochemistry is (,~~, S~).
S H OI' ~N~ N~Oi CI
w H iI
$ CI
Example 79 was prepared as described in Scheme B from D-cysteine and cyclohexanone using ethyl chloroformate to form the requisite carbamate. Physical data as follows: IR
(mull) 1745, 1704, 1683, 1668, 1607, 1561, 1538, 1514, I43I, I4I3, 1327, 1269, 1213, 1196, I 117 crri'; 'H NMR (CDCl3) S 7.57 (2 H), 7.46 (1 H), 7.33 (3 H), 7.11 (2 H), 6.72 ( 1 H), 4.88 (2 H), 4.14 (2 H), 3.74 (3 H), 3. I 3 (4 H), 2.51 ( 1 H), 1.69 (8 H), 1.22 (5 H);
'3C NMR (CDCl3) 8 171.4, 170.7, 168.1, 162.3, 136.3, 135.7, 132.4, 131.0, 128.2, 120.3, 66.9, 62.8, 62.0, 55.1, 53.1, 52.5, 42.0, 39.9, 37.3, 36.9, 31.1, 29.6, 27.6, 27.1, 26.0, 25.3, 24.7, 23.1; 14.5; MS (ESI-) for Ci9H3~CI2N3O6S m/Z 621.9 (M)'; HRMS {FAB) calcd for C29HssC1zN30eS+HI 622.1545, found 622.1536.
Example 80.
[S--(R*,R*)]--3-[[[1-Carboxy-2-[4-{(2,6-dichlorobenzoyl)amino]phenyl]ethyl]amino]carbonyl]-~I-thia-4-azaspiro[4.5]decane-4-carboxylic acid 4~thy1 a ter (Scheme B, B-7: where Rs_, and Rs_Z are the same and equal to H, RB.3 and Ray together form a earboeyclic ring of 6 atoms, Y is CO,, R3 is ethyl: R5 is 4-[(2,6-dichlorobenzoyl)~mino]phenyl and stereochemistry is (~~, f~).
s ~ o N~ N~OH
~O~O O ~ ~ CI
/ H I ~
Cir /

Example 80 was prepared from example 79 by the procedure described in preparation 6.
Physical data as follows: IR (mull) 3276, 1710, i 664, I X606, 1562. 1537, 1515, 1432, 1413, 1329, 1272. 1256, 1195, i I 17, 800 cm ';'H NMR (CDCl3) b 8.07 (I H), 7.62 (2 H), 7.24 {3 H), 7.14 (2 H), 6.75 (I H), 4.88 (2 H), 4.12 (3 H;I, 3.14 (4 H), 2.74 {I H), 2.50 ( I H), 1.69 (6 H), 1.19 (5 H); ' 3C NMR (CDC13) 8 175.4, 175.1. 171.3, 162.6, 136.7, 135.7, 132.3, 132.0, 130.7, 130.3, 130./, 128.0, 120.2, 66.8, 62.1, 53.2, 42.0, 36.9, 30.5, 27.0, 26.0,25.3, 25.0, 24.6, 20.5. 14.4, 3.7; MS {ESI+) for C28H3,C1~N306S mlz 608.1 (M+H)'; MS (ESI-) for CZgH3~CIzN3O6S m/Z 605.9 (M-H)'; HRMS (EI) calcd for C,gH3'C12N306S 607.1310, found 607.1309; Anal. Calcd fvr CZgH3~C1,N3O6S ~ 0.3 HBO: C, 54.78; H, 5.19; N, 685. Found: C, 54.56; H. 5.24; N, 6.S>0. % Water (KF):
0.87.
Example 81.
[S-(R*,R*)]-4-[[[1-[{4-[(2,6-Dichlorobenzoyl)aminojphenyl)methyl]-2-methoxy 2-oxoethyl]amino)carbonyl]-2,2,S,S-tetramethyl-3-thiazolidinecarboxylic acid 3-ethyl ester (Scheme B, B-6: where RB_,, RB.2, R$_3 and Re~, are the same and equal to CH3, Y is COZ, R3 is t-butyl, RS is 4-[(2,6-dichiorobenzoyl)amino]phenyl and stereochemistry is (S, S)).
S~ H O
~CN~ NJ~o ~O~O O I ~ O CI
'N
H~I ~
CI
Example 81 was prepared as described in Scheme B from D-penicillamine and acetone using ethyl chloroformate to form the requisite carbamate. Physical data as follows: IR
(mull) 1748, 1666, 1606, 1562, 1538, 1 S 16, 1432, 1413, 1327, 1275, 1233, 1215, I 195, 1080, 799 cm'; 'H NMR (CDCl3) b 7.55 (2 H), 7.33 (4 H), 7.09 (3 H), 6.59 (1 H), 4.91 ( 1 H), 4.47 { I H), 4.16 {2 H), 3.75 (3 H), 3.13 (2 H), 1.9:? (3 H), 1.75 (3 H), 1.67 (3 H), 1.60 (3 H), 1.21 (3 H);'jC NMR (CDC13) 8 171.5, 170.0, 162.2, 136.1, 135.7, 132.5, 132.3. 131.9. 130.9, 130.7, 129.7, 128.1. 120.3. 120.1, 1:20.0, 61.6. 61.4, 52.9, 52.4, 52.2, 49.3, 37.4, 37.3, 34.1, 31.4, 30.8, 29.5, 24:9; MS (ESI-) :for C28H33C1zN3O6S
mlz 607.9 (M-H)'; HRMS (EI) calcd for CZ8H33C12N306S 609.1467, found 609.1461; Anal. Calcd for CZ8H3~CIzN3O6S ~ O.I9 H~O: C, 54.77; H, 5.48; N, 6.84. Found: C, 55.00; H, 5.48; N, 6.78.
Water {KF): 0.56.
Example 82.
[S-(R*,R*)]-4-[[[1-Carboxy-2~-[4-((2,6-dichlorobenzoyl)amino]phenyl]ethyl]amino]carbonyl]-2,2,5,5-tetrarnethyl-3-thiazolidinecarboxylic acid 3-ethyl ester (Scheme B, B-7: where RB_,, RB_Z, Rs_, and RBA are the same and equal to CH,, Y is CO2, Rz is t-butyl, RS is 4-[(2,6-dichlorobenzoyl)amino]phenyl and stereochemistry is (S, S)).
S~ H OI' (v[~'~~OH
~O~O O ~ ~ O CI
N !~
H
CI
Example 82 was prepared from example 81 by the procedure described in preparation 6.
Physical data as follows: IR (mull) 3275,1750, 1735, 1678, 1666, 1609, 1562, 1543, 1516, 1432, 1413, 1333, 1276, 1195, 1077 crri';'H NMR (DMSO-d~} 8 12.48 (1 H), 10.63 ( 1 H), 8.36 { 1 H), 7.53 (5 H), 7.19 (2 H}, 4.49 {2 H), 3.9fi (2 H), 3.03 ( 1 H), 2.79 ( 1 H), 1.78 (6 H}, 1.48 (3 H), 1.15 (3 H), 0.90 (3 H); "C NMR (DMSO-db) b 172.9, 168.7, 161.7, 152.3, 137.0, 136.3, 132.9, 131.2, 131:1, 129.5, 128.1, 119.2, 74.7, 71.3, 60.5, 53.5, 49.0, 48.4, 38.3, 36.7, 33.5, 31.8, 28.1, 24.7, 21.0, 14.0; MS (F?SI+) fox Cz7H3,CI2N306S m/z 595.8 {M+H)'; MS (ESI-) for C27H3,C1zN3O6S m/z 593.8 {M-H)'; HRMS (FAB) calcd for C,7H3,C1,N306S+H, 596.1389, found 596.1362: Anal. Calcd for C2,H3,C1,N,O6S ~
0.56 HzO: C, 53.46; H, 5.34; N, 6.93. Found: C, 53.73, H, S.aS; N, 6.73. % Water (KF): 1.67.
Example 83.
N-[[(4S}-3-Acetyl-2,2-dimethyl-4-thiazolidinyl]carbonyl]-4-[(2,6-dichlorobenzoyl)amino]-!r-phenylalan.ine methyl ester (Scheme B, B-6: where R~_, and RB_2 are the same and equal to H; RB_3 and R~~
are the same and equal to CH;, Y is CO, R3 is methyl, R, is 4-j(2,6-dichlorobenzoyl)amino]phenyl and stereochemistry is (S, S)).
s-. H o H3C~p O f ~ O CI
H
CI
Example 83 was prepared as described in Scheme B from D-cysteine and acetone using acetyl chloride to form the requisite amide. Physical data as follows: IR
(mull) 1745, 1682, 1662, 1628, 1610, 1579,1561, 1541, 1515, 1431, 1412, 1326, 1270, 1240, i2I 1 cm' I0 ';'H NMR (CDCl3} b 7.55 (3 H); 7.32 (3 H), 7.19 (1 H), 7.11 (1 H), 6.66 (1 H), 4.89 (1 H), 4.60 (1 H), 3.78 (3 H), 3.24 (4 H), 2.04 (3 H}, 1.87 (3 H), 1.79 (3 H); I'C
NMR (DMSO-db) b I7I.6, 171.5, 169.9, 169.4, 167.9, 161.8, 137.1, I3fi.3, 132.8, 132.4, 131.1, 129.5, 128.1, 119.2, 72.6, 66.5, 53.7, 53.3, 52.0, 51.9, 35.8, 31.'7, 29.0, 26.9, 24.7, 24.5; MS
(ESI+) for CZSHZ,C1zN305S m/z 551.9 (M+H)+; HRMS (l::I) calcd for 551.1049, found 551.1053; MS {EI ) m/z (rel. intensity) 551 (M+, 7), 351 (46), 349 (68), 278 {16), 186 (14 ), 175 (63), 173 (98), 158 (23), 116 (99), 100 (20), 99 (69).
Example 84.
N-j[(4S}-3-Acetyl-2,2-dimethyl-4-thiazolid.inyl]carbonyl]-4-[(2,6-dichlorobenzoyl)amino]-L-phenylalanine (Scheme B; B-7: where RB_, and RB_2 are the same and equal to H. RB_3 and Re~, are the same and equal to CH3, Y is CO, R3 is methyl, RS is 4-[{:?,6-dichlorobenzoyl)amino]phenyl and stereochemistry is (S, S)).
S-. H O
~~N~pH
O
H3C O I ~ O CI
CI

Example 84 was prepared from example 83 by the procedure described in preparation 6.
Physical data as follows: IR (mull) 3279, 1723, 1661, I 608, 1562, 1542, 1516, 1432, 1413, 1349, 1329, 1270, 1238, 1207, 1195 crri';'H NMI~t (DMSO-d6) 8 12.47 (1 H), 10.62 ( I H), 7.5 I (5 H), 7. i 8 (2 H), 4.80 ( 1 H), 4.67 ( 1 H), 4.4'7 { i H), 2.98 (3 H), 1.68 (9 H);
'3C NMR (DMSO-db) 8 184.2, 172.6, 171.9, 169.8, 169.2, 167.8, 136.9, 136.3, 133.1, 131.2, 131.0, 129.5, 128.1, 119.2, 72.6, 66.6, 53.7, 53.3, 3b.2, 31.7, 29.0, 27.0, 24.8, 24.6, 21.0; MS (ESI+) for CZ4HzsC1zN30sS ~Z 538.0 (M+H}'; MS (ESI-) for C~4HZSCl,N305S
m/z 535.9 (M-H)'; HRMS (FAB) calcd for C,4HZSC1ZN3CtSS+H, 538.0970, found 538.0961.
Example 85..
[S-(R*,R*}]-4-[[[1-Carboxy-2-[4-[{2,6-dichlorobenzoyl)amino]phenyl]ethyl]amino]carbonyl]-2,2-dimethyl-y-oxo-3-thiazolidinebutanoic acid (Scheme B, B-7: where RB~, and RB_2 are the same and <:qual to H, RB_3 and RH,~ are the I5 same and equal to CH3, Y is CO, R3 is CH,CH~CO,H, RS is 4-[(2,6-dichlorobenzoyl}amino]phenyl and stereochemistry is (S., S"}).
~N~N~OH
HO~O O ~ w ~ CI
[O~ - ~N
H
CI
Example 85 was prepared as described in Scheme B from D-cysteine and acetone using methyl succinyl chloride to form the requisite amide. Physical data as follows: IR (mull) 3264, 3125. 3071, 1724, 1658, /607, 1562, 1537, 1517, 1432, 1414, 1326, 1241.
1195, I I 81 crri'; 'H NMR (DMSO-db) 8 12.31 ( 1 H), 10.65 ( 1 H), 8.20 ( I H), 7.50 (5 H), 7.19 {2 H), 5.81 (1 H), 4.50 {1 H), 3.02 (3 H), 2.30 (3 H), 1.71 (6 H); '3C NMR
(DMSO-d6) 8 /74.1. 172.8, 169.4, 161.9, 137.1, 136.5. 133.2, 131.4, 131.3; 129.7, 128.3, 119.3, 73.1, 65.7, X3.5, 36.3, 32.0, 30.5, 29.1, 29.0, 27:1; MS (ESI+) for C,6H27C1,N3O,S
m/z 595.9 (M+H)'; MS (ESI-) for C~6Hz,CI,N30,S m/z 593.8 (M-H)'; Anal. Calcd for C,6H,7C1,N307S

~ 0.51 H,O: C, 51.55; H, 4.66; N, 6.94. Found: C, 51.71. ; H, 4.85; N, 6.93. %
Water (KF):
I .53.
Example 86.
[S--(R*,R*)]-4-{[[1-[[4-[(2,6-Dichlorobenzoyl)amino]phenyl]methylJ-2-methoxy-2-oxoethyl]amino]carbonylJ-2,2,5,5-tetramethyl-y-oxo-3-thiazolidinebutanoic acid methyl ester (Scheme B, B-6: where Ra_,, RB_Z, Rs_3 and RB~ are the same and equal to CH3, Y is CO, R3 is CHZCH,CO,CH~, RS is 4-[(2,6-dichlorobenzoyl)amino]phenyl and stereochemistry is I O (S, S~}.
s-'-~ H o ~N~N~O~
i0 0 ~ ~0 C!

O I i N. ~
H I , C:I
Example 86 was prepared as described in Scheme B from D-penicillamine and acetone using methyl succinyl chloride to form the requisite amiide. Physical data as follows: IR
(mull) 3287, 1741, 1660, 1608, 1562, 1540, 1516, 1432, 1413, 1323; 1267, 1241, 1225, 1196, i 168 cm '; ' H NMR (CDC13) S 7.55 (2 H), 7.29 (=i H), 7. I 3 (2 H), 6.94 ( 1 H), 4.95 1 H), 4.39 ( 1 H), 3.74 (3 H}, 3.67 (3 H), 3.27 ( I H), 3.10 ( I H), 2.80 ( 1 H), 2.57 (3 H), 2.18 (1 H), 1.95 (3 H), 1.77 (3 H), 1.72 (3 H), 1.68 (3 H) 1.63 (3 H);'3C NMR
(CDC13) b 173.3, 171.6, 170.3, 169.9, 162.4, 136.3, 132.5, 132.4, 1.31Ø I30.2, 129.8, 128.2, 120.8, 120.7, 120.5, 73.8, 53.1, 52.6, 51.8, 49.9, 40.0, 37.4, 33.9. 31.6, 31.4, 29.4, 29.1, 24.3; MS
(ESI+) for C3oH35C1~N~07S m/z 652.1 (M+H)~; Anal. Ca.lcd for C3°H35CI,N307S ~ 0.3I
H,O: C, 54.75; H, 5.45: N. 6.38. Found: C, 55.04; H, 5.,50; N, 6.69. % Water (KF): 0.84.
Example 87.
N-[[(4S)-3-Acetyl-2,2,5,5-tetramethyl-4-thiaz;oiidinyl]carbonylJ-4-[(2,6-dichlorobenzayl)amino]-~-phenylalanine methyl ester (Scheme~B, B-6: where RB_" Rp_,; RB.3 and RB.~ are the s,~ne and equal to CH;, Y is CO, R3 is methyl, R, is 4-[(2,6-dichlorobenzoyl)amino]phenyi and stereochemistry is (S, S)).
s~- H o'I
~N~N~Oi li3C~0 C ~ ~ 0 CI
_N
CI
Example 87 was prepared as described in Scheme B fronn D-penicillamine and acetone using acetyl chloride to form the requisite amide. Physical data as follows:
IR {mull) 1741, 1692, 1676, 1629, 1606, 1563, 1538, 1516, 1431, 1410, 1352, 1320, 1276, 1251, 1223 cm'; 'H NMR (DMSO-db) 8 10.70 (I H), 8.57 (1 I;f), 7.56 (4 H), 7.22 (2 H), 4.63 ( 1 H), 4.49 ( I H), 3.65 (3 H), 3.30 ( 1 H), 3.12 { I H), 2.84 ( 1 H), 1.92 (3 H), 1.82 (3 H), I .78 (3 H), 1.51 (3 H), 0.80 (3 H); "C NMR (DMSO-db) 8 184.2, 17I.9, 168.9, 168.1, 161.8, I37.I, 136.3, 132.4, 131.3, 131.2, 131.0, 129.4, 1:?8.1, 119.3, 75.9, 72.8, 53.5, 52.0, 49.2, 48.4, 36.0, 33.5, 31.9, 27.6, 24.9, 24.5; MS (ESI+) for Cz7H3,CI,N305S
mlz 580.1 {M+I-I)'; MS (ESI-) for CZ,H3,C1zN3O5S m/Z 577.9 (M-H;f; Anal. Calcd for C,,H3,C1ZN305S
I5 ~ 0.12 HBO: C, 55.66; H, 5.40; N, 7.21. Found: C, 55.68:, H, 5.39; N. 7.16.
% Water (KF):
0.36.
Example 88.
[R-(R*,S*)]--4-[[I I-Carboxy-2__[4-[(2,6-dichlorobenzoyl}amino]phenyl]ethyl]amino]carbonylJ~-2,2,5,5-tetramethyl-S-oxo-thiazolidinepentanoic acid (Scheme B, B-6: where RB.,, RB_2, RB_3 and Ra~, are the same and equal to CH3, Y is CO, R~ is CH,CH,CH,COZH, RS is 4-[(2,6-dichlorobenzoyl)amino]phenyl and stereochemistry is (R, S)).

H~ ,~
'OH
O O ' ~ O CI
HD-~ i O N' w H
C;i Example 88 was prepared as described in Scheme B fronn D-penicillamine and acetone using methyl glutaryl chloride to form the requisite amide. Physical data as follows:
'H NMR (DMSO-db) 8 10.65 (1 H), 8.45 (1 H}, 7.53 (5 H), 7.22 (2 H), 4.51 (1 H), 3.11 (3 H), 2.77 (1 H), 2.21 {4 H), 1.89 (3 H), 1.82 {3 H), 1.11 (2 H), 1.48 (3 H), 0.77 (3 H};
'3C NMR (DMSO-db) 8 184.2, 174.2, 173.1, 170.1, 168.'x, 161.7, 137.0, 136.3, 133.1, 131.3, 131.1, 129.4, 128.1, 119.2, 74.9, 73.0, 53.8, 49.3, 36.1, 34.8, 33.5, 32.7, 31.9, 27.7, 24.5, 20.0; MS (ESI+) for C29H33C1zN3O7S m/Z 638.0 (M+H)+; MS (ESI-) for C2qH33C1zN~O,S mlz 635.9 {M-H)'; HRMS (FAB) calcd for CZ9H3,Cl,N~O,S+H, 638.1494, found 638.1481; Anal. Calcd for C29H33C1ZN3O7S ~ 0.751Ei20: C, 53.42; H, 5.33;
N, 6.44.
Found: C, 53.20; H, 5.26; N, 6.45.

WO 99!67230 PCT/US99/14233 Scheme C
NH-Fmoc i w I , ~ .~ ~~~NH-Fmoc C-1 ~O O O
O
Rink-amide-MBHA resin ~NHz C-2 O
Fmoo-HN- ~
~OH C-3 O
~N~NH-Fmoc Rs O
~ NHp "' H C-5 RC-t S R~_z Rc.3~~OH C-6 RCS N
Fmoc O
O Rc-2y! C ~Rc-s /~H
~.N N II N Rc-a C-7 H O Fmoc Rs Rc-2 J ~~s O \/R-H N~H~RC.a C-8 R O
s Scheme C (continued) RC.2 RC.S
O H \' RC.a N N~RC~ C:-8 H O H

R .2 RC-t ~N N~1J~RC-4 H 0 Y'R3 RC_~
RCS ~ RC.z O
NH
RCS Y O ~HH2 C:-10 Where: Rc-,, Rc_2, and Rc_3 are defined independently as R,. Rc~ is defined as R2.
Scheme C describes a method for the preparation of examples of the formula C-10.
Commercially available Rink Amide MBHA resin is de~protected under standard solid-phase peptide synthesis conditions (Atherton. E.; Sheppa~rd R.C. Solid Phase Peptide Synthesis: A Practical Approach; IRL Press at Oxford Llniversity Press:
Oxford, 1989) to afford the amine of formula C-2. Acylation with a comnnercially available or readily prepared amino acid residue of general C-3 affords the r<ain bound derivative of formula C-4. Removal of the Fmoc group under standard conditiions provides amine of general structure C-5 which is acylated with a commercially available or readily prepared thiazolidine-4-carboxylic acid of general formula C-6 to afford the resin bound intermediate C-7. Standard Fmoc deprotection affords the resin bound amine of general formula C-8 which may be reacted with a variety of electrophilic reagents as described in Scheme A to afford resin bound amides, ureas. sulfonamides and carbamates of general structure C-9. Preparation 18 details an example of the reaction of a mixed carbonate to afford a carbamate of general structure C-9 (where Y is equal to CO~).
Standard acidolysis affords the amide of general structure C-10.
Preparation I8 and Example 89.
[S-(R*,R*)]-4-[[[ 1-[[4-[(2,6-Dichlorophenyl)methoxy]phenyl]methyl]-2-amino-2-oxoethyl]amino]carbonyl]-3-thiazolidinecarboxylic acid 3-[2-(4-morpholinyl)ethyl]
ester (Scheme C, C-10: where R~_,, Rc_2, Rc_3 and ltc~, are the same and equal to proton, R3 is 2-(4-morpholinyl}ethyl, RS is 4-[(2,6-dichlorophenyl)methoxy]phenyl, Y is COZ
and stereochemistry is (S, S)).
S-. H O
O~ ~~~N~NHZ
O I ~ C1 ~, ~ w I 5 To a mixture of Rink Amide MBHA resin (Scheme C, C-1 ) (Nova Biochem., 1.2 g, ca. 0.59 mmol) in methylene chloride (20 mL) was added a solution of piperidine in DMF (30%, 20 mL}. A slow stream of nitrogen was bubbled through the mixture to effect mixing for 20 min. The resin was filtered and washed vvith DMF. The resin was suspended in a solution of piperidine in DMF (30%, 40 ml) and mixed for 40 min. The resin was filtered and washed with DMF, methylene chloride, methanol and methylene chloride to afford resin C-2, which was diluted with DMF (40 mL}. To this mixture was added Fmoc-Tyr{2,6-Cl,-Bn) (Scheme C, C-3: where R,S is 4-[(2,6-dichiorophenyl)methoxy]phenyl and stereochemistry is (S)) (Advanced Chemtech, I.32 g, 2.35 mmol), HOBt (0.36 g, 2.35 mmol), PyBOP (1.20 g, 2.35) and D1EA (1.03 mL, 5.90 mmol). The reaction was mixed for 4 h and the resin filtered and washed with DMF, methylene chloride, MeOH and methylene chloride to afford the intermediate resin-bound amino acid derivative C-4 (Scheme C, where R5 is 4-[(2,6-dichlorophenyl)methoxy]phenyl and stereochemistry is (S)) which was used without characterization.
To a mixture of resin C-4 described above in methylene chloride (20 mL) was added a solution of piperidine in DMF (30%, 20 mL). A slow stream of nitrogen was bubbled through the mixture to effect mixing for 20 min.. The resin was filtered and washed with DMF. The resin was suspended in a solution of piperidine in DMF
(30%, 40 ml) and mixed for 40 min. The resin was filtered and washed with DMF, methylene chloride, methanol and methylene chloride to afford the resin of structure C-5 (Scheme C, where RS is 4-[(2;6-dichlorophenyl)methoxy]phenyl and stereochemistry is (S)) , which I0 was diluted with DMF (40 mL). To this mixture was added Fmoc-D-thiazolidine-carboxylic acid (Scheme C, C-6: where Rc_,, Rc_2, Rc.3 and Rc~ are the same and equal to proton and stereochemistry is (S}) (Advanced Chemtech, 832 mg, 2.35 mmol), HOBt (0.36 g, 2.35 mmol}, PyBOP (1.20 g, 2.35) and DIEA (I.03 mL, 5.90 mmol). The reaction was mixed for 4 h and the resin filtered and washed with DMF, methylene chloride, MeOH and methylene chloride to afford the intermediate resin-bour,~d derivative C-7 {Scheme C, where R~_,, Rc_~, Rc_3 and Rc~, are the same and equal to proton, Rs is 4-[(2,6-dichlorophenyl}methoxy]phenyl and stereochemistry is (S, S)) which was used without characterization.
To a mixture of resin C-7 described above in methylene chloride (20 mL) was added a solution of piperidine in DMF (30%, 20 mL}. A slow stream of nitrogen was bubbled through the mixture to effect mixing for 20 min: The resin was filtered and washed with DMF. The resin was suspended in a solution of piperidine in DMF
(30%, 40 ml) and mixed for 40 min. The resin was filtered and washed with DMF, methylene chloride, methanol and methylene chloride to provide the intermediate of structure C-8 (Scheme C, where Rc_,, Rc_z, Rc_3 and Rc~, are the same and equal to proton, R5 is 4-[(2,6-dichlorophenyl)methoxy]phenyl and stereochemistry is I;S, S)) , which was diluted with methylene chloride ( 10 mL). To this mixture was added a solution of the mixed carbonate prepared from 4-{2-hydroxyethyl)morpholine (2.14 mL, 17.7 mmol) and N,N-disuccinimidyl carbonate (4.53 g, 17.7 mmol) as described in preparation 8 in methylene chloride (20 mL} followed by triethyIamine (0.33 mL, 2"36 rnmol). The reaction was WO 99/b7230 PCT/US99/14233 mixed for 24 h and the resin filtered and washed extensively with DMF, methylene chloride, MeOH, and anhydrous ethyl ether. The resin was dried in vacuo to afford the resin-bound carbamate C-9 (Scheme C, where R~_,, Rc_2, Rc._3 and Rc~ are the same and equal to proton, R~ is 2-(4-morpholinyl)ethyl, RS is 4-[(2,6-dichlorophenyl)methoxy]phenyl, Y is COZ and stereoche;mistry is (S, S)).
Resin C-9 was swelled with a minimum of methvlene chloride (ca. 2 mL) and suspended with 95 % aqueous TFA (20 mL). The mixture was mixed by magnetic stirring for lh and filtered. The resin was washed with additional TFA (2 X 5 mL), followed by methylene chloride and methanol. The combined filtrates were evaporated in vacuo, and partioned between ethyl acetate and saturated aqueous sodium bicarbonate. The arganic layer was separated and washed with brine, dried (MgSC>4), filtered and evaporated in vacuo. The residue was purified by flash chromatography using methylene chloride/methanol ( 1 to 3%) as eluant to afford the title compound (215 mg) as an amorphous powder: IR (mull) 3288, 1676, 1657, 161 l, 1564, 15I l, 1439, 1424, 1346, 1302, 1237, 1179, 1116, 1021, 767 ctri';'H NMR (CDC13, 300 MHz) 8 7.24 (5 H), b.93 (2 H), 5.20 (2 H), 4.63 (3 H), 4.34 (1 H), 4.22 (2 H), 3.63 (4 H), 3.11 (4 H), 2.50 (6 H); "C
NMR (CDCl3, 75 MHz) 8 173.4, 170.1, 157.9, 154.5; 1x6.9, 132.0, 130.4,129.1, 128.4, I 15.1, 66.8, 65.2, 63.4, 57.1, 54.0, 53.7, 53.5, 49.4, 35.2.; MS {EI ) m/z (rel. intensity) 610 (M+, 1 ), 323 ( 13), 321 (20), 161 {34), 159 (53}, 114 (31 ), 113 {98), 100 (99}, 88 {13), 70 (8), 56 ( 11 ); MS (FAB) m/z (rel. intensity) 611 (MH', T 1 }, 614 ( I 8), 613 (49), 612 (27), 611 (71), 123 (60), 114 (99), 113 (76), 1I2 (19); 107 (22), 100 (28}; HRMS
(FAB) calcd for CZ,H32C12N4O6S +H, 6I 1.1498, found 611.1494. An<~1. Calcd for Cz7H32C12N,O6S: C, 53.03; H, 5.27; N, 9.16. Found: C, 52.74; H, 5.17; N, 9.01.
Example 90.
[S-(R*,R*)]-4-([[1-[[4-[(2,6-Dichlorophenyl)metho:xy]phenyl]methyl]-2-amino-2-oxoethyl]amino]carbonyl]-3 thiazolidinecarb~oxylic acid 3--ethyl ester (Scheme C, C-10: where It~_,, Rc_2, Rc_3 and R~~ are the same and equal to proton, R3 is ethyl, RS is 4-((2,6-dichlorophenyl)methoxy]phenyl, Y is CO, and stereochemistry is (S, S)).

w0 99lb7230 PCT/US99l14233 .

/S-. H O
~N~N~Nii2 ~O~O O 1 ~ CI
'O
CI
Example 90 was prepared as described in Scheme C. Plhysical data as follows:
IR (mini) 3369, 3308, 3192, 1713, 1667, 1650, 1629, 1539, 1513, 1441, 1344, 1290, 1240, 1016, 768 cni';'H NMR (CDC13, 300 MHz) b 7.33 (3 H), 7,16 (2 H), 6.95 (2 H), 5.25 (2 H), 4.48 (4 H), 4.20 (2 H), 3.03 (4 H), 1:26 (3 H); "C NMR (CDCl3, 75 MHz) 8 173.6, 170.5, 157.8, 154.7, 136.8, 313.9, 130.4, 130.2, I29.0, 128.4, 114.9, 67.9, 65.1, 63.1, 62.5, 53.8, 36.5, 14.3; MS (EI ) mlz (reH. intensity) 525 (M', 1), 32.3 (44), 322 {i3), 321 (68), 267 (9), 265 (I4), 163 (I2), 161 (65), 160 (35), I59 (99), 88 (30~); MS (FAB) mlz (rel.
intensity}
526 (MH~, 58), 528 (40}, 527 (19), 526 (58), 32I (27), 188 (29), 161 (37), 160 (99), 159 (48), 107 (26), 88 (39); HRMS (FAB) calcd for CZ3HzsCIZN345S +H, 526.0970, found 526.0942. Anal. Calcd for C23HzsChN305S: C, 52.47; ~C, 4.79; N, 7.98. Found:
C, 52.34;
H, 4.81; N, 7.90.

ii Scheme D

~ D-t Fmoc.N~OH
H (~O
H2NOt Bu D-2 H
Fmoc~N~N,O~ D-3 H O
Rs H ~
H N ~ N'0I \ D-4 z O
RD-t ~'z D-5 R~
N OOH
R~ FmocO
F,moc O RsH
Ro3~(N N~N,O~ D-6 Rw~S~H O
Rp-z H O H
RD3 N N~N~O~ D-7 R ~S~H IiOII
RO-z ~Y 0 sH
R~ N N~N~O~ D-$
~~../-R I'H
R XS ~R~p.~ O

,Y 0 sH
Roy N N~N~OH D-9 Rp S'1 RDH IIO
Ro_2 R0.,, Ra2, and R~3 are defined.independentiy as R,. RD.~ is defined as RZ.
Scheme D describes a method for the preparation of examples of general formula D-9. Commercially available or readily prepared N-a-Fmoc protected amino acids of general structure D-1 are coupled with O-(tent-butyl)hydroxyiamine (D-Z) under standard coupling conditions as previously referenced to afford tlhe t-butyl hydroxamate of general structure D-3. Standard Fmoc deprotection affords the iintermediate amine of formula D-4.
Coupling of this amine with a commercially available or readily prepared N-a-Fmoc-thiazolidine-4-carboxylic acid of general structure D-5 affords the pseudodipeptide intermediate of general structure D-6. Standard Fmoc d:eprotection affords the intermediate amine of general structure D-7 which may be reacted under the variety of conditions described in Scheme A to afford amides, carlbamates, sulfonamides and areas of general structure D-8. Preparation 22 provides a specific example of the reaction of an amine of general structure D-7 with a carbonate to afford a carbamate of general structure D-8. Mild acidolysis affords the hydroxamate of general structure D-9.
I S Preparation 19.
(Scheme D, D-3: where RS is 4-[(2,6-dichlorophenyl)mE;thoxy~phenyl and stereochemistry is (,f~).

Fmoc'N~H'O
Ct ,.
ci To a cooled (0-5 °C) solution of Fmoc-Tyr(2,6-CI,-Bn) (Scheme D, D-1:
where RS is 4-[(2,6-dichlorophenyl)methoxy]phenyl and stereochemistry is (,S~) (Advanced Chemtech, 6.0 g, I0.7 mmol), HOBt (1.63 g, 10.7 mumol), O-(tert-butyl)hydroxylamine hydrochloride (Scheme D, D-2) (1.61 g, 12.80 mmol) in methyIene ch'.ioride (30 mL) was added PyBOP
(6.66 g, 12.80m~mol) followed by DIEA (6.5I mL, 37.35 mmol). The mixture was stirred at 0-5 °C for 1 hour, gradually allowed to warm to rooms temperature and stirred an additional 2 h. The mixture was diluted with methylene; chloride and 0.25 N
HCI, the organic layer separated and washed with saturated aqueous NaHC03, and brine, dried (MgSO,), filtered and evaporated in vacuo. The residue was purified by flash chromatography using methylene chloridelmethanol (0-~2.5%) as eluant to afford the title compound (5.87 g) as an amorphous powder: 'H NMR (CDCI,, 300 MHz ) b 8.08 (1 H}, 7.76 (2 H), 7.54 (2 H), 7.29 (9 H), 6.95 (2 H), 5.43 (1 Hl), 5.30 {2 H), 4.28 (4 H), 3.06 (2 H), 1.19 (9 H); "C NMR (CDCI3, 75 MHz) 8 169.7, 157.8, 156.3, 143.6, 141.2, 136.8, 132.0, I 30.4, 128.9, 128.4, 127.7, 127.0, 125.0, I 19.9,_ I 15.0, 82.3, 67. I
, 65. I , 54.0, 46.9, 37.6, 26.0; MS (ESI+) for C35H34CIZNZOS m/z.632.9 (M-~H)'. MS (ESI+) for C3sH3aCI,N,Os m/z 654.9 (M+Na}+.
Preparation 20.
(Scheme D, D-6: where RD_,, Rfl_2, Rti_3 and Rfl~ are the same and equal to proton, RS is 4-[(2,6-dichlorophenyl)methoxy]phenyl and stereochemistry is (S, S)).
S-. H OI[
C ~N~N.O~
N H
Fmoc O k w CI
cl l To a solution of D-3 (Scheme D, where RS is 4-[(2,6-dichlorophenyl)methoxy]phenyl and stereochemistry is (S)) (5.87 g, 9.28 mmol) in anhydrous DMF (94 mL) was added diethylamine (9.4CI mL, 90.84 mmol) at ambient temperature. The solution was stirred for 90 rnin and volatiles were removed in vacuo to afford the intermediate amine D-4 (Scheme D, where RS is 4-[(2,6-dichlorophenyl}methoxy]phenyl and stereochemistry is (S)) as an oil which was used without further purification.
To a cooled (0-5 °C) solution of, Fmoc-D-thiazolidine-4-carboxylic acid (Scheme D, D-5: where Rp_,, RD-2, Rp_3 and Ro.~ are the same andl equal to proton and stereochemistry is (S)) (Advanced Chemtech. 3.93 g, i I .10 mmol) and HOAt ( I
.5 I g, 11. IO mmol) in methylene chloride/DMF {4:1,-30 mL) 'was added EDC (2.12 g, i 1.10 mmol). The reaction mixture was allowed to stir for 15 min and a solution of the amine (D-4 described above) in methylene chloride/DMF (4:1, 30 mL) was added followed by DIEA ( 1:61 mL, 9.28 mmol). After 1 h at 0-5 °C, an adcfitional equivalent of DIEA ( 1.61 mL, 9.28 mmol) was added and the mixture allowed to warm to room temperature.
After stirring overnight, volatiles were removed in vacuo and the residue partitioned between ethyl acetate and 0.25 N aqueous HCI. The organic layer was separated and washed with water, saturated aqueous NaHC03, brine, dried {Na~S04), filtered and concentrated in vacuo. The residue was purified by flash chromatography using CHZClzlacetone (3%) containing isopropanol (0.1 %) as eluant to afford the titlc: compound (2.4 g) as an amorphous solid: 'H NMR (300 MHz, CDC13) S 7.77 (2 :H), 7.55 (2 H), 7.32 (7 H), 7.12 (2 H), 6.92 (2 H), 6.70 (1 H), 5.19 (3 H), 4.55 (5 H), 4.26 {2 H), 3.30 (1 H), 3.11 {3 H), 1.I4 (9 H);'3C NMR (75 MHz, CDC13) 8 170.0, 168.8, 158.0" 143.4, 141.3, 137.0, 132.1, 130.4, 128.5, 127.9, 127.2, 124.9, 120.1, 115.3, 82.5, b8.4, 65.3, 52.$; 47.1, 36.5, 2b.2.
MS (ESI+) for C,9H39C1,N;O6S m/Z 747.9 (M+H)'; MS (IESI+) for C39H39CI,N3O6S
m/Z
769.8 {M+Na)~; MS (ESI-) for C39H39C1zN3O6S mlz ?45.'r (M-H)'.
Preparation 2I .
{Scheme D, D-7: where Ra,, Ro_Z, Rp_3 and R~ are the s~rzne and equal to proton, RS is 4-[(2,6-dichlorophenyi)methoxy]phenyl and stereochemist~ry is (S, S)).
S-. H O
CN~N~N.O~
H
~ Cn v 'o To a solution of D-6 (Scheme D, where R~_,, Ro_Z, Ro_3 and Rpm are the same and equal to proton, RS is 4-[(2,6-dichlorophenyl)methoxy]phenyl and stereochemistry is (S, S}) (500 mg, 0.67 mmol) in anhydrous DMF (7 mL} was added di.ethylamine (0.70 mL, 6.55 mrnol) at ambient temperature. The solution was stirred for 90 min and volatiles were removed in vacuo. The residue was washed with ethyl ether/hexane (3:2) to afford the title compound (352 mg) as an amorphous solid which was used without further purification: 'H
NMR
(300 MHz, DMSO-d6) s 10.61 (1 H), 8.27 (1 H), 7.54 (2 H), 7.44 (1 H), 7.15 (2 H), 6.94 (2 H}, 5.15 {2 H), 4.50 ( 1 H), 4.03 (2 H), 3.75 { 1 H). 3.19 ( 1 H), 2.82 {3 H}, 2.57 ( 1. H), 1.06 (9 H); MS (ESI+) for C24Hz9C1zN3O4S m/Z 526.1 (M:+H)+; MS (ESI-) for Cz4H29CI2N304S m~2 524.1 {M-H)'.
Preparation 22.
(Scheme D, D-8: where Rp_,, RD_z, RD_3 and RDA are the :>ame and equal to proton, R3 is 2-(4-morpholinyl)ethyl, RS is 4-[(2,6-dichlorophenyl)methoxy]phenyl, Y is COZ
and stereochemistry is (S, S)).
O~ CN~N~N.O~~
I~ - ~ H
~N~O~O O ~ ~ CI
O' \
i/y~\ i i To a solution of 4-{2-hydroxyethyl)morpholine (1.22 mL, 10.05 mmol) in CH3CN
(55 mL) at ambient temperature was added N,N-disuccinimidyl carbonate (2.49 g, 10.05 mmol) and triethylamine (4.20 mL, 30.15 mmol). The solution was stirred at room temperature for 4 h and concentrated in vacuo to give a viscous oil. The oil was dissolved in a minimal amount of methylene chloride ( 15 mL) and. added to a solution of (Scheme D, where Rte,, Rp_2, RD_3 and Ro_4 are the same and equal to proton, RS is 4-[(2;6-dichlorophenyl)methoxy]phenyl and stereochemistry is {S, S) (350 mg, 0.67 mmol), triethylamine (0.10 m, 0.74 mmol) and DMAP (1 mg) in CH2Clz (4 mL). The reaction mixture was stirred overnight and diluted with CHzCl2 ('l5 mL). Propylamine (8.6 mL, 100.5 mmol) was slowly added (exothermic) and the solution stirred vigorously fox 15 min, then diluted with water. The organic layer was separated and washed with 0.1 M
HCI, saturated aqueous NaHC03, and brine, dried (MgS04), filtered and concentrated in vacuo. Purification of the residue by flash chromatography using ethyl acetatelacetone {3:1) as eIuant afforded the title compound (251 mg) as .an white powder: IR
(mull) 3264, 1709, 1661, 1564, 1531, 1512, 1439, 1419, 1345, 1301, 1241, l I81, 1118, 1016, 767 cm';
'H NMR (300 MHz, CDCI3) 8 8.48 (1 H), 7.36 (2 H), 7.:24 (1 H), 7.17 {2 H), 6.96 (2H), 5.23 {2 H), 4.60 (3 H), 4.31 {3 H), 3.71 {4 H}, 3.33 {4 H ), 2.59 (6 H), 1.15 (9 H); '3C
NMR {75 MHz, CDCl3) S 168.9, 158.0, 137.0, 132.1, 130.5, 128.7, 128.5, 115.3, 82.5, 66.8, 65:3, 63.4, 57.2, 53.7, 52.9, 36.4, 30.6, 29.3, 26.2, 19.1, 13.7; MS
(ESI+) for C31H40C12N4O7S mlZ 682.9 (M+H)*, MS (ESI+) for C3lHaoC12N407S mlz 705.0 (M+Na)*;
Anal. Calcd for C3,HaoC12N4O7S ~ 0.35 HzO: C, 53.97; H:, 5.95; N, 7.95. Found:
C, 54.22;
H, d.l 1; N, 7.95. % Water {KF): 0.91.
Preparation 23 and Example 91.
(Scheme D, D-9: where Ro_,, RD_Z, RD_3 and Rpm are the same and equal to proton, R3 is 2-{4-morpholinyl)ethyl, RS is 4-[(2,6-dichlorophenyl)methoxy]phenyl, Y is COZ
and stereochemistry is (S, S)).
o~~ CNi~r"'~~"~LN.ol~l ~ - H
~N~O~O C ~ ~ C!
CI
Hydroxamate D-8 (Scheme D, where RD_,; RD_2, Ro_3 and. RDA are the same and equal to proton, R3 is 2-(4-morphoiinyl)ethyl, RS is 4-[(2,6-dichlorophenyl)methoxy]phenyl, Y is COZ and stereochemistry is (S, S)) ( 1 SO mg, 0.22 mmol) was dissolved in anhydrous TFA
( 12 mL) at ambient temperature and gradually warmed to 40 °C. After 5 h at 40 °C, volatiles were removed in vacuo and the residue partitioned between ethyl acetate and saturated aqueous NaHC03. The organic layer was separated and washed with brine, dried (MgSOa), filtered and concentrated in vacuo. Purification of the residue by flash chromatography using methylene chloride/methanol (S°r'o} as eluant afforded the title compound (51 mg) as an amorphous solid: IR (mull} 32 73, 3229, 1708, 1652, 1564, 1546, 151 l, 1439, 1422, 1346, 1236, 1180, 1114, 1022, 768 cm'';'H NMR (300 MHz, DMSO-d6) 8 10.70 (1 H), 8.93 (1 H}, $.32 (1 H), 7.54 (2 H}, 7.4E5 (1 H), 7.12 (2 H), 6.93 {2 H), 5.16 (2 H), 4.56 (2 H}, 4.36 (I H}, 4.25 (1 H), 4.06 (2 H}, 3.51 (4 H), 3.15 (1 H), 2.76 (3 H), 2.36 (4 H); "C NMR (75 MHz, DMSO-d6) b 169.8, 167.9, 157.6, 136.5, 132.2, 132.0, 130.8, 130.5, 129.2, i 14.7, 66.7, 65.3, 63.3, 59.1, 57.1, :53.8, 52.1, 37.8, 31.3, 30.1; MS
(ESI+) for Cz7H32C12N4O7S mlz 627.0 (M+H}+; MS (ESI-} for Cz7H32C12NaO7S mlz 624.9 WO 99/6'7230 PCT/US99/I4233 {M-H)'; Anal. Calcd for C27H3ZCIZN40,S ~ 0.46 H20: C, S 1.00; H, 5.22; N, 8.81. Found: C, 51.34; H, 5.23; N, 8.67. % Water (KF): 1.31.
Example 92.
(Scheme D, D-9: where RD_,, Raz, RD_3 and Rpm are the same and equal to proton, R3 is S ethyl, RS is 4-[(2,6-dichlorophenyl)methoxy]phenyl, Y is CO~ and stereochemistry is (S, S).
S_ H O
~N~N~N,OH
I H
~O~O O I ~ CI
'O~
CI
Example 92 was prepared as described in Scheme D from Fmoc-Tyr(2,6-C12-Bn) using ethyl chloroformate to provide the requisite carbamate. Physical properties as follows: IR
(mull) 3278, 1654, 1612, 1585, 1564, 1547,1 S 11, 1439, 1347, 1237, 1 I95, 1 I
79, 1022, 782, 769 cm';'H NMR (300 MHz , CDC13) 8 7.39 (3 H;), 7.I7 (2 H), 6.94 (2 H), 5.24 (2 H), 4.53 (4 H), 4.18 (2 H), 3.15 {2 H), 2.87 (2 H), I .28 (:3 H); '3C NMR (75 MHz , IS CD30D) 8 172.7, 170.1, 159.4, 156.2, 138.1, 133.7, 132.1, 131.6, 130.8, 129.8, 115.9, 66.3, 64.4, 63.6, 38.6, 36.8, 35.1, 15.0; HRMS (FAB) ca.lcd for C23HzsCL,N3O6S
+H, 542.0919, found 542.0921; Anal. Calcd for C23H2sC1zN3O6S: C, 50.93; H, 4.64;
N, ?.75.
Found: C, 50.79; H, 4:79; N, 7.52.
Example 93.
(Scheme D, D-9: where Rp_,, Rp_,, RD_3 and Rp~ are the same and equal to proton, R3 is 2-(1-piperidinyl)ethyl, RS is 4-[(2,6-dichlorophenyl)methoxy]phenyl, Y is COZ
and stereochemistry is (S, S)).
S-. H O
~N~N~N.OH
I ~I H
~N~O~O O ~ CI
O:
C:I

Example 93 was prepared as described in Scheme D from Fmoc-Tyr(2,6-Cl2-Bn) using 1-(2-hydroxyethyl)piperidine to provide the requisite cart~arnate. Physical properties as follows: IR (mull} 3276, 1707, 1653, 161 I, 1584, IS64., 1511, 1439, 1237, l I9S, I 179, S 1144, I 1 I3, 1093, 1021 cm -';'H NMR (300 MHz, DM:SO-d6) 8 7.54 (2 H), 7.44 (1 H), 7.12 (2 H), 6.93 (2 H), 5.16 (2 H), 4.58 (2 H), 4.36 (I Hf), 4.25 {1 H), 4.00 (3 H), 2.76 (3 H), 2.31 (3 H), 1.62 {1 H), I.42 (3 H), 1.26 (8 H};."C NMR (7S MHz, DMSO-db) 8 172.2, 168.9, 167.3, I57.0, 135.9, 131:7, 131.4, 130.2, 129.9,a28.7, 1I4.1, 64.7, 63.0, 54.0, 51.6, 36.2, 30.9, 2S.S, 24.7, 23.8, 22.0, 21.5, I3.9; MS (ESI+) for CZ8H34CIZN406S
m/z 624.9 IO (M+H)+.

W(3 99/67230 PCT/US99/I4233 Scheme E
0,~
i~s E-1 °b O
O/

W
O
O O/
N

/
O
'O~r-~~OH

Rs H2N~0'~ E-5 O
Rs O
O N Ow N H O
O
y E-6 Scheme E (continued.) O
~O ~~~~~ Ow N H
O O
I ~ E-6 O R' ~O ~r~N~OH
N H
Q ~ O E_7 I, O
HO~r~~ N~OH
l N H O E-8 O
I
Preparation 24.
{Scheme E, E-2 where stereochemistry is (S)).
5- (2-Methoxy-2-oxoethylidene)-1- (phenylmethyl)-L-Proline 1,1-dimethylethyl ester °~L...~o~

I
To a stirring solution of E-1 (Scheme E where stereochemistry is (S)) (3.628, 12.4mmo1), prepared by the method of Rapoport (J. Am. Chem. Soc. 1984,106, 4539), in CH3CN~ (IOrnL) was added methyl bromoacetate (1.4rnL, I4.9rnmol). After stirring for 70h, CH2Cl2 (70mL) was added. The solution stirred i:or IO minutes before Ph3P
(4.89g, 18.6mmoi) was added, and after 2 minutes Et3N (5.2mL, 37.3mmo1) was added.
After stirring for 20h, the solution was washed with 1 M NaH2P04 ( 100mL), and the aqueous phase was extracted with CH2Ci2 (SOmL). 'The combined organic phases were washed with brine, dried (Na2SO4), filtered, and evaporated in vacuo. The resulting yellow oillwhite solid was dissolved in CHC13 and chromatographed on silica gel (300g, 230-400 mesh, 70mm OD column, packed CHC13, eluted with CHC13, 3L, then 10:90 EtOAc-CHC13, 250mL fractions) using the flash technique. Fractions i 9-23 provided the title compound (3.23g) as a pale yellow oil. IH-NMR: (300MHz, CDCl3): 8 = 7.17-7.36 (5 H), 4. 75 ( 1 H), 4.54 ( 1 H), 4.20 ( 1 H), 3 .96 ( 1 H), 3 .61 (3 H), 3.3 6-3.47 ( 1 H), 3 .08 (1 H), 2.04-2.28 (2 H), I.4I (9 H); EI/MS (70eV) mlz (rel. intensity): 33I
(M+, 17.3), 275 (1 I.9), 230 (95.0), 170 (26.0), 91 (base); IR (neat): :?979, 2948, 1735, 1692, 1600, 1454, 1435, 1414, 1369, 1299, 1277, 1184, I I37, 1059, 964, 843, and 789cm-I;
HRMS:
IS Calcd. for ClgH2SNI04: 331.1783. Found: 33I.I771; [a]D25: +p07~ ( c= 0.939, CH2C12).
Preparation 25.
(Scheme E, E-3 where stereochemistry is (2R,SS)).
(2R-cis)-5-[ (1;1-dimethylethoxy)carbonyl]-1- {phenyimethyl)-2-pyrrolidineacetic acid methyl ester ( (2R,SS)) ~o~l"~~"~,~o~
°b Raney-Nickel (20g of a 50% slurry in H20) was washed with abs. EtOH (3x25mL) and suspended in abs. EtOH (SOmL), and a solution of E-2 (Scheme E, where stereochemistry is (S)) {9.34g, 28.2mmo1) in abs. EtOH (SOmL) was added. After stirring for 3h, the Ra-Ni was removed by filtration, and the filtrate was evaporated in vacuo. The residue was dissolved in EtOAc ( 1 OOmL), ;5% PdC (3.Og) was added, and the mixture was hydrogenated under 50 psi Hz for 12 h. The catalyst was removed by S filtration and the filtrate was evaporated in vacuo. The residue was chromatographed on silica gel (300g, 230-400 mesh, 70mm OD column, packed and eluted with 15:85 EtOAc-hexanes, 270mL fractions) using the flash technique. Fractions S-8 provided the title compound (6.SSg) as a clear, colorless oil. 1H-NMR: (300MHz, CDC13): & =
7.22-7.34 (S H), 3:86 (1 H), 3.79 (I H), 3.62 (3 H), 3.2I~-3.29 (2 H), 3.57 (I
H), 2.33 (1 H), 1.64-2.OS (4 H), 1.37 (9 H); EI/MS (70eV) m/z (rel. intensity):232 (base), 91 (39.8); IR
(nujol): 2977, 1739, 1454, 1437, 1367, 1295, I2S l, 1 I9'l, 11 S3, 1074, 844, 753, and 699cm-1; Anal: Calcd. for C19H27N104: C, 68.44; H, 8.16; N, 4.20. Found: C, 68.39;
H, 8.1 S; N, 4.11; Ia]D2S; _22° (c = 1.OS I, CH2Cl2).
Preparation 26.
1S (Scheme E, E-4 where stereochemistry is (2R,SS)).
(2R-cis)-5-[ (1,1-dimethylethoxy)carbonyl]-1- (phenylmethyl)-2-pyrrolidineacetic acid ( (2R,SS}) y .~~y ~,~'OH
~o~l N
~b To a stirring solution of E-3 (Scheme E, where stereochemistry is (2R,SS)) {2.OOg, 6.OOmmoI) in MeOIi {60mL) was added 1 M K2C03 (2~OmL). After stirring for 12h, the reaction mixture was evaporated in vacuo, the residue was dissolved in H20 (0.1 L), the pH was adjusted to ca. 6 with 1M HCI, and the mixture was extracted with CHCI3 2S (2XO.IL). The combined extracts were washed with H2~D, brine, dried (Na2S04), and evaporated in vacuo to afford the title compound (I.89g) as a white solid. MP:
9S-96°C

(lit. 98-101 °C); 1H-NMR: (300MHz, CDCl3}: & = 7.30-7.37 (5 H), 4.00 (1 H), 3.68 (1 H), 3.45 (1 H), 3.20 (i H), 2.59 (1 H), 2.46 (1 H), 1.76-2.21 (4 H), 1.31 {9 H);
El/MS (70eV) m/z (rel. intensity):218 (base), 91 (86.7); IR (nujol): 1719, 1497, 1451, 1367, 1296, 1285, 1260, 1160, 1153, 1079, 965, and 757cm-1; Anal: Calc~d. for C18H25N104:C, 67.69; H, 7.89; N, 4.39. Found: C, 67.55; H, 7.97; N, 4.15; [a]D25: +27° ( c =
0.795, CH2C12).
Preparation 27.
{Scheme E, E-6 where RS is 4-[ (2,6-dichlorophenyl)methoxy]phenyl, and stereochemistry of the pyrrolidine ring is (2R,SS) and the amino acid is (S~).
(SR)-5-[2-[( (1S)-1-Methoxycarbonyl-2-[4-[ (2,6-dichlorophenyl)methoxyJphenyl]ethyl]amino]-2-axo~ahylJ-1- (phenyimethyl}-L-proline 1,1-dirnethylethyl ester ( (1S, SR, L)) ~ o w i ci o °.

To a stirring solution of E-4 (Scheme E, where stereochernistry is (2R,SS)) (0.48g, 1.50mrn0I) in CH2Cl2 (lOmL) was added 1- (3-dimethyIaminopropyl)-3-ethylcarbodiimide hydrochloride (0.29g, 1.50mmol), 1-hydroxybenzotriazole hydrate (0.20g, l.SOmmo1), 4-dimethylarninopyridine (0.05g, 0.45mmol), and 2,6-dichlorobenzyl-L-tyrosine methyl ester hydrochloride (Scheme E, E-S: where RS
is 4-[
(2,6-dichlorophenyl)methoxy]phenyl and stereochemistry is (f~) (0.59g, I.SOmmol) to give a heterogeneous mixture. Upon addition of triethylamine (0.3mL) the reaction mixture became homogeneous and stirred for 12h. The reaction mixture was partitioned between CH2C12 (SOmL) and IN HCl (SOmL). The organic phase was washed with sat'd aq. NaHC03, H20, brine, dried (Na2S04), filtered and evaporated in vacuo, The resulting yellow oil was chromatographed on silica gei (1508, 230-400 mesh, 70mm OD
column, packed and eluted acetone/CH2C12 5:95, 40mL fractions). Fractions 36-furnished the title compound (0.90g) as a glass. 1H-NM:R: (300MHz, CDCl3): 8 =
9.09 (1 H), 7.38 (2 H), 7.10-7.30 (8 H), 6.97 (2 H), 5.22 (2 H), 4..75 (1 H), 3.81 (1 H), 3.68 (3 H), 3.60 (1 H), 3.i5-3.35 (3 H), 3.04 (1 H), 2.42 (I H), 2.21 (1 H), 1.86-2.07 {4 H), 1.37 (9 H);
FAB/MS m/z (rel. intensity): 655 {M+H, 46.4), 599 (11.3), 553 (23.6), 260 (18.8), 204 (91.4), 91 (base); IR {nujol):3262, 3001, 1733, 1665, 16 L2, 1585, 1565, 1512, 1439, 1392, 1240, 1226, 1 I97, 1177, 1 IS3, 1018, and 768 cm-1; Anal: Calcd. for C35H40N206C12:
C, 64.12; H, 6.15; N, 4.27; Cl, 10.82. Found: C, 63.751H, 6.29; N, 4.11; Cl, 10.88;
[a]D25; +6~ ( c = 0.863, CHCI3).
Preparation 28.
1S (Scheme E, E-7 where RS is 4-[ (2,6-dichlorophenyi)methoxy]phenyl, and stereochemistry of the pyrrolidine ring is (2R,SS) and the amino acid is (S~).
(5R)-5-(2-[[ (1S)-I-Carboxy-2-[4-[ (2,6-dichlorophenyl)methoxy)phenyl]ethyl]amino]-2-oxoethyl]-1- {phenylmethyl)-L-proline 1,1-dimethyiethyl ester ( (1S, 5R, L)) ca ~ o. w i w I c~
o o~l '.~.H OH
ob o To a stirring solution of E-6 (Scheme E, where Rs is 4-[ (2,6-dichlorophenyl)methoxy]-phenyl, and stereochemistry of the pyrrolidine ring is (21f~,5S) and the amino acid is (S)) (I.00g, 1.53mmo1) in MeOH (50mL) was added 1M K2,C03 (IOmL). After stirnng for 12h, the reaction mixture was evaporated in vacuo, the residue was dissolved in H20 (0.1 L), the pH was adjusted to ca. 6 with 1 M HCI, and the mixture was extracted with CHCl3 (2X0.1 L}. The combined extracts were washed with H20, brine, dried (Na2S04), and evaporated in vacuo to afford the title compound (0.85g) as a white solid.
MP: 80-83°C; 1H-NMR: (300MHz, CDCl3): 8 = 9.87 (1 H}, 7.35 {2 H), 7.21-7.26 (7 H), 7.13 (2 H}, 6.94 (2 H), 5.22 (2 H}, 4.64 (1 H), 3.80 (1 H), 3.55 (1 H}, 3.29-3.37 (3 H}, 3.04 1 H), 2.48 { 1 H}, 2.26 ( 1 H}, 1.94 ( 1 H}, 1.76 ( 1 H}, 1.59 ( 1 H), 1.41 ( 1 H), 1.34 {9 H);
FAB/MS m/z (rel. intensity): 641 (M+H, 45.8), 585 (13.0}, 260 (6.1), 204 (base}, 91 {96.8); IR (nujol): 1732, 1642, 1612, 1585, 1565, 1534, 1511, 1439, 1240, 1230, 1196, 1178, 1153, 1018, 779, and 767cm-1; HRMS: Calcd. for C3qH38C12N~O6: 641.2185.
Found. 641.2164; [a]D25: +5° ( c = 0.795, CHCl3).
Preparation 29 and Example 94.
{Scheme E, E-8 where RS is 4-[ (2,6-dichlorophenyl)methoxy]phenyl, and stereochemistry of the pyrrolidine ring is (2R,5S) and the amino acid is (S~).
(SR)-5-[2-[[ (1S)-1-Carboxy-2-(4-( (2,6-dichlorophenyi)methoxy]phenyl]ethyl]amino]-2-oxoethyl]-1- (phenylmethyl)-L-proline ( (1S, 5R, L)) ci. ~
°~ ~ I
I c~
°
HO~j, ,~,",.~H OH
°b °

To a solution of E-7 (Scheme E, where RS is 4-[ (2,6-diichlorophenyl)methoxy]phenyl, and stereochemistry of the pyrrolidine ring is (2R,SS) and the amino acid is (S)) (0.85g, 1.32mmoi) in H20/n-PrOH ( 1:1, 0.1 L) was added HOAc {6mL), and the solution refluxed for Sh, then stirred at RT for 12h. Evaporation. in vacuo afforded the title compound (0.78g) as a white solid. MP: 198-202°C; 1 H-NMR: (300MHz, DMSO}: b =8.56 (1 H), 7.56-7.59 (2 H), 7.45-7.50 (1 H), 7.25-7.29 (5 H), 7.21 (2 H), 6.96 (2 H), 5.18 (2 H), 4.41 ( 1 H}, 3.89 { 1 H), 3.74 ( 1 H), 3.31 ( 1 H), 3.03-3.09 (2 H), 2.85 ( 1 H), 2.18-2.34 (2 H), 1.88-2:00 (I H), 1.63-1.84 (2 H}, 1.44-I.58 (1 H); FAB/MS m/z (rel.
intensity): 585 (M+H, 21.6}, 539 (2.1), 246 (14.5), 204 (60.9), 159 (12..6), 91 (base); IR
(nujol): 3309, 3083, 3037, 3014, 1662, 1644, 1562, 1514, 1440, 1377; 1348, 1241, 1197, 1178, 1018, 998, 815, and 771cmI; Anal: Calcd. for C3oH3oNZO6C1zO.38H20: C, 60.83; H, 5.24; N, 4.73. Found: C, 60.83; H, 5.33; N, 4.69; Karl Fischer water: 0.42%.
Example 95.
(Scheme E, E-8 where RS is 4-( (2,6-dichlorophenyl)methoxy]phenyl, and stereochemistry of the pyrroiidine ring is (2S,SR} and the amino acid is (S)).
(5S)-5-[2-([ (1S)-1-Carboxy-2-[4-[ (2,6-dichlorophenyl)methaxy]phenyl]ethyl]amino]-2-oxoethyl]-1- (phenylmethy!)-D-proline ( (1S, 5S, I))) G
~I
G
O
HO~~~~N OH
I N H O
ob I, Example 95 was prepared as described in Scheme E from E-1 (Scheme E where stereochemistry is (R) prepared by the method of Rapoport (.7. Am. Chem. Soc.
1984, 106, 4539). Physical data as follows: 198-204°C; IH-NMR: (300MHz; DMSO): cS
= 8.60 (1 H}, 7.54-7.68 (3 H), 7.26-7.41 (8 H), 7.05 (2 H), 5.27 (2, H), 4.57 (I H), 3.96 (1 H), 3.82 (1 H), 3.40 ( I H), 3.14 (2 H), 2.86-2.94 ( 1 H), 2.27-2.47 (2 H), 1.96-2:10 ( 1 H), 1.72-1.88 ( 1 H), I.SS-1.72 (1 H), I.30-1.42 (1 H}; FAB/MS m/z (rel. intensity): S8S (M+H, SO.S), S39 (4.S), 332 (32.1), 331 (18.1}, 246 (6.2}, 244 (6.0), 204 ('77.2), 91 (base);
IR (nujol): 3211, 3033, 3006, 1724, 1647, 1610, 1S6S, 1512, 1438, i3S4, 1301, 1273, 1240, 1196, 1018, S 871, and 767ctri'; Anal: Calcd. for C30H30N246C12~0.43HZO:C, 60.77; H, 5.24;
N, 4.72.
Found: C, 60.76; H, 5.37; N, 4.59; Karl Fischer water analysis: 1.71%.
Scheme F
$ RF-t ~RF~2 F-1 ~OH
[~N~
~O.-~O O

O. F-2 H2N~ RF-a O
RF.t S RF-2 O $ RF-1 RF_Z O
N~NM O.Rp.~ C NH
//O N~ OH

O O R5 ~ O~O O ~ F-7 $ R
RF.2 O $ F-~
~ RF_p O
N~ NH O, RF_3 NN
[O~ ~ F-4 H [~ OH
R5 O ~ F-j ~$ RF RF-2 ~ $ Rf'_t NH R ~ ~'RF_y O
N ~O ~ N ~NH pH
R3 Y O R5 F-5 R ,Y O ~ F-6 s R5 Where RF_3 is defined as proton or C,-6 alkyl.

Scheme F describes a general method for the prf;paration of examples of the formula F-4, F-S, F-6, F-7, and F-8. A commercially available or readily prepared sulfur containing amino acid of structure F-1 is condensed with amino acid derivative F-2 under standard peptide synthesis conditions as described in Scheme A. Deprotection of the carbamate from F-3 provides the useful intermediate F-4. The amine group may be reacted with a variety of electrophilic reagents as described in Scheme A to provide esters of general structure F-S. Mild base hydrolysis provides acids of structure F-6. Mild hydrolysis of esters of general structure F-3 provides acid of formula F-7. In those cases in which R~_3 is equal to t-butyl, mild acidolysis of compounds of general structure F-3 afford the amino acid of general structure F-8.
Preparation 30 and Example 96.
(Scheme F, F-3: where RF_, and RF_2 are the same and equal to proton, RF_3 IS
CH3, RS is 4-[(2,6-dichlorobenzoyl)amino]phenyl and stereochemistry is (R, S}) s o N N O~
~O~O O ~ ~ O~~ CI
~N~
cl To a cooled (0 °C) solution of Boc-L-thiomorpholine-3-carboxylic acid ((a) Van Der Auwera, C.; Anteunis, M.J.O. Int. J. Peptide Protein Res. 1987, 29, 574: (b) Kogami, Y.;
Okawa, K. Bull. Chem. Soc. Jpn. 1987, 60, 2963: (c) L.~rsson U.; Carlson R.
ACTA
Chemica. Scared. 1994, ~8, 517: (d) Carson 3.F.; Wong F.F. J. Org. Chem. 1964, 29, 2203.} (Scheme F, F-1: where RF_, and RF_2 are the same and equal to proton and stereachemistry is (R)) (6.7 g, 27 mmol) in CHZCIz (100 mL) was added HOBt (4.0 g, 29.7 mmol), DMAP (700 mg}, EDC (5.7 g, 29.7 rnmol) and l:riethylamine ( 13.5 mL, 97 mrnol).
The reaction mixture was stirred for IO min, then the amino acid derivative F-2 (Scheme F, where RS is 4-[(2,6-dichlorobenzoyl}amino]phenyl, R.H_31$ CH3, and stereochemistry is (S)) (10.0 g, 24.7 mmol) was added. After 20 h, volatile;s were removed in vacuo and the residue partitioned between 2.5% aqueous HCl (100 mL,) and H20 (I00 mL). The organic layer was separated and washed saturated aqueous NaHC03 (100 mL), dried and concentrated in vacuo. Purification of the residue by cl>J-omatography on Si02 (500 g) using CHZC12 /ethyl acetate (10%) as eluent afforded thE; title compound (12.31 g) as a solid:'H NMR (CDCl3) S 1.44 (9 H}, 2.35 (I H), 2.70 (3 H), 3.13 (2 H), 3.33 (1 H), 3.77 {3 H), 4.22 (1 H), 5.00 (1 H), 6.48 ( I H), 7.18 {2 H), 7.3~ 1 (3 H), 7.44 (I
H), 7.56 (2 H);
'3C NMR (CDC13) 8 171.6, 168.9, 162.5, 136.5, 135.9, 132.4, 131.0, 130.2, 128.2, 120.5, 81.7, 77.3, 53.3, 52.6, 37.0, 28.2, 26.5; IR {mull) 3296, 2924, 1744, 1685, 1668, 1605, IS36, 15I5, 1432, 1412, I321, I294, 1260, 1244, 1213, 1195, 1161, 798 cm'; MS
(FAB) mlz (rel. intensity) 598 (M+H, 3), 596 (M+H, 5). Anal. Calcd for C27H3,C12N3O6S : C, 54.36; H, 5.24; N, 7.04. Found: C, 54.23; H, 5.24; N, 6.86. Corrected for 0.60% HZO, found by Karl Fischer analysis.
Preparation 31 and Example 97.
(Scheme F, F-4: where RF_, and RF_z are the same and equal to proton, RF_31S
CH3, RS is 4-[(2,6-dichlorobenzoyl)amino]phenyl and stereochemistry is (R, ,f}) s o r~ N~:o H o o c;l ~ HCI I ~ N
H ~~
Acetyl chloride (1.75 mL, 24 mmol) was slowly added to MeOH (26 mL} at 0-5 °C. After I5 min, a solution of the carbamate F-3 (Scheme F, where RF_, and RF.2 are the same and equal to proton, RF.3 is CH3, RS is 4-[(2,6-dichlorobenzoyl)amino]phenyl and stereochemistry is (R, S~) (2.4 g, 4.0 mmol) in methanol (8 mL) was added.
After 50.5 h at 0 °C, the solvent was removed in vacuo to yield the title compound (2.11 g): 'H NMR
(300 MHz, DMSO-d6) s 2.68 (I H), 3.00 (6 H), 3.47 (1 H), 3.64 (3 H), 4.02 (1 H), 4,52 (I H), 7.28 (2 H), 7.54 (5 H), 9.15 (1 H), 9.3 (I H}, 9.70 (1 H), 10.7 (I H);
IR {mull) 3191, 3031, 1742, 1664, 1604, 1577, 1561, 1540, 1516, 1432, 1414, 1326, 1271, 1210, 799 cm' '; MS (EI} m/z (rel. intensity) 495 (M+, 1).

Preparation 32 and Example 98.
(Scheme F, F-5: where RF_, and Rr_2 are the same and equal to proton, RF.a is CH3, R3 is CHZCHZCOZCH3, RS is 4-[(2,6-dichlorobenzoyl)amino]phenyl, Y is CO-, and stereochernistry is (R, S~).
s o °.
-°~o ° ~ ~ cl I
H I ~
CI
To a solution of amine F-4 (Scheme F, where RF_, and R,:.2 axe the same and equal to proton, Rr_3 is CH3, RS is 4-[(2,6-dichlorobenzoyi}amino=phenyl and stereochemistry is (R, ,S~) (650 mg, 1.2 mmol) was added mono-methyl succinate (320 mg, 2.4 mmol), EDC
(460 mg, 2.4 mmol), pyridine (10 mL) and DMAP at ambient temperature. After 27 h, the mixture was diluted with 25 mL of saturated NaHC03 was extracted with methylene chloride. The combined organic extracts were dried and concentrated in vacuo.
Purification of the residue by flash chromatography using methylene chloride/ethyl acetate {3:2) as eluant followed by lyophilization afforded the title compound (600 mg} as an amorphous solid: IR {mull) 1742, 1659, 1657, 1608; 1537, 1516, 1432, 14/4, 1324, /269, 1259, 1228, 1214, 1195, 1176 crri';'H NMR (300 MHz, CDCl3) S 2.63 (7 H), 3.21 (3 H), 3.68 (3 H), 3.78 (3 H), 3.90 (I H), 4.80 (2 H), 5.50 (1 H), 6.56 (1 H); 7.29 {5 H), 7.57 (2 H);'3C NMR (75 MHz, CDCl3) 8 173.9, 172.0, 171.7., 168.5, 162.7, 136.1, 135.9, 133.3, 132.3, 13x.0, 130.1, 128.2, 121.0, 120.7, 53.1, 52.5, 52.3, 52.0, 44.4, 36.7, 29.4, 27.7, 26.9, 26.4; MS (EI) m/z (rel. intensity} 609 (M+, 5). Anal. Calcd for . C, 53.12; H, 4.79; N, 6.88. Found: C, 53.04; H, 4.81; N, 6.83. Corrected for 0.74%
Hz0 found by Karl Fischer analysis.
Preparation 33 and Example 99.
[R-(R*,S*)]- 3-[[jl-Carboxy-2--[4-[(2,6-dichlbrobenzoyl)amino]phenyl]ethyl]amino]carbonyl] ~-oxo-4-thiomorpholinebutanoic acid WO 9916'1230 PCTlUS99/14233 (Scheme F, F-6: where RF_, and RF_2 are the same and equal to proton, RF_3 IS
proton, R3 is CHZCH2COZH, RS is 4-[(2,6-dichlorobenzoyl)amino]ph.enyl, Y is CO-, and stereochemistry is (R, S)).

N
HO
O
O
S
To a solution of the diester F-5 (Scheme F, where RF_, a'nd RF_2 are the same and equal to proton, Rg_g IS CH,, R3 is CHZCHZCOZCH3, RS is 4-[(2,6-dichlorobenzoyl)amino]phenyl, Y
is CO-, and stereochemistry is (R, ,S~) {490 mg, 0.80 mrnol) in THF (20 mL) and MeOH (6 mL) was added a solution of LiOH~H20 ( 178 mg, 4.25 mmol) in H20 (6 mL). After 22 h, the mixture was concentrated in vacuv. The residue ways partially dissolved in 10% HCI
(20 mL) and the resulting solid collected by filtration. 'The solid was washed with water and lyophilized from aqueous acetonitrile to afford the title compound (400 mg) as an amorphous solid: IR {mull) 3267, 3 L93, 3058, 3034, 2924, 1725, 1658, 1607, 1562, 1537, 1516, 1432, 1414, 1326, 1195, 1178, 800 cm'; 'H NMR {300 MHz, DMSO-d6) S 2.62 (7 H), 3.17 (3 H), 3.95 (1 H), 4.57 (2 H), 5.26 {1 H), 7.18 (2 H), 7.55 (5 H);
8.02 (1 H), 10.64 (1 H), 12.34 ( 1 H); MS (FAB) m/z (rel. intensity;} 582 (M+H, 18).
Preparation 34 and Example 100.
[R-(R*,S*)]-3-[[[1-Caurboxy-.'.'?-[4-[(2,6-dichlorobenzoyl)amino]phenyl]ethyl]amino]carbonyl]~-4--thiomorpholinecarboxylic acid 4-{ 1,1-dimethylethyl) ester (Scheme F, F-7: where RF_, and RF_z are the same and equal to proton, RF_3 is proton, RS is 4-[(2,6-dichlorobenzoyl)amino]phenyl and stereochemistry is (R, S)).

s N NH v 'OH
~0~0 O ~ O CI
r~ H
CI
To a solution of ester F-3 (Scheme F, where RF_, and R,:_2 are the same and equal to proton, Rr_3 is CH3, RS is 4-[(2,6-dichlorobenzoyl)amino]phenyl and stereochemistry is (R, S}) (656 mg, 1.02 mmoI) in MeOH (25 mL) was added KZCO~ (554 mg, 4 mmol) and H20 (13 mL). After 3 h, volatiles were partially removed and the solution diluted with 10% HCI
(20 mL) causing precipitation of a solid. The product cvas collected by filtration, washed with H20 and dried in a vacuum oven to afford the product (610 mg): IR {mull) 1736, 1665, 1606, 1562, 1537, 1516, I432, 1413, 1323, 1294., 1260, 1244, 1211, I
195, 1160 cm-~; 'H NMR (300 MHz, DMSO-d6) 8 1.35 (9 H), 2.45 (:2 H}, 2.74 (5 H), 4.00 (I
H), 4.47 { 1 H}, 4.70 ( 1 H), 7.19 {2 H), 7.52 (5 H), 7.92 ( 1 H), I 0.60 ( 1 H), 12.75 ( 1 H); MS (FAB) m/z (rel. intensity) 582 {M+H, 12). Anal. Calcd for CZ6Hz9CIzN3O6S : C, 53.61;
H, 5.02;
N, 7.21;. Found: C, 53.20; H, 5.12; N, 7.10. Corrected for 2.30% HZO found by Karl Fischer analysis.
Preparation 35.
(Scheme F, F-3: where RF_t and RF_2 are the same and equal to proton, RF_3 is t-butyl, RS is 4-[(2,6-dichlorobenzoyl}amino]phenyl and stereochemi.stry is (R, f~).
s N N O
O 00 ( ~ OIt CI
~N
H
CI
To a cooled {0-5 °C) solution of Boc-L-thiomorpholine-3-carboxylic acid (Scheme F, F-1: where Rr_= and RF_Z are the same and equal to proton and stereochemistry is (R}) ( 1.34 g, S.4 mmol) in methylene chloride (20 mL) was added HOBt (800 mg, 5.94 mmol), DMAP

(140 mg; EDC (1.14 g, 5.94 mmol) and triethylamine (2.7 mL, 19.4 mmol). After min, F-2 (Scheme F where RF_, and RF_Z are the same and. equal to proton, RF_3 IS t-butyl, RS
is 4-[(2,6-dichlorobenzoyl)amino]phenyl and stereochemistry is (~) (2.02 g, 4.94 mmoi) was added, the reaction allowed to warm to ambient temperature and stirred for 24 h.
Volatiles were removed in vacuo and the residue partitioned between methylene chloride and 2.5% aqueous HCI. The organic layer was separated and washed with sat.
aqueous NaHC03, dried and concentrated in vacuo: Purification of the residue by flash chromatography using methylene chloride/ethyl acetate ( 5%) as eluant afforded the title compound (1.64 g): IR (mull) 1730, 1687, 1667,1606, I538, 1515, 1431, 1412, 1395, 1320, 1294, 1258, 1250, 1194, 1158 cm''; 'H NMR (300 MHz, CDC13) 8 I.44 (9 H), 1.46 (9 H), 2.3 5 ( 1 H), 2.67 (3 H), 3.22 (3 H), 4.25 ( 1 H), 4.73 ( 1 H), 4.97 ( 1 H), 6.52 ( I H), 7.29 (5 H), 7.53 (3 H); MS (FAB) mlz (rel. intensity) 638 {M+H, 2). Anal.
Calcd for C3oH37C12N,O6S: C, 56.42; H, 5.84; N, 6.58. Found: C, 56.13; H, 5.98; N, 6.58.
Preparation 36 and Example 101.
4-[(2,6-Dichlorobenzoyl)amino]-N-[[(3R)-3-thiomorpholinyl]carbonyl]-t,-phenyIalanine monohydroch.loride {Scheme F, F-8: where RF_, and RF_z are the same and equal to proton,. RF.31s proton, R5 is 4-[(2,6-dichlorobenzoyl)amino]phenyl and stereochemistry is (R, S)).

NH_ ~
N~ v 'OH
H I' i I O Cl \ NHS / I
Cl \
To a solution of HC1 saturated in ethyl ether (5 mL) at ambient temperature was added carbamate F-3 (Scheme F, where RF_, and RF_z are the sanne and equal to proton, RF_3 IS t-butyl, RS is 4-[(2,6-dichlorobenzoyl)amino]phenyl and stereochemistry is (R, S)) (100 mg, 0.15 mmol) with vigorous stirring. After 43.5 h, the precipitate was collected by filtration and washed with ethyl ether to afford the title compound {90 mg): IR (mull) 3241, 3189, 3033, 2731, 1725, 1661, 1605, 1578, 1562, 1542, 1515, :1432, 1414, 1328, 1195 cm'';'H

WO 99/67230 PCTlUS99/14233 NMR (300 MHz, DMSO-d6) 8 2:66 (1 H), 2.99 {6 H), 3.50 (1 H), 3.98 (1 H), 4.45 (I H), 7.26 (I H), 7.52 (5 H), 9.00 (2 H), 9.30 (1 H), 10.69 (1 H:); MS (FAB) m/z (rel. intensity) 482 (M+H, 83), 540 (32), 539 (9), 538 (42), 486 (13), 485 (16), 484 (60), 483 (24), 482 (83), 173 {11), 102 (99). Anal. Calcd for CZ,HZ,C12N304S ~ HCI: C, 48:61; H, 4.27; N, 8.I0; Cl, 20.50; S, 6.18. Found: C, 48.92; H, 4.27; N, 7.'79; Cl, 19.68.
Corrected for 6.53% HZO found by Karl Fischer analysis.
Example 102.
4-{(2,b-Dichlorobenzoyl}amino]--N-[[{3R)-4--[ I-oxo-3-( I H-tetrazol-S-yl)propyl]-3 thiomorpholinyl]carbonyl]-r.-phenylalanine methyl ester (Scheme F, F-5: where RF_, and RF_, are the same and equal to proton, RF_3 is CH3, R3 is 2-(5-1H-tetrazolyl)ethyl, RS is 4-[(2,6-dichlorobenzoyl)amino]phenyl, Y is CO-, and stereochemistry is {R, S~).
g O .
CN II N~Oi N~C p ~ OII Ct NN.N L / N~ W
H , I r Ci i5 Example I02 was prepared as described in Scheme F using 1H-tetrazole-5-propanoic acid (Hutchinson, D. W.; Naylor, M. Nucleic Acids Res. 1985,13, 8519) to form the requisite amide.,.Physical data as follows: IR {mull) 3264, 3047, 11742, 1659, 1607, 1561, 1537, 1516, 1432, 1415, 1324, 1268, 1219, 1195, 799 cxri';'H NMR (300 MHz, DMSO-d6) 2.26 (1 H), 2.66 (2 H), 3.02 (8 H), 3.61 (3 H}, 3.87 (I H), 4.56 (1 H), 5.25 (1 H), 7.21 . (2 H), 7.50 (5 H), 8.18 ( 1 H), 8.45 ( 1 H), 8:64 { 1 H); MS (FAB) mlz (rel.
intensity) 620 (M+H, 61 ).
Example 103.
4-[(2,6-Dichlorobenzoyl)amino]-N-[[(3R)-4-[ 1-oxo-:3-( 1 H-tetrazol-5-yl)propyI]-3 thiornorpholinyl]-carbonyl]-L-phe;nylalanine (Scheme F, F-6: where RF_, and RF_2 are the same and equal to proton, RF_31S
proton, R3 is 2-(S-1H-tetrazolyI)ethyl, RS is 4-[(2,6-dichlorobenzoyl)arnino]phenyl, Y is CO-, and stereochemistry is (R, S)).
S
O
H
N N v 'OH
.N O
N ~ 'O .~ I O Cl N-N
N
H
Cl Example I03 was prepared from example 102 by the procedure described in preparation 34. Physical data as follows: IR (mull) 3376, 3296, 3267, 3127, i 746, 1683, 1669, 1641, 1623, 1610, 1542, 1522, 1444, 1436, 1411 cm' ~ MS (E;iI+) for CZSHzsC12N705S
m/z 605.8 (M+H)~; MS (FAB) m/z (rel. intensity) 606 (MH~, S l )., 682 (17), 608 (40), 607 (28), 606 (S1), 605 (16), 254 (99), 226 (23), 175 (17), 137 (20), 1!02 (33); HRMS (FAB) calcd for C,SHz5C1zN705S +Hi 606.1093, found b06.1105.
Example 104.
N-[[(3R)-4-(3-Cyano-1-oxopropyl~3-thiomo:rphoiinyl]carbonyl]-4-[[2,6 dichlorobenzoyl)amino]-L-phenylalanine (Scheme F, F-6: where RF_, and RF_z are the same and equal to proton, RF_~ is proton, R3 i5 CHZCHZCN, RS is 4-[(2,6-dichlorobenzoyl)amino)phenyl, Y is CO-, and stereochemistry is (R, S)).

S
O
H
N N OH
N=C O ~ ~ ~ O Cl N
H

Example 104 was prepared as described in Scheme F u;>ing 3-cyanopropanoic acid (readily prepared from commercially available 3-cyanopropanoi.c acid) to form the requisite amide.
Physical data as follows: IR (mull) 2251, 1735, / 655, I6I2, 1585, 1565, 1512, 1439, 1298, /240, 1 i96, 1179, 1016, 1000, 779, 768 cm'; 'I-I NMR (300 MHz, CDCl3) 8 2.40 (12 H), 4.88 (1 H), 5.22 (2 H), 6.72 (I H), 6.96(2 H), 7.23 (5 H).
Example 105.
[R-(R*,S*)]-3-[[[I-Carboxy-2-[4-[(2,6-dichlorophenyl)methoxy]-phenyl]ethyl]amino]carbonyl]-y-oxo-4-thiomorpholinebutanoic acid I O (Scheme F, F-6: where RF., and RF_Z are the same and eq~,ual to proton, RF_3 iS proton, R3 is CHzCH2COzH, RS is 4-[{2,6-dichlorophenyl)methoxy]p:henyl , Y is CO-, and stereochemistry is (R, S)).
S
H O
N N~OH
HO O~ _ ~O
O
Example 105 was prepared as described in Scheme F using mono-methyl succinate to form the requisite amide. Physical data as follows: IR (mull;t 3031, 1726, 1646, /612, 1585, 1565, 1511, 1439, 1421, 1297, 1240, 1 I96, 1179, 1016, 768 crri'; 'H NMR (300 MHz, DMSO-d6) 8 2.62 (8 H), 3.64 (3 H), 4.39 (2 H), 5.20 (2 H), 6.92 (2 H), 7.15 (2 H), 7.50 (3 H), 7.98 (2 H); "C NMR {75 MHz, DMSO-d6) 8 174.5, 173.2, 171.9, 168.9, 136.5, 132.3, 132.0, 130.8, 130.7, 129.2, 114.8, 65.3, 54.3, 52,.5, 36.0, 29.7, 28.0, 27.0; MS
(FAB) m/z (rel. intensity) 569 {M+H, 24). Anal. Calcd for CZSHa6C1zN207S: C, 52.73; H, 4.60; N, 4.92; Cl, 12.45. Found: C, 52.51; H, 4.60; N, 4.94; Cl, 12.78.
Corrected for 3.37% Hz0 found by Karl Fischer analysis.

Scheme G

O NH

RG_2_O g ll O
O RG_t O
O N'RG-~
Gi-2 R~,.~-O 9 O
O R~_t O
O N-RG-~ G..3 RGa'O ~ ~9 ~-OH
O
Rs HZN~O~ G-4 'IO
O
O N-RG_s H~ O
RG.~'O g N ~O~ G-5 ~O

O

H ti-6 HO 9~N~OH
O

Where R~_, and Re_2 are defined independently as H or CH 3; R~-3 is defined as H, C,~ alkyl or C3_6 alkenyl; and g is defined as 0 or 2.

Scheme G describes a general method to prepare lactam examples of general structures G-5 and G-6. Readily prepared iactams of general structure G-1 may be aIkylated by the reaction of an appropriate alkylating in the presence of a suitable base as described in preparation 37 to provide intermediates of general structure G-2.
Mild hydrolysis provides the monoacid of general structure G-3 which may be condensed with an amino acyl intermediate of structure G-4 as describef. in Scheme A. Full hydrolysis of the diester of general structure G-5 affords the diacid of structure G-6.
Preparation 37.
(Scheme G, G-2: where R~_, and RG_z are CHI, RG_3 is CH3 and g is equal to 2).

O O
O O
To a cooled (0-5 °C) solution of dimethyl ester G-1 {Sch.eme G, where R~_, and R.~_2 are CHI, R~_3 is H and g is equal to 2) (Thomas, E.T.; Rynbrandt, R.H; Zimmermann, D.C.;
IS Bell, L.T.; Muchmore, C.R.; Yankee, E.W. J. Org. Chem. 1989, 54, 4535) (25.7 g, 0.1 mole) and iodomethane {30 mL, 0.48 mol) in THF {200 ~mL) was added NaH (4.8 g, 0.12 mmol, 60% in oil dispersion). After 22 h, the reaction was quenched by the addition of HZO ( 100 mL) and diluted with CHZC12 (50 mL). The organic layer was separated, dried and dried in vacuo. The crude brown oil was triturated v~rith hexanes {200 mL) and the residue concentrated in vacuo to afford the crude produce: ( 18.44 g) which was used without further purification: 'H NMR (300 MHz, CDCI3;! 8 2:03 (I2 H), 2.64 (3 H), 3.64 (6 H).
Preparation 38.
(Scheme G, G-3: whereR~_2 is CH3, RG_3 is CH3 and g is f:qual to 2).

O OH
O O

To a cooled (0-5 °C) solution of diester G-2 (Scheme G,, where RG_, and RG_2 are CH3, R~3 is CH3 and g is equal to 2) (10.0 g, 36.9 mmol) in aqueous methanol (66%, 75 mL) was added LiOH~H20 (1.55 g, 36.9 rnmol). After 22 h, the mixture was partially concentrated in vacuo and diluted with water. The aqueous layer was washed with methylene chloride and acidified (pH ca. 2) with 1Q% HCI. The aqueous layer was extracted with methylene chloride and the combined organic extracts dried and concentrated in vacuo to afford the title compound (3.63 g) as a yellow solid: IR (mull) 1735, 1630, 1442, 1429, 1418, 1405, 1330, 1308, 1287, 1255, 1217, I 185, 1122, 1016, 642 crri';'H NMR (300 MHz, CDCl3) 8 1.90 (6 H), 2.24 (4 H), 2.43 (2 H}, 2.68 (3 H), 3.67 (3 H}; '3C NMR (75 MHz, CDCl3) 8 176.3, 175.5, 173.2), 64.6, 52:0, 33.1, 32.9, 29.9, 28.41, 28.38, 26.0, 24.9;
MS (EI) m/z (rel: intensity) 257 (M+, 1 ).
Preparation 39 and Example 106.
2-j3-j[( 1 S)-1-[[4-[(2,6-Dichlorophenyl)methoxy]phenyl]methyi]-2-rizethoxy-2-oxoethyl]amino]-3-oxopropyl]-1--methyl-5-oxo-2-pyrrolidinepropanoic acid methyl ester (Scheme G, G-5: where Rc_2 and R~~ are both equal to C:H3, RS is 4-[(2,6 dichlorophenyl)methoxy]phenyl, g is equal to 2 and ster~eochemistry is (S~).

N-CH3 O~~
% N~Oi O O
CI
Or \
Cs To a solution of acid G-3 (Scheme G, whereRG_2 and R~3 are equal to CH3 and g is equal to 2) (1.0 g, 3.9 mmol), amine G-4 (Scheme G, where RS is 4-[(2,6-dichlorophenyl)-methoxy]phenyl and stereochemistry is (S'~) (1.82 g, 4.67 mmol), and DMAP (100 mg, 0.8 mmol} in pyridine (15 mL) was added EDC (895 mg, 4.iS7 mmol). After 21 h, the reaction was diluted with saturated aqueous NaHC03 and methylene chloride. The organic layer was separated and washed with 10% aqueous HCI, dried and concentrated i~
vacuo.
Purification of the residue by flash chromatography using methylene chloride/ethyl acetate (20%) as eluant followed by lyophiiization from aqueous acetonitrile afforded the title compound (i.71 g} as an amorphous solid: IR (mull} 3284, 2924, 1738, 1666, 1665, 1564, 1539, 1511, 1439, 1398, 1299, 1240, 1198, 1178, 1117., 1016, 768 cm'';'H NMR
{300 MHz, CDC13) 8 2.10 (12 H), 2.66 (3 H), 3:07 (2 H), 3.66 (3 H}, 3.73 (3 H), 4.83 {1 H), 5.24 (2 H), 5.98 (1 H), 6.95 (2 H), 7:02 ( 2 H), 7.25 (1 H), 7.36(2 H);'3C NMR
(75 MHz, CDCI3) S 174.7, 1?4.66, 173.2, 172.0, 171.2), 158.1, 137.0), 132.1, 130.5, 130.3, 128.5, 128:3, 115.2, 65.2, 64.3, 53.3, 52.4, SI.9, 37.0, 33.2, 30.2, 30.17, 28.4, 26.0, 24.7; MS (EI) mlz (rel. intensity) 592 (M+, 4). Anal. Calcd for CZ9H34t~IzNzO,: C, 58.69; H, 5.77; N, 4.72;
CI, 11.95: Found: C, 58.33; H, 5.65; N, 4.76; Cl, 11.89.
Preparation 40 and Example 107.
2-[3-[[( I S)-1--Carboxy-2-[4-[(2;6-dichlorophenyl}methoxy]phenyl]ethyl]amino]-oxo-propyl]-1-methyl-5-oxo-2-pyrrolidinepropanoic acid (Scheme G, G-6: where RG_3 is equal to CHI, RS is 4-[{2,6-dichlorophenyl)methoxy]phenyl, g is equal to 2 and stelreochemistry is (,f~).

N-CHg O
H~ ~
HO N~OH
O O
~ CI
O' CI
To a solution of diester G-5 (Scheme G, where R~z and RG_3 are both equal to CHa, RS is 4-[(2,6-dichlorophenyl)methoxy]phenyl, g is equal to 2 arwd stereochemistry is (S) (1.0 g, 1.68 mmol), in THF (30 mL) and MeOH (9 mL) was added LiOH~H20 (370 mg, 8.8 mmol). After 22.5 h, the reaction mixture was acidified with 10% aqueous HCI
(30 rnL) causing precipitation of a solid. The solid was collected) by filtration and lyophilized from aqueous acetonitrile to afford the title compound (0.91 ~;) as an amorphous solid: IR
(mull) 3031, 2925, 1727, 1637, 1585, 1564, 1543, 1511', 1439, 1424, 1404, 1299, 1240, 1196, 1 I79, 768 crn''; 'H NMR (300 MHz, DMSO-d6) ~8 1.77 (12 H), 2.76 (1 H), 3.97 ( 1 H), 4.36 ( 1 H), 5.16 (2 H); 6.94 (2 H), 7.1 S (2 H), 7.4.9 (3 H), 8.16 ( 1 H); ' 3C NMR (75 MHz, CDCI3) 8 174.6, 174.1, 173.6, 172.2, 157.6; 136.~i, 132.2, 132.0, 130.7, 130.6, 129.2, 114.7, 65.3, 64.1, 54.0,.36.5, 33.7, 33.1, 30.1, 30.05, 29.8, 28.7, 25.7, 24.6; MS
S {FAB) nz/z (rel. intensity) S6S (M+H, 99). Anal. Calcd for C27H3oC12N2O7: C, S7.3S; H, S.3S; N, 4.95; Cl, 12.54. Found: C, 56:93; H, S.1 S; N, 5.02; CI, 12.42.
Corrected for 1.03% H20 found by Karl Fischer analysis.
Example 108.
2-[3-[[(1S)-1-[[4-[(2,6-Dichlorophenyl)methoxy]phenyl]methyl]-2-methoxy-2-oxoethyl]amino]-3-oxopropyI]-1-(3-methyl-2-butenyl}--S-oxo-2-pyrrolidinepropanoic acid methyl ester (Scheme G, G-5: where RG_Z is CH3, Re_3 is 1-(3-methyl-2-butenyl), RS is 4-[(2,6-dichlorophenyl)methvxyJphenyl, g is equal to 2 and stereochemistry is (S'~).

o~

ci I ~ o' I~
c:' Example 108 was prepared as described in Scheme G using 1-bromo-3-methyl-2-butene to form the requisite N-alkyl lactam. Physical data as follows: IR (mull) 32.95, 29.52, 1740, 1678, 1662, 1564, 1538, 1512, 1439, 1414, 1300, 1279, 1240, 1199, 1178, 1017, 768 cm'';
'H NMR (300 MHz, CDC13) 8 I.64 (3 H), 1.70 (3 H), 2.06 (12 H), 3.09 (2 H), 3.66 (3 H), 3.74 (2 H), 3.74 (3 H), 4.85 ( 1 H), 5.20 ( 1 H), 5.24 (2 H;y, 6.95 (2 H), 7.02 (2 H), 7.25 {1 H), 7.36 (2 H);'3C NMR (7S MHz, CDCI3) 8 174.7, 1.73.3, 172.1, 172.0, 171.3, 158.1, 137.0, 135.1, 132.1, 130.5, 130.3, 128.5, 128.3, 119.7, I 15.2, 65.2, 65.1, 53.2, 52.4, 51.9, 37.5, 37.0,. 34.4, 34.2, 30.6, 29.9, 28.6, 26.6, 25.6, 2S.S, I7.9; MS (FAB) mlz (rel.
intensity) 647 (M+H, 24).

WO 99/6'7230 PCT/US99/1a233 Example 109.
2-[3-[[( I S)-1-Caxboxy-2-[4-[{2,6~iichlorophenyl)rnethoxy]phenyl]ethyl]amino]-oxo-propyl]-1-(3-methyl-2-butenyl)--5-oxo-2;-pyrroIidinepropanoic acid (Scheme G, G-b: where RG_3 is I-(3-methyl-2-butenyl), RS is 4-[(2,6-dichlorophenyl)methoxy]phenyl, g is equal to 2 and stereochemistry is (S~).
o~
N
H O
HO N~OIi O O.
CI
0' I \
(:I
Example 109 was prepared from example 108 by the procedure described in preparation 40. Physical data as follows: IR (mull) 3290, 2921,1726, 1635, 1585, 1565, 1545, 1511, 1439, I4I9, 1341, 1299, 1240, 1197, I 179, 780, 768 cm-'; 'H NMR (300 MHz, DMSO-d() b 1.57 (3 H}, 1.62 (3 H), 1.72 (6 H); 2.02 (6 H), 2.77 (I H), 2.98 (1 H), 3.55 (2 H), 5.05 (I H), S.I6 (2 H), 6.94 (2 H), 7.15 (2 H), 7.49 (2 H;), 7.54 (2 H), 8.15 (1 H); '3C
NMR (75 MHz, DMSO-d6) $ 174.6, 174.3, 173.6, 173..'i6, 172.2, 157.6, 136.5, 134.0, IS 132.2, 132.0, I30.6, 129.2, 121.1, 121.0, 114.7, 65.2, 65.0, 54.1, 54.0, 37.1, 36.5, 34.5;
34.1, 30.0, 29.9, 28.8, 26.3, 25.84), 25.81, 18.1; MS (FA~B) mlz (rel.
intensity} 619 (M+H, 99).
Example 1 I0.
2-[3-[[( 1 S)-1-[[4-[(2,6-Dichlorobenzoyl)amino]plhenyl]methyl]-2-methoxy-2-oxoethyl]aminoJ-3-oxopropyl]-1-methyl-5--oxo-2-pyrralidinepropanoic acid methyl ester {Scheme G, G-S: where R~_2 and RG_3 are equal to CH3, R$ is 4-[(2,6-dichlorobenzoyl)-amino]phenyl, g is equal to 2 and stereochemistry is (S~).

O
v H
O NJL,Oi O O
0 C!
N' W
H I
C:f Example 110 was prepared as described in Scheme G using iodomethane to form the requisite N-alkyl Iactam. Physical data as follows: IR (mull} 3258, 2922, 1738, 1662, S 1606, 1561, 1539, 1SIS, 1432, 1414; 1401, 1323, 1268, 1196, 1177, 799 cm:';'H NMR
(300 MHz, CDCl3} 8 2.01 (I2 H), 2.61 (3 H), 3.09 (2 H)~; 3.64 (3 H), 3.75 (3 H}, 4.84 (1 H), 6.15 (1 H), 7.09 (2 H), 2.31 (3 H), 7.58 (2 H), 7.99 {1 H);MS (EI) mlz (rel. intensity) 607 (M+, 4), 60S {M+, 6); Anal. CaIcd for C29H33C12N3O7: C, 57.43; H, 5.48; N, 6.93; CI, 11.69. Found: C, 57.18; H, S.S6; N, 6.85; Cl, 11.68. Corrected for 0.93% HzO, found by Karl Fischer analysis.
Example 111.
2-[3-[[( 1 S)-1-Carboxy-2-[4-[(2;6-dichlorobenzoyl)aminoJphenyl)ethyl]amino]--3-oxo propyl]-1-methyl-S-oxo-2-pyrroIidinepropanoic acid (Scheme G, G-6: where R.~_3 is CH3, RS is 4-[(2,6-dichlorobenzoyl)amino]phenyl; g is 1 S equal to 2 and stereochemistry is {,S~).

H~ J~
HO ~N~OH
O O
O CI
i 1 ~
c;!
Example 111 was prepared from example 110 by the procedure described in preparation 40. Physical data as follows: IR (mull) 3265, 3056, 29:>.S, 1724, 1658, 1609, IS79, 1561, 1542, 1516, 1432, 1414, 1327, 1271, 1217, 1195, 800 cW ';'H NMR (300 MHz, DMSO--i46-d6) 8 i.89 (12 H), 2.49 (3 H), 2.78 (1 H), 2.99 (1 H), 4.:38 (1 H), 7.18 (2 H}, 7.51 (S H), 8.17 (1 H), 10.64 {1 H); MS (FAB) mlz (rel. intensity) :580.5 (M+H, 68).
Example 112.
2-[3-[[(1 S)-1-[[4-[{2,6-Dichloraphenyl)methoxy]phenyl]methyl]-2-methoxy-2-oxoethyi]amino]-3-oxopropyl]-S-oxo--2-pyrrolid:inepropanoic acid methyl ester (Scheme G, G-5: where R~_z is CH,, R~_31S proton, RS is 4-[(2,6-dichlorophenyl) methoxy]phenyl; g is equal to 2 and stereochemistry is (,S~).

NH
O
N Oi O O
Cl O
C:I
Example 112 was prepared as described in Scheme G. Physical data as follows:
IR (mull) 3276, 3029, 1738, 1686, 1564, 1538, 1 S I 1, 1439, 1299, 1279, 1239, 1197, 1178, 1016, 767, cm'; 'H NMR (300 MHz, CDCl3) 8 1.8S {6 H}, 2.2.4 (2 H), 2.35 (4 H), 3.03 (2 H), 3.66 (3 H), 3.74 (3 H), 4.82 {1 H), 5.24 (2 H), 6.50 (2 Hj, 6.95 (2 H), 7.05 (2 H), 7.27 I5 (1 H}, 7.37 (2 H); MS (EI) mlz (rel. intensity) 578 (M+, 0.2); Anal. Calcd fox Cz$H3zC12N2O7: C, 58.04; H, 5.57; N, 4.83. Found: C, ST.93; H, 5.43; N, 4.97.
Corrected for 1.14 % H20 found by Karl Fischer analysis.
Example i 13.
2-[3-[[(1 S)-1-Carboxy-2-[4-[{2,6-dichlorophenyl)methoxyjphenyl]ethyl]amino]-3-oxo-propyl]-5-oxo--2 pyrrolidinepropanoic acid (Scheme G, G-6: where RG_3 is proton, RS is 4-[(2,6-dichlorophenyl)methoxy]phenyl, g is equal to 2 and stereochemistry is (,S~).

NH O
H ~
HO ~N~OH
O O
I ~ CI
o- w I~
(.~
Example 113 was prepared from example 112 by the procedure described in preparation 40. Physical data as follows: IR (mull) 3294, 3033, 1716, 1647, 1585, 1565, 1544, 1511, 1439; 1420, 1299, 1240, 1197, 1179, 768 crri'; 'H NMR; (300 MHz, DMSO-d6) 8 1.60 (6 H), 2.12 (6 H), 2.78 ( I H), 2.99 ( 1 H), 4.36 ( i H), 5.19 (2 H), 6.97 (2 H), 7.17 (2 H), 7.45 (1 H), 7.58 (2 H), 7.70 (1 H}, 8.22 (1 H); MS {FAE~} m/z (rel. intensity) 551 (M+H, 99); Anai. Calcd for C26HZgCIzNZO7: C, 56.63; H, 5.12; Cl, 12.86; N, 5.08.
Found: C, 56.28; H, 5.01; Cl, 13.08; N, 5.24. Corrected for 1.47% Hz0 found by Karl Fischer analysis.
Example 114.
2-[3-[[( 1 S}- I -[ [4-[(2, 6-Dichlorobenzoyl)amino]phenyl]methyl]-2-methoxy-2-oxoethyl]amino]-3--~xopropyl]-5-oxo-2-pyrrolidiinepropanoic acid methyl ester {Scheme G, G-5: where Ro_z is CHI, RG_3 is proton, RS is 4-[{2,6-dichlorobenzoyi)-amino]phenyl, g is equal to 2 and stereochemistry is (S}}.

~H O
O ~N~Oi O O
O CI
~N~
H I
(:I
Example 114 was prepared as described in Scheme G. Physical data as follows:
'H NMR
(300 MHz, CDCI3) 8 1.81 (6 H), 2.27 (6 H), 3.10 (2 H), 3.63 (3 H); 3.75 (3 H), 4.89 (I H), 6.46 (I H), 6.58 (1 H), 7.10 (2 H), 7.26 (3 H), 7.58 (2 H), 8.14 (1 H); MS
(FAB) m/z 592 (M+H)+, 568, 367, 349, 307, 278, 226, 194, 173.

Example 115.
2-[3-[j( 1 S)- I-Carboxy-1-[4-j(2,6-dichlorobenzolyl).amino]phenyl]ethyl]amino]-3-oxopropyl]-5-oxo-2-pyrrolidinepropanoic acid (Scheme G, G-6: where R.~_3 is proton, RS is 4-[(2,6-dichlorobenzoyl)amino]phenyl, g is equal to 2 and stereochemistry is (f~).

NH
H O
HO N""OH

N~
H ( , C;I

Example i 15 was prepared from example 1 I4 by the procedure described in preparation 40. Physical data as follows: IR (mull) 3272, 3195, 3 /:21, 3063, 2953, 2923, 286$, 2855, /715, 1659, 1608, /579; 1561, 154/, 15/6, 1456, /432, 1414, 1377, 1367, 1326, 1271, 1221, i 195, 800 cm-I; 'H NMR (300 MHz, DMSO-ds ~i 1.63 {6 H), 2.13 (6 H), 2.79 (1 I 5 H), 3 .00 ( I H), 4.3 8 ( I H), 7.19 (2 H), 7.51 (5 H), 7.64 ( 1 H), 8.16 ( I H), 10.5 8 ( 1 H), 12.37 {2 H); MS (FAB) mlz 564 (M+H)+; 546, 519, 33'.i, 280, I94, 173. Anal.
Calc'd for CZ6H27C12N3O7: C, 55.33; H, 4.82; Cl, 12.56; N, 7.44. Found: C, 55.10; H, 4.76; Cl, 12.56; N, 7.36. Corrected for 2.49% H20, found by Karl Fischer analysis.
Example I16.
20 2-[3-jj(1ST-1-j[4-[(2,6-Dichlorophenyl)methoxy]phenyl]methyl]-2-methoxy-2-oxoethyl]amino]-3-oxopropyl]-5-oxoproline (Scheme G, G-5: where R~_2 and RG_3 are equal to proton, RS is 4-[(2,6-dichlorophenyl)-mathoxy]phenyl, g is equal to 0 and stereochemistry is (~).

WO 99167230 PCTlUS99/14233 NH
HO O N~Or O
I ~ CI
O~
rl CI
Example I 15 was prepared as described in Scheme G from 2-carboxy-5-oxo-2-pyrrolidinepropanoic acid (Majer, Z.; Kajtar, M.; Tichy, M.; Blaha, K. Coll.
Czech. Chem.
Commun. 1982, 47, 950). Physical data as follows: IR (mull) 3302, 1736, 1671, 1612, 1S8S, 1564, 1S3S, 1511, 1439, 1298, 1240, I 197, 1179, 1016, 768 crn';'H NMR
(300 MHz, CDC13} S 2.12 (8 H), 3.02 (2 H), 3.65 (3 H}, 4.81 ('1 H), 5.21 (2 H), 6.94 (2 H), 7.07 (2 H), 7.22 (1 H}, 7.35 (2 H), 7.86 (1 H), 8:34 (I H); MS (FAB) m/z {rel.
intensity) 537 (M+H, 99).
Example 117.
2-[3-[[( 1 S)- I-Carboxy-2-[4-[(2,6-dichlorophenyl)m:ethoxy]phenyl]ethyl]amino]-3 oxo-propyl]-5-oxoproline {Scheme G. G-6: where R~.3 is proton, RS is 4-[(2,6-dichlorophenyl)methoxy]phenyl, g is equal to 0 and stereochemistry is (,S~).

HO ~N
OH
O
C~
"' 'O
CI
Example 116 was prepared from example 1 I 5 by the procedure described in preparation 40. Physical data as follows: IR (mull} 3292, 3059, 3029, 1718, 1650, 1612, 1585, 1565, IS37, 1511, 1439, 1240, 1196, 1179, 768 crri';'H NMR (300 MHz, CDC13) 8 2.I 1 (8 H), 2.83 ( 1 H), 3.20 ( 1 H), 4.74 ( 1 H), 5.24 (2 H), 6.95 (2 H), 7.15 (2 H), 7.25 ( 1 H), 7.36 (2 H); MS (FAB) m/z (rel. intensity) 523 (M+H, 99); Anal: Calcd for Cz4HzaC12Nz07: C, 55.08; H, 4.62; N, 5.35, Cl, 13.55. Found: C, 54.68; H, 4.66; N, 5.13: Cl, 13.70.
Corrected for 1.59% H20 found by Karl Fischer analysis.
Scheme H.
off 1 ~ H-~
N CI
OH
I i H_2 i N CI
CI
I
~I CI H_3 ICI
CI
w O w I
I N "CI CI
Boc~N O~ H-4 H O
CI
w 0 w I
I N "Ct CI

H2N Ow O ~ 2 HCI

Scheme H teaches a genexal method for the preparation of 6-chloroazatyrosine examples of structures H-4 and H-S, by adaption of he methodology for the preparation of protected azatyrosine reagents as described by Kawata, S.; Ashizawa, S.; Hirama, M. J.
Am. Chem.
Soc. 1997, 119, 12012-12013 and references cited therein. Thus regioselective iodination of 2-chloro-3-pyridinol gives the chloro-iodopyridinol ~3f-2, that is O-alkylated as exemplified by the synthesis of H-3. Palladium-catalyzed reaction of H-3 with the organozinc derived from a suitably protected (3-iodoalanine, provides the protected 5-chloroazatyrosine H-4. N deprotection of H-4 gives the ;aminoester H-S, that is used (as I O exemplified by reagent A-4 of Scheme A, and by reagent B-5 of Scheme B) for the synthesis of Examples of this invention Preparation 4I .
(Scheme H: H-2) 2-Chloro-G-iod0-3-pyridinoi (CSH3C1IN0).
To a solution of 2-ehloro-3-pyridinol H-1 (10.2, g, 78.7 mmol) and K2C03 (38.9 g, 0.274 mol) in H20 (120 mL) is added I2 (24.3 g, 95.8 mmol), and the reaction mixture is stirred at rt for 4 h. The reaction mixture is quenched by the addition of aq satd Na2S203~5H20, and its pH is lowered to pH 2 with the addition of I2 M aq HCi.
The mixture is extracted with EtOAc. The combined EtOAc extracts are dried, filtered and concnetrated to a yellow solid, that is crystallized from 120:25 heptane/EtOAc (145 mL) to give, as a yellow solid, 11.2 g of the title compound: 1 H NMR (CD3 SOCD3, MHz) 8 9.87 (IH), 7.59 {1H), 7.06 (1H); 13C NMR (CD3SOCD3, 75 MHz) 8 150.68, 138.07, 134.98, 127.02, 101.18.
Preparation 42.
(Scheme H: H-3) 2-ChlorO-3-((2,6-dichlorophenyl)methoxy]~-iodop;yridine (C12H7C13IN0).
To a solution of H-2 (5.11 g, 20.0 mmol), PPh3 (5.30 g, 20.0 mmol), and 2,6-dichlorobenzylalcohol (3.54 g, 20.0 mmol) in dry THF ( 100 mL) at 0 °C
under Ar is added DEAD (3.15 mL, 20.0 mmol). The reaction mixture is kept at 0 °C for 1.5 h and at rt for 1.5 h. It is concentrated to a residue, that is purifed by silica flash chromatography (17:3 hexanesIEtOAc) to give 7.61 g of the title compound: T'LC (17:3 hexanes/EtOAc) R f0.57;
IH NMR (CD3SOCD3, 300 MHz) b 7.85 (1H}, 7.62 (1H), 7.58-7.45 (3H), 5.34 (2H}.
Preparation 43.
{Scheme H: H-4}
(S)-2--Chloro-3-[(2,G-dichlorophenyl)methoxy]-a-~;[(1,1-dimethylethoxy)-carbonyI]amino)-6-pyridinepropanoic acid methyl ester (C21H23C13N205)~
To an amberized flask containing activated Zn dust (0.777 g, 1 i .89 mmol) under I0 Ar is added sequentially N-[(l,l-dimethylethoxy)carbonylJ-3-iodo-t,-alanine methyl ester [93267-04-OJ (3.91 g, I.89 mmol), THF (11.9 mL,), and dimethyiacetamide (11.9 mL). The reaction mixture was purged of 02 by the bubbling of Ar through the mixture for 5 min. It is stirred at 655 °C for 2 h, and is cooled t:o rt. To this mixture is added PdCl2(PPh3)2 (0.412 g), followed immediately afterward by a degassed solution of H-3 15 {2.46 g, 5.94 mmol} in 1:1 THF/dimethylacetamide (1 I..8 mL). The reaction mixture is stirred at 655 °C for S h. it is cooled to 0 °C and quenched with sat'd aq NH4Cl {100 mL). The reaction mixture is extracted with EtOAc. The: combined extracts are washed with brine, dried, filtered and concentrated to a green-yellow oiI; that is purified by silica flash chromatography to give 1.90 g of the title compound: TLC (7:3 hexanes/EtOAc) R f 20 0.32; I H NMR (CDCl3, 300 MHz) b 7.76 ( i H), 7.57 (2H), 7.48 (1 H), 7.29 ( 1 H}, 7.27 ( 1 H); 5.30 (2H), 4.32 ( 1 H), 3.b0 (3 H), 3.0 I ( 1 H), 2.98 ( 1 H), 1.31 (9H).
Preparation 44.
(Scheme H: H-4) (S')--2-Chloro-3-[(2,6-dichlorophcnyl)methoxy]-~c-amino-6-pyridinepropanoic acid 25 methyl ester dihydrochloride salt (CI6HISC13N203'~ZHCI).
A solution of H-4 (1.90 g, 3.88 mmol) in 4 M H:CI in dioxane (35 mL) is stirred at rt under Ar for 20 h. The reaction mixture is concentrated in vacuo. The residue is taken up in H20 (40 mL), and extracted with Et20. The aqueous solution is frozen and lyophilized to give I .39 g of the title compound: I H NMR {CD3SO~CD3, 300 MHz) 8 8.62 (3H), 7.81 {1H), 7.58 {2H); 7.48 (IH), 7.38 (1H), 5.32 (2H), 4.37 (IH), 3.72 (3H), 3.27 (2H).
Example 118.
(Scheme A, A-5) S [S-(R*,R*)]-4-[[[1-[[2-Chloro-3-[(2,6-dichloropheruyl)methoxy]-6-pyridyl]methyl] Z-methoxy-2-oxoethyi]amino]carbonyl] 3-thiazolidinecarboxylic acid {l,l-dimethylethyl) ester (C30H37C13N306S).
Example 118 was prepared as described in Scherne A from D-cysteine using the product of preparation 44 as amino acid intermediate A-.4. Physical properties as follows:
TLC (1:1 hexanes/EtOAc) R f0.27; 1H NMR {CDC13, 300 MHz) b 8.43 {1H), 7.74 (IH), 7.58 (2H), 7.48 {1H); 7.29 {1H), 5.29 (2H), 4.67 (1H), 4..53 (1H), 4.44 (IH), 4.23 (1H), 3.62 (3H), 3.06 (3 H), 2.82 ( 1 H), 1.27 (9H}.
Example 119.
(Scheme A, A-9) (S-{R';R*)]-4-((1-Carboxy-2-[[2-Chloro-3-[(2,6-dichlorophenyl)methoxy]-&-pyridyi]ethyl]amino]carbonyl]-3-thiazolidinecarbox;ylic acid (1,1-dimethylethyl) ester (C24H26CI3N306S).
Example 119 was prepared from example 118 by the pra~cedure described in preparation 12. Physical data as follows: mp 93-95 °C; TLC (600:400:2 EtOAc/hexanes/HC02H) R f 0.38; IH NMR (CD3SOCD3, 300 MHz) 8 8.30 (1H}, 7.'74 (1H), 7.5'7 (2H), 7.48 (1H), 7.27 ( 1 H), 5.29 (2H), 4.67-4.36 (2H); 4.53 ( I H), 4.23 ( 1 H), 3.37-3.11 (3 H), 2.97 ( 1 H), 1.27 {9H).

Scheme i.
OH

O O
i ~ N Ci v N "CI
Boc.N O~ I-3 H O

~NJ
Boc.H O~ I~d O
OH
I N' Boc,N O~ I-S
H O
CI
O
~ NJ
Boc.N O~ t-6 H O
CI
O ~ I
~NJ
O I=7 HyN
O ~2HCI

Scheme I teaches a general method for the preparation o:P azatyrosine reagents I-3, I-4, I-5, I-6 and I-7, by adaptation of the methodology for the preparation of protected azatyrosine reagents as described by Kawata, S.; Ashizawa, S.; Hira~na, M. J. Am. Chem.
Soc. 1997, 119, 12012-12013 and references cited therein. Thus O-protection of chloroiodopyridinoi S I-1 (identical to H-2) is followed by reaction with the or;ganozinc, derived from a suitably protected j3-iodoalanine, to provide the protected 6-chloroazatyrosine I-3.
Reductive dehalogenation of I-3 gives I-4, that is D-deprotected to give I-5. Reagent I-5 is O-alkylated, as exemplif ed by the preparation of I-6. N de;protection of I-6 gives the aminoester I-7, that is used (as exemplified by reagent A-4 of Scheme A, and by reagent B-5 of Scheme B) for the synthesis of Examples of this invention.
Preparation 45.
(Scheme I, I-2) (f}-2-Chloro-3-[(2-tetrahydropyranyI)oxyj--6--iodopyridine (C I OH I 1 C1IN02).
To a solution of chloroiodopyridinol I-1 (same as H-2, the product of preparation 41 ) IS (1.00 g, 3.91 mmol) and dihydropyran (1.0 mL, 10.6 mrnol) in CH2C12 (10 mL}
under Ar at rt is added pyridinium chloride (0.050 g). The reactiorA mixture is stirred for 72 h. It is diluted with CH2Cl2, and is washed with satd aq NaHCO3 and brine. The CH2Cl2 solution is dried, filtered and concentrated to an oii, that is purified by silica flash chromatography (19:1 hexanes/EtOAc) to give 1.06 g of the title product: TLC
(19:1 hexanes/EtOAc) R f0.24; 1H NMR (CDC13, 300 MHz) Ci 7.55 (1H), 7.17 (IH), 5.50 (1H), 3.77 (1H), 3.61 (1H), 2.07-1.57 (6H).
Preparation 46.
(Scheme I, I-3) (S~-2-Chloro-a-[[(1,1-dimethylethoxy)carbonyl]amino] 3-[(2-tetrahydro-pyranyl)oxy)-6-pyridinepropanoic acid methyl ester (CI9H27C1N206).
To an amberized flask containing activated Zn dust (0.349 g, 5.51 mmol) under Ar is added THF (2 mL) and 1,2-dibromoethane (0.018 mL, 0.2I rnmol). The suspension is WO 99!67230 PCT/US99/14233 brought to reflux for several minutes, cooled to approximately 30 °C, and TMSCI (0.17 mL of a 1 M solution in THF) is added. The reaction mixture is stirred at 405 °C for 30 min and then is cooled to below rt. A solution of N-j(l,lL-dimethylethoxy)carbonyl]-3-iodo-t,-alanine methyl ester [93267-04-0] (1.81 g, S.SO mmol) in 11:7 dimethyiacetamide/THF (9.0 mL) is added, and the resulting reaction mixture is stirred at 45 °C for 5 h. The reaction mixture is cooled to below rt, and solid PdCl2(PPh3)2 (0.192 g) is added, followed immediately by addition of a degassed solution of the iodopyridine (0.936 g, 2.76 mmol) in I :1 THF/dimethylacetamide (5.6 mL). This reaction mixture is stirred for 4 h at 45 °C. It is cooled to 0 °C, quenched with sat'd aq NH4Cl, and extracted with EtOAc. The combined EtOAc portions are washed with sat'd aq NH4C1 and brine.
The EtOAc solution is dried, filtered and concentrated to give a green-yellow colored foam, that upon purification by silica flash chromatography (7:3 hexanes/EtOAc) gives 0.879 g (I.85 mmol, 60%) of the title product: TLC (7:3 hexaneslEtOAc} R
f0.21; IH
NMR (CDC13, 300 MHz) d 7.39 ( 1 H), 7.00 ( 1 H), 5.46 ( 1 H), 4.61 ( I H), 4.13 ( I H), 3.80 I S (3 H), 3.62 ( 1 H), 3.20 ( I H), 2.13-1.53 (6H), I .42 {9H}.
Preparation 47.
(Scheme I, I-4) (S)-a.-[[(I,I-Dimethylethoxy)carbonyl]amino]-3-[(2-.tetrahydropyranyl)oxy]-6-pyridinepropanoic acid methyl ester {C19H28N2O6).
A suspension of pre-reduced Pd/CaC03 (3.5 g) and I-31;1.15 g, 2.77 mmol) in EtOH (40 mL) is hydrogenated (30 psi H2) for I9 h at rt. The mixtv:~re is filtered, and the filtrate is evaporated to give a yellow-colored foam, that is purified by silica flash chromatography (600:400:I hexanes/EtOAc/iPrOH) to give 0.367 g ofthe title compound: TLC (I:1 hexanes/EtOAc) R j0.27; 1H NMR (CDCl3, 300 MHz) 8 8.30 (1H), 7.29 (1H), 7.03 (1H), 5.81 (1H}, 5.39 (1H), 4.65 {1H), 3.86 {IH); 3.73 (3H), 3.fi2 (1H}, 3.21 (2H), 1.96-1.53 (6H), 1.42 (9H).

Preparation 48.
(Scheme I, I-5) (Sj--a,-[[{l,l-Dimethylethoxy)carbonyl]amino]-5.-hydroxy-2-pyridinepropanoic acid methyl ester (C14H20N205)~
A solution of I-4 (0.346 g, 0.91 mmol) and pyridinium ~rtoluenesulfonate (0.031 g, 0.12 mmol) in EtOH (8 mL) is stirred at 555 °C for 20 h. The reaction mixture is cooled to rt, and concentrated in vacuo. The residue is taken up in Et~~Ac. The solution is washed with brine, and dried, f ltered and concentrated to a pale yellow-colored oil that is purified by silica flash chromatography (500:500:1 hexanes/EtOAc/iPrOH). Evaporation of the column fractions gives 0.132 g of the title compound: TLC (1:1 hexanes/EtOAc) R f0.18;
1H NMR (CDCI3, 300 MHz) 8 8.I3 (1H), 7.13 (1H), 7.03 (1H), 5.71 (1H}, 4.65 (1H), 3.70 (3H), 3.20 (2H), 1.39 (9H).
Preparation 49.
(Scheme I, I-6) (.S'}~-5-((2,G-Dichiorophenyl)methoxy)-oc-(((1,1-dimethylethoxy)carbonyl)amino] 2-pyridinepropanoic acid methyl ester (C21H24C12N205).
To a solution of I-5 (0.126 g, 0.43 mmol}; 2,6~iichlorobenzylalcohol (0.075 g, 0.43 mmol) and PPh3 (0.113 g, 0.43 mmol) in dry THF (4 ml.) at 0 °C under Ar is added DEAD (0.068 mL). The reaction mixture is permitted to warm to rt, and is stirred for 18 h. It is concentrated, and the residue is purif ed by silica flash chromatography (700:300:1 hexanes/EtOAc/iPrOH) to give 0.149 g of the title compound: TLC (7:3 hexanes/EtOAc) R f0.34; 1 H NMR (CDCl3, 300 MHz) 8 8.31 ( 1 H), 7.37 (2H), 7.25 (2H), 7.08 ( 1 H), 5.81 { 1 H), 5.29 (2H), 4.65 ( 1 H), 3.70 (3H), 3.24 (2H), i .63 ( 1 H), 1.43 (9H).
Preparation 50.
(Scheme I, I-7) (S}-a,-Amino-a-[(2,6-dichlorophenyl)methoxy] 2-p;yridinepropanoic acid methyl ester dihydrogen chloride salt (C16H16C12N203~2HC.'1).

A solution of carbamate I-6 (0.546 g, 1:20 mmol) in 4 M HCl in dioxane (12 mL) is stirred at rt under Ar for 16 h. The reaction mixture is concentrated ih vacuo. The residue is dissolved in H20 (40 mL), and this solution is extracted with Et20. The aqueous solution is frozen and lyophilized to give, as a light yellow-colored solid, 0.485 g of the title compound: 1H NMR (CD3SOCD3, 300 MHz) 8 8.'75 (3H), 8.47 (1H), 7.81 (1H), 7.57 (3H), 7.48 (1H), 5.35 (2H), 4.49 (1H), 3.67 (3H), 3.42 (2H).
Example 120.
(Scheme A, A-5) [S-{R*,R*)]-4-[[[I-[[3-[{2,6-Dichlorophenyl)methoxy]-6-pyridyl]methyl] 2-methoxy-2-oxoethyi]amino]carbonyl]-3-thiazolidinecarboxyiic acid (I,I-dimethylethyl) ester (C25H30C12N306S).
Example 120 was prepared as described in Scheme A from D-cysteine using the product of preparation 49 as amino acid intermediate A-4. Physical properties as follows:
TLC (1:1 hexanes/EtOAc) R~ 0.22; 1H NMR (CDCl3, 300 MHz) 8 8.28 {2H), 7.38 (2H), 7.28 (2H), 7.09 (1H), 5.29 (2H), 4.90--4.74 (3H), 4.40 (IH), 3.67 (3H), 3.38-3.22 (3H), 1.6I (2H), 1.40 (9H).
Example 121.
(Scheme A; A-9) [S-{R*,R*)]-4-[[[1-Carboxy 2-(3-[(2,6-dichlorophenyi)methoxy]-6-pyridyl]ethyl]amino]carbonyl]-3-thiazolidinecarbox;ylic acid (1,1-dimethylethyl) ester (C24H2gC12N3O6S).
Example 121 was prepared from example 120 by the procedure described in preparation 12. Physical data as follows: mp 92-94°; TLC (500:500:3 hexanes/EtOAc/HC02H) R f 0.10; 1H NMR (CDC13, 300 MHz) 8 8.31 (1H), 8.26 (1H), 7.55 (2H), 7.28 (2H), 7.46 ( 1 H), 7.2I ( 1 H), 5.25 (2H}, 4.72-4.38 (2H), 4.60 ( 1 H), 4.23 ( 1 H), 3.21-3.12 (2H), 3.09-2.94 ( 1 H), 2.74 ( 1 H), I .29 (9H).

WO 99/6'7230 PCT/US99/14233 Scheme J.
NHZ
I ~ ~ N J-1 CI
O CI

I ~ ~ CI / ~
CI /
O ' CI
i N N O CI J_3 CI /
Boc~N O~
N O

lHti1 Scheme J teaches a general method for the preparation ofpara-acylamino derivatives of aza-phenylalanine. Thus bis-acylation of 2-amino-5-iodopyridine J-1 gives the imide J-2, that is reacted with the organozinc, derived from a suita>:dy protected ~3-iodoalanine, to provide the protected acylamino azaphenylalanine J-3. l~J deprotection of J-3 gives the aminoester J-4, that is used (as exemplified by reagent E~-4 of Scheme A, and by reagent B-5 of Scheme B) for the synthesis of Examples of this;invention.
Preparation 51.
{Scheme J: J-2) 2-[[Bis(2;trDichlorobenzoyl)]amino]-5-iodopyridina (CI9H9C1;IIN202).
To a solution of 2-amino--5-iodopyridine J-I (2.20 g, 10.0 mmol) and Et3N
(2.I2 mL, I5.0 rnmoi) in dry THF (I00 mL) at rt under Ar, is added dropwise 2,6-dichlorobenzoylchloride (1.60 mL, 1 I.0 mmoi) over 45 min. The reaction mixture is stinted, for 15 h. It is diluted with EtOAc (300 mL), and its washed with cold aq 1 M NaOH
and brine. The solution is dried, filtered and concentrated to give a yellow-colored waxy solid, that is purified by silica flash chromatography (3:1 hexanes/EtOAc) to give 2.60 g of the title compound: TLC (7:3 hexanes/EtOAc) Rf 0.60; 1H NMR (CDCl3, 300 MHz) 8 8. S 9 ( I H), 8 .03 ( 1 H), 7.99 ( 1 H), 7.44-7.26 (6H).
Preparation 52.
(Scheme J: J-3) (S~-2-[[Bis--(2,6-dichlorobenzoyl)]amino]-oc-[[(1,1-dimethylethoxy)carbonyl]amino]-5--pyridinepropanoic acid methyl ester {C28H25C14N3~6)~
To an amberized flask containing activated Zn dust (0.8ti5 g, 13.23 mmol) under Ar is _ added sequentially N-[(I,1-dimethylethoxy)carbonyl]-3-iodo-~-alanirie methyl ester (4.36 g; I3.23 mmol), THF (13 mL) and N,N-dimethylacetamide {13 mL). The reaction mixture is purged of 02 by the bubbling Ar through the mixture for 5 min, and then is warmed to 4515 °C for 7 h. It is cooled to rt. To this mi~;ture is added PdCl2(PPh3)2 {0.461 g) followed immediately by a degassed solution of iodide J-2 (2.60 g, 4.59 mmol) in 1:I THF/N,N-dimethylacetamide (I8 mL). The reaction mixture is stirred at 455 °C
under Ar for 13 h. It is cooled to 0 °C and quenched with satd aq NH4CI
( 1 SO mL). The mixture is extracted with EtOAc. The combined EtOAc extracts are washed with brine, dried, filtered and concentrated to a green-yellow~olore;d paste, that is purified by silica hash chromatography (700:300:1 hexanes/EtOAc/iPrOH) to give 1.43 g of the title compound: TLC (7:3 hexanes/EtOAc) R~0.29; 1H NMR (CDC13, 300 MHz) 8 8.13 (1H), 7.57 { 1 H), 7.46 ( 1 H), 7.26 (6H), 4.80 (1 H), 4.50 { 1 H), 3.67 (3H), 3.05 (2H), 1.46 (9H).
Preparation 53.
(Scheme J: J-4}
{S)-a.-Amino-2-[[bis-(2,6--dichlorobenzoyi}]amino]-.5--pyridinepropanoic acid methyl ester dihydrochloride salt (C23H1~C14N304~HfC1).
A solution of J-3 (0.69 g, 1.08 mmol) in 4 M HCI in dio:Kane (15 mL) is stirred under Ar for 20 h. The reaction mixture is concentrated in vacuo, dliiuted with H20, and extracted with Et20. The aqueous solution is frozen and lyophilized to give, as a pale yellow-colored solid, 0.627 g of the title compound: I H NMR (C;D3SOCD3, 300 MHz) 8 8.80 (2H), 8.27 ( 1 H), 7.82 ( 1 H), 7.67-7.26 (7H), 4.25 ( 1 H), 3.52 (3 H}, 3.16 (2H), 3.04 ( 1 H);
MS {ESl+) m/z 541.7.
Example 122.
1 S {Scheme A, A-5) (S-(R *,R*)J-4-[[[1-[(2-[[Bis-{2,6~iichlorobenzoyl)]a~minoJ-5-pyridyl]methyl]-methoxy-2-oxoethyl]amino]carbonylJ-3-thiazolidinecarboxylic acid (1,1-dimethylethyl) ester (C~SH30C12N306S).
Example 122 was prepared as described in Scheme A from D-cysteine using the product of preparation 52 as amino acid intermediate A-4. Physical properties as follows:
TLC (l:l hexanes/EtOAc) R f0.22; 1H NMR (CDC13, 300 MHz) 8 8.28 {2H), 7.38 (2H), 7.28 (2H), 7.09 (1H), 5.29 (2H), 4.90--4.74 {3H}, 4.40 (IH), 3.67 (3H), 3.38-3.22 (3H), 1.61 (2H), 1.40 (9H).
Example 123.
(Scheme A, A-9) [S-{R*,R*)]--4-(([[1-Carboxy-2-(2-[[Bis-{2,6-tiichloro~benzoyl)]amino]-5-pyridyl]]ethyl]amino]carbonyl] 3-thiazolidinecarboxyiic acid (1,1-dimethylethyl) ester (C31 H'8C14N407S).

WO 99/67230 PCTIUS9911~233 Example 123 was prepared from example 122 by the procedure described in preparation 12. Physical data as follows: mp 158-160°; TLC (50:SC1:2 hexanes/EtOAc/HC02H) Rf 0.18: 1 H NMR (CD3 SOCD3, 300 MHz) 8 8.42 ( 1 H), 8.22 ( 1 H), 7.75 ( 1 H);
7.69-7.17 (5H), 7.53 ( 1 H); 4.59 ( 1 H), 4.40 (2H), 4.19 ( 1 H), 3.19-3 .02 (2H), 2.84 ( 1 H), 2.56 ( 1 H), 1.34 (9H).
Scheme K.
~os~
C
N K_1 ,Y O

HzN~O~ !<-2 O
O O
O~
O ~ K-3 Rg Y R5 O-.,, H O
L ~N~ON

R Y O Rs Scheme K teaches a general method for the preparation of oxazolidinecarboxylic acid Examples K-3 and K-4, where R,, RS and Y are identical to the definitions of Scheme B.
Thus coupling of oxazolidinecarboxylic acid K-1 and aminoester K-2 (as exemplified by the reaction of reagents A-3 and A-.~ of Scheme A, and B-4 and B-5 of Scheme B) provides Examples K-3, that are hydrolyzed to Examples K-4 of this invention.

Example 124.
(Scheme K: K-3, where R3 is {phenyl)methyl, Rs is 4-[(2,6-dichlorobenzoyl)amino]phenyl, Y is CO, and the stereochemistry is [S-(R *, R *)]) [S (R*,R*)]-4-[([Z-[[4-((2,6-Dichlorobenzoyl)amino]pHenyl]methyl]-2-methoxy-2-oxoethyl]amino]carbonyl]-3-oxazolidinecarboxylic acid 3-phenylmethyl ester (C29Hz~C1zN30,}.
Example 124 was prepared as by coupling commercially available (S)-3,4-oxazolidinedi-carboxylic acid 3-{phenylmethyl) ester to amino acid K-a (Scheme K, where RS
is 4-[(2,6-dichlorobenzoyl)amino]phenyl stereochemistry is (S)) under the conditions described by preparation 3. Physical properties as follows: TLC (3:2 Heptane/EtOAc) Rf=
0.17; UV
(MeOH) lmax 225 (e 12600, sh), 251 (17900); "C NMR (db dimethylsulfoxide) 8 188.75, 171.96, 169.86, 162.40, 162.30, 152.99, 137.59, 137.47, 136.87, 136.81, 133.23, 131.79, 131.65; 130.08, 128.80, 128.67, 128.28, 127.76, I 19.84, 119.75, 79.82, 66.77, 57.85, 53.85, 52.47, 36.62 (23 lines expected; 26 lines observed); MS (FAB) m/z 602, 600, 558, 556, 531; 466, 371, 351, 349, 280, 278, 175, 173; MS (F,AB} m/z 600:1312 (calcd [M+H]+
600.1304; Anal. C, 57.75; H, 4.75; N, 6.80; Cl, 11.86 (calcd for 0.42% H20: C
57.77, H
4.56, N 6.97, CI 11.76).
Example 125:
(Scheme K: K-4 where R3 FS (phenyl)rnethyl, RS is 4-[(2.,6-dichlorobenzoyl)amino]phenyl, Y is CO, and the stereachemistry is [S (R*,R*)]) [S (R*,R*)]-4-[[[1-Carboxy-2-[4-[(2,6-dichlorobenzoy!!)amino]phenyt]ethyl]amino]-carbonyl]-3-oxazolidinecarboxylic acid 3-phenylmeth;yl ester (CzgH25C1zN30~).
Example 125 was prepared from example 124 by the procedure described in preparation 12.
Physical properties as follows: TLC {950:50:1 CH,CI,/MeOH/HCOzH} Rf= 0.34;'H
NMR (db-dimethylsulfoxide) 8 IO.bS (1H); 8.31 (1H), 7.61-7.42 (SH), 7.40-7.20 (SH), 7.15 (2H), 5.19-4.85 (2H), 4:90 ( 1 H), 4.76 ( 1 H), 4.43 ( 1 H), 4.36 ( 1 H), 4.11 ( 1 H), 3 .65 (1H), 3.04 (1H), 2.87 (1H); MS (FAB) m/z 588, 586 544,. 542, 532; 391, 337, 335, 327, 269, 267, 161, 147.133, 129, 117, 1 I5, 103, 101, 91: MS (FAB) 586.1132 (calcd 586.1147).

Example 126.
{Scheme K: K-3 where R, is benzyl, RS is 4-[(2,6-dichlorobenzoyl)amino)phenyl, Y is C02 and the stereochemistry is [R-(R*.S*)]) [R-(R*,S*)]-4-[[[1-[[4-~(2,6-Dichlorobenzoyi)amino]pHenyl]methyl]-2-methoxy-2-oxoethyl]amino]carbonyl]-3-oxazolidinecarboxylic acid 3-phenylmethyl ester (C29H27C12N3~7)~
Example 126 was prepared as described in Scheme K from commercially available (R)-3,4-oxazolidinedicarboxylic acid 3-(phenyimethyl) ester. Physical properties as follows:
TLC (3:2 heptane/EtOAc) R f= 0.19; UV (MeOH) ~.,"~ 2:2,5 (e 12400, sh), 252 ( 17700), 284 {2960, sh);'3C NMR (CDCI3) & 171.23, 169.14, 162.43, 154.26, 136.47, 135.93, 135.65, 132.37, 132.28, 130.91, 130.00, 128.62, 128.39, 128.1 l, 120.30, 79.66, 67.94, 58.38, 53.14, 52.49, 37.19 (23 lines expected; 2I lines observed); MS (FAB) m/z 602, 600, 558, 556, 466, 351, 349, 280, 278, 175, 173; MS (FAB) m/z 600.1299 (calcd for [M+H]+
600.1304); Anal. C 57.69, H 4.90, N 6.71, CI 11.49 (calcd for 0.35% H20: C
57.81, H
4.56, N 6.97, Cl I 1.77).
Example 127.
(Scheme K: K-4 where R~ is benzyl, RS is 4-[(2,6-dichlorobenzoyl)amino]phenyl, Y is C02 and the stereochemistry is [R-(R*,S*)]) [R-(R*,S*)}-4-[[[1-Carboxy-2-[4-[(2,6-dichlorobenzoyl)amino}phenyl]ethyl]amino]-carbonyl]-3-oxazolidinecarboxylic acid 3-(phenylmethyl) ester (Cz$Hz5C1zN30,). ..
Example 127 was prepared from example 126 by the procedure described in preparation 12.
Physical properties as follows: TLC (950:50:1 CH2C12/MeOHIHCO2H) Rf= 0.31;'H
NMR (dQ-methanol} 8 7.60 (2H),7.49-7.23 (8H), 7.21 (2H), 5.23-4.97 (2H), 4.95 {1H), 4.88 (1H), 4.70 (1H), 4.36 (1H), 4.14 (1H), 3.85-3.73 (1H), 3.23 (1H), 3.00 (1H); MS
(FAB) m/z 588, 586, 544, 542, 532, 391, 371, 337, 335, '<?45, 177, 173, 149, 123, 105, 103, 91; MS (FAB) m/z 586.1163 (calcd 586:1147).

Scheme L.
RL-2 ~ Rl-t O N O
-O~L~O- L_1 R~-2 ~ RL-t O N O L_2 -O~~~OH

HyN~O~ L-3 O
RL-2~ RL-~
O~~-~O
O
-O HN~Oi ll,,~~ L-4 R1.2 ~ R~-t I ~~''/~.~~/ O
HO HN ~ L-OH
R$
S Scheme L teaches a general method for the preparation of N alkylaryl azetidinedi-carboxylic acid Examples L-4 and L-5, where R~-, is C,~, alkyl, RL-Z is C~,o aryl and RS is defined as in Scheme B. The N phenylethyl-2.4-azetidinedicarboxylic acid dimethyl ester stereoisomers of general structure L1 were prepared as described (Hoshino, :1.; Hiraoka, J.;
Hata, Y.; Sawada. S.; Yamamoto, Y. J. Chem. Soc. Perkin Trans. I 1995, 693-697) and separated by silica flash chromatography. Thus partial saponification of diester L-1 gives the half acid L-2, that is coupled with reagent L-3 (as exemplified by the use of reagents A-3 and A-4 of Scheme A, and B-4 and B-5 of Scheme 13) to provide Examples L-4, that are then hydrolyzed to Examples L-5 of this invention.
Preparation S4.
S (Scheme L: L-1 where R~_, is methyl, R~_Z is phenyl and stereochemistry is [2S
[ 1 (R*),2a,4(3]]).
[2S-[1(R*),2a,4(3]]-1-(1-Phenylethyl)-2,4-azetidinedic,arboxylic acid dimethyl ester [168647-92-S] (C,SH,9NO4).
Physical properties as follows: TLC (4:1 Hexanes/EtOA,c) R f= 0.42; "C NMR
(CDC13) 8 173.61, 142.41, 128.31, 127.39, 127.35, 60.95, 60.67, 51.64, 24.96, 21.72.
Preparation SS.
(Scheme L: L-1 where R~_, is methyl, R, _z is phenyl and stereochemistry is [2R-[ 1 (S'''')~2a~4 ~]])~
[2R-[I(S*),2a,4ji]]-1-(1-Phenylethyl)-2,4-azetidinedicarboxylic acid dimethyl ester I S (C,SH,9NO,).
Physical properties as follows: TLC (4:1 Hexanes/EtOAc) R f= 0.31; '3C NMR
(CDC13) S
i 72.97, 141.21, 128.44, 128.07, 127.68, 61.54, 60.69, S 1.61, 24.91, 19.55.
Preparation S6.
(Scheme L: L-1 where RL_, is methyl, RL_z is phenyl and stereochemistry is jl(S~-cis]).
jI(S')-cu]-1-(1-Phenylethyl)-2,4-azetidinedicarboxylic acid dimethyl ester [168753-32-0] (CisHi9N~a)~
Physical properties as follows: TLC (4:1 Hexanes/EtOA,c) Rf= 0.21; '3C NMR
(CDC13) S
172.58, 172.08, 140.84, 128.22, 128.15, 127.65, 66.32. 60.10, 59.65, 52.06, S1.S9, 24.26, 19.91.
2S Preparation 57.
(Scheme L: L-I where RL_, is methyl, R, _z is phenyl and stereochemistry is [2R-[1 (R*),2a,4[3]]).
[2R-[1(R*),2a,4[3]]-1-(1-Phenylethyl)-2,4-azetidinedicarboxylic acid dimethyl ester (C~sH~eNOa)~

Physical properties as follows: TLC (8:2 hexanesIEtOAc) R, f= 0.42; '3C NMR
(CDCI3) b 173.61, 142.41, 128.31, 127.39, 127.35, 60.95, 60.67, 51.64, 24.96, 21.72; MS
(+ESI) mJz 278.3.
Preparation 58.
(Scheme L: L-1 where R~_, is methyl, RL_2 ss phenyl and stereochemistry is [2S
[1 (S*),2a,4(3]].
[2S [1(S*),2a,4(3]]-1-(I-Phenylethyl)-2,4-azetidinedicairboxylic acid dimethyl ester (CisH~9NOa)~.
Physical properties as follows: TLC (8:2 hexanes/EtOA.c) R f= 0.31; "C NMR
(CDC13) 8 172.97. 141.21, 128.44, 128.07, 127.68, 61.54. 60.69, 51.61,24.91. 19.55; MS
(+ESI). »tlz 278.3.
Preparation 59.
(Scheme L: L-1 where R~_, is methyl, R~_z is phenyl and stereochemistry is [ 1 (R)-cis]).
[1(R)-cis]-1-(1-Phenylethyl)-2,4-azetidinedicarboxylic acid dimethyl ester (C,SH19N04)~
Physical properties as follows: TLC (8:2 hexanes/EtOAc) R f= 0.2 I ; ' 3C NMR
(CDC13) F
172.58, 172.08, 140.84, 128.22, 128:15, 127.65, 66:32, 60.10, 59.65, 52.06, 51.59, 24.26, 19.91; MS (+ESI) m/z 278.3.
Preparation 60.
(Scheme L: L-2 where R,~, is methyl, RL_2 is phenyl and stereochemistry is [2S-[ 1 (R*),2a,4(3]]).
[2S-(1(R*),2a,4(3]]-1-(1-Phenylethyi)-2,4-azetidinedicarboxylic acid monomethyl ester (C~aHpN04)~
A mixture of L-1 (Scheme L, where RL_, is methyl, R, _Z is phenyl and stereochemistry is [2S-[I(R*),2a,4(i]], the product of preparation 54) (7.95 g; 28.7 mmol) and LiOH (30 mmol) in 1:1 MeOHIH20 (240 mL) is stirred at rt for 42 h. The reaction mixture is adjusted to pH 5 with HOAc, and is concentrated. The resulting concentrate is diluted with brine and extracted repeatedly with CHCI,. The combined CHCI~ extracts are dried, filtered and concentrated to give a yellow foam (6.61 g), that is purified by preparative CI8 reverse phase chromatography to give the title compound as a crystalline solid: mp _ 168-112-113 °C; TLC (6S0:3S0:1 hexanes/EtOAc/HC02H) lei= 0.17; MS (FAB) m/z 527, 264, 248, 218, 204, 192, 186, 177, 160, 114, 105; Anal. C 64.04, H 6.57, N 5.37 (calcd C
63.87, H 6.S 1, N 5.32).
Preparation 61 and Example 128.
S (Scheme L: L-4 where R~_, is methyl, R~_2 is phenyl, Rs is 4-[(2,6-dichlorobenzoyl}-amino]phenyl and stereochemistry is [2S [1(R*),2a,4(3(iQ*)]]) j2S-[1(R*),2a,4(3(R*)j]-4-([[I-[(4-[(2,6-Dichlorobenzoyl)amino]phenyl]methyl]-methoxy-2-oxoethyl]amino[carbonyl[-1-(1-phenylethyl)-2-azetidinecarboxylic acid methyl ester (C" H3 'C12N3O6).
A mixture of L-2 (Scheme L, where RL_, is methyl, RL_2 its phenyl and stereochemistry is [2S-[1(R*),2a,4(3]], the product of preparation 60) (0.62 g, 2.4 mmol), L-3 (Scheme L
where RS is 4-[(2,6-dichlorobenzoyl)amino)phenyl and stereochemistry is (S)) (0.95 g, 2.4 mmole), and BOP-CI (0.68 g; 2.7 mmol) in CH2Cl2 (10 rnL) is treated with (i-Pr)2NEt (1.7 mL, 9.8 mmol). The reaction mixture is stirred at rt under N2 for 19 h. It is diluted with 1 S half saturated NaHC03 and extracted with CH,Cl2. The CH2C12 extracts are dried, filtered and concentrated to give a beige-colored foam ( I .40 g), that is purified by silica flash chromatography to give the title compound: TLC ( 1:1 Hexanes/EtOAc) Rf= 0.23;
"C
NMR (CDCl3) 8 173.25, 172.73, 171.63, 162.57, 141.8d, 136.76, 136.01, 132.44, 132.39, 130.90, 130.00, 128.57, 128.12, 127.SS, 127.08, 120.37, 63.25, 60.06, 59.17, 52.41, 52.12, 51.47, 37.65, 26.06, 21.25; MS (FAB) m/z 612.1658: Anal. C 59.66, H 5.14, N
6.64 (calcd C 60.79, H 5.10, N, 6.86).
Preparation 62 and Example 129.
(Scheme L: L-S where RL_, is methyl, RL_2 is phenyl, RS is 4-[(2,6-dichlorobenzoyl)-amino]phenyl and stereochemistry is [2S [1(R*),2a,4[i(R*)]]}
2S (2S-[1(R*),2a,4[3(R*))]-4-[([1-Carboxy-2-[4-[(2,6-dichlorobenzoyt)amino)phenyl]-ethyl)-amino]carbonyl]-1-(1-phenylethyl)-2-azetidine~carboxylic acid dilithium salt (C29H25CI2L1,N3O6).
A mixture of L-4 (Scheme L, where R~_, is methyl, R, _2 is phenyl, RS is 4-[(2,6-dichlorobenzoyl)amino]phenyl and stereochemistry is [2S-[1(R*),2a,4ji(R*)]], the product of preparation 61 ) (0.684 g, 1.12 mmol) and LiOH~H,O 1;0.25 g, 6.0 rnmol) is dissolved by WO 99/b7230 PCT/US99/14233 warming in MeOH ( 10 mL). Thin solution is diluted with 1:1 H~O/THF (20 mL), and the reaction mixture is stirred at rt for 22 h. The mixture is adjusted with 1 N
HCI to pH 6. The solution is concentrated to give a white solid, that is purified by preparative C I 8 reverse phase chromatography (MeCN/H,O gradient). Evaporatiion of the column fractions gives a S white solid, that is dissolved in warm HzO. The solution is frozen and lyophilized to give, as a white solid, the title compound: mp 270 °C; TLC (850:150:1 CHCI,/MeOH/HC02H}
Rf= 0.21-0.36; "C NMR (CD30D) S 178:05, 174.59, 174.01, 162.20, 142.33, 135.09, 134.91, 133.04, 130.54, 129.24, 128.61, 126.46, 126.41,126.17, 124:94, 118.33,82.70, 61.70, 60.50, 53.30, 36.23. 25.85, 18.65; MS (FAB) m/z 584.1350: Anal. C
SS.I7, H 5.01, I 0 N 6.63, Cl 11.16 (calcd for 7.52% H~O: C 54.02, H 4.75, N 6.52. Cl, I 1:21 ).
Example 130.
(Scheme L: L-4 where RL_, is methyl, RL_2 IS phenyl, RS is 4-[(2,6-dichiorabenzoyl)-amino]phenyl and stereochemistry is [2R-[I(S*),2a,4[i(S*)]]).
[2R-[1(S*),2a,4(i(S*}]]-4-[[(1-[[4-[(2,6-Dichlorobenzo~yl)amino]phenyl]methyl]-I5 methoxy-2-oxoethyl]amino]carbonyl]-1-(i-phenyleth;yl)-2-azetidinecarbaxylic acid methyl ester (C3,H3,ChN306).
Example 130 was prepared as described in Scheme L usiing the product of preparation SS
as intermediate L-1. Physical properties as follows: TLC (3:2 EtOAc/Hexanes) Rf=
0.43; [a]ZSp +58 (c 0.91, MeOH); "C NMR (CDCl3} 8 1'3.24, 172.15,172.05, 162.58, 20 140.75, 136.45, 136.01, 132.89, 132.38, 130.91, 129.60, 128.67, 128.39, 128.11, 127.97, 120.39, 63.54, 60.19, S9.S4, 53.15, 52.16, 51.91, 37.86, 26.12, 18.3 ~, MS
(EI) mlz 613, 61 I, 598, 596, 554, 552, 527, 525, 508, 506, 450, 448, 351, 349, 218, 191, 175, 173, 160, 131, I I4, 105; Anal. C 60.68, H 5.18, N 6.67, Cl 11.24 (calcd for C 60.79, H
5.10, N 6.86, Cl 11.58).
25 Example 131.
(Scheme L: L-5 where RL_, is methyl, RL_2 is phenyl, RS is 4-[(2,6-dichlorobenzoyl}-amino]phenyl and stereochemistry is [2R-[1(S*),2a,4[i(S*)]]).
[2R-[1{S*),2a,4[3(S*)]]-4-[[[1-Carboxy-2-[4-[(2,6-dichllorobenzoyl}-amino]phenyl]ethyl]-amino]carbonyl]-1-(1-phenylethyl)-2-azetidinecarboxylic acid, 30 dilithium salt (C,9H,SChLi,N,06).

Example 131 was prepared from Example 130 by the procedure described in preparation 62. Physical properties as follows: [aJ 'Sp +84 (c 0.95, :MeOH); '3C NMR
(CD30D) S
179.18. 176.55, 174.13, 163.58, I4I.88, 136.32, 136.29, 134.96, 131.90, 130.86, 129.47, 128.49, 128.07,127.87, 127.16, 119.74, 63.70, 63.49, 59,.77, 56.27, 38.24, 26.25, 18.70;
MS (FAB) m/z 598, 596, 592, 590, 552, 550, 546. 544, 161; Anal. C 55.20, H
5.52, N, 6.59 (calcd for 10.98% H20: C 52.00, H 4.99, N 6.27}.
Example 132.
(Scheme L: L-4 where R~_, is methyl, R~_Z is phenyl, RS is 4-[(2,6-dichlorobenzoyl)-amino]phenyl and stereochemistry is [I (S~,2a,4a(,S~], a single diastereomer having a cis I 0 relative conf guration but unknown absolute configuraticrn at C-2 and C-4 of the azetidine.) [1(,f~,2a,4a(,5~]-4-(([1-[[4-[(2,6-Dichlorobenzoyl)amino]phenyl]methyl]-2-methoxy-2-oxoethyl]amino]carbonyl]-1-(1-phenylethyl)-2-azetidinecarboxylic acid 2-methyl ester (Cg'H3tC12N3O6}~
I S Example 132 was prepared as described in Scheme L using the product of preparation 56 as intermediate L-1. Physical properties as follows: TLC (9:1 CHC131acetone) R
f = 0.29;
'3C NMR (CDC13) 8 172.70, 172.29, 171.65, 162.49, 144.97, 136.71, 136.12, 132.47, I32.39, 130.81, 130.22, 128.35, 128.07, 127.82, 120.17, 66.61, 61.52, 59.99, 52.38, 52.24, 51.79. 37.73. 25.16, 20.09.
20 Example 133.
{Scheme L: L-5 where R~., is methyl, R,~_2 is phenyl, RS i.s 4-[{2,6-dichlorobenzoyl)- --amino]phenyl and stereochemistry is [1(S');2a,4a], a single diastereomer having a cis relative configuration but unknown absolute configuration at C-2 and C-4 of the azetidine.) 25 [1(S'),2a,4a(,S~]-4-([[1-Carboxy-2-(4-((2,6-dichlorobenzoyi)amino]phenyl]ethyl]-amino]-carbonyl]-1-(1-phenylethyl)-2-azetidinecarboxylic acid (C,9H,,CI,N3O6}.
Example 133 was prepared from Example 132 by the procedure described in preparation 62. Physical properties as follows: [aJ-'SO +20 (c 0.88, MaeOH); '3C NMR
(CD,OD) 8 I73.70. 173.05, 172.61, 163.69, 140.09, 136.93, 136.20, 133.18, I3I.89, 130.89, 129.95, 30 128.09, 127.89,127.88, 127.65, 120.03, 66.07, 61.29, 59.86, 52.70, 36.98.
25.03, 18.81;

MS {FAB) m/z 662, 660, 586, 584, 539, 482, 480, 436, 434, 204, I75, 173, 160, 133, 109, 105; Anal. C 57.90, H S.OI, N 6.93 (calcd for 4.98% H,O: C 56.63, H 4.98, N
6.83).
Example 134.
(Scheme L: L-4 where RL_, is methyl, RL_z is phenyl, RS is 4-[(2,6-dichlorobenzoyl)-amino]phenyl and stereochemistry is [2R-[1(R*),2a,4[i('S*)]]) [2R-(1(R*),2a,4[3(S*)]]-4-[[[1-(j4-[(2,6-Dichlorobenzoyl)amino]phenyl]methyl]-methoxy-2-oxoethyl]amino]carbonyl]-1-(1-phenyleth;yl}-2-azetidinecarboxylic acid methyl ester (C3,H3,ChN,06).
Example 134 was prepared as described in Scheme L using the product of preparation 57 as intermediate L-1. Physical properties as follows: TLC; ( 1:1 EtOAc/Hexanes) R~= 0.30;
'3C NMR (CDCl3) 8 173.78, 172.76, 172.10, 162.47, 141.81, 136.70, 135.96, 132.43, 132.38, 130.88, 129.79, 128.55, 128.10, 127.58, 127.00, 120.58, 63.32, 60.06, 59.27, 52.70, 52.50, 51.44, 37.08, 25.76, 21.52; MS (+ESI, 200:1 MeOH/HCO,H solution) m/z 613.8, 611.8.
Example 135.
{Scheme L: L-5 where RL_, is methyl, R, _2 is phenyl, RS is 4-[{2,6-dichlorobenzoyl)-amino]phenyl and stereochemistry is [2R-[1(R*),2a,4[3(S*)]]) [2R-[1(R*),2a,4(3(S*)]]-4-[([1-Carboxy-2-(4-[(2,6-dichlorobenzoyi)amino]phenyt]-ethyl]-amino]carbonyl]-1-(1-phenylethyl)-2-azetidinecarboxylic acid dilithium salt (Cz9H25C12L1~N3O6).
Example 135 was prepared from Example 134 by the procedure described in preparation 62. Physical properties as follows: [a]ZSD +76 (c 0.89, MeOH); '3C NMR (CD30D) 179.44, 176.71, 175.90, 163.55, 143.81, 136.54, 136.26. 134.47, I3I.90, 120.81, 129.70, 127.83, 127.34, 126.33, 119.88, 63.06, 62.1 l, 58.71, 55.46, 37.17, 26.76, 20.56; MS
{FAB) m/z 598, 596, 592, 590, 552, 550, 546, 544, 237. 305; Anal. C 55.12, H
5.24, N
6.59, Cl 10.56 (calcd for 6.21 % H,O: C 54.78, H 4.66, N 6.61, Cl 11.15).
Example 136.
(Scheme L: L-4 where R,: , is methyl, R~_2 1S phenyl, RS is 4-[{2,6-dichlorobenzoyl)-amino]phenyl and stereochemistry is [2S-[1(S*),2a,4[i{R*)]]) [2S-[1(S*),2a,4(3(R*)]]-4-[[(I-[(4-((2,6-Dichlorobenzoy!)amino]phenyl]methyl]-methoxy-2-oxoethyl]amino]carbonyl]-1-(1-phenyleth~~l)-2-azetidinecarboxylic acid methyl ester (C3,H3,CIzN3O6) Example 136 was prepared as described in Scheme L using the product of preparation 58 as intermediate L-1. Physical properties as follows: TLC (85: I5 CHCI,/acetone) Rf= 0.54;
"C NMR (CDCl3) 8 173.44, 172.62, 171.72, 162.79, 14CL46, 136.69, 136.34, 1 x3.12, 132.79, 131.29, 130.40, 129.08, 128.52, 128.45, 128.23, 120.57, 64.I5, 60.51, 60.09, 53.11, 52.59, 52.19, 37.73, 26.70, 18.75; Anal. C 60.70, H 5.39, N 6.62 (calcd C 60.79, H
5.10, N 6.86).
Example 137.
(Scheme L: L-S where RL_, is methyl, RL_2 is phenyl, RS is 4-[(2,6-dichlorobenzoyl)-amino]phenyl and stereochemistry is [2S-[1(S*),2a,4(3{R*)]]) (2S (I(S*),2a,4[3(R*)]]-4-[[(I-Carboxy-2-(4-[{2,6-dichllorobenzoyl)amino]phenyl]-ethyl]-amino]carbonyl]-1-(I-pheny!ethyl)-2-azetidinecarboxylic acid (C~9H,7ChN3Ob).
Example 137 was prepared from Example 136 by the procedure described in preparation 62. Physical properties as follows: [a]ZSD +2 (c 1.00, Me;OH);'3C NMR (CD30D) 172.31, 169.43, 167.37, 163.72, 161.39, 160.93, 136.98, 136.11, 134.40, 133.20, 131.84, 130.93, 129.42, 129.39, 128.60, 127.89, 120.1 I; 62.68, 61.41, 53.51, 36.35,25.00, 16.17;
MS (FAB) m/z 586, 584, 482, 480, 204, 175. 173, 106, I ~05; Anal. C 53.07. H
4.52, N
6.15, CI 10.46 (cakd for 0.80 equiv TFA and 2.13% HZO: C 53.20, H 4.30, N
6.08, CI
10.26).
Example 138.
(Scheme L: L-4 where RL_, is methyl, R,.2 is phenyl, RS i.s 4-[{2,6-dichlorobenzoyl)-aminoJphenyl and stereochemistry is [ 1 (R);2a,4a{S)], a s~ingie diastereomer having a cis relative configuration but unknown absolute configuration at C-2 and C-4 of the azetidine.) [I(R),2a,4a(,S~]-4-([(1-((4-[(2,6-Dichlorobenzoyl)amino]phenyl]methyl]-2-methoxy-2-oxoethyi]amino]carbonyl]-I-(I-pheny!ethyl)-2-azetidinecarboxyiic acid 2-methyl ester (C,~H3IC13N306)~

Example 138 was prepared as described in Scheme L using the product of preparation 59 as intermediate L-1. Physical properties as follows: TLC Rf= 0.47 (85:15 CHC13/acetone); "C NMR (CDCl3) 8 173.42, 172.40, 171.74. 162.46, 140.80, 136.76, 136.03, 132.64, 132.35, 130.80, 129.82, 128.38, 128.04., 127.85, 127.69, 120.39, 66:11, 61.50, 59.78, 52.83, 52.42. 51.72, 37.12, 25.03, 20.20; MS {+ESI, 200:1 MeOH/HCO2H
solution) mlz 6 i 4.2, 612.2; Anal. C 60.66, H 5.18, N 6.80, Cl l 1.42 (calcd C 60.79, H
5.10, N 6.86, CI 11.58).
Example 139.
(Scheme L: L-5 where RL_, is methyl, R~_2 is phenyl, Ra is 4-[(2,6-dichlorobenzoyl)-amino]phenyl and stereochemistry is [I(R),2a,4a(,S~]. a single diastereomer having a cis relative configuration but unknown absolute configuration at C-? and C-4 of the azetidine) [1(R),2a,4a(,f)]-4-[[[1-Carboxy-2-[4-[(2,6-dichlorobenzoyi)amino]phenyl]ethyl]-amino]-carbonyl]-1-(I-phenylethyl)-2-azetidinecarba~xylic acid (CZ9H,SC12N3O6).
Example 139 was prepared from Example I38 by the procedure described in preparation 62. Physical properties as follows: [a]z5D -30 (c 0.90, MeOH); '3C NMR (CD30D) 172.71, 172.44, 171.81, 163.71, 138.03, 136.99, 136:15, 133.31, 131.89, 130.89, 129.45, 128.33, 128.29,128.02, 127.86, 120.23, 65.62, 61.51. 59'.60, 53.47, 36.04, 24.91, 17.68;
MS (FAB) m/z 586. 584, 371, 298, 204, 177; 175. 173. 133. 105, 100; Anal. C
55.69, H
4.49, N 6.55, Cl 11.81 (calcd for 0.38 equiv TFA and 2.06% HZO: C 55.80, H
4.54, N
6.56, Cl 11.07).

Scheme M.
RM.2 ~ RM-1 OQ N O
-O, v 'O- M-1 O, N ,.O
-O~--~--l~O- M-2 R3'Y
O' N O
~ ~ M-3 -O~~O._ R3,Y
O N ,O
~~''' M~4 -O " OH

HzN~O~ M-5 [JO
R3'Y
O N O
\'~~''~ O
-Ol' ' HN Oi NI-6 R3'Y
O ~ O
\'~~''~ O
HO~~~N OH M-7 RS

Scheme M teaches 'a general method for the preparation of N acyl azetidinedicarboxylic acid Examples M-6 and M-7, where RM_, is C,_b alkyl, RM.2 is Cb_,°
aryl, and R~, RS and Y are defined as in Scheme B. Thus removal of the N alkylaryl substituents RM_, and RM_2 of M-1 gives aminodiester M-2, that is acylated to provide M-3. Partial saponification of diester S M-3 gives half acid M-4, that is coupled with reagent M-5 (as exemplified by the use of reagents A-3 and A-4 of Scheme A, and B-4 and B-5 of Scheme B) to provide Examples M-6, that are then hydrolyzed to Examples M-7 of this invention.
Preparation 63.
(Scheme M: M-2 where stereochemistry is (2R-traps)) (2R-traps)-2,4-Azetidinedicarboxylic acid dimethyi diester (C,H"N04).
To an N,-purged solution of freshly chromatographed Preparation M-1 (Scheme M
where RM_, is methyl, RM_2 IS phenyl and stereochernistry is [2R-[I(R*),2a,4[3]]
prepared as described by preparation 57) (656 mg, 2.37 mmol) in Me;OH (20 mL) is added 20%
Pd(OH)z/C ( 120 mg), and this mixture is hydrogenated for 19 h under an H~
atmosphere IS (approximately 42 psi pressure). The mixture is filtered and concentrated to give the title compound as a colorless oil: TLC (4:1 HexaneslEtOAc) Rf= 0.04;'H NMR (CDC13) 8 4.33 (2H), 3.77 (6H), 3.38 (1H), 2.71 (2H); MS {+ESI) m/z I74.2.
Preparation 64.
(Scheme M: M-3 where R3 is ethyl, Y is CO,-, and the stereochemistry is (2R-traps)) (2R-traps}-1,2,4-Azetidinetricarboxylic acid i-ethyl-2,4-dirnethyl triester (C,°H,SN06).
To a mixture of freshly prepared amine M-2 (Scheme M where stereochemistry is (2R-trans)} (14 mrnol} in CHZCl2 {20 mL) under N, at 0 °C is added Et3N
(3.0 mL, 22 mmol), followed by the dropwise addition of C1CO,Et ( 1.5 mL, :l 8 mmol). After 22 h the reaction is quenched with saturated NaHC03, diluted with H,O, and extracted with EtOAc.
The combined organic extracts are dried, filtered and concentrated to give 2.79 g of the carbamate, that is purified by silica flash chromatography: TLC (4:1 Hexanes/EtOAc) R f=
0.17; [a]'-SD + 183 (c 0.83, MeOH); 1 H NMR (CDCIz) S 4.77 (2H), 4.15 ( 1 H), 4.10 ( 1 H), 3.80 (6H), 2.58 (2H), 1.23 {3H); "C NMR (CD,OD) b 173.11, 173.05, 157.47, 63.30, 61.00, 60.18, 53.41, 26.43, 15.27; MS (EI) miz 245. 186, 172, 142, 114; Anal.
C 48.90, H
6.21, N 5.73 (calcd C 48.98, H 6:16, N 5.71 ).

WO 99!67230 PCTIUS99l14233 Preparation 65.
(Scheme M: M-4 where R, is ethyl, Y is COZ-, and the stereochemistry is (2R-traps)) (2R-traps)-1,2,4-Azetidinetricarboxylic acid 1-ethyl-2.-methyl diester (C9H,3N06).
A mixture of M-3 (Scheme M, where R3 is ethyl, Y is CO,-, and the stereochemistry is (2R-traps)) (1.68 g, 6.85 mmol) and LiOH (7.00 mmol) iin I :1 MeOH/H,O} (40 mL) is stirred at rt for 45 h, and then is concentrated. The residue is dissolved in half saturated NaHC03, and the solution is extracted with Et20. The Et,O solution is discarded. The aqueous solution is adjusted with concentrated HCI to pH 4, and is concentrated to a yellow solid. This solid is triturated with CHCl3. The CH;CI, solution is filtered and concentrated to give, as a light brown oil, the title compound: TLC (600:400:1 HexaneslAcetoneIHCO,H) Rf= 0.21-0.45;'H NMR (CD~C13) S 4.87 (1H), 4.77-4.68 (1H), 4.64-4.50 (1H), 4.18-3.97 (2H), 3.76 (3H), 2.52-2.33 (2H), 1.26-1.13 (3H}; MS
(-ESI, MeOH solution) m/z 230.1. This maternal is used without: purification.
Preparation 66 and Example 140.
(Scheme M: M-6 where R3 is ethyl, Rs is 4-[{2,6-dichlorobenzoyl)amino]phenyl, Y is COZ-, and the stereochemistry is [2R-(2a,4[i(S*)]) [2R-(2a,4/3(S*)]-4-[ [[1-[ [4-[(2,6-Dichlorobenzoyl)amino]phenyl] methyl]-2-methoxy-2-oxoethyl]amino]carbonyl]-1,2-azetidinedicarboxyiic acid i-ethyl-2-methyl diester (C26H27C12N3~8)~
To a mixture of Preparation M-4 {1.08 g, 4.67 mmol) and HOBt+H~O (0.63 g, 4.7 mmoI) in CHzCI, {10 mL} at 0 OC is added a solution of EDC (1.04 g, 5.42 mmol) in CHzCh (15 mL}. This mixture is stirred at 0°C for 30 min. It is then treated with M-S (Scheme M
where RS is 4-[(2,6-dichiorobenzoyl)amino)phenyl and stereochemistry is (S)) (1.88 g, 4.66 mmol) and N methylmorpholine (0.52 mL, 4.7 mmol). The resulting solution was stirred at 0°C for 2 h and at rt for 2 h. The reaction mixture is diluted with 10% IGIiS04 and extracted with CH,Ch. The combined CH~CI, extracts are washed with satd NaHC03 and brine, and are combined, dried, filtered and concentrated to give a yellow foam (2.58 g), that is purified by flash chromatography to give, as a white solid, the title compound:
mp 97-99°C; TLC (9:1 CHCl,/acetone) Rf= 0.30; [a]''Sp -+-79 {c 1.02.
MeOH); UV
(MeOH) ~m~ 225 (E 12200: sh), 251 {17500);'3C NMR (C17,OD) S 171.50, 171.30, WO 99167230 PCT/US99l14233 171.08, 163.67, 156.23, 155.96, 136.92, 136.19, 133.21" 133.03, 131.87, 130.93, 129.64, 129.44, 127.92, 119.97, 61.61, 60.56, 59.82, 59.1 I, 58.41, 53.45, SL.58, SI.52. 36.57, 36.29. 24.91. 13.43 (22 lines expected; 28 lines observed); MS (FAB) m/z 580.1260 (calcd for [M+HJ+, 580.1253); Anal. C S 1.95, H 4.56, N 6.89, Ci 15.18 (calcd for 0.61 H,O: C 53.48, H 4.73, N 7.20, Cl 12.14).
Preparation 67 and Example 141.
(Scheme M: M-7 where R3 is ethyl, RS is 4-[(2,6-dichlorobenzoyl)arnino)phenyl, Y is CO,-, and the stereochemistry is [2R-(2oc,4[3(S*)]) [2R-(2oc,4~(S*}]-4-[[[I-Carboxy-2-[4-[(2,6-dichlorobenzoyl)aminoJphenyllethyl]-amino]-carbonylJ-1,2-azetidinedicarboxylic acid 1-etlhyl ester (C24H,3C1,N,08).
To a suspension of M-6 (Example 140, Scheme M where R3 is ethyl, R~ is 4-[(2,6-dichlorobenzoyl)aminojphenyl, Y is CO,-; and the stereochemistry is [2R-(2a,4[i(S*)]) (0.201 g, 0.347 mmol) in MeOH (5 mL) is added HBO (4.3 mL}and1.00 M LiOH (0.70 mL}. The reaction mixture is stirred at rt for 23 h. It is concentrated in vacuo. The aqueous I5 concentrate is diluted with H20, and the solution is adjusted to approximately pH 12 with 1 N NaOH. It is extracted with Et,O, and the Et,O extract is discarded. The aqueous solution is adjusted to approximately pH 3 with 1N HCI.. It is extracted repeatedly with EtzO. The combined Et,O extracts were dried, filtered and concentrated to give, as a white solid, the title compound: TLC (500:500:1 MeOH/CH~CIi/HCO,H) Rf= 0.20; 'H NMR
(CD;OD) 8 7.59 (2H), 7.50-7.37 (3H), 7.23 (2H), 4.78-4.64 (2H), 4.61-4.51 (1H), 4.22-3.89 (2H), 3.30-3.185 (1H), 3.07-2.93 (1H), 2.42-2.23 (2H), 1.21 and 1.1 l (3H
total); MS
(FAB) mlz 552.0946 (calcd for [M+HJ' 552.0940); Anal. C 50.4$, H 4.61, N 6.64, Cl 12.95 (calcd for 1.60% H20: C 51.35, H 4.31, N 7.49, Cl 12.63).

Scheme N.

OH

m O
n OH
R3-Y-X~~ N-2 m HzN~O~ N-3 O

O
n N~'O~ N~1 R3 Y X~~H 'IO
m Rs O r N~OH N_5 R3-Y-xr~H JO~
m Rs O ~OH
n N [J N~
H-X~~~H O
m Scheme N teaches a general method for the preparation of N acyl azetidinecarboxylic acid Examples N-S where n equals 0, 1 or 2, rn equals 0, 1 or 2. (m + n} equals 2, X is nitrogen and R3, Rs and Y are defined as in Scheme B, and azetidine-carboxylic acid Examples N-6 where n equals 0, 1 or 2. m equals 0, 1 or 2, (m + n) equals 2, X is nitrogen and RS is defined as in Scheme B. Thus acyiation of aminoacid N-I gives Itr'-acylacid N-2, that is WO 99!67230 PCT/US99/14233 coupled-with reagent N-3 (as exetnplified by the use of reagents A-3 and A-4 of Scheme A, and B-4 and B-5 of Scheme B) to provide Examples N-4. Ester hydrolysis of N-provides Examples N-5. N deacylation of Examples N-~> provides Examples N-b.
Preparation 68.
{Scheme N: N-2 where n is 2, m is 0. X is N, Y is -COZ-, Ra is ( 1,1-dimethyl)ethyl, and the stereochemistry is (S~).
(S)-1,2-Azetidinedicarboxylic acid 1-(1,1-dimethyle#hyl) ester (C~H,SN04).
To a mixture of (S')-(-)-2-azetidinecarboxylic acid (I 10 mg, i. l mmol), Boc40 (290 mg, 1.30 mmol), and DMAP (0.017 g, 0.14 mmol) in 4:1 DMF/H,O (10 mL) is added Et3N
(0.30 mL, 2.2 mmol). The reaction mixture is stirred at i~t for 68 h, and then is concentrated. The concentrate is diluted with EtOAc, and the EtOAc solution is washed with cold 10% KHS04. The combined organic extracts are dried, filtered and concentrated to give the title compound as a colorless oil: TLC (750:250:1 Hexanes/acetone/HCOZH) R~ 0.26; 1 H NMR (CD30D) ~ 4.97 ( 1 H), 4.57 ( 1 H), 3:~~8 ( 1 H), 3.87 ( 1 H), 2.57 (H), 2.13 ( 1 H), 1.42 (9H); MS (-ESI) m/z 200.3.
Preparation 69 and Example 142.
(Scheme N: N-4 where n is 2, m is 0, X is N, Y is -COz-, R3 is { l , l -dimethyl)ethyl, RS is 4-[(2,6-dichlorobenzoyl)amino]phenyl and stereochemistry is (,S~).
[2S-(R*,R*)]-2-[[[1-[[4-[(2,6-Dichlorobenzoyl)amino]phenyl]methyl]-2-methoxy-2-oxoethyl]amino]carbonyl]-1-azetidinecarboxyiic acid 1-(1,1-dimethyl)ethyl es#er (C26H29C1zN3O6)~
To a mixture of acid N-2 (Scheme N. where n is 2, m is t), X is N; Y is -CO,-, R3 is (1,1-dimethyl)ethyl, and the stereochemistry is (.S'~) (1.04 g; 5.I7 rnmol) and HOBt~H,O (0.71 g, 5.3 mmol) in CHzCIz (10 mL) at 0 °C is added a mixture of EDC~HC1 (1.00 g, 5.22 mmol) in CHZC12 (20 mL). The reaction mixture is stirred at 0 °C for 30 min, and then N-3 (Scheme N where R5 is 4-[(2,6-dichlorobenzoyl)amino)phenyl and stereochemistry is (S}) (2.10 g, 5.20 mmol) and N methylmorpholine (0.60 mL, 5.46 mmol) are added. The reaction mixture is stirred at 0°C for 30 min and at rt for 3 h. The reaction mixture is partitioned between 10% KHSO, and CH,C1,. The aqueous phase is extracted twice more with CH,CI,. The combined organic extracts are washed with saturated NaHCO, and brine, and then are dried, filtered and concentrated to a yellow oiI (2.54 g) that is purified by silica flash chromatography to give the title compound as a white foam: mp i06-108 °C;
TLC (l :l Hexanes/EtOAc); Rf= 0.21; [a]ZSD -38 (c 1.01., MeOH); "C NMR (CD,OD) 172.37, 171.58, 163.64, IS6.68, 136.98, 136.22. 133.11, 131:87; 130.90, 129.49, 127.91;
S 120.00, 80.42, 61.87, 53.31, S 1.45, 36.40, 27.16. 20.08; MS (EI) m/z SS 1, 549, 478; 476, 451; 449, 396, 394, 351, 349, 280, 278, 175, 173; Anai. C 56.33, H 5.48, N
7.23, CI 12.43 (calcd for 0.S2% H,O: C 56.44, H 5.34, N 7.59, Cl 12.82).
Preparation 70 and Example 143.
{Scheme N: N-S where n is 2, m is 0, X is N, Y is -COZ-, R3 is (I,I-dimethyl)ethyl, RS is 4-[(2,6-dichlorobenzoyl)aminojphenyl and stereochemi stry is [2S-(R*,R*}]) [2S (R*,R*)]-2-[[[1-Carboxy-2-[4-[(2,6-dichlorobenzoyl)amino]phenyl]ethyl]amino]-carbonyl]-1-azetidinecarboxylic acid 1-{1,1-dimethylethyl) ester (CZSHZ,Cl,N306).
A solution of N-4 (Scheme N, where n is 2, rn is 0. X is N, Y is -COZ-, R~ is (1,1-dimethyl)ethyl, RS is 4-[(2,6-dichlorobenzoyl)arnino]phenyl and stereochemistry is (S)) 1S (S07 mg, 0.92 mmol) and LiOH (1.25 mmol) in 1:1 MeOH/H20 (10 mL) is stirred at rt for 18 h. The reaction mixture is diluted with cold 10% KHS04 and extracted with CH2CI2.
The organic extracts are dried, f Itered and concentrated to a white foam (498 rng), that is purifed by silica flash chromatography to give the title compound: TLC
(7S0:2S0:1 hexanes/acetone/HCO~H) R f= 0.12; [a]z5D -27 (c 0.94, CHC33); "C NMR (CD30D) 8 210.OS, 172.70, 172.27, 163.63, 1S6.7S, 136.89, 136.22, 133.36, 131.88, 130.90, 129.56, 127.91, 119.95, 80.47, 61.93, 53.18, 36.47, 27.1 S, 20.09; MS (-ESI) nr/z 533.8; MS (EI) m/z 435, 419, 417, 401, 399, 373, 371, 280, 278, 175, 1 i'3, 147, 145; Anal. C
SS.23, H
S.2S, N 7.42, CI 12.87 (calcd for 1.10% H20: C SS:36, H 5.14, N 7.75, CI
13.07).
Preparation 7 i and Example 144.
2S (Scheme N: N-6 where n is 2, m is 0, X is N, RS is 4-[(2,6-dichlorobenzoyl)amino]phenyl and stereochernistry is {2S), ~) N [[(2S~-2-Azetidinyi]carbonyl]-4-[(2, 6-dichlorobenz;oyl)amino]-L-phenylalanine trifluoroacetic acid salt (C,°H~9CI,N3O6 .C,HF~O=).
A solution of N-5 (Scheme N, where n is 2, m is 0. X is N, Y is -CO~-, R3 is (1,1-dimethyl)ethyi, RS is 4-[(2,6-dichlorobenzoyl}amino]phemyl and stereochemistry is [2S-(R*,,R*)]) (900 mg; 1.7 mmol) in 1:1 TFA/ CHzCl2 (5 mL) is stirred at rt for 1.5 h, and is concentrated. The residue is thrice diluted with CHCIj anal re-concentrated.
This residue is dissolved in MeOH and concentrated to a white foam, that is dissolved in 1:1 MeOH/H20 and then concentrated to remove most of the MeOH. The; solution is frozen and lyophilized to give the product as a white powder: [a]zsp -6 (c 0.72, MeOH);
'3C NMR
(CD30D) 8 172.62, 167.54, 163.78, 136.82, 136.13, 133.43, 131.84, 130.97, I29.38, 127.93, 120.15, 58.38,.54.03, 43.73, 36.27, 23.33; MS (+ESI) mlz 436.0; MS
(FAB) mlz 438, 436; Anal. C 46.77, H 3.75, N 7.24, Cl 12.44 (calcd for a l:l TFA salt with 1.68%
H20: C 47.21, H 3.79, N 7.S 1, Cl 12.67).
Example 145.
{Scheme N: N-4 where n is 1, m is 1, X is N, R3 is (l,l-dimethyl)ethyl, RS is 4-[{2,6-dichlorobenzoyl)amino]phenyl, Y is COZ- and the stereochemistry is {,S'~) (S]-3-[[[1-( [4-[{2,6-Dichlorobenzoyl)amino]phenyl] methyl)-2-methoxy-2-oxoethyl]amino]-carbonyl]-I-azetidinecarboxylic acid I-{l,I-dimethyl)ethyl ester I S (C26H29C12N3~6O
Example 14S was prepared as described in Scheme N from 3-azetidinecarboxyIic acid.
Physical properties as follows: TLC ( 1:1 EtOAc/hexanes) R f = 0.22; [a]'SD
+18 (c 0.92, MeOH);'3C NMR (CD,OD) b 172.92, 171.91, 163.68, 1S6.SS, 136.87, 136.20, 133.27, 131.89, 130.91, 129.36, 127.90. 120.04, 79.80, 53.85; S 1.45. 36.43, 32.26, 27.24; MS (EI) m/z 469, 467, 4S I, 359, 3S 1, 349. 280, 278, 175, 173, 57., Anal: C 56.82, H
5.39, N 7.52, Cl 12.81 (calcd for 0.06% HBO: C 56.70, H 5.31, N 7.63, Cl 12.87).
Example 146.
(Scheme N: N-5 where h is 1, m is 1, X is N, R3 is (1,1-dimethyl)ethyl, RS is 4-[(2,6-dichlorobenzoyl)amino]phenyl, Y is COZ- and the stereoc:hemistry is (~) 2S {S~-3-[[[1-Carboxy-2-[4-[(2,6-dichlorobenzoyl)amino]phenyl]ethyl]amino]carbonyl]]-I-azetidinecarboxylic acid 1-(1,I-dimethylethyl) ester (C,SH,7Cl;N306).
Example i46 was prepared from example 14S by the procedure described in preparation 70. Physical properties as follows: TLC (600:400:1 Hexanes/Acetone/HCO,H) Rf=
O.I7;
[a]'gyp +33 {c 0.92, MeOH); "C NMR (CD30D) 8 I73Ø'i, 172.89, 163.69, 1S6.S6, 136.78, 136.19, 133.59, 131.89, 130.91. 129.40, 127.90. 120.00, 79.78, 53.67, S1.72, 36.47, 32.31, 27.24; MS (-ESi) m/z 533.9; MS (FAB) m/z 538, 536; 438, 436, 337, 335. 280, 278, 175, 173. 57; Anal. C 55.03, H 5.21, N 7.52, CI 12.81 (calcd for 1.22% H20: C
55.30, H 5.15, N 7.74. Cl 13.06}.
Example 147.
(Scheme N: N-b where n is l, m is l, X. is NH, RS is 4-[(2,6-dichlorobenzoyl)amino]-phenyl. and the stereochemistry is (L)) N [[3-Azetidinyl]carbonyl]-4-[(2,6-dichlorobenzoyl)amino[-1,-phenylalanine, trifluoroacetic acid salt {CZ°H~gCI2N3O6 .C,HF30z).
Example 147 was prepared from Example 146 by the procedure described in preparation 71. Physical properties as follows: [a.]-'SD +32 (c 0.87, MeOH); "C NMR
(CD,OD) 8 i 73.32, 170.57, 163.80, 136.70, 136.13, 133.76, 131.84, 130.97, 129.45, 127.93, 120.17, 54.03, 36.59, 35.32); MS (FAB} m/z 438, 436, 391, 331, 175, 173, 101, 55;
Anal. C
46.85, H 4.07, N 7.33, CI 12.39 (calcd for a 1:1 TFA salt with 3.34% H,O: C
46.41, H
3.92, N 7.38, CI 12.45).
Example 148.
[S--(R*,R*)]-4-[[[1-[[4-[(2,6-Dichlorobenzoyl)amino]phenyl]methyl]-2-methoxy 2-oxoethyl]amino]carbonyl]-3-thiazolidinecarboxyiic acid 3-{2-pyridinyImethyl) ester (Scheme A, A-7: where RA_, and RA_2 are the same and equal to proton, R3 is 2-pyridinylmethyl, Y is CO,-, RS is 4-[(2,6-dichlorobenzoyl)amino]phenyl and stereochemistry is (S, S)).
S-- H O
" " O~
~ "~ oho ° ~ ~ p cl "
H I ~
CI
Example 148 was prepared as described in Scheme A from D-cysteine using 2-pyridinemethanol to form the requisite carbarnate. Physical data as follows:
'H NMR
(300 MHz, CDCI,) b 8.37 (1 H), 7.70 (1 H), 7.51 (2 H), 7.27 (6 H), 7.08 (2 H), 6.92 (1 H}, 5.24 (2 H), 4.77 (3 H). 4.40 (1 H), 3.74 {3 H). 3.37 (1 H;), 3.15 (3 H); "C
NMR (75 MHz, CDC13) b 171.4, 162.5, 155.2, 149.0, 137.1, 136.5, 136.01, 132.4, 130.7,L29.9, 128.0, 123.1, 120.6, 63.0, 53.4, 52.5, 36.8; MS (ESI+) for C~$H,~CI,N,O~S mlz 616.8 (M+H),.;
HRMS (EI) calcd for C,$Hz6Cl,N406S 616.0950, found 1516.0946. Anal. Calcd for Cz8H26CI2N4O6S: C, 54.46; H, 4.24; N, 9.07. Found: C, 54.61; H, 4.32; N, 8.97.
Example 149.
[S-{R*,R*)]-4-[[[I-Carboxy--2-[4-[(2,6-dichlorobenzoyl)-amino]phenyl]ethyl]amino]carbonyl]-3-thiazolidinecarboxylic acid 3-(2-pyridinylrnethyi) ester (Scheme A, A-8: where RA_, and RA_z are the same and equal to proton, R3 is 2-pyridinyl-methyi, Y is CO,-, RS is 4-[(2,6-dichlorobenzoyl)amino]phenyl and stereochemistry is (S, /S-. H~ O
~N~'N~OH
I Nw O~p O ~ ~ ~1 CI
Nl' W
H
I S CI
Example 149 was prepared from example 148 by the procedure described in preparation 6.
Physical data as follows: IR (mull) 1713, 1666, 1605, 1576, 1561, 1539, 1515, 1442, 1431, 1413, 1351, 1325, 1271, 1194, 766 cni';'H NMR (300 MHz, CD30D) 8 8.80 (1 H), 8.56 (1 H), 7.99 (2 H), 7.58 (2 H), 7.45 (3 H), 7.25 (2 H), 5.43 (2 H). 4.60 (3 H), 3.30 (3 H), 2.93 (2 H); 130 NMR (75 MHz, CD,OD) 8 172.7, 171.5, 163.7, 152.8, 151.3, 146.6, 141.9, 136.8, 136.1, 133.6, 131.8,,130.9, 129.6, 127.9, 126.1, 125.4, 120.1, 63.2, 62.8, 59.4, 53.5, 36.4, 35.1; MS (ESI+) for C27H24C1zN~O6S nv'z 602.9 (M+H)+; MS
(FAB) mlz (rel. intensity) 603 (MH+, 59), 605 {43), 603 (59), 154 (5I ), 139 (99), 137 (46), 136 (47), 123 (67), 105 (58), 103 (61); 93 (38); HRMS (FAB) calcd for C,7H,aCl,N406S +H, 603.0872, found 603.0876; Anal. Calcd for C,~H,,CI,NaO~S ~ 0.3 HBO: C, 53.26;
H, 4.07;
N, 9.20. Found: C. 52.97; H, 4.23; N, 9.04.

WO 99/67230 PGTlUS99/14233 Example 150.
[S~R*,R*)]-4-[[[1-[[4-[(2,6-Dichlorobenzoyl}amino]phenyl]methyl]-2-methoxy-2 oxoethyl]amino]carbonyl]-~-oxo-3-thiazolidinepentanoic acid {Scheme A, A-?: where RA_, and RA.Z are the same and equal to proton, R, is (CHZ)3COzH, Y is CO-, RS is 4-[(2,6-dichlorobenzoyl)amino]phenyl and stereochemistry is (S, S)).
S- H OII
O CN~N~Oi HO'~O O I ~ O CI
/ w H, I
CI
Example 150 was prepared as described in Scheme A from D-cysteine using glutaric anhydride to form the requisite amide. Physical data as follows: IR (mull) 3077, 3053, 3040, 1738, 1728, 1696, 1682, 1641, 1557, 1437, 1430, 1414, 1307, 1232, 1209 crri '; 'H
NMR (300 MHz, CDC13) 8 7.56 (2 H), 7.30 (3 H), 7.08 (2 H), 4.96 ( 1 H), 4.62 (3 H), 3.72 (3 H), 3.28 (4 H), 2.37 (4 H), 1.90 (2 H); '3C NMR (75 MHz, CDC13) 8 179.5, 176.0, 175.6, 173.6, 167.2, 140.6, 140.0, 136.1, 134.5, 133.7, 133.4, 131.8, 124.4, 66.7, 65.9, 57.2, 56.3, 40.3, 39.3, 37.3, 36.7, 36.2, 33.5, 23.6; MS (FAB) m/z {rel.
intensity) 596 (MH*, 90), 598 (63), 597 {40), 596 {90), 341 {25), 263 (.?S}, 230 (32), 225 (31}, 193 (31), 141 (99), 88 (36); HRMS (FAB) calcd for CZ6H,7C12N3O7S +H, 596.1025, found 596.1036.
Anal. Calcd fox Cz fiH27C12N307S ~ 0.3 H,O: C, 51.88; H, 4.62; N, 6.98. Found:
C, 51.69;
H, 4.69; N, 6.59.
Example 151.
[S-{R*,R*)]-4-[[[I-Carboxy-2-[4-[(2,6-dichlorobenzoyl)amino]
phenyl]ethyl]amino)carbonyl]-S-oxo-3-thiazolidinepentanoic acid methyl ester (Scheme A, A-8: where RA_, and R"_Z are the same and equal to proton, R3 is (CH,)3CO,CH3, Y is CO-, RS is 4-j(2,6-dichlorobenzoyl)amino]phenyl and stereochemistry is (S, S)).

S--. H O
O ~N~N~OH
~O~O O I ~ O Ci N. ~
H I /
CI
Example 151 was prepared as described in Scheme A from D-cysteine using methyl glutaryl chloride to form the requisite amide. Physical data as follows: IR
(mull) 3287, 3196, 1724, 1662, 1607, 1562, 1540, 1516, 1431, 1414, 1326, 1268, 1217, 1195, 799 crri';
MS (FAB) m/z (rel. intensity} 596 (MH+, 72), 598 (52), 596 (72), 229 (37), 193 (37), 167 (34), 133 (44), 129 (69), I21 (48), 103 (83}, 89 (99); ' H NMR (300 MHz, CD30D} 8 7.56 (2 H), 7.43 (3 H), 7.23 (2 H), 4.53 (3 H), 3.63 (3 H), 2.915 (4 H), 2.45 (3 H), 2.24 (2 H}, I.93 (2 H); "C NMR (75 MHz, CDC13) 8 174.0, 172.1, 1.69.9, I62.9, 162.8, 136.1, 132.2, 130.6, 130Ø 127.9, 120.3, 62.9, 54.5, 51.6, 49.8, 36.8, ?.3.5, 33:0, 32.7;
29.6, 19.6; HRMS
(FAB) calcd for C,6H~,C1,N30,S +H~ 596.1025, found 596.1047. MS {FAB) mlz (rel.
intensity) 596 (MH', 72), 598 {52), 596 (72), 229 (37), 193 (37), 167 (34}, 133 (44), 129 {69), 121 (48), 103 (83}, 89 (99).
Example 152.
[S-{R*,R*)]-4-[[[1-Carboxy-2-[4-[(2,6--dichlorophenyl)methoxyJphenyl]ethyl]amino]-carbonyl]-3-thiazolidinecarboxylic acid 3-{2--{1-piperidinyl)ethyl] ester (Scheme A, A-8: where RA., and RA.2 are the same and equal to proton; R3 is 2-(1-piperidinyl)ethyl, Y is CO,-, RS is 4-[(2,6-dichlorophenyl)methoxy]phenyl and stereochemistry is (S, S)).
S-- H O
~N~N " OH
~N~O~O O ( ~ CI
~O~
I/
CI
Example I52 was prepared from example S by the procedure described in preparation 6.
Physical data as follows: IR (mull) 3254, 2654. 171 I , 1565, 1547, 15I2, 1438, 1344, 1300, 1240, 1196, 1179, 1 I 19, 1014, 767 crri ';'H NMR (300 MHz, CD30D) 8 7.45 (2 H), 7.36 (1 H), 7.19 (2 H), 6.97 (2 H), 5.26 (2 H), 4.50 (5 H), 3.60 {11 H), 1.83 (6 H); MS
(ESI+} for C38H33CIZN3O6S m/Z 610.0 (M+H)T; Anal. Caicd for C,8H33C1,N306S ~
1.5 HZO
HCI: C, 49.90; H, 5.53; N, 6.24; Cl, 15.78. Found: C, 49:86; H, 5.43; N, 6.29;
C1, 15.65.
% Water (ICF): 3.99.
Example i 53.
[S-{R *,R* )]-4-[[[ 1-Carboxy-2-[4-[(2,6-dichlorophenyl)methoxy]phenyl]ethyl]aminoJ
carbonyl]-N-methyl-N-[2-(2-pyridinyi}ethyl]-~3-thiazolidinecarboxamide (Scheme A; A-8: where R,,_, and RA_Z are the same and equal to proton, R3 is 2-(2-pyridyl)-ethyl, Y is CON(CH,)-, RS is 4-[(2,6-dichlorophenyl)methoxy]phenyl and stereochemistry is {S, S)).
s-. H~ o ~N~OH
N N O I ~ CI
O
I 5 Example 153 was prepared as described in Scheme A using 2-(2-methylaminoethyl)-pyridine to form the requisite urea and hydrolysis according to the procedure described in preparation 6. Physical data as follows: mp 80°C (softens), 125°C; IR {mull) 1661, 1611, 1585, 1565, 1511, 1489, 1439, 1394, 1300, 1240, 1196, 1179, 1017. 779, 768 cni';'H
NMR (300 MHz, CD30D) 8 8:44 (1 H), 7.75 (1 H), 7.35 (5 H), 7.I2 (2 H), 6.93 (2 H), 5.22 (2 H), 4.83 ( I H), 4.65 ( 1 H), 4.32 (2 H), 3.77 ( I H;?, 3.45 ( 1 H), 3.20 ( 1 H), 3.00 (5 H), 2.84 (3 H); "C NMR (75 MHz. CD30D) 8 173.0, 1'70.8, 162.4. 158.4, I57.9, 147.9, 138.0, 136.6, 132.2, 130.6, 130.1, I29.3, 128.3, 124.2, 122.0; 114.5, 64.8, 64.7, 53.3, 52.5, 49.7, 35.7, 34.8, 32.8; MS (ESI+) for C,9H3°ClzN4O5S rrxlz 617.0 (M+H}'; Anal. Calcd for C,9H3oC12N405S: C, 56.40; H, 4.90; N, 9.07. Found: C, :56.31; H, 5.07; N, 8.98.
Preparation 72 and Example 154.
[S-{R*,R*)]-4-j[[ 1-[[4-[(2,6-Dichlorobenzoyl)amino]phenyl]methyl]-2-[(4-pyridinyl}
methoxy]-2-oxoethyl]amino]carbonyl]-3-thiazolidinecarboxylic acid 3~thy1 ester S- O
~N : NH~ / .
O
/ ~ CI
NH %

To a solution of Example 12 (Scheme A, A-8: where RA_, and RA_z are the same and equal to H, R3 is ethyl, Y is COZ, RS is 4-[{2,6-dichlorobenzoyl)amino]phenyl and stereochemistry is (S, S)) (400 mg, 0.74 mmol) in dimetlhylformamide (4 mL) was added tetramethylguanidine (204 ~L, I.63 mmol) follovi~ed by 4-picolyl chloride (138 mg, 0.81 mmol). The solution was heated to 65 °C for 3 h and volatiles removed in vacuo.
Purification of the residue by flash chromatography using methylene chloride/methanol (2%) as eluant afforded the title compound (320 mg) as ~an amorphous solid: IR
(mull}
3275, 1748, 1677, 1608, 1561, 1539, 1515, 1431, 1415, /344, 1325, 1271, 1222, 1194, 799 crri':'H NMR (300 MHz, CDCl3) S 8.87 (1 H), 8.48 (2 H), 7.50 (2 H), 7.25 (3 H), 7.10 (2 H), 6.93 (2 H), 5.08 (2 H), 4.79 (2 H), 4.61 (1 H), 4.28 (1 H), 4.13 (2 H), 3.16 (4 H), 1.21 (3 H); "C NMR {75 MHz, CDC13) 8 174.6, 170.7, 170.6, 162.6, 149.2, 144.5, 136.9, 136.0, 132.3, 131.7, 130.7, 129.8, 128.0, 122.5, 120.3, 65.0, 63.0, 62.7, 53.3, 37.3, 20.9, 14.5; MS {ESI+) for Cz9Hz8C12N4O6S m/z 630.8 (M:+H)'; Anal. Calcd for CZ9HZ8C12N4O6S: C, 55.15; H, 4.47; N, 8.87. Found: C, 54.85; H, 4.58; N, 8.74.
Anal. Calcd for CZ9HZ8C12N4O6S: C, 55.15; H, 4.47; N, 8.87; Ci, 11.23; S, 5.08.
Found: C, 54.85; H, 4.58; N, 8.74.
Preparation 73 and Example 155.
[S-(R*,R*)]-3-[[[1-Carboxy-2-[4--[(2,6-dichlorophenyl}methoxy]phenyl]ethyl]amino]-carbonyl]-8-methyl-I-thia-4,8-diazaspiro[4.5]decane~-carboxylic acid 4-ethyl ester (Scheme B, B-7: where RB_, and RB_z are the same and equal to H, RB_3 and R~,~
together form a cyclic ring of 6 atoms of the formula -CH,CH,N(CH3)CH,CH,-, Y is CO~, R3 is ethyl, RS is 4-[{2,6-dichlorophenyl)methoxy]phenyl and stereochemistry is (S, S)).

S H O
sC N N~tJ~OH
~O~O O ( ~ CI
i O~ I w C
t-Butyl ester B-6 (Scheme B where RB_, and RB_Z are the same and equal to H, Ra_3 and RH_ together form a cyclic ring of 6 atoms of the formula -CH,CHZN(CH3)CHZCH2-, Y
is CO2, R3 is ethyl, Ra_5 is O-t-butyl, R5 is 4-[(2,6-dichlorophenyl)rnethoxyjphenyl and stereochemistry is (S, S), prepared according to Scheme I3 from 1-methyl-4-piperidone and D-cysteine) (681 mg, 1.02 mmol) was dissolved in a solultion of HCI in dioxane (4 M, 28 mL) at ambient temperature. After 18 h, volatiles were removed in vacuo to afford a residue (650 mg) which was lyophilized from water. Further purification of a portion of this product (200 mg) was effected by chromatography on a Biotage Flash 40~'~"'' system using a 40 g KP-C 18-HS (35-70 p,m) silica gel cartridge using aqueous acetonitrile (40%) as eluant to afford the title compound (94 mg) as an amorphous powder: IR
(mull) 1696, 1611, 1585, 1565, 1511, 1439, 1404, 1335, 1303, 1271, 1239, 1196, I 178, 1017, 769 cm '; 'H NMR (DMSO-d6, 300 MHz) S 8.25 (I H), 7.54 (2 H}, 7.43 (1 H), 7.13 (2 H), 6.94 (2 H), 5.16 (2 H), 4.84 ( 1 H), 4.41 ( 1 H), 4.00 (2 H), 3.07 (4 H), 2.73 (4 H), 2.53 (3 H), 1.96 (1 H), 1.69 (1 H), 1.11(3 H);'3C NMR (CDCI3, 75 MHz;I 8 173.9, 169.2, 157.7, 153.2, 136.9, 132.1, 130.7, 130.5. 129.3, 128.5, I 14:7, 73.2, 66.'7, 65.2, 62.8, 54.0, 43.5, 36.5, I4.6; MS (ESI+) for C~gH33C1,N3O6S m/Z 610.0 (M+H)'; :MS (ESI-) for CzgH33C~I2N3O6S
n~lz 607.9 (M-H)'; HRMS (FAB) calcd for CZ8H,3C1,N3OE,S+H~ 610.1545, found 610.1561.
Anal. Calcd for CZ8H33ChN3O6S ~ 0.6 HC1 ~ H20: C, 51.70; H, 5.52; N, 6.46; Cl, 14.17.
Found: C, 51.28; H, 5.49; N, 6.50; Cl, 14.57. % Water (I1F): 2.72.
Example 156.
[S~R*,R*)J-4-[[[1-[[4-[(2,6-Dichlorophenyl)methoxy]phenylJmethylJ-2-methoxy-2-oxoethylJamino]carbonylJ-3-thiazolidinecarboxylic aced 3-(3-tetrahydrofuranyl) ester (Scheme A, A-7: where RA_, and RA_Z are the same and equal to proton, R3 is 3-tetrahydrofuranyl; Y is CO,-, R~ is 4-[(2,6-dichlorobenzoyi)amino]phenyl and stereochemistry is (S, S)).

WO 99!67230 PCT/US99I14233 S-- H O
O O O I ~ CI
.~ O~' ~ w C
Example 156 was prepared as described in Scheme A from D-cysteine using 3-hydroxytetrahydrofuran to form the requisite carbamate. Physical properties as follows:
mp 125-126:5°C. IR (mull) 3311, 1750, 1744, 1708, 1661, 1549, 1515, 1439, 1408, 1307, 1243, 1227, 1212, 1 173, 1019 cm''; 'H NMR (300 MHz;, CD30D) & 7.38 (3 H), 7.14 (2 H);
7.96 (2 H), 5.20 (i H), 5.25 (2 H}, 4.61 (4 H), 3.79 (4 H); 3.74 (3 H), 3.19 (2 H}, 2:84 (2 H), 2.29 {2 H); '3C NMR ( 75 MHz, CDCIj, spectra cornpIicated via the presence of diastereomers) 8171.?, I7I.6, 158.1, 137.0, 132.1, 130.'.>, 130.4, 130.3, 128.5, 128.2, 115.1, 77.2, 77.2, 73.2, 67.0, 65.2, 63.1, 63.0, 53.3, 52.5, 52.4, 36.9, 32.9;
MS (ESI+) for C,6H;gChN,O,S mlz 582.8 (M+H)*; Anal. CaIcd for C,6HZ8C12NZO,S: C, 53.52; H, 4.84; N, 4.80. Found: C, 53.34; H, 4.87; N, 4.86.
Example 157.
[S-(R*,R*)]-2-[[[1-Carboxy-2-[4-[(2,6-dichlorobenzoyl)amino]phenyl]ethyl]amino]carbonyl]~-hexahydro- y-oxo-1 H-azepine-1-butanoic acid N NH~OH
HO O
O r ~ O CI
O
~ ~NH
Cl ~
Example 157 was prepared as described for the preparation of Example 167.
Physical properties as follows: IR {mull) 1781, 1709, 1651, 1625, 1612, 1550, 1537, I5I5, 1444, 1431, I4I8, 1398, 1331, 1193, 798 crri '; 'H NMR (300 MHz, DMSO-d6) 8 1.45 (8 H), 2.30 (4 H), 2.90 {3 H), 3.80 { 1 H), 4.50 (2 H), 7. I 6 (2 H), 7.50 (5 H), 7.94 ( I H), 10.62 WO 99167230 PCT/US99/i4233 (1 H), 7.71 (1 H); MS (FAB) mla {rel. intensity) 578 (M+H. 43), 581 {9), 580 {29), 579 (19), 578 (43), 577 {10), 227 {11), 226 (99), 198 (18), 173 (9), 98 {46).
Preparation 74 and Example 158.
(Scheme N, N-6: where n is 2, m is 0, X is N, RS is 4-[(2,6-dichlorobenzoyl)arnino]phenyl and stereochemistry is 2~~-(R*,R*)) (2S-(R*,R*)j-2-(([1-[(4-[(2,6-Dichlorobenzoyl)amino]phenyijmethylj-2-methoxy-2-oxoethyljamino[carbonyljazetidine (CZ,HZ,CiZN304).
A solution of the product of example 142 (Scheme N: N'-4 where n is 2, m is 0, X is N, Y
is -COZ-, R3 is (l,l-dimethyl)ethyl, RS is 4-[(2,6-dichlorobenzoyl)amino]phenyl and stereochemistry is (,S~) (512 mg; 0.93 mmol) in 1:1 TFA.ICH,Ch ( 10 mL) is stirred at rt for 1 h. The reaction mixture is concentrated under reduced pressure. The residue is taken up in a mixture of CH~CI, and satd aqueous NaHCO,. The aqueous phase I extracted twice additionally with CHZCI,. The combined CHZCI, portions are dried, filtered and concentrated to give a yellow oil (440 mg); that is purifce;d by silica flash chromatography (95:5 CHZC12lMeOH) to afford the title compound (324 mg) as a white foam: mp 1150C; TLC (95:5 CHZCI,/MeOH) Rf= 0.10; [a]'-Sp -34 (c 0.96, MeOH); UV (MeOH) 7v",~ 224 (sh, s 12100), 251 ( 17700), 284 (sh, 2880); IR (mineral oil mull) 3260, 1744, .
1664, 1606. 1561, 1537, 15 i 5, 1431, 1414, 1323, 1270, 1223, 1195, 799, 782 cm '; 'H
NMR (CD30D) b 7.61 (2H), 7.50-7.38 (3H), 7.25 {2H), 4.86 (1H), 4.75 (1H), 4.2I
(1H), 3.73 (3H), 3.61 (2H), 3.39-3.28 (1H), 3.23 (1H), 3.05 (lI-I), 2.63-2.50 (1H), 2.21-2.08 (1H); MS (+ESI) mlz 450.0; MS (EI) mlz 451, 449, 396, 394, 351, 349, 278, 211, 175, 173; 96, 70, 56; Anal. C 55.68, H 4.79, N 8.96, CI 15.43 (calcd for +1.08%
HzO: C 55.41, H 4.77, N 9.23, Cl 15.58).
Example 159:
O-[{2,6-Dichlorophenyl)methyl]-N-[[(4S~:3-(methylsulfonyl)-4-thiazolidinyl]carbonyl]-L-tyrosinamide {Scheme C, C-10: where R~_,_ R~_z, R.c_3 and R~~ are the same and equal to proton, R3 is methyl , Y is SO,-, RS is 4-[(2,6-dichlorophenyl)methoxy]phenyl and stereochemistry is ).

WO 99/6'I230 PCTIUS99/14233 S-. H O~~
CN~N~NH2 O=S=O O
I G
O
G I r Example 159 was prepared as described in Scheme C using methanesulfonyl chloride to form the requisite sulfonamide. Physical properties as follows: mp 228-230°C; 'H NMR
(300 MHz, DMSO-db) 8 8.03 (1 H), 7.54 (2 H), 7.44 {2 H), 7.14 (3 H), 6.92 (2 H), 5.16 (2 H), 4.69 (2 H), 4.41 ( 1 H), 4.31 ( 1 H), 3.2 I ( 1 H}, 3.01 (3 H), 2.87 (3 H); ' 3C NMR (75 MHz, DMSO-d6) 8172.9, 169.1, 157.5, 136.5, 132.3, 132.0, 130.8, 130.6. 129.2, 114.6, 65.3, 64.4, 54.3, 52.0, 37.3, 35.0; MS (ESI-} fox CZ,Hz3C12N3O5S2 m/z 530.2 (M-H)'; Anal.
Calcd for C,,H23C1ZN305S2: C, 47.37; H, 4.35; N, 7.89. Found: C, 47.43; H, 4.46; N, 7.81.
Example 160.
[S-{R*,R*)]-3-[[[I-[[4-[(2,6-Dichlorophenyl)metho~:y]phenyl]methyl]-2-methoxy oxoethyl]amino]carbonyl] -I-this-4-azaspiro[4.4]nonane-~4-carboxylic acid 4-ethyl ester (Scheme B, B-6: where RB_, and RB_z are the same and equal to H, RB_3 and RB.~
together form a carbocyclic ring of 5 atoms, RH_5 is OCH3, Y is CO2, R3 is ethyl, RS is 4-[(2,6-dichlorophenyl)methoxy]phenyl and stereochemistry is (S, S)).
S-- H O
~N~N~O~
~O~O O I ~ CI
O~
Ir CI
Example 160 was prepared as described in Scheme B. Physical properties as follows: IR
(mull) 1746, 1705, 1681, 1510, 1439, 1399, I336, 1301" 1276, 1241, 1203, 1178, 1110, 1017, 769 cm ';'H NMR (CDCl3) 8 7.36 (2 H), 7.25 (I JEI), 7.03 (2 H), 6.93 (2 H), 6.64 ( 1 H), 5.22 (2 H), 4.85 (2 H}, 4.15 (2 H), 3.73 (3 H), 3.15 (4 H), 2.69 ( 1 H), 2.48 { 1 H), 1.76 (6 H), 1.23 (3 H); '3C NMR (CDC13) b 171.5, 170. 7, 158.0, 152.5, 137.0, 132.0, 130.5, 130.3, 128.5, 128.2, 1 I5.0, 66.4, 65.2, 6I.9, 53.1, 52.4, 37.1,32.3, 25.1. 24.6, 14.5;
MS (ESI+) for CZ8H3zC1,N,ObS mlz 594.9 (M+H)+. MS (ESI-) for C,8H3,Cl,N,O6S
mlz 592.8 (M-H)'; Anal. Calcd for CZ8H32Cl~N,O6S ~ 0.10 H'O: C, 56:30: H, 5.43; N;
4.69.
Found: C, 56.20; H, 5.24; N, 4.69. % Water {KF): 0.31.
Example 161.
[S-(R*,R*)]-3-[[[ 1--Carboxy-2-[4-[(2,6-dichlorophenyl)methoxy]phenyl]ethyl]amino]carbonyl]--I thia-4-azaspiro[4.4]nonane-4--carboxylic acid 4-ethyl ester (Scheme B, B-7: where R$_, and RB_2 are the same and equal to H, RB_3 and RB.~
together form a carbocyclic ring of 5 atoms, Y is COZ, R3 is ethyl, RS is 4-[{2,6-dichiorophenyl)-methoxy]phenyl and stereochemistry is (S, S)).
S- H~ O
~N~~~OH
~O~O O I ~ CI
~ o Cl Example 161 was prepared ftom example 160 by the procedure described in preparation 6.
Physical properties as follows: IR (mull) 1737, 1708, 1675, 1612, 1511; 1439, 1402, 1338, 130I, 1241, 1197, 1179, 1115, 1018, 769 cm'';'H NMR (DMSO-db) 8 8.07 (1 H), 7.54 (2 H), 7.45 ( 1 H), 7.12 (2 H), 6.94 (2 H), 5.15 (2 H), 4.63 ( 1 H), 4.3 3 ( 1 H), 3.91 (2 H), 3.05 (2 H), 2.79 {I H), 2.60 (1 H), I,60 (6 H), 1.07 (3 H); "C NMR
(DMSO-d~) b 172.7, I69.4, 157.1, 155.7, I35.9, 131.6,, 131:4, 130.3, l:?9.6, 128.7, 114.1, 83.9, 64.7, 60.5, 53.1, 38.0, 36.2, 31.8, 24.2, 24.1, I4.1; MS (ESI+) for C27H3oC12N206S
m/z 580.8 (M+H)+; MS (ESI-) for Cz,H3oCI,N206S mlz 578.8 (M-H)'; HRMS (EI) calcd for Cz7H3flC1zN,O6S 580.1202, found 580.1172; Anal. Calcd for CZ,H3oC12NzO6S ~ 0, i 9 HzO:
C, 55.44; H, 5.24; N, 4.79. Found: C, 55.24; H, 5.32; N, 4.79. % Water (KF):
0.59.
Preparation 75.

HZN~a.cH3 . Hc' ~ o ci N W
H
CI
The aminoester product of preparation 75 i useful as a synthetic intermediate (for example, reagent A-4 of Scheme A).

To a cold (0-5°C) solution of anhydrous methanolic HCl was added i 00 g of L-4-nitrophenylalanine (Advanced ChemTech) portionwise over 15 min. The mechanically stirred mixture was heated to gentle reflex for 48 h. The mixture was allowed to cool and then filtered through a sintered glass filter funnel, washing the collected solids with hot MeOH until only insoluble residues remained. The filtrate was concentrated in vacuo to afford the methyl ester ( 120 g) as waxy off white solid which was used without further purification.
To a suspension of methyl ester described above (87 g, 0:33 mole) in CH2CI, (1500 mL) at ambient temperature was added di-t-butyldicarbonate ( 109 g, 0.50 mole) followed by the dropwise addition of Et3N (51 mL, 0.37 mole). After 15 min additional Et3N (40 mL, 0.29 mol) was added to maintain a slightly basic mixture (ca.. pH 8). The reaction mixture was stirred 18 h and additional CH~Ch (1400 mL) and Et3N {15 mL, 0.11 mol) were added.
After an additional 2 h the reaction mixture was quenched by the slaw addition of MeOH
{100 mL), stirred for I h and then partitioned between CHZCI, and cold 10%
aqueous KHS04. The organic layer was washed with saturated NaHC03 and brine, dried (Na2S04), filtered and concentrated in vacuo. Flash chromatography of the residue using hexane and a gradient of a 1:1 mixture of EtOA~/CHZCIz (25-33%) afforded the Boc-methyl ester (69 g) as a white solid. Physical properties as follows: ~H NMR (300 MHz; CDCl3) S
8.16 (2H), 7.31 (2H), 5.04 ( 1 H), 4.63 ( 1 H), 3.73 (3H), 3.18 (:ZH), 1.41 (9H);
MS (ES+) for 2O C,SHZ°N2O6 m/z 325.2 (M+H)'.
Palladium on carbon ( 10% w/w, 1.25 g) was added to a Parr hydrogenation flask under a N, atmosphere and carefully wetted with 100 mL of MeOH/THF ( 1:1 ). A solution of the Boc-methyl ester described above (25 g, 77 mmol) in 400 mL of MeOH/THF ( 1: i ) was added and the mixture shaken on a hydrogenation apparatus under a hydrogen atmosphere {20 psi) for 1 h at ambient temperature. The reaction mixture was filtered through a pad of Celite and the solids washed several times with MeOH. The combined filtrates were concentrated in vacuo to afford the 4-aminophenylalanyl derivative (22.7 g) which was used without further purification. Physical properties as. follows: 'H NMR
{300 MHz, CDC1,) 8 6.89 (2H), 6.61 (2H). 4.96 {1H), 4.50 {IH), 3.59 {3H). 2.95 (2H), 1.4I (9H); MS
(ES+) far C,SH"N,O, m/~ ?95.2 (M+H)'.

A cold (0-5°C) solution of 2,6-dichlorobenzoyl chloride (l I.1 mL, 77.5 mural) in 125 mL
of ~THF was treated dropwise with a solution of the 4-alminophenylalanyl derivative described above (22.7 g, 77.1 mmol) and Et,N ( 16 mL, 1:15 mmol) in 125 mL of THF.
The reaction mixture was allowed to warm to temperature and stir an additional 18 h. The mixture was diluted with EtOAc (2 L) and then washed with 1 N HCI, H~O, 1 N
NaOH and brine. The organic extract was dried (Na,S04), filtered, and concentrated in vacuo to give the crude product as a pale yellow solid. This material r~ras recrystallized from acetone/hexanes (ca. I : I ) to afford the amide (30.8 g} as a crystalline solid. Physical properties as follows: mp 192.2-193.1°C; IR (mull) 3305, 1747, 1736, 1690, 1665,1609, I548, I S I2, 1433, 1414, 1325, 1277, 1219, 1 I 7I. 781 cni'; 'H NMR (300 MHz;
CDCI3) 8 7.57 {2H), 7.34 (4H), 7. I4 (2H), 4.98 ( 1 H), 4.60 ( 1 H), 3.74 (3H), 3.1 i (2H), 1.42 (9H);
MS (ES+) for C,zH24C12Nz05 mlz 467:0 {M+H)+:
To 650 mL of anhydrous 4M HCI in dioxane at ambient temperature was added the amide described above (30.6 g, 65.5 mmol) portionwise and the; resulting mixture was stirred until all the solids had dissolved (ca. 1 h). Volatiles were removed in vacuo to give a light yellow solid which was partitioned between water (500 mL) and ether ( I L).
The water layer was separated and concentrated in vacuo to approximately 200 mL. The.
aqueous solution was then frozen and lyophilized to afford the aminoester product (25.6 g) as a light yellow solid. Physical properries as follows: [a]25,~ _ +5 (c 1, MeOH);
IR (mull) 3244, 3186, 3112, 1747, 1660, 1604, 1562, 1539, 1516, u431, I4I6, 1327, 1273;
1243, 799 crri';'H NMR (300 MHz; CD30D) 8 7.69 (2H), 7.45 (3H), 7.29 (2H), 4.34 (IH), 3.83 (3H), 3.2I (2H); '3C NMR (300 MHz; CD30D) 8 169.0, 163.9, 137.8, 136.08, 131.8, 131.0, 130.3, 129.7, 127.9, 120.6, 53.8, 52.3, 35.4; MS (13S+} for C"H,6Cl,N,O, m/z 367.1 (M+H)'.
Preparation 76.

li2N~a.CHg ~ HC!
CI
a w i CI

WO 99J6'1230 PCT/US99114233 The aminoester product of preparation 75 is useful as a synthetic intermediate (for example, reagent A-4 of Scheme A).
To a cold {0-5°C) solution of anhydrous methanolic HCI (200 mL) was added 25 g of N
a-t-Boc-O-2,6-dichlorobenzyl-L-tyrosine (Sigma) portionwise over 15 min. After minutes at 0-5°C, the mixture was heated to 50°C for 2 h. The solution was cooled to room temperature and the volatiles removed in vacuo. T'he solid was suspended in ethyl ether and collected by filtration to afford the title compound (21.4 g) which was used without further purification. Physical properties as follows: [a]ZSp _ +I6 (c 1.00, ethanol};'H NMR (300 MHz, CD30D) b 7.44 (2 H}, 7.35 (1 H), 7.21 (2 H), 7.02 (2 H), 5.28 (2 H), 4.29 {1 H), 3.81 (3 H), 3.18 (2 H); MS (ESI-+~) for C"H"C1,N03 mlz 354.1 {M+H}+; Anal. Calcd for C"H"C12N03~ HCI: C, 52.26; l~, 4.64; N, 3.59. Found:
C, 52.17; H, 4.74; N, 3.6I.
Example 162 2-[[(( 1 S)-1-[[4-[(2,6-Dichlorobenzoyl)amino]phenyl]methyl] -2-methoxy-2-oxoethyl]amino]carbonyl-1-piperidinecarboxylic acid l-((1,1-dimethyl)ethyl]
ester O
OH N
O
O. ~ w O d > Vibe O ' ~ ~ 0 d N
d li ~ w Ex.162 HG
Example 162: HC1 gas was bubbled through a solution of N (tert-butoxycarbonyl)-4-(2,6-dichlorobenzoylamino}-L-phenylalanine (2.51 g, 5.53 mrnol) in MeOH (20 mL) for minutes. The solution was stirred for additional 2 hours at room temperature.
The solvent was removed in vacuo and the excess HGl was removed by the addition of Et20 (3 x 15 mL) and evaporation under reduced pressure. The resultant gum was dissolved in THF
( 10 mL) and N-ten-butoxycarbonyl-pipecolinic acid ( 1.28 gm, 5.59 mmol), BOP-reagent (2.69 grri, 6.09 mmol) and DIEA (2.9 mL, 16.6 mmol) were added and the reaction mixture was stirred overnight. EtOAc (25 mL) was added and the mixture was extracted with 1N HCl (20 rnL). The organic phase was washed vvith saturated LiCI (20 mL) then saturated NaHCO3 (30 mL). The organic layer was dried over Na2S04, filtered and evaporated. Chromatography of the residue (silica gel, Hexanes -> 50%
EtOAcIHexanes gradient elution) provided Example 162 as a solid (1.45 gm, 45 %): ESMS (m/z) 578, 580 (MH+).
Example 163 2..[[[(1 S)-1-[[4-[(2,6-Dichlorobenzoyl)amino]phenyljmethyl]-2-methoxy-2-oxoethyl]aminoJcarbonyl]-y-oxo-1-piperidinebutanoic acid F~Ya ~ O N~NH~,O/
pi Example ~~ I ~~~~p ~~ O CI
162 D C1 ---r CfI))' I ~ NH
Example 163 CI
Q
HCI gas was bubbled through a MeOH (20 mL) solution of Example 162 (1.27 gm, 2.20 mmol) for IO min. Stirring was continued overnight at room temperature.
The solvent was removed irr vacuo and the excess HCl was removed by washing with Et20 (3 x 10 mL) on a vacuum filter. The HCl salt was completely dried under highvacuum to provide Compound 1 (1.09 gm, 97 %) as a solid: ESMS (m/z) 478; 480 {MH+).
Example 163: Compound 1 (147 mg, 0.285 mmol) was dissolved in DMF~(5 mL) containing DIEA {I50 pL, 0.88 mmol). To this solution was added succinic anhydride (59 rng, 0.59 mmol) and the mixture was stirred at 50°C for :S hr under dry nitrogen. The solvent was evaporated and the residue was purified by column chromatography {silica gel, Hexanes -> EtOAc gradient elution) to provide Exannple 163 as a solid ( 164 rng):
ESMS (m/z) 578, 580 (MH+) Examples 164-166 The following mono methyl esters were prepared in a similar manner as Example NH~O~
O

~NH~ /
CI
ex# R3 MS

Hooc (MH'~

165 ~ 620 Hooc (MH+) 166 Hp0~ 574 ([M=H]-) Example 167 2-[[[(1S)-1-Carboxy-2-[4-[(2,6-dichlorobenzoy!)amino]phenyl]ethyl]amino]carbonyl]-y-axo-1-piperidinebutanoic acid N NHv 'OH
O
HO~~~~ / ( p C!
O ~~,;H /
CI
Example 167 Example 163 ( 154 mg, 0.266 mmol) was treated with LiOH {26 mg, 1.07 mmol) in H20 (5 mL) for 3 hours. The product was then precipitated by the addition of 3 N HCI.

WO 99/6723b PCT/US99/14233 -19$-The product was collected by vacuum filtration and washed with cold H20 (2 x 3 mL).
Drying under high vacuum provided Example 167 as a solid ( 109 mg): ESMS (m/z) ([M-HI )~
Example 168-170 The following compounds were prepared in a similar manner as 167.

N NN~nu O

ex# Rs MS

( ) HOOC"' ([M-HJ->

HOOC"' ( [M-H)-) 170 Hood 560 ([M-HJ-) Preparation 77 P ~~~OH .1, ~~H~O~Re C ~ / +
Rs-OI HC ' ~ HC ~
llerrifield resin fntertnediate-1 p O = polymer Intermediate-1: Attachment of N-tent-butoxycarbonyl-~[4-(2,6;
dichlorobenzoylamino)]-L-phenylalanine to Merrifield resin was done using Horiki's method (Horiki et al., Chem.
Lett. 1978(2) 165-168). In a 250 mL round bottom flask fitted with a drying tube, Merrifield resin (Biorad, 10.0 g, 13.5 mmollg) and anhydrous potassium fluoride (Aldrich, 1.57g, 27.0 mmol) were added to a solution of N-tert-butoxycarbonyl-[4-(2,6,-dichlorobenzoylamino)]-L-phenylalanine {Bachem California, 6:13 g, 13.5 mmol}
in dry DMF ( 100 mL). The reaction mixture was stirred at 80QC in an oil bath for 24 hr. The cooled resin was then filtered and washed thoroughly with DMF (2 x 250 mL), 50%
aqueous DMF (3 x 250 mL), methanol (3 x 250 mL}, dichioromethane (3 x 250 mL), and fnally methanol {3 x 250 mL). The resin was then dried under reduced pressure to constant weight to give intermediate-1. Incorporation ofN-tent-butoxycarbonyl-[4-(2,6,-dichlorobenzoylamino)]-L-phenylalanine onto the resin was estimated to be 0.045 mmol/g from the increase in resin mass.
Example 171 N [[2-(I,3-Benzodioxol-5-yl)-1-methyl-5-oxo-3-pyrrolidinyljcarbonyl]-4-[(2,6-dichlorobenzoyi)amino]-L-phenylalanine ° ~ \ /
O N ~°~ Rg 1V
O~ N' ~
O CI "..~, v 'OH

~ ~ O CI
Intem~ediate-1 CI ~ Examq~le 171 ~ N /
H
CI
Example 171: The Intermediate-1 (0.15 g, 0.1065 tnmol/g) was pretreated with (2x 3 mL). The swollen resin was then deprotected with 50% TFA/CH2Cl2 (3mL, 30min). The resin was rinsed in the following order: CH2Cl2 (2 x 3 mL), CH30H
{2 x 3 mL), CH~CI~ {2 x 3 mL). The resin was swollen with DMF (2 x 3 mL). 2-(3,4-methylenedioxyphenyl)-1-methyl=5-oxo-3-pyrrolidine carboxylic acid (84 mg, 0.32 mmol}
in DMF (1.0 mL) was activated with 0.5 M HBTU/HOBT in DMF (0.7 mL) and DIEA
(0.139 mL, 0.799 mmol), and then added to the swollen resin. The mixture was vortexed for 2 hr at room temperature. The resin was filtered and washed in the following order:
DMF(2 x 3 mL}, CH2Cl2 {2 x 3 mL), CH30H {2 x 3 mL), CH2Cl2 (2 x 3 mL), respectively. If a Kaiser test on a small quantity of the resin is positive (blue) then repeat the coupling procedure until a negative result is obtained. The resulting resin was then dried in vacuo to constant weight. The resin was placed in the polypropylene column and pretreated with 3 mL of THF. Then to the preswollen resin 1.6 mL of THF, 0.48 mL of I 0 CH30H, and 0.160 mL of 2N LiOH were added. The mixture was vortexed for I5 min and filtered to a clean and preweighed test tube. The resin was next washed with 2mL of THF/S% CH30H (2x) and the combined filtrates were evaporated. The resulting gum was dissolved in I mL of water. The solution was then acidified with I N HCl to pH
2Ø The precipitate was centrifuged, washed with water (SmL, 2x) and dried in vacuv to furnish 15.4 mg of Example 17I as a solid. ESMS (m/z): 596, {[M-H]-).
Preparation 78 O NH~O~RB R
Bac~x~NH~O~ B
t / O CI
--i / O CI
NH ./
NH
Lrtctmadiate-1 ~ ~ Irttertrtedeic-2 CI

~ ~ E O F G
~~ N'~(' ~ ~O
I O I ~ _ N
O
X,I~ I
H ~ J _ K
'i 10 ~~O N~O ~N~~O
I. I
Intermediate-2F: The resin bound N-tert-butoxycarbonyl-[4-(2,b-dichlorobenzoylamino)J-L-phenylaianine (Intermediate-1), (250 mg, 0.1 I25 mmollg) was placed in a 8.0 mL, polypropylene filter column fitted with a 2-way polypropylene stopcock. The resin was pretreated with CH2C12 (2 x 3 mL). The swollen resin was then deprotected with 50% TFA/CH2Cl2 (3-4 mL, 30min) with shaking. The resin was rinsed in the following order: CH2C12 (2 x 3 mL), CH30H (2 x 3 mL), CH2C12 (2 x 3 mL).
The resin was swollen with DMF {2 x 3 mL). N-Tert-butoxycarbonyl-nipecotic acid (103 mg, 0.45 mmol) in DMF ( I .0 mL) was activated with 0:5 M HBTU/HOBT in DMF
(0.9I 0 mL) and DIEA (0.195 mL), then added to the swollen resin. The mixture was vortexed for 2 hr at room temperature. The resin was washed in the fallowing order: DMF (2 x 3 mL), CH2Cl2 (2 x 3 mL), CH30H (2 x 3 mL), CH2Cl2 (2 x 3 mL) and dried (Intermediate-ZF). If a Kaiser test on a small quantity of the resin is positive (blue) then repeat the coupling procedure until a negative result is obtained.
The intermediate resins Intermediate-2D, 2E, 2G, 2H; 2I, 23 & 2K were each produced following this procedure.
Example I72 S-[[(2S)-2-[ [[( 1 S )- I -Carboxy-2-[4-[(2,6-dichlorobenzoyl)amino]phenyl]ethyl)amino]carbonyl]-1-piperidinyl]carbonyl]-3-pyridinecarboxylic acid ~N~~s N O
.b O U' ~ ~ _'~O H
O O ~ O C I -~,- O
I~ N i' N~ O I~ O CI
i ~ N
COON I~ I i Intermediate-2D
Example 172 Example i 72: Resin bound Intermediate-2D (2.0 g, 1.~ mrnollg) was pretreated with CH2C12 (2 x 20 mL). The swollen resin was then deprotected with 50% TFA/CH2Cl2 (20 mL, 30min). The resin was rinsed in the following order: CH2C12 (2 x 20 mL), (2 x 20 mL), CH2Cl2 (2 x 20 mL). The resin was swollen with DMF (2 x 20 mL).
3;5-Pyridine dicarboxylic acid (652 mg, 3.9 mmol) in 20 mL of DMF was activated with 0.5 M HBTUIHOBT in DMF (8.0 mL) and DIEA ( 1.7 mL, 9.75 mmol), then added to the swollen resin. The mixture was vortexed for 2 hr at room temperature. The resin was fltered and washed in the following order: DMF(2 x 20 mL), CH2C12 (2 x 20 mL), CH30H (2 x 20 mL), CH~CI2 (2 x 20 mL), respectively.. If a Kaiser test (Kaiser et al., Anal. Biochem. 1970, 3-~, 594-598) on a small quantity of the resin is positive (blue) then repeat the coupling procedure until a negative result is obtained. The resulting resin was then dried in vacuo to constant weight (2.2 g). The resin was treated with 25 mL of liquid HF by stirring for 60 min at 0°C in an HF-reaction apparatus (Peninsula Laboratories Inc., I S Belmont, CA). The HF was rapidly evaporated off by vacuum aspiration at 0°C. Then 100 mL of dry ethyl ether was added. The resin and the resulting precipitates were filtered off and washed three times with 50 mL of ethyl ether, and dried in vacuo. The mixture was then treated with 25 mL of 1N NaOH (4x), and the combined solutions were Lyophilized. The crude product was purified by HPLC using a C-18 column and a linear acetonitrile/0. l % HCI gradient. The gradient was run from 60% solvent A (D.1 % HC1) to 80% solvent B (80% acetonitrile in 0.1 % HCi) in 20 mina Lyophilization furnished 20 mg (2.5%) of Example 172. ESMS (m/z): 612 ([M-H]').
Examples I73-267 Boc~ X~NH~O~ Rg Q~ X~ NH~ OH
\ ~ O C~ ~,. ~ ~ O Cl NH ~ ~~
Cl~ CI \
Method-A (Example 173) 4-[{2,6-Dichiorobenzoyl}amino]-N [[1-(3-methoxy-1-oxopropyl)-3-piperidinyl]carbonyl]-1.-phenylalanine iO~ N ~N'~OH
O o O CI
i Hi I ~
CI
Example 173 The Intermediate-2F (0.25 g, 0.1125 mmol/g) was pretreated with CH2C12 (2 x 3 mL}.
The swollen resin was then deprotected with 50% TFA/CH2Cl2 (3mL. 30min). The resin was rinsed in the following order: CH2C12 (2 x 3 mL), CH30H (2 x 3 mL), CH2Cl2 (2 x 3 mL). The resin was swollen with DMF (2 x 3 mL). 3-methoxypropionic acid (53 mg, 0.45 mmol) in DMF ( 1.0 mL) was activated with 0.5 M HBTU/HOBT in DMF (0.910 mL) and DIEA (0. i 95 mL), then added to the swollen resin . The mixture was vortexed for 2 hr at room temperature. The resin was filtered and washed in the following order: DMF

WO 991b7230 PCT/US99/14233 (2 x 3 mL), CH2C12 {2 x 3 mL), CH30H (2 x 3 mL), CH2C12 (2 x 3 mL), respectively. If a Kaiser test on a small quantity of the resin is positive (blue) then repeat the coupling procedure until a negative result is obtained. The resulting resin was then dried in vacuo to constant weight. The resin was placed in the polypropylene column and pretreated with THF (3 mL). Then THF (3.5 mL), CH30H ( 1.0 mL) and 2N LiOH (0.175 mL) were added. The mixture was vortexed for 15 min and filtered to a clean and preweighed test tube. The resin was next washed with THF/5% CH30H (2mL) and the combined filtrates were evaporated. The resulting gum was dissolved in H?O (1 mL). The solution was then acidified with 1N HCl to pH 2Ø The precipitate was centrifuged, washed with water (2 x 5 mL} and dried in vacuo to furnish 38.3 mg of Example; 173 as a solid: ESMS
(m/z} 548 ([M-H]-).
Method B (Example 174):
3-[[[( 1 S}-1-Carboxy-2-[4-[(2,6-dichlorobenzoyl)amino]phenyl]ethyl]amino]carbonyl]-y-oxo-1-piperidinebutanoic acid O H O
HO~'N~N'~OH
O O ~ ~ O CI
H 1~
CI
Example 174 The Intermediate-2F (0.25g, 0.1125 mmollg) was pretreated with CH2C12 (2 x 3 mL). The swollen resin was then deprotected with 50% 'rFA/CH2CI2 (3mL. 30min}.
The resin was rinsed in the following order: CH2C12 (2 x 3 mL), CH30H (2 x 3 mL), CH2Cl2 (2 x 3 mL). The resin was then swollen with DMF (3mL). Succinic anhydride (45 mg, 0.45 mmol} dissolved in DMF (4 mL) was added to the swollen resin and stirred at 50°C
for 2hr. The resin was filtered arid washed in the following order: DMF (2 x 3 mL), CH2Cl2 (2 x 3 mL), CH30H (2 x 3 mL), CH2Ch (2 x 3 mL), respectively. if a Kaiser test on a small quantity of the resin is positive (blue} then repeat the coupling procedure until a negative result is obtained. The resulting resin was then dried in vacuo to constant weight: The resin was placed in the polypropylene cohunn and pretreated with THF (3 mL). Then to the swollen resin THF (3.5 mL), CH30H ( 1.0 mL) and 2N LiOH
(0.175 mL} were added. The mixture was vortexed for 15 min and f ltered to a clean and preweighed test tube. The resin was next washed with 'THFIS% CH30H (2 x 2 mL) and the combined fprates were evaporated. The resulting gum was dissolved in H20 (1 mL).
The solution was then acidified with 1 N HC1 to pH 2.0~. The precipitate was centrifuged, washed with H20 (2 x 5 mL} and dried in vacuo to furnish 30.5 mg of Example 174 as a solid: ESMS (m/z} 562 ([M-H]-).
Method C (Example 175}:
N [[1-[[(4-Carboxyphenyl)amino]carbonyl]-4-piperidinyl]carbonyl]-4-[(2,6-dichlorobenzoyl)amino]-t,-phenylalanine O~ O
H N '~OH
w NON
O Ct HO ( i O ~ 1 ,~ N
O H I~
Cl Example 175 The Intermediate-2G (0.25g, 0.1 I25 mmol/g) was pretreated with CH2Cl2 (2 x 3 mL). The swollen resin was then deprotected with 50% TFAlCH2C12 (3mL, 30min).
The resin was rinsed in the following order: CH2Cl2 (2 x 3 mL), CH30H (2 x 3 mL), (2 x 3 mL). The resin was then swollen with DMF (3mL). Ethyl 4-isocyanatobenzoate (22 mg, 0.108 mmol} dissolved in DMF (3 mL) and DIEA (471zL 0.27 mmol) were added to the swollen resin. This reaction mixture was vortexed for 6-8 hr at room temperature.
The resin was filtered and washed in the following order: DMF (2 x 3 mL), CH2CI2 (2 x 3 mL), CH30H (2 x 3 mL), CH2Cl2 (2 x 3 mL), respectively. if a Kaiser test on a small quantity-of the resin is positive (blue) then repeat the coupling procedure until a negative result is obtained. The resulting resin was then dried in vacuo to constant.
The resin was placed in the polypropylene coiumn and pretreated with THF (3 mL). Then to the swollen resin THF (3.5 mL}, CH30H (1.0 mL) and 2N LiOH (0.175 mL) were added respectively.
The mixture was vortexed for 15 min and filtered to a clean and preweighed test tube.
The resin was next washed with THF/S% CH30H (2mL) and the combined filtrates were evaporated. The resulting gum was dissolved in H20 ( 1 rnL}. The solution was then acidified with 1N HCl to pH 2Ø The precipitate was centrifuged, washed with H20 (2 x 5 mL) and dried irr vacuo to furnish 18 mg of Example 175 as a solid: ESMS
(m/z) 625, (~M-H]-) Examples 176-266 The following compounds were prepared in a similar manner as described above.

H
N
~ X;
~ \ o cl H
CI
ex# Method Q X, MS

(~z) 176 A "-:~ ~ 560 UM-H]-) 177 A '~co~ ~ 548 .a (LM-Hl ) 178 A o 616 C'~' -i-o (fM-Hl ) ( [M-H]-) ~i 1-80 A ~c° \ ° ~ 626 "~~° i N o ([M-H)-) 181 A ° 610 ~ ' cooH ~ ([M-H _ 182 A ° ) ) ' ' ' N o ([M-H)-) cooH
183 A ~ I ° ~'~ 660 ~ o ( [M-H)-) HOOC ' 184 A ° 611 H00 ' ~
" ~ o ([M-H)-) 185 A ' i ° ~ 567 N ~ o ([M-H)-) 186 A ° 611 ~~ ~
~ " ~ o ~[M-H)-) HOOC
187 A ° ~ 611 Hooc ~ " N ° ([M-H)-) 188 A °" ~ 633 ~ ' H ([M-H)-) 189 A HOOC ' NN ~~ 600 N o ([M-H)-) O
190 A "°°c~.,,S 621 HN..( N ° M-H ' o/\j~
19I A °~" 603 ° C~
° ([M-H)-) M-H _ 193 A ~ ~ ([ ) ) o ~ ([M-H)-) 194 B Hood ~~° 562 ' QM-H)-) 195 B ~~° 630 Hooc ° '~ ([M-H)-) 196 B ~ ~°

HOOC ° ~N
( [M-H)-) 19? B \ "~~y ~ S60 ' ([M-Hl-198 A "c.~ ~~ 560 ~ ([M-H]-) 199 A ~,co a S48 ('~.~

N
' ([M-H]-) ' ([M-H]
0 ) 201 A ~ ~~ S60 o % ( [M-H]-) 202 C , HOOC~N~ ~ S63 ' ([M-H]-) 203 A ,~co~ (~-.~ 626 rtco ~ ~ ~ ([M-H]-) ~-~..~ 610 cooH ~ (~M-H]-) 20S A ~ 610 ~

' ([M-H]-) CooH

.

i i ' ' ([M-H]-) HOOC
20? A "~ ~~ 611 N
' ( [M-H]-) 2os c "~ ~ . ~~ 62s " ' ([M-HI-) 209 B "~,~ _ ~~ S62 ' ([M-H]-) _ H~

Hooc ([M-H]-) 211 B _ ~ 604 HpOC' "
([M H]
) 212 B Hoocw _ S60 N

( [M-H]-) 213 A "c.~ -N~ S60 o ~

_ (~M
] ) 214 A ~co~ ' ~o g O ~N

([M-H]
) i;, 215 A _ ~° 616 N
° ([M-HJ-) 216 A ~ _ N~° 560 ([M-HJ-) 217 C "ooc~N~ _h~° 563 o ([M-HJ-) 218 A ° ~ ~~° 626 h6C0~ - h~
~,co /''~~ ~/ ~ ([M-HJ-) 219 A ° _ ~° 610 i. N
' co°H ([M-HJ-) 220 A ° _ ° 610 N
cooH ([M HJ ) 22 I A ° _ N~° 660 ~ ~ 1 "ooc ~ ~ ([M-HJ-) 222 A ° ° 611 HOOC~ - N
L~ ~9T ~ ([M-HJ ) N
223 C "°°c ~ ~ ~ _ ~~° 625 N
" ([M-HJ ) 224 B ° 0 548 "~.~ «..~
([M-HJ-) 225 B ~0 616 HOO~ W
([M-HJ-) 226 B ~0 590 "~~ ~~ -([M-Hl-) 227 B "o~~° .- ~~0 546 a 228 A "°°c~ ° ([M ~J ) 229 A ~,co ([M-HJ-) '~1~ ~~0 534 ([M-HJ-}
230 A ~0 602 ~N
° ( [M-HJ-) 231 A ~ C~o 546 o .~i ([M-HJ-) 232 C HOOCvN~ ~0 549 '°1 ~ ~ ~ ([M-H]") i., WO 99/67230 pCT/US99/14233 233 A ~c ~ (~0 6I 2 ~

' ' ( CM-H]-) ~CO

234 A (~o S96 N
' Coo" i ([M-HJ-) 23S A ' ( o S96 (CM-H]-) coo"
236 A (~0 646 ' ~ ; ~ ' (fM-H]-) HOOC
237 A "oo S97 ' I ([M-H] ) N

238 C "ooc ~ 0 6I1 I ~
JL

/ N N
~

" ~ (CM-HJ-) ~
~

~ N ~ ([M_H]-) 240 A ~'''~''~~ 615 r I '~
~N~O

' N y LM-H]-) Nooc 241 A ~~ 61S
~ N~

"ooC ' " ~ ~ (CM-HJ-) 242 A " ~ 637 I ' ~ N~O

' N ([M-H]-) 243 A HOOC N, ~S~ 604 ([M-HJ-) O
244 A roo ~S ~ 62S

N~ (CM-H] ) ' <
o i~~ (CM-HJ-) 246 A ~ ~~ S64 ~ ([M-H]-) ' 247 A ~ j~ C = S62 "OC

r~ ([M-H]-) 248 A ~ J~ C~ S60 HOOC

" (CM-HJ ) 249 A C~ S48 ~CO''~

(CM-HJ-) i,, 250 A H~ ~~ 611 ~~ "~ (LM-HJ-) 251 A i ~ _ 611 ~

'1~
Hooc N ~ (fM-Hl-) 252 A ~a 567 i N ; ~ O ((M-HJ
) 253 A a 560 ~'1t' M-H _ o (f l ) H~

' (fM-HI'>

255 A ~~ ~ ~~"~ 546 HOOC~

N (f M-HI-) ' 256 A ,~. 534 ~co'~

UM-~~-257 A H~ ~~ 597 ' ) 258 A I ~ ~~"y 597 HOOC N
o N ( fM-HJ-) I N ~~ (fM-Hl-) N'' o ~ (fM-Hl') "

261 A 'i ~-s 564 ~ <

HOOC N -.
(fM-H1 ) 262 A c~ ~ y 552 ~ ~ -(fM-Hl ) 263 A Hooc ~'' 615 (LM-Hl ) 264 A J~ 615 I <

HOOC N ([M-H]
N ) 265 A '~ 571 C

I N~O

N ' (fM-HI

266 A ('~ 564 0 ~
" (fM-HJ-) Example 267 5-[[[( 1 S)-1-Carboxy-2-[4-[(2,6-dichlorobenzoyl)aminoJphenylJethylJamino]carbonyl]
tetrahydro-y-oxo-1,4-thiazepine-4{SIB-butanoic acid O S O
H H
O N~O~Rg ~ N~ FRB
N O
O ~ O
/ O CI ~,~ o 'O / O CI
/ ~ \ H /
Intermediate-1 Cl \ Irnem~ediate-3 Cl S
H O
N N ~~0~ RB
O
HO O ~ / O CI
O \
H
~ 2b7 CI \
The Intermediate-1 (0.3g, 0. i 95mmo1/g) was pretreated with CH2CIz (2x 3 mL).
The swollen resin was then deprotected with 50% TFAICH,Cl2 (3mL, 30 min). The resin was rinsed in the following order: CHZC12 (2x 3 mL), CH~OH (2x 3mL), CH,C12(2x 3mL). The resin was swollen with DMF (2x 3mL). N-Tert-butoxycarbonyl-1,4-thiazoline-5-carboxylic acid (204 mg, 0.78 mmol) in DMF (2.0 mL) was activated with 0:5 M
HBTUIHOBT in DMF (1.6 mL) and DIEA (0.340 mL, 1.95 mmol), then added to the swollen resin. The mixture was vortexed for 2 hr at room temperature. The resin was filtered and washed in the following order: DMF (2x 3 mL), CH,C12 (2x 3mL), (2x 3mL), CHzCI,(2x 3mL), respectively. If a Kaiser test on a small quantity of the resin is positive (blue) then repeat the coupling procedure until a negative result is obtained. The resin (intermediate-3, 0.2 g, 0..13mmollg) was pretreated with CH~C12 (2x 3 mL). The swollen resin was then deprotected with 50% TFA/CH,CI, (3mL. 30 min). The resin was rinsed in the following order: CH~C12 (2x 3mL), CH30H (2x 3mL), CH~CIZ (2x 3mL). The resin was then swollen with DMF (3mL). Succinic anhydride (78 mg, 0.78 mmol) dissolved in DMF (4mL) was added to the swollen resin and stirred at 50°C for 2hr. Then the resin was filtered and washed in the following order: DMF (2x 3mL}, CH,C12 (2x 3mL), CH30H (2x 3mL), CH,CI, (2x 3mL) respectively. If a Kaiser test on a small quantity of the resin is positive (blue) then repeat the coupling procedure until a negative result is obtained. The resulting resin was then dried in vacuo to constant weight. The resin was placed in the polypropylene column and pretreated with THF (3 mL). Then THF (3.9 mL), CH,OH (1.2 mL} and 2N LiOH (0.195 mL) were added to the swollen resin.
The mixture was vortexed for 15 min and filtered to a clean and preweighed test tube. The resin was next washed with THF/S% CH30H (2x 2mL) and the combined filtrates were evaporated. The resulting gum was dissolved in H20 (1 mL). The solution was then acidified with 1N HCl to pH 2Ø The precipitate was centrifuged, washed with HBO (2 x SmL} and dried in vacuo to furnish 80 mg of Example 267 as a solid: ESMS (m/z) 594([M-H]').

-zl4-Scheme O
~~~OH O-1 Wang resin ~ o Fmoc-HN OH

.w o i .~ NOZ
O NH-Fmoc \ O-3 O
O NH-Fmoc \ O-4 HpN I /
O
O NH-Fmoc Ro-f YtN
H
O

1~' O-6 i\
RO_i Y~.H /

Scheme O (continued) O NH
w O-6 Ro-f/Y'.N I /
H Ro-3 Ro~~L
H0, / S,Ro.S
N~R~ O-7 O
O~O~Ro-2 O Roy R S3RO-5 O RO.a R S 80.5 H
-O N~N~Ro'e HO N N~R0.6 Ro-2 Ro-, Yt.N / O-8 4R ~YtN I /
\ O O~O' -.-.. \ O O~O~Ro-2 H o.~ H 0.9 Ro3 O Ros~ SVRo_5 O N~N~R0.6 ~O H
Y
Ro-i ~~H / O-10 Ro-a ~ S Ro-5 O N~N~RO~
\ O Y2-Ra Y I
Ro-i LH / O-11 Ro-3 O Ho~~ S Ro-5 HO N~N~~~
D Y2-Ra Y I
Ro-i ~~H / O-12 Where: Rq_, is defined as R,2; Ro_2 is defined as C,~ alkyl or C,_,7 arylalkyl; Ro_3, Rte, and Ro_5, are defined independently as R,. Ro_6 is defined as Rz. Y, and YZ are defined independently as Y.
Scheme O describes a method for the preparation. of examples of the formula O-and O-12. Commercially available Wang resin (O-1} is acyiated with commercially available N a-Fmoc-Phe(NOZ)-OH {O-2) under standard conditions to afford the resin of formula O-3. Reduction of the aromatic nitro group (Meyer et al., Mol.
Diversity 1995, 1, 13-20} affords the resin bound aniline (O-4) which may be reacted v~~ith a variety of electrophilic reagents to afford resin bound amides (O-5 where Y, is C(=O)), ureas (O-5 where Y, is C{=O)NH), sulfonamides (O-5 where Y, is SOz), and carbamates (O-5 where Y, is C(=O)O). Removal of the Fmoc group under standard conditions provides amine of general structure O-6 which is acylated using standard solid-phase peptide synthesis conditions (Atherton, E.; Sheppard R.C. Solid Phase Peptide Synthesis: A
Practical Approach; IRL Press at Oxford University Press: Oxford, 1989) with a commercially available or readily prepared thiazolidine-4-carboxylic acid of general formula O-7 to afford the resin bound intermediate O-8. Mild cleavage under standard conditions (Atherton, E.; Sheppard R.C. Solid Phase Peptide Synthesis: A Practical Approach; IRL
Press at Oxford University Press: Oxford, 1989) affords the acid of general structure O-9.
In those cases where Ro_2 is a 9-fluorenylmethyl group, standard Fmoc group removal affords the amine of general structure O-10, which may be reacted with a variety of electrophilic reagents as described in Scheme A to afford resin bound amides, ureas, sulfonamides and carbamates of general structure O-11. Mild cleavage under standard conditions affords the acid of general structure O-12.
Preparation 79 and Example 268.
(4S)-4-[[[( 1 S)-1-Carboxy-2-[4-[(benzoyl)amino]phenyl]ethyl]amino]carbonyl]-3 thiazolidinecarboxylic acid 3-ethyl ester <s, o H_ ~
N~N~OH
/.~0~0 O I ~ O
N
H I
To a mixture of Wang resin (I% DVB, Advanced Chemtech, 2.75 g, 2.20 mmol based on manufacture's loading of 0.8 rnmol/g resin) in DMF (12 mL) was added N oc-Fmoc-Phe(NOz)-OH, O-2 {Advanced Chemtech, 1.90 g; 4.40 mrnol) at room temperature.
Aftex mixing for 10 min {by passing a slow stream of nitrogen through the mixture) pyridine (587 ~.L, 7.26 mmol) and 2,6-dichlorobenzoyl chloride (630 ~,L, 4.40 mmol) were added. The mixture was agitated overnight via nitrogen bubbling, filtered, washed with DMF, methylene chloride and methanol and dried in va~:uo. In order to cap any unreacted hydroxymethyl groups, the resin was suspended in dichloroethane (5 mL} and to this mixture was added benzoyl chloride (0.75 mL) and pyridine (0.75 mL). The mixture was agitated for 2 h, filtered, washed with DMF, methyIene chloride, methanol, methylene chloride and methanol, and dried in vacuo to afford the resin O-3 (3.30 g). IR
(diamond anvil) 1733, 1606 (resin), 1520 (resin), 1494 (resin), 1452 (resin), 1347, 1247, 1174, 1029 cm'.
To the prewashed (2 X 20 mL DMF) resin O-3 (1.0 g, ca. 0.6 mmol based on an adjusted loading of 0.6 mmol/g) was added SnCl2~ 2 Hz0 (6 mL of a 2M solution in DMF, I2 mmol). The viscous-suspension was agitated for 4 hours by nitrogen bubbling, filtered and washed with DMF (2 X 20 mL). The resin was resospended with SnCIZ~ 2 HZO
(6 mL of a 2M solution in DMF, 12 mmol), agitated overnight via nitrogen bubbling, filtered, washed extensively with DMF, water, 2-propanol, methylene chloride and methanol and dried in vacuo to afford the resin O-4. Examination of tlhe FTIR spectra of a small sample of resin O-4 failed to exhibit an absorption at 1347 crri'.
To a mixture of prewashed (2 X 20 mL CHZC12) resin O-4 (0.30 g, ca. 0.18 mmol based on an adjusted loading of 0.6 mmol/g) in 1,2-dichlioroethane (3 mL) was added benzoyl chloride (174 pL, 1.50 mmol) and DIEA (313 p,L, 1.80 mmol). The mixture was agitated overnight via nitrogen bubbling, filtered, washed with methylene chloride, DMF, methanol, and methylene chloride and dried in vacuo to afford resin O-5. To a mixture of resin O-S in methylene chloride (S mL} was added a solution of piperidine in DMF (30%, mL). A slow stream of nitrogen was bubbled through the mixture to effect mixing for 20 min. The resin was filtered, washed with DMF and resuspended in a solution of piperidine in DMF (30%, 10 ml). After gentle mixing for 40 min, the resin was filtered and washed 5 with DMF, rnethylene chloride, methanol and methylene chloride and diluted with DMF
(40 mL). To this mixture was added N ethoxycarbonyl-r>-thiazolidine-4-carboxylic acid (O-7, 0.15 g, 0.72 mmol}, HOBt (0.11 g, 0.72 mmol), PyBOP (0.37 g, 0.72 mmol) and DIEA (313 pL, 1.80 mmol). T'he reaction was mixed for 4 h at which point the qualitative Kaiser test was negative. The resin was filtered and washed with DMF, methylene chloride and MeOH and dried in vacuo to afford resin O-8. After swelling with a minimum of methylene chloride (ca. 0.5 mL), the resin O-8 was suspended with aqueous TFA (5 mL). The mixture was mixed by magnetic stirring for 1 h, filtered and washed with TFA (2 X 3 mL) and methylene chloride. T'he combined filtrates were evaporated in vacuo to afford a residue that was purified by flash chromatography using 1 S methylene chloride/methanol (2%) containing glacial acetic acid (0.1 %) as eluant to afford the title compound (80 mg). Lyophilization from glacial acetic acid afforded an amorphous powder: IR (drift) 331 I, 3298; 1670, 1601, 11579, 1531, 1487, 1412, 1380, 1345, 1324, 1265, 1205, 1190, 709 czri';'H NMR (300 MHz, DMSO-d6) b 10.39 (1 H}, 8.39 (1 H), 8.14 {2 H), 7.86 {2 H), 7.74 (3 H), 7.36 (2 H), 4.83 (2 H), 4.59 (1 H), 4.48 (1 H), 4.22 (2 H), 3.48 (2 H), 3.26 {1 H), 3.06 (2 H), 1.35 (3 H);'3C NMR (75 MHz, DMSO-d6} b 173.4, 169.8; 165.8, 154.0, 138.0, 135.4, 133.3, 131.9, 129.8, 128.8, 128.0, 120.4, 61.8, 54.2, 48.8, 36.7, 14.8; MS (ESI+) for C~H25N306S m/z 472.0 (M+H)+; MS
{ESI-) for C2sHzsNaObS ~Z 470.1 (M-H)-; MS (FAB)' mJz (rei. intensity) 472 (MH+, 99), 472 (99), 371 (31), 160 (31), 8I (31), 71 (45), 69 (46), 57 (71}, 55 (58), 43 (47), 41 (42); HRMS
(FAB) caIcd for C~HZSN30~S +H~ 472.1542, found 472.1563; Anal. Calcd for C23H25N3~6S ~ 1.5 H20: C, 55.41; H, 5:66; N, 8.43. Found: C, 55.47; H, 5.21;
N, 8.00.
Example 269.
(4S}-4-[[[{ 1 S')-1-Carboxy-2-[4-[(acetyl)aminojphenyijethyljaminojcarbonylj-3-thiazolidinecarboxylic acid 3-ethyl ester ~s~ o H~ ~
N~N~OH
~O~O O I ~ O
~hf~CH3 H
The title compound was prepared as described in Scheme O using acetyl chloride to form the requisite amide. Physical data as follows: IR (drift) 331 I , 1709, 1667, 1602, 1536, 1517, 1412, 1378, 1344, 1321, 1266, 1218; 1 I 85, 1116, 769 cni'; 'H NMR
(300 MHz, DMSO-d6) 8 9.79 (1 H), 8.15 (1 H), 7.37 (2 H}, 7.02 (2 H), 4.54 (2 H), 4.31 (1 H), 4.19 ( I H), 3.95 (2 H), 3. I 2 ( 1 H), 2.93 { 1 H); 2. 75 (2 H), 1.82 (3 H), I .09 (3 H); ' 3C NMR
(75 MHz, DMSO-d6} b 173.2, 169.8, 168.5, 154.0, 138.2, 132.4, 129.8, 119.1, 62.1, 61.7, 53.9, 36.7, 24.4, 21.5, 14.$; MS (ESI+) for C,8Hz3N3O6S m/Z 410.0 (M+H)+; MS
(ESI-) for C,8Hz3N3O6S mlZ 408.0 (M-H}-; MS (FAB) mlz (rel. intensity) 410 (MH+, 99), 486 (20), 411 (22), 410 (99), 409 (9), 205 (22), 188 (9), 177 (9}, 160 (35), 148 (9), 88 (14}; HRMS
(FAB) calcd for C,8Hz3N3O6S +H' 410.1385, found 410.I379. Anal. Calcd for C,gH23N306S ~ 0.3 H20: C, 52.1 I; H, 5.73; N, 10.13. Found: C, 51.73; H, 5.73;
N, 9.82.
Example 270.
(4,5~-4-[[[{1S)-1-Carboxy-2-[4-[(3-phenylpropanoyl)amino]phenyl]ethyl]amino]carbonyl]-3-thiazolidinecarboxylic acid 3-ethyl ester ~s~ o H_ ~
H~N~OH
/~O~O O I \ O
~O.N~. , H I/
The title compound was prepared as described in Scheme O using hydrocinnamoyl chloride to form the requisite amide. Physical data as follows: IR (drift) 331 I, 2978, 2930, 1665, 1601, 1534, 1517; 1413, 1379, 1344, 1252, 1216, 1187, 1115, 700 crri';'H
NMR (300 MHz, CDC13/CD30D (10%)) 8, 7.34 (2 H), 7.21 (5 H), 7.02 {2 H), 4.67 (3 H), 4.30 (1 H), 4.09 (2 H), 3.I 1 (4 H), 2.97 (2 H), 2.58 (2 H), 1.19 (3 H);'3C
NMR {75 MHz, CDCl3) S 172.7, 171.3, 170.0, 154.8, 140.7, 137.0, 131.6, 129.7, 128.4, 128.2, 126.2, 119.9, 63.0, 62.6, 53.I, 38.9, 36.7, 31.5, 29.6, 14.2; MS (ESI+) for Cz5Hz9N3O6S m/z 500.2 (M+H)+;~MS (ESI-) for Cz5H2g1V3O6S m/z 498.3 (M-H)'; Anal. Calcd for CZSHz9N30sS~ C, 60.10; H, 5.85; N, 8.41. Found: C, 59.85; H, 6.07; N, 8.09.
Example 271.
(4S)-4-[[[(1,5'~-1-Carboxy-2-[4-[(3-pyridinylcarbonyl)amino]phenyl]
ethyl]amino]carbonyl]-3-thiazolidinecarboxylic acid 3-ethyl ester H_ ~
N~N~OH
~O~O O ! W O
v _N ~N
H
The title compound was prepared as described in Scheme O using nicotinoyl chloride to form the requisite amide. Physical data as follows: IR {drift) 3301, 3061, 2983, 2935, 1709, 1675, 1603, 1535, 1SI7, 1415, 1380, 1345, 1326, 1204, 1140 crri';'H
NMR (300 MHz, DMSO-d6) 8 12.74 (1 H), 10.42 (1 IT), 9.11 (1 H), 8.76 (1 H), 8.29 (2 H), 7.67 (2 H), 7.55 ( 1 H), 7.19 (2 H), 4.62 (2 H), 4.44 ( 1 H), 4.29 ( 1 H), 4.OS (2 H), 3.24 (1 H), 3.04 (1 H), 2.88 {2 H), 1.15 (3 H);'3C NMR (75 MHz, DMSO-d6) 8 173.1, 170.0, 164.3, 154,0, 152.4, 149.0, 137.7,135.9, 133.5, 131.1, 129.8, 123.9, 120.5, 62.4, 61.8, 53.8, 36.7, 14.8; MS (ESI+) for C22H24N4~6'S m/z 473.3 {M+H)+; MS (ESI-) for C22Hz4N406S m/z 471.3 {M-H)'; HRMS (FAB) cakd for CzZHzaNaOaS +H, 473.1494, found 473.1509.
Example 272.
(4~-4-[[[(1S')-1-Carboxy-2-[4-[(4-methoxybenzoyl)amino]phenyl]ethyl]amino]carbonyl]-3-thiazolidinecarboxylic acid 3-ethyl ester ~s~ o H_ ~
NI~N~OH
~O~O O ~ ~ O
v 'N
H ~

The title compound was prepared as described in Scheme O using p-anisoyl chloride to form the requisite amide. Physical data as follows: IR (drift) 1709, 1667, WO 99!67230 PCT/U599/14233 1604, 1532, 1514, 1439, 1412, 1379, 1343; 1323, 1255, 1221, 1178, 1027, 763 crri';'H
NMR (300 MHz, CDC13/CD30D (10%)) 8 7.79 (2 H), 7.47 {2 H), 7.05 {2 H), 6.87 (2 H), 4.68 {2 H}, 4.58 (1 H), 4.28 (1 H), 4.07 (2 H), 3.79 (3 H}, 3.66 (2 H), 3.04 (4 H), 1.17 (3 H);'3C NMR (7S MHz, CDCl3) 8 177.9, 174.0, 170.1, 166.3, 158.8, 141.1, 135.8, 133.7, I33.0, 130.8, 124.6, 117.7, 66.9, 66.d, 59.3, 40.7, 33.5, 24.5, 18.2; MS
(ESI+) for C24H2TN3~7S ~Z 502.0 (M+H)+; MS (ESI-) for Cz4H27N3O7S m/z 500.1 (M-H)-; MS
(FAB) m/z (rel. intensity) 502 (MH+, 52), 503 (I7), S02 (52), 297 (12), 240 (12), 160 (21), 135 (99), 88 (12), 73 {20), 69 (13), 57 (12); HRMS (FAB) calcd for C24H27N3O7S +H, 502.1648, found 502.1657. Anal. Calcd for C24H27N3O,S ~ 0.3 H20: C, 56.86; H, 5.49; N, 8.29. Found: C, 56.65; H, 5.34; N, 7.92.
Example 273.
(4f~-4-[[[( LSD-1-Carboxy-2-[4-[(4-methylbenzoyl)amino jphenyl]ethyl]amino]carbonylj-3-1 S thiazolidinecarboxylic acid 3-ethyl ester H_ ~
N~N~OH
~O~O O I ~ O
~N
H/~\

The title compound was .prepared as described in Scheme O using p-tolouyl chloride to form the requisite amide. Physical data as follows: IR {drift) 3310, 2981, 2929, 1671, 1608, 1599, 1531, 1517, 1413, 1379, 1344, 1324, 1265, 1210, 1188 cni';'H
NMR (300 MHz, DMSO-d6) 8 10.10 {1 H), 8.24 {1 H), 7.85 (2 H), 7.67 (2 H}, 7.33 (2 H), 7.17 (2 H), 4.62 (2 H), 4.4I (1 H), 3.28 {2 H), 4.02 {2 H), 3.23 (1 H), 3.04 (I H}, 2.87 (2 H), 2.38 (3 H), 1.1 S (3 H); "C NMR (75 MHz, DMSO-db) b I73.2, 169.8, 165.6, 154.0, 141.9, 138.1, 133.1, I32.S, 129.7, 129.7, 128.1, 120.4, 62.4, 61.8, 54.0, 36.7, 21.4, 14.8;
MS (ESI+) for Cz4Hz7N3O6S mlZ 486.2 {M+H)+; HRMS (FAB) calcd for C24H27N306S
+H, 486.1699, found 486.1713; Anal. Calcd for C24Hz,N~O6S ~ 0.3 HzO: C, 58.71; H, 5.67; N, 8.56. Found: C, 58,37; H, 5.67; N, 8.35.

Example 274.
(4,5~-4-[[[{ 1,5~-1-Carbaxy-2-[4-[[2-(trifluoromethyl)benzoyl]amino]phenyl]ethyl]amino]
carbonyl]-3-thiazolidinecarboxylic acid 3-ethyl ester ~s~ o H~ ~
N~N~OH

N W
H
S
The title compound was prepared as described in Scheme O using (2 trifluoromethyl)benzoyl chloride to form the requisite amide. Physical data as follaws:
IR (drift) 3295, 1709, 1663, 1603, 1533, 1518, 1414, 1380, 1344, 1316, 1269, l 176, 1 I32, 1108, 769 crri';'H NMR (300 MHz; DMSO-d6) b 10.48 (1 H), 8.23 (1 H), 7.77 (2 H), 7.S 8 (2 H), 7.17 (2 H), 4.64 (2 H), 4.44 ( I H), 4.29 ( I H), 3.99 (2 H);
3.24 { 1 H), 3.OS (2 H), 1.09 {3 H); '3C NMR (7S MHz, DMSO-d6) 8 173.2, 169.2, I6S.8, 154.1, 137.8, I36.7, 133.0, 130.4, 129.9, 128.9, 126.7, 126.4, 126.0, 119.8, 62.2, 61.8, 54.0, 37.1, I4.7; MS
(ESI+) for C24H25F3N3~6's ~Z 540.0 (M+H)+; MS (ESI-) for CZ4HZSF3Na06S m/z 538.1 (M-H)-; HRMS (FAB) calcd for Cz4H24F3N3O6S +H~ 540.1416, found 540.1423; Anal.
Calcd for Cz4H24F3N3O~S ~ O.S HZO: C, S I .49; H, 4.70; N, 7.83. Found: C, S 1.42;
H, 4.42; N, 7.45.
Example 275.
(4S'~-4-[[[(15~-1-Carboxy-2-[4-[(2,4,6-trichlorobenzoyl)amino]phenyl]ethyl]amino)-carbonyl]-3-thiazolidinecarboxylic acid 3-ethyl ester ~s~ o H-~ ~
N~N~OH
~O O O ' ~ O C1 N
H I ~
CI CI

The title compound was prepared as described in Scheme O using 2,4,6-trichlorobenzoyl chloride to form the requisite amide. Physical data as follows: IR (drift) 3286, 2926, 1709, 1664, 1604, 1578, 1542, 1 S 17, I 413, 1379, i 345, 1325, 1269, 12I 8, 1187 crri';'H NMR (300 MHz, CDC13/CD30D {10%)) ~i 7.58 (2 H), 7.41 (2 H), 7.20 (2 H), 4.84 (2 H), 4.b9 (I H}, 4.41 (1 H), 4.19 (2 H), 3.27 (4 H), 1.26 (3 H);'aC
NMR (75 MHz, DMSO-dø) 8 173.0, I69.8, 161.5, 154.0, 137.2, 1:35.9, 135.1, 133:9, 132.6, 130.1, 128.5, 119.6, 62.2, 61.7, 54.0, 36.7, 14.8; MS (FAB) mOz (rel. intensity) 574 (MH+, 95), 576 {96), 574 {95}, 160 (99), 91 (79), 88 (40), 69 (64), 5'7 (59), 55 (59), 43 (S6), 41 (39};
HRMS (FAB) calcd for C2gH22CI3N3O6s +H, 574.0373, :found 574.0364. Anal. CaIcd for lO C23HZZC13N3O6S: C, 48.06; H, 3.86; N, 7.31; Cl, 18.50. 1~ound: C, 48.52; H, 4.13; N, 7.08.
Example 276.
(4S}-4-((((1,5~-1-Carboxy-2-[4-[[(2,5-dichlorophenyl;isulfonyl]amino) phenyl]ethylJ
amino]carbonyl)-3-thiazolidinecarboxylic acid 3-ethyl ester IS
~s~ o H '' N~N~OH
~O~O O ~ Cl ~ N 6 _ H n O
CI
The title compound was prepared as described in Scheme O using 2,5-dichlorobenzene sulfonyl chloride to form the requisite sulfonamide. Physical data as 20 follows: IR (drift) 1709, 1676, I531, 1512, 1450, 1428" 1409, 1378, 1344, 1221, 1167, 1143, 1113, 1101, 1041 crri'; 'H NMR (300 MHz, DMSO-d6) S 8.36 (1 H}, 7.90 (3 H), 7.20 (2 H), 7.12 (2 H), 4.70 (2 H), 4.47 ( 1 H), 4.34 ( I H}, 4.10 (2 H}, 3.19 (4 H), 1.27 (3 H); '3C NMR (75 MHz, DMSO-d6) 8 173.0, 169.8, 153.9, 138.7, 135.5, 134.8, 134.1, 132.6, 131.0, 130.5, 130.0, 120.0, 62.4, 61.7, 53.5, 36.3, 14.8; MS (FAB) m/z (rel.
25 intensity) 576 (MH+, 99), 652 (27), S78 (83), 577 (31), 576 (99), 160 (98), 106 (47), 88 (40), 81 (32), 69 (31 }, 57 (28); HRMS (FAB) calcd for C:zZHz3CI2N3O7S2+H~
576.0433, found 576.0400. Anal. Calcd for Cz2H23C1zN30,Sz ~ 0.1 H20: C, 45.70; H, 4.04;
N, 7.27.
Found: C, 45.94; H, 4.04; N, 6.87.
Example 277.
(4~'}-4-[[[{1S?-1-Carboxy-2-[4-[[[(2,6-dichlorophenyl}amino]carbonyl]
amino]phenyl]-ethyl]amino]carbonyl]-3-thiazolidinecarboxylic acid 3-ethyl ester <s~ o H' ~
~ v 'OH
OCI~ /
I / ~LN ~ I
H H OI
The title compound was prepared as described in Scheme O using 2,6-dichlorophenyl isocyanate to form the requisite urea. Physical data as follows: IR (drift) 3284, 3277, 1709, 1655, 1600, 1569, 1544, 1452, 1431, 1415, 1347, 1238, 1217, 1 i95, 771 crri';'H NMR (300 MHz, DMSO-d6) 8 9.09 {1 H), 8.41 (1 H}, 8.09 (1 H), 7.52 (2 H), 7.31 (3 H), 7.08 (2 H), 4.62 (2 H), 4.35 ( 1 H), 4.28 ( 1 H;), 3.27 ( 1 H), 3.02 ( 1 H), 2.85 {2 H), 1.10 (3 H);'3C NMR (75 MHz, DMSO-d6) S 173.6, 169.8, 154.0, 152.8, 138.7, 134.4, 133.9, I31.3, 130.0, 128.8, 128.7, 118.1, 62.4, 61.8, 54.:3, 36.7, 14.8; HRMS
(FAB} calcd for Cz3H,4C12N406S +H, 555.0872, found SS5.0877. Anal. Calcd for Cz3HzaC12NQO6S ~ 2 H20: C, 46.71; H, 4.77; N, 9.47. Found: C, 47.08; H, 4.53; N, 9.06.

Scheme P
~~~-OH p-1 Wang resin Boc-HN OH

y O I I
~O NH-8oc I ( /
O
NH-Boc N
R~~
O
O

t'-5 \ H
/ N.
Rp-y O
O
H2N O~CH3 H
N, O

Scheme P (continued;) Rp.~
Rpm~~..
HO' / S'Rps ~N~RPS P_7 O
O~O~Rp_z O HRp~ R S O Rpa Rps w0 N /\Rps N~S Rp5 RP.s P'8 -----~ HO N~R P-9 O p.s rN I / O~O.Rp.2 N I \ O O~O.Rp.2 Rv.t Rwi w O HRp~ R S
N~,~- ~-~'/Rps ~/~Rps P-10 \ O H
i/
R
O
O Rpm Rpa H S RP.S
O ~~RP~6 P-~ 1 \ O Y
N I / wRa R~lr O
O ~ pa R S
N Rps HO ~~Rps P-'12 O
( Y2wR3 R r a-~
O

Where: RP_, is defined as R,2; RP_Z is defined as C:,_6 alkyl or C,_,~
arylaIkyl; RP_3, Rr_ 4, and RP_5, are defined independently as R,. Rp_6 is defined as RZ.
Scheme P describes a method for the preparation of examples of the formula P-9 S and P-12. Commercially available Wang resin (P-1) is a.cylated with commercially available N a-Boc-Phe(I)-OH (P-2) under standard conditions to afford the resin of formula P-3. Carbonylation of the resin bound aryl iodide with carbon monoxide and an amine in the presence of a source of palladium(0) affords the resin bound amide of general formula P-5 (for a general review of carbonylation chemistry, see: C'~lquhoun, H.M.;
Thompson, D.3.; Twigg, M.V. Carbonylation Plenum Press: New York, 1991}. Mild cleavage under standard conditions affords the amino acid of general structure P-5 which is esterified under mild acid catalysis to afford the amino ester of general structure P-6.
Condensation with a commercially available or readily prepared thiazolidine-4-carboxylic acid of general formula P-7 under conditions described in Scheme A affords the pseudodipeptide of general structure P-8. Mild base hydrolysis of the ester of general structure P-8 affords the acid of general structure P-9. In the case where RP_Z is a 9-fluarenylmethyl group, standard Fmoc group removal (A.therton, E.; Sheppard R.C. Solid Phase Peptide Synthesis: A Practical Approach; IRL Press at Oxford University Press:
Oxford, 1989) affords the amine of general structure P-10, which may be reacted with a variety of electrophilic reagents as described in Scheme A to afford amides, areas, sulfonamides and carbamates of general structure P-11. Mild base hydrolysis of the ester in general structure P-11 affords the acid of general structure P-12.
Preparation 80 and Example; 278.
(4,5~-4-[[[(IS}-I-Carboxy-2-[4-[[(2,4,6-trichlorophenyl;)amino]carbonyl) phenyl]ethylJ-aminoJcarbonyl]-3-thiazolidinecarboxylic; acid 3-ethyl ester S- H' O.
~NI~N~OH
'~O~O ~ , ~ H CI
N

CI CI
To a cooled (0-SOC) mixture of Wang polystyrene resin P-1 {Advanced Chemtech, 2.0 g, ca. 1.5 mmol), N Boc-4-iodo-L-phenylalanine P-:! {Bachem, 4.OO g, 10 mmol), and PPh3 (1.30 g, 5.0 mmoI) in THF (20 mL) was added diethyl azodicarboxylate (0.80 mL, 5.0 mmol) in 4 approximately equal portions at 5 min intervals. When the orange color had discharged, the mixture was warmed to ambient temperature and stirred for 5 h. The mixture was diluted with THF (30 mL) and f ltered. Thf; resin was washed with DMF, THF and MeOH and dried in vacuo to afford the esterifind resin P-3 (2.68 g) as a colorless powder: "C NMR (100 MHz, CDZC12, 4 mm MAS probe) 8 171.86, 155.33, 137.85, 136.40, 131.87, 128.00, 92.74, 80.09, 54.05, 38.05, 28.51.
N2 was bubbled through a mixture of N Boc-4-iodo-L-phenylalanine functionalized Wang resin P-3 (500 mg, ca. 0.3 mmol), PPh3 (0.21 g, 0.8 mmol), 2,4,6-trichloroaniline (0.98 g, 5.0 mmol) and DIEA (3.48 mL, 20 mmol) in NMP (20 mL) for 10 min.
Pd2dba3 (0.18 g; 0.2 mmol) was added and the reaction mixture was placed under a CO
atmosphere and heated (bath temp. 70 °C) for 18 h. Upon cooling to ambient temperature, the mixture was diluted with 3% (w/v) sodium diethyldithiocarbamate in 95:5 NMP:DIEA (10 mL).
After an additional 10 min, the mixture was filtered and the resin washed with NMP, THF
and MeOH and dried in vacuo to afford the functionalize;d resin P-4 as a colorless powder.
Resin P-4 was swollen with methylene chloride (0.5 mL) and diluted with 95:5 TFA:H20 ( 10 mL). After 90 min the mixture was filtered and the resin washed with TFA
(3 x 5 mL) and CHZC12. The combined filtrates were concentrated in vacuo and the residue lyophilized from glacial acetic acid to provide the amino acid P-5 ( 152 mg) as a powder which was used without purification. Physical data as follows: MS (FAB) rnlz (rel.
intensity) 387 (M+H, 42), 427 (26), 426 (80); 389 (46), 387 {42), 366 (33), 279 (99), 177 (54), 146 (18), 119 (26), 23 (26); HRMS (FAB) calcd for C,6H~3C13NZO3+HI
387.0070, found 387.0084.

The amino acid P-5 was dissolved in methanolic HCI (20 mL) and stirred at room temperature for 18 h. Concentration in vacuo afforded tire methyl ester P-6 which was used without purification. Physical data as follows: MS (ES+) for C=,H,SC13NZOa m/z 400.9 (M+H)+, To a cooled (0-5 °C) solution of N ethoxycarbonyl-~-thiazolidine-4-carboxylic acid P-7 (82 mg, 0.4 mmol) and HOAt (54 rng, 0.4 mmol) in CHZCIz/DMF (1:I, 4 mL) was added EDC (76 rng, 0.4 rnmol). After stirring fox 10 min, the solution was added to the amino ester P-6 described above at 0-5 °C followed by DIEA (208 p,L, 1.2 mmol).
After an additional 30 min at 0-5 °C, the solution was allowed to warm to room temperature and stirred an additional hour. Volatiles were removed in vacuo and the residue partitioned between ethyl acetate and 0.1 N aqueous HCI. The organic layer was separated, washed with 0.l N aqueous HCl, saturated aqueous NaHC03, brine;
dried (MgS04}, filtered and concentrated in vacuo. Purification of the residue by flash chromatography using CHZCIZ/ethyl acetate/hexanes (1:1:2} containing 2-propanol (0.1 %) IS as eluant afforded the ester P-8 as a powder: 'H NMR {300 MHz, CDC13} 8 7.99 (I H), 7.87 (2 H), 7.40 (2 H), 7.24 (2 H), 4.92 ( 1 H}, 4.70 (2 H), 4.34 ( I H), 4. I
0 (2 H), 3:74 {3 H), 3.20 (4 H), 1.25 (3 H);'3C NMR (75 MHz, CDCl3) 8 171.2, 169.7, 165.4, 154.9, 140.6, 134.3, 133.4, 132.2, 131.3, 129.7, 128.4, 127.9, 6:3.1, 62.7, 60.4, 53.0, 52.6, 37.6, 2I.0, 14.5; MS (ESI+) for C24H2aCI3N3O6S m/z 589.9 (M~+H)+; MS (ESI-) for 2O Cz4Hz4C13N3O6S m/Z 588.0 (M-H}'.
To a cooled (0-5°C ) solution of the ester P-8 (72 mg, 0.12 mmol) in THF (5 mL) and water (0.5 mL) was added an 0.1 N aqueous solution of NaOH { 1.3 mL, 0.13 mmol) via a syringe pump over 1 h. After an additional 45 min at 0-5°C, the reaction mixture was diluted with ethyl acetate and acidified with 0.25 N 1HC 1 to a pH of ca.
3. The organic 25 layer was separated, washed with water and concentrated) in vacuo.
Purification of the residue by flash chromatography using methylene chloride and methanol {0-5%) as eluant provided a solid which was crystallized from ethyl acetat:e/CHZCI2/hexanes to afford the title compound (45 mg) as colorless solid: IR (drift) 1743, 1726, 1709, 1691, 1675, 1663, 1553, 1521, 1490, 1428, 1415, 1379, 1345, 1290, 1189 crri';'H NMR (300 MHz, DMSO-30 d6) 8 10.27 (1 H), 8.35 (1 H), 7.92 (, 2 H}, 7.81 (2 H), 7.:37 (2 H), 4.62 (2 H), 4.53 (1 H}, 4.29 (2 H), 4.00 (2 H), 3.11 (3 H), 2.77 (1 H), I.12 (3 H);'3C NMR (75 MHz, DMSO-d6) 8 172.9, 170.0, 165.4, 154.0, 142.5, 135.5, 133.9, 133.0, 131.6, 129.8, 128.7, 128.0, 62.0, 61.7, 53.4, 37.0, 14.8; MS (FAB) m/z (rel: intensity) 574 (MH+, 80), 576 (80), 574 {80), 379 (99), 160 (82), 91 (95), 81 (72), 69 (93), 57 (86), 551;86), 43 (90); HRMS
(FAB) calcd S for CZ~HZZC13N3O6S +H, 574.0373, found 574.0358.

Scheme Q
Hs ~-~
:2 Q-1 O.
HyN Rp-3 O
Rp-~
~5 Rq '"N Rq.O. O-2 H ~-s O
Rp_~
H~Rq~ Rq-20, Q-3 Rq-a O
Rp-~
~~2 (/~N~O_Rp-a Q-4 Z- < O
O
Rq-~
S'~ Rp-2 ~OH p 5 Z--~ O
O

HZN w O
Rp.t N NH O~
Z--~ O ~ 4-7 Rp_1 S Rp_Z O
NH OH q-g Z-~ (?
O Rs WO 99/67230 PCTlUS99/14233 Rø, and RQ_Z are defined independently as R,. ~RQ_, is deoned as C,~ alkyl or C,_"
arylalkyl. RQd is defined as oxygen or N-R". ItQ.s is defined as a suitable protecting group for a nitrogen (such as Boc or Fmoc) or oxygen (such as t-butyldimethylsilyl) (Greene, T.W.; Wuts, P.G.M.. Protective Groups in Organic Synthesis, John Wiley and Sons, New York, 1991 ).
Scheme Q describes a general method for the preparation of examples of the formula Q-7. A commercially available or readily prepared sulfur containing amino acid of structure Q-1 is condensed with a suitably protected aldehyde to afford the thiazolidine-4-carboxylic acid of general formula Q-2. ;>tandard deprotection (Greene, T.W.; Wuts, P.G.M.. Protective Groups in Organic Synthesis, John Wiley and Sons, New York, 1991 ) affords intermediate Q-3 which is readily cyclized to the bicycle Q-4 using 1,1'-carbonyldiimidazole or phosgene or a suitable equivalent. For the preparation of bicycles of general structure Q-4 in which Z is CHz, see as examples: (a) Aszodi, 3.;
Bonnet, A.; Teutsch, G. Tetrahedron 1990, 46, 1579. (b) Baldwin, J.E.; Lee, V.;
Schofield, C.J. Heterocycles 1992, 34, 903. (c) Genin, NLJ.; Johnson, R.L. J.
Am. Chem.
Soc. 1992.114, 8778. (d) Siddiqui, M.A.; Preville, P.; Tarazi, M.; Warder, S.E.; Eby, P.;
Gorseth, E.; Puumalay K.; DiMaio; J. Tetrahedron Lett. 11997, 38, 8807.
(e)Subasinghe, M.L.; Bontems, R.J.; McTntee, E.; Mishra, R.K.; Johnson, R.L. J. Med. Cherry.
1993, 36, 2356. Removal of the ester protecting group affords the acid of general structure Q-5 which is condensed with amino acyl derivative Q-G under standard peptide synthesis conditions to provide Q-7 (for a review of procedures of peptide synthesis see: Bodansky, M.; Bodansky, A. The Practice of Peptide Synthesis; Springer-Verlag: Berlin, 1984).
Mild base hydrolysis of the ester of general structure Q-'7 provides acid Q-8.
Preparation 81.
(Scheme Q, Q-2: where RQ_, and Ro_, are equal to hydrogen, RQ_3 is ethyl, RQ~, is NH, R~5 is Boc and stereochemistry is (S)).
S~
Boc~N
H HN
--OEt O

To a suspension of D-cysteine 1.5 hydrate hydro~;hloride (Q-1, Scheme Q where RQ_, and RQ_, are equal to hydrogen, R~3 is hydrogen and stereochemistry is (S')) {5 g, 27.1 mmol) in absolute ethyl alcohol (50 mL) was added triethylorthoformate (13.5 mL, 81.2 mmol) at ambient temperature. A stream of anhydrous HCl gas was bubbled through the solution for 30 min. The stream of anhydrous HCl gas was maintained as the mixture heated to 70°C for 2 h. The reaction mixture was concentrated in vacuo and the resulting residue triturated with diethyl ether to afford D-cysteine ethyl ester (4.43 g) as a white solid which was used without further purification. Physical data as follows:
'H NMR
(300 MHz, D20) 8 4.36 (1 H), 4.27 (2 H), 3.12 (2 H), 1.25 (3 H); MS (ESI+) for CSH"NOZS m/z 150.0 (M+H)*.
To a solution of ~-cysteine ethyl ester (1.89 g, Ii).2 mmol} in HZO {46 mL) was added potassium acetate ( 1.22 g, 12.4 mmol) and t-butyl N (2-oxoethyl)carbamate (Aldrich, 2.38 g, 12.0 mmol based on 80% purity as detE;rznined by'H NMR) in ethyl 1 S alcohol (46 mL) at ambient temperature. After 8 h, the reaction mixture was concentrated in vacuo and the residue purified by flash chromatography using methylene chloride/methanol (1%) as eluant to afford the title corn;pound (1.9 g) as an oil: 'H NMR
(300 MHz, CDC13) b 5.01 {1 H), 4.75 (1 H), 4.26 (2 H), :3.93 (1 H), 3.37 (2 H), 3.12 (1 H), 2.91 (1 H), 1.47 (9 H), 1.32 (3 H); MS (ESI+) for C,zHZ2N204S mlz 291.1 (M+H)+. MS
(ESI-) for C,ZHZZNZO4S m/Z 288.9 (M-H)'.
Preparation 82.
(Scheme Q, Q-3: where RQ_, and R~,, are equal to hydrogen, RQ.3 is ethyl; RQ~
is NH, and stereochemistry is (S~).
~..~S

HN
--OFt O

WO 99/6'7230 PCT/US99I14233 To a cooled (10-15°C) solution of Q-2 (Scheme Q where RQ_, and RQ_, are equal to hydrogen, RQ_3 is ethyl, ItQ~, is NH, RQ_5 is Boc and stereochemistry is (S~) (1.9 g) in dioxane (38 mL) was added dropwise anhydrous 4 M HC:I in dioxane {156 mL). The solution was allowed to warm to ambient temperature and stirred -for 2 h. The reaction S mixture was concentrated in vacuo and azeotroped three times with methanol which afforded the title compound (1.72 g) as a tacky yellow solid: 'H NMR (300 MHz, CDC13) 8 8.57 (2 H}, 5.80 {1 H), 5.25 (1 H), 4.39 (2 H), 4.17 {1 I-I), 3.79 (4 H), 1.37 {3 H); MS
(ESI+) for C7H,4NZOzS mlZ 191.1 (M+H)+. MS (ESI-) for C,H,4NZO2S ~ 2HCI mlz 261.0 (M_H)_.
Preparation 83.
(Scheme Q, Q-4: where R.Q_, and R~_, are equal to hydrogen, RQ_~ is ethyl, Z
is NH, and stereochemistry is (,S~).
~S~
HN/~'N
--OEt To a cooled (0-5°C) solution of Q-3 (Scheme Q vvhere RQ_, and RQ_, are equal to hydrogen, RQ_3 is ethyl, RQ~ is NH, and stereochemistry i s (,S'}) (1.72 g, 6.54 mrnol) in THF
{650 mL) was added triethylamine (2.83 mL, 20.3 mmol) and 1,1'-carbonyldiimidazole (1.11 g, 6.87 mmol). After 3 d at ambient temperature, the mixture was recooled (0-5°C), treated with additional 1,1'-carbonyldiimidazole (S30 mg, 3.27 mmol) and allowed to warm to ambient temperature. After 18 h, the reaction mixture was concentrated in vacuo and the resulting residue was partitioned between ethyl acetate and 0.25 N
HCI. The organic layer was separated, washed with brine, dried (MgS04), filtered and concentrated in vacuo. The diastereorneric mixture was separated by chiral chromatography [5 x 25 cm (R,R) Whelk-O I, SO mL/min 40% Isopropanol/heptane, :210 nm,]. Further purification of each isolated diastereomer by flash chromatography using methyiene chloride/ethyl acetate (25%) as eluant afforded the diastereomers (255 mg, 464 mg) as oils.
Physical data for the faster eluting diastereomer (analytical column conditions 0.46 x 25 cm (R,R) Whelk-O I, 0.5 mL/min 40% IPA/heptane; 210 nm) as follows: 'H NMR (300 MHz, CDCl3} 8 5.51 ( 1 H), 5.15 ( 1 H), 4.32 (2 H), 3.96 ( 1 H), 3.86 ( 1 H), 3.53 ( 1 H), 3.26 ( 1 H}, 3.13 (1 H), I.34 (3 H); MS (ESI+) for CBH,ZN203S m/z 217.1 (M+H)+. MS (ESI+) for CBH,ZNZO3S mlZ 239.0 (M+Na)+. MS (ESI-) for CgH,2N20jS mlz 215.1 (M-H}'.).
Preparation 84.
(Scheme Q, Q-5: where RQ_, and RQ_, are equal to hydrogen, and Z is NH).
~S
HNI~1N
OH
O O
To a cooled (0-5°C) solution of the faster eluting diastereomer of general structure Q-4 (Scheme Q where RQ_, and RQ_, are equal to hydrogen, R~~ is ethyl, Z is NH, and stereochemistry is (,S~) (100 mg, 0.46 mmol) in THF (13 mL) and H20 (1.5 mL) was added via syringe pump over 1 h 0.1 N NaOH (9.7 mL, 0.97 m.mol). The reaction mixture was stirred for 2 h at 0°C, acidified with 1.0 N HCl (0.97 mL,} and concentrated in vacuo. The resulting residue was dried over P205 in a vacuum desiccator to afford the title compound (87 mg} as a glassy solid which was used without further purification: MS
(ESI+) for C6H8NZO3S mlZ 189.0 (M+H}+. MS (ESI+) for C6H8NZC~3S mlz 211.0 (M+Na)+. MS
(ESI-) for C6H$Nz03S mlz 187.0 (M-H}'.
Preparation 85.
(Scheme Q, Q-7: where RQ_, and RQ_, are equal to hydrogen, Z is NH, RS is 4-[(2,6-dichIorobenzoyl)amino]phenyl, and stereochemistry of the C-terminal amino acid is (~).

HN N
OMe O O
O CI
H I ~
C!
To a cooled {0-5°C) suspension of Q-5 (Scheme Q where RQ_, and RQ_, are equal to hydrogen, and Z is NH) (87 mg, 0.46 mmol) in methyh;ne chloride ( 10 mL) was added O-(7-azabenzotriaol-1-yi)-N,N,N',N'-tetramethyluronium hexafluorophosphate {HATU) (I75 mg, 0.46 mmol), Q-6 (Scheme Q where R5 is 4-[(:?,6-dichlorobenzoyl)amino]phenyl, and stereochemistry is (,f}) (204 mg, 0.51 mmol) and N,N diisopropylethylamine (0.24 mL, 1.38 mmol). After 7 h, the reaction mixture was diluted with methylene chloride, washed with 0.1 N HCl and brine, dried (MgSC?4), filtered and concentrated in vacuo.
Purification of the residue by flash chromatography using methylene chloride/ethyl acetate (2S%) as eluant afforded the title compound (89 mg} as a white solid: ~H NMR
(300 MHz, CDC13) 8 7.57 (2 H), 7.31 (3 H), 7.13 (2 H), 4.97 (1 H), 4.82 (1 H), 4.47 (1 H), 3.80 (4 H), 3.55 (1 H), 3.46 (1 H), 3.34 (1 H}, 3.08 (2 H); MS (ESI+) for Cz3H22C12N4~5S m/z 537.0 (M+H)+. MS (ESI+) for C,3HZZCIZN405S m/z 558.9 (M+Na)+.
Preparation 86 and Example 279.
4-[(2,6-Dichlorobenzoyl)amino]-N [[(7a,S'~-hexahydro-~5-oxoimidazo[5,1-b]thiazol-3-yl]
carbonyl]-~-phenylalanine (Scheme Q, Q-8: where Rte, and RQ_, are equal to hydrogen, Z is NH, RS is 4-[(2,6-dichlorobenzoy!)amino]phenyl, and stereochemistry of the C-terminal amino acid is (S'~).
O
H N N_ ~~
'ONI
O O
O CI

cl WO 99/6'7230 PCT/US99/14233 To a cooled (0-S°C} solution of Q-7 (Scheme Q where RQ_, and RQ_, are equal to hydrogen, Z is NH, RS is 4-[(2,6-dichlorobenzoyl)amir~o]phenyl, and stereochemistry of the C-terminal amino acid is (,S~) {88 mg, 0.I6 mmol) in THF (S mL) and HZO
(O.S mL) was added via syringe pump over 1 h 0.1 N NaOH (3.4 mL, 0.34 mmol). After 2 h, the reaction mixture was partitioned between ethyl acetate and 0.1 N HCl (7 mL) and diluted with H20 (20 mL). The organic layer was separated, washed with H20, dried (MgS04), f ltered and concentrated in vacuo. The resulting white solid was lyophilized from glacial acetic acid to afford the title compound (22 mg) as white solid: IR (drift) 2924, 1726, 1720, 1663, 1657, 1608, 1 S 1 S, 1456, 1431, 1402, 1398, 1243, 1194, 797, 780 cm'' : 'H
NMR (300 MHz, CD30D) 8 8.OS ( I H), 7.61 {2 H), 7.46 (3 H), 7.25 (2 H), 4.93 (2 H), 4.74 (2 H), 4.47 (1 H), 3.77 (1 H), 3.39 (2 H), 3.25 (1 H), 3.04 {2 H);'3C NMR
{7S MHz, CD30D) 8 171.8, 165.2, 164.7, 138.2, 137.7, I3S:1, 13=1.4, 132.4, 130.9, 129.4, 121.7, 66: 3, 64.4, S4.S, 44.9, 37.4, 33.9; HRMS (FAB) calcd fbr Cz2HZOCL2N40$S +H, 523.0610, found 523.0629. MS (ESI+) for CZZHZOCIzN4O5S m/Z 523.0 (M+H)+. MS (ESI-) for CZZHZaC12N4O5S mla 521.1 (M-H)'.
Example 280.
4-[(2,6-Dichlorobenzoyl)amino]-N [[(7aR}-hexahydro~~S-oxoimidazo[S,1-b]thiazol-3-yl]-carbonyl]-L-phenylalanine (Scheme Q, Q-8: where RQ_, and RQ_, are equal to hydrogen, Z is NH, RS is 4-[(2,6-dichlorobenzoyl)amino]phenyl, and stereochemistry of 'the C-terminal amino acid is (S}).

O
H N N, OH
O O
O CI
CI

Example 280 was prepared as described in Schenne Q from the slower eluting diastereomer of general structure Q-4 {Scheme Q where RQ_, and RQ_, are equal to hydrogen, RQ-3 is ethyl, and Z is NH). Physical data as follows: IR {drift) 3251, 3079, 1730, 1662, 1611, 1549, 1516, 1482, 1431, 1333, 1306, 1269, 1229, 1196, 792 cni';'H
NMR (300 MHz, CD30D) b 7.59 (2 H), 7.44 (3 H), 7.24 (2 H), 4.65 (1 H), 3.81 (1 H), 3.44 ( I H), 3.23 (2 H), 3.08 (2 H); '3C NMR (75 MHz, CD30D} 8 175.3, I 72.22, 164.6, 155.3, 139.7, 139.1, 136.1, 134.1, 133.9, 132.3, 131.8,130.9, 122.0, 68.4, 64.6, 45,6, 44.0, 36.3; HRMS (FAB) calcd for CzzHzoClzNaOsS +H, 523.0610, found 523.0629. MS
(ESI+) for CzzHzoC1zN405S mlz 523.0 (M+H)+. MS (ESI-) for CzzHzoClzN4O5S mlZ 52I .0 (M-H)-.
Anal. Calcd for CzzHzoClzNaOsS ' 0.13 HzO: C, 50.26; H:, 3.88; N, 10.66.
Found: C, 50.72; H, 3.96; N, 10.13. % Water (KF): 0.45.
Example 281.
4-j(2,6-Dichlorobenzoyl)amino]-N [(tetrahydro-5-oxo-~5H thiazolo[3,2-c]oxazol-3-yl}
carbonyl]-L-phenylalanine (less polar diastereomer) (Scheme Q, Q-8: where RQ_, and RQ_, are equal to hydrogen, Z is O, RS is 4-[(2,6-dichlorobenzoyl)amino]phenyl, and stereochemistry of the C-terminal amino acid is (S~).
S O
N N
OH
0 o w c~ cl J
H
CI

Example 281 was prepared as described in Scheme Q using commercially available (t-butyldimethylsilyloxy)acetaldehyde to form the requisite thiazolidine-4-caroxylic acid.
Physical data as follows: IR (drift) 3293,3194, 1754, 1667, 1603, 1533, 1517, 1431, 1411, 1392, 1324, 1266, 1206, 798, 78I cni';'H NMR (300 MHz, DMSO-d6) 8 8.44 (1 H), 7.53 (5 H), 7.2I (2 H), 5.00 (1 H), 4.84 (I H), 4.65 (1 H), 4.42 (2 H), 3.08 (2 H), 2.91 (1 H);'3C NMR (75 MHz, CD30D) 8 169.4, 163.8, 160.6, 136.7, 136.2, 133.9, 131.9, 130.9, 129.5, 127.9, 120.4, 68.1, 64.4, 63.2, 53.4, 36.I, :33.7; MS (ESI+) far CZZH~9C12N3O6S mlZ 524.0 (M+H)+. MS (ESI-) for CzzH.~9C12N306S mlz 522.0 (M-H)-.
Anal. Calcd for CZZH,9C1zN3O6S ~ 0.31 HZO: C, 49.86; Ii, 3.73; N, 7.93. Found:
C, 49.61;
H, 3.82; N, 7.54. % Water (KF): I.06.
Example 282.
4-[(2,6-Dichlorobenzoyl)amino]-N [(tetrahydro-5-oxo-SH thiazolo[3,2-c}oxazol-3-yl) carbonylJ-1.-phenylalanine (more polar diastereomer) (Scheme Q, Q-8: where RQ_, and RQ.~ are equal to hydrogen, Z is O, RS is 4-[(2,6-dichlorobenzoyl)amino]phenyl, and stereochemistry of t:he C-terminal amino acid is (,S~).
N v 'O
H
O O
I ~ ~ CI
H I ~
CI~ i Example 282 (diastereomer of Example 281 ) was prepared as described in Scheme Q. Physical data as follows: IR (drift) 3296, 1753, 1666, 1603, 1579, 1535, 1517, 1431, I41 i, 1390, 1324, 1267, 1207, 798, 781 cm''; 'H NMR (300 MHz, DMSO-d6) 8 8.57 (1 H), 7.54 (5 H), 7.20 (2 H), 5.23 (1 H), 4.86 (I H), 4.66 (1 H), 4.45 (2 H), 3.22 {l H), 3.09 (1 H), 2.93 (m, 2 H);'3C NMR (75 MHz, CD30D) 8 172.8, 169.7, 163.8, 160.6, 136.8, 136.2, 133.7, 131.9, 130.9, 129.5; 127.9, 120.2, 68.1, 69.9, 63.1, 53.6, 37.5, 36.2; 34.2;
MS (ESI+) for CZZH,9C12N3O6S mlz 523.9 (M+H)+. MS (ESI-) for C2zH~9C12N3O6S
mlz 521.9 (M-H)'; HRMS (EI) calcd for CZZHL9CL,zN306S 5:?3.0372, found 523.0366.
.Anal.
Calcd for CZZH19C1zN3O6S ~ 0.35 H20: C, 49.79; H, 3.74E; N, 7.92. Found: C, 50.14; H, 4.08; N, 8.13. % Water (KF): 1.19.
Exairiple 283.
(45')-4-[[[( I,f)-1-Carboxy-2-[4-[(2,6-dichlorobenzoyl)amino]phenyl]ethyl]amino]carbonyl]-2-(4-pyridinyl)-3 thiazolidinecarboxylic acid 3-ethyl ester N~ ~ 5 : ~ 0 ~NI~ v 'OH
~O~O ~ I ~ O CI
H I
CI
Example 283 was prepared as described in Scheme B using ~-cysteine and 4-pyridinecarboxaldehyde to from the requisite thiazolidine carboxylic acid.
Physical data as follows: IR (drift) 3055, 2981, 2928, 1679, 1604, 1535, 1515, 1450, 1431,1406, 1378, 1331, 1 I94, 797, 778 cnri I; 'H NMR (300 MHz, CD30D~) b 8.68 (2 H), 8.28 {2 H), 7.55 (2 H), 7.42 (4 H), 7.25 (2 H), 6.28 ( 1 H), 4.70 ( 1 H), 4.09 (2 H), 3.4G ( 1 H), 3.16 ( 1 H), 2.94 (I H), 2.73 (1 H), 1.I7 (3 H);'3C NMR (75 MHz, CD30D) 8 190.2, 171.1; 162.1, 153.8, 141.4, 135.3, 134.6, 131.9, 130.3, 129.4, 128.2; 126.4, 122.4, I 18.5, 61.0, 51.7, 35.5, 26.6, 11.7; MS (FAB) mlz (rel. intensity) 617 (MH+, 99), 621 (35), 620 (72), 619 (99), 618 (91 ), 6I 7 (99), 371 (22), 179 (23), 173 {28), 124 (27), 5 ;~ (24); HRMS
(FAB) calcd for CZgH26CI2N4O6S +HI 617.1028, found 617.1019. Anal. Calcd for CZgH26C1zN4O6S ~
0.9 HCl ~ I.1 H20: C, 50.19; H, 4.38; N, 8.36; CI, 15.34. Found: C, 49.79; H, 4.49; N, 8.11;
CI, 15.05. % Water (KF): 2.96.

w0 99/6723U PCT/US99/14233 Example 284.
4-[[[(1,5~-2-Amino-1-[4-[(2,6-dichlorophenyl)methoxy]phenyl]methyl]-2 oxoethyl)aminoJ-carbonyl]-3-thiazolidinecarboxylic acid 3-[2-(I-pyrrolidinyl)ethyl] ester S- H O
CNN, n~u_ cN~o~o O
Example 284 was prepared as described in Scheme C. Physical data as follows:
IR (drift) 1709, I675, 1511, 1458, 1435, 1421, 1390, 1380, I354, 1299, 1240, 5, 1179, 1114, 765 cm -1;'H NMR {300 MHz, CD30D;) & 8.40 (1 H), 7.4I (3 H), 7.22 (2 H}, 6.99 (2 H}, 5.29 (2 H), 4.46 (6 H}, 3.77 {2 H); 3.50 (2 H), 3.19 (4 H}, 2.89 (1 H), 2.04 (1 H), 2.I2 (4 H);'3C NMR (75 MHz, CD30D) b 174.5, 171.6, 171.1, 157.9, 153.3, 136.6, 132.2, 130.6, 130.0, 129.7, 128.3, 114.5, 64.9, 63.2, 62.1, 60.9, 54.4, 53.6, 50.0, 49:0, 37.0, 36.5, 35.2, 22.6; MS (ESI+) for Cz7H32C12N4O5S m/z 595. i (M+H)+. HRMS
(FAB) calcd for C~,H32C12N4OSS +H~ 595.1548, found 595.1531.
Example 285.
E4s~-4-[[[(IS}-I-Carboxy-2-[4-[(2,6 dichlorophenyl)methoxyjphenyl]ethyl]amino]carbonyl]-3-thiazolidinecarboxylic acid 3 (3-tetrahydrofuranyl) ester /s- w ~o ~N~N~/~OH
O~O~O O \ /
O CI
Cr /

Example 285 was prepared as described in Scheme A. Physical data as follows:
'H NMR (300 MHz, CD30D) S 7.41 (3 H), 7.18 (2 H), 6.98 (2 H), 5.28 (2 H), 5.15 (I H) 4.69 (2 H), 4.44 {1 H), 3.82 (4 H); '3C NMR (75 MHz, DMSO-d6) 8 172.8, 157.9, 136.7, 132.2, 130.6, 130.1, 129.5, 128.3, 114.5, 76.8, 72.7, 66.5, 64.9, 62.4, 53.5, 36.3, 34.9, 32.4; MS (FAB) m/z (rel. intensity) 569 (MH+, 7S), 571 (51), 570 (29), 569 (75), 322 (22), 161 {20), 159 (30), 89 {2S}, 73 (31), 71 (99), 43 (41); HRMS (FAB) calcd for Cz5Hz6CLzN207S +H' 569.0916, found 569.0939. Anal. Calcd for CZSHZeCI2NzO7S:
C, 52.73; H, 4.60; N, 4.92;. Found: C, 52.41; H, 4.80; N, 4.62.
Example 286.
(45~-4-[[[(I,f)-2-Amino-I-[[4-[{2,6-dichlorophenyl)mei:boxy]phenyI]methyl]-2-oxoethyl]-amino]carbonylJ-3-thiazolidinecarboxylic acid 3-[2-(I-piperidinyi)ethyl] ester S' H O
~N~N~~NH2 O
~O~O
Example 286 was prepared as described in Scheme C. Physical data as follows:
'H NMR {300 MHz, CD30D) 8 7.43 (3 H); 7.22 (2 H), 6.98 (2 H), 5.28 (2 H), 4.66 (2 H}, 4.59 (1 H}, 4.47 (I H), 4.47 (2 H}, 3.05 (IO H), 1.78 {4 H), 1.62 (2 H); '3C
NMR (75 MHz, CD30D) 8 175.9, 172.9, 159.3, 138.1, 133.6, 132.0, 131.4, 131.1, 129.7, 120.1, 115.9, 66.3, 64.6, 63.7, 62.3, 61.9, 57.8, 55.8, 55.1, S 1.3, 50.3, 38.5, 37.8, 36.6, 25.0, 23.5; MS
{ESI+) for Cz$H34CIZN4:OSS m/z 609.0 (M+H}+.

Example 287.
(4S~-4-[[[( 1 S~-2-Amino-1-[[4-[(2;6-dichlorophenyl)meiboxy]phenyl]methyl]-2-oxoethyl]-amino]carbonyl]-3-thiazolidinecarboxylic acid 3-[2-{4-methyl-1-piperazinyi)ethyl] ester S- H O
\N~ ~N~N~'~NH2 ~N~O~O O
O CI
C!
Example 287 was prepared as described in Scheme C. Physical data as follows:
'H NMR (300 MHz, CD30D) 8 7.41 (3 H), 7.21 {2 H), 6.98 (2 H), 5.28 {2 H), 4.67 (I H), 4.58 {I H), 4.46 (1 H), 4.23 (2 H), 3.20 (2 H), 2.7i {13 H), 2.50 (3 H); MS
{ESI+) for C2gH35CIzN505S m/z 624.0 (M+H)+; Anal. Calcd for Cz81-i35C12N5O5S ~ 0.5 CZH402 ~ 0.5 H20: C, 49.82; H, 5.54; N, 10.02. Found: C, 49.82; H, :5.77; N, 9.65.
Example 288.
(4S)-4-[[[( 1 S~-2-Amino-1-[[4-[(2,6-dichlorobenzoyl)amino]phenyl]methyl]-2-oxoethyl]-amino]carbonyl]-3-thiazolidinecarboxylic acid 3-[2-{4-morpholinyl)ethyI] ester S- H O
O~ ~N~N~~NH2 N ~O~O O I ~
NH CI
~ HCI CI /
O

Example 288 was prepared' as described in Scheme C. Physical data as follows:
IR (drift) 1671, 1603, 1536, 1518, 1430, 1415, 1361, 1349, 1324, 1269, 1194, 1 I34, 1118, 1 I04, 799 crri';'H NMR (300 MHz, CD30D) 8 7.62 (1 H), 7.46 (3 H), 7.31 (2 H), 4.68 (3 H), 4.41 (3 H), 3.95 {4 H), 3.48 (5 H), 3.22 (3 H), 2.90 (2; H); '3C NMR {75 MHz, CD30D) 8 175.8, 173.1, 165.3, 154.7, 138.2, 137.6, 135.2, /33.3, 132.4, /30.9, 129.4, 121.7, 121.5, 65.0, 64.8, 63.7, 60.6, 57.4, 55.8, 53.6, 51.4, 50.4, 38.6, 38.1, 36.6, 35.0;
MS (ESI+) for C27H3'C12NSO6S m/Z 623.9 (M+H)+; HRMS (FAB) calcd for C27H3'C1zN506S+I-I
624.1450, found 624.1452.

Scheme R

R-i R~ R8 I
i \
R~ _ Rx O \
O~~ OCH3 s0 ~ R9 R~ R.~ I
\

H2N ~ ~2HC1 O
~ R9 o R~
R-4 R~ N O
R2~ ~m _ ,OCH3 X ~ HN
O~ O

o R' ~ Rg R_5 R1 N O
.OH

O In O

-24b-Scheme R
Scheme R teaches a general method for the preparation of Examples corresponding to structures R-4 and R-5, where R6 is nitrogen. Thus reaction of the amide R-1 (obtained from the imide J-2), with the organozinc derived from a suitable protected (3-iodoalanine, provides the acylamino azaphenylalanine R-2. N deprotection of R-2 gives the aminoester R-3, that is used (as exemplified by reagent A-4 of Scheme A, and by reagent B-5 of Scheme B) far the synthesis of Examples R-4 and R-5 of this invention.
Preparation 87 (Scheme R: R-1 where R6 is N, R, is H, R8 is -NHC{O)-, and R~ is 2,6-dichloro) 2,6-Dichloro-N (S-iodo-2-pyridinyl)benzamide (C,ZH7ChIN20). A mixture of J-2 and NHZNHZ~H20 in MeOH is refluxed for 6 h under Ar. The reaction mixture is cooled, and the MeOH is removed in vacuo. The residue is partitioned between H20 and EtOAc.
The EtOAc extracts are dried, filtered and concentrated ~to give a brown-colored solid, that is purified by silica flash chromatography (99:1 toluene~'EtOAc) to provide Preparation 87: TLC (98:2 toluene/EtOAc) Rf= 0.43; 'H NMR (CDCI3, 300 MHz) b 10.23 (1H), 8.26 ( 1 H), 7.99 ( I H), 7.57 ( 1 H}, 7.41-7.31 (3H}; '3C NMR (CDC13, 75 MHz) 8 163.40, 153.22, 150.95, 147.16, 135.83, 132.72, 131.90, 130.34, 128.65,, 128.50, i 17.09, 86.55; MS (ESI) 393, 391.
Preparation 88 (Scheme R: R-2 where R6 is N, R7 is H, R8 is -NHC(O)-, R, is 2,6-dichloro and the stereochemistry is S~
(S)-6-[(2,6-Dichlorobenzoyl)amino]-a-[[(1,1-dimethylethoxy)carbonyl]amino]-3-pyridinepropanoic acid methyl ester (CI,H23C1ZN3O5). To an amberized flask containing activated Zn dust (0Ø802 g, 12.27 mmol) under Ar is added dry THF (b mL) and 1,2-dibromoethane (0.045 mL). This suspension is brought briefly to a gentle reflux, and then is cooled to rt. A solution of TMSCI (1 M in THF, 0.39 mL) is added. The reaction mixture is stirred at 45 t 5 °C for 30 min, and then is cooled to rt.
To this mixture is added a degassed solution of N-[(1,1-dimethylethoxy)carbonyl]-3-iodo--L alanine methyl ester (4.04 g, 12.27 mmol) in 2:1 N,N-dimethylacetamide/THF (18 mL). The reaction mixture is stirred at 45 ~ 5 °C for 5 h, and then is cooled to 0 °t',.
To this mixture is added PdCl2(PPh3)Z (0.428 g) followed immediately by a degassed solution of Preparation 87 in 1:1 N,N~iimethylacetamide/THF (19 mL). This reaction mixture is stirred at 45 ~ 5 °C for 44 h. It is cooled to 0 °C, and is quenched with cold aqueous satd NH4Cl. This mixture is extracted with EtOAc. The combined EtOAc extracts are washed with aqueous satd NH4Cl and brine. The EtOAc extracts are dried, filtered and concentrated to provide a green-brown colored oil, that is purified by silica flash chromatography (steps of 750:250:1, 700:300:1 and 650:350:1 heptane/EtOAc/iPrOH) to provide Preparation 88: TLC
R~=
0.28 (7:3 hexanesIEtOAc).
Preparation 89 (Scheme R: R-3 where Itb is N, R7 is H, R8 is -NHC(O)-, R9 is 2,6-dichloro and the stereochemistry is S) {S'~-a-Amino-6-[(2,6-dichiorobenzoyl)amino]-3-p~yridinepropanoic acid methyl ester dihydrochloride salt (C,6H,SC1ZN303~2HCl, R-3). A solution of Preparation 88 (0.812 g, 1.73 mmol) in 4 M HCl in dioxane (20 mL) is stirred under Ar at rt for 20 h. The reaction mixture is concentrated in vacuo, and the residue is taken up in H20 (60 mL).
This aqueous mixture is extracted with Et20 (3 60 rnL), and the Et20 extracts are discarded. The aqueous solution is frozen and lyophilized to provide Preparation 89: IR
(diffuse reflectance) 3021, 2995, 2953, 2893, 2884, 2866, 2853, 2844, 2341, 2015, 1916, 1749, 1646, 1569, 1252 cm '; MS (EI) 367 (M+), 282, 280, 262, 175, 173, 147, 145, 109, 107, 88.

Preparation 90 & Example 289 [S-(R *, R *)]-4-[ [[ 1-[[2-[{2,6-Dichiorobenzoyl}amino)-5-pyridinyl]methyl]-2-methoxy-2-oxoethyl]amino]carbonyl]-3-thiazolidinecarboxylic acid ethyl ester (C23H24C12N4~6'rl}
(Scheme R: R-4 where R, is H, RZ is H, R3 is -Et, X is S., (Y) is -C(O)O, m is 2, n is 0, o is 1, Itb is N, R7 is H, R8 is -NHC{O)-, R, is 2,6-dichloro and the stereochemistry is [S
{R * R *)I ) NH
EtC O Cl To a mixture of the N acylthiazolidinecarboxylic acid' (0.292 g, 1.42 mmol), HOAt (0.193 g, 1.42 mmol) in 4:1 CH2CIzlDMF (5.25 mL) at 0 °C is added EDC
(0.272 g, I .42 mmol}. This reaction mixture is stirred at 0 °C for 20 miry. Solid Preparation 89~ (0.568 g, 1.29 mmol) and NMM (0.316 mL, 3.27 mmol) are added.. The resulting reaction mixture is stirred at 0 °C for 4 h, and then is kept at 4°C for 40 h. Tlle mixture is concentrated in vacuo, and the residue is taken up in CHZC12. The CHZCI? mixture is extracted with HzO, aq satd NaHC03, and H20. The combined aqueous washes are back-extracted with CHZCIZ. The combined CHZCIz extracts are dried, filtered and concentrated to a pale yellow-colored foam, that is purified by silica flash chromatgraphy (600:400:1 EtOAc/heptane/iPrOH) to give Preparation 90 (Examplle 289): IR (diffuse reflectance) 3275, 1742, 1697, 1665, 1586, 1559, 1532, 1476, 1427, 1.398, 1382, 1351, 1344, 1311, 1284, 1279, 1242, 1223, 1 I96, 1100, 1023, 802, 787, 7 70, 697 cm '; MS (EI) SS4 (M+), 495, 422, 395, 352, 315, 293, 280, 172, 160, 144, 116, 107, 88, 60.
Example 290 S [S-(R *,R *)]-4-[[[ I-Carboxy-2-[2-[(2,6-dic:hlorobenzoyl)amino]-S-pyridinyl]ethyl]amino]carbonyl)-3-thiazolidine;carboxylic acid ethyl ester {C22H22C12N4~6"~~ EXa1T1p1f: 290) (Scheme R: R-4 where R, is H, RZ is H, R3 is -Et, X is S~, (Y) is -C(O)O, m is 2, n is 0, o is l, R6 is N, R~ is H, R8 is -NHC(O}-, R9 is 2,6-dichloro and the stereochemistry is [S
to (R*.R*)D
Cl NH ~ /
Et0 O
O
N
S
To a solution of Preparation 289 (0.400 g, 0.72 mmol) in 6:1 THF/H20 (25.6 rnL) 15 at 0 °C under Ar is added slowly over 4 h (via syringe pump} an aqueous solution of NaOH ( 1 M, 7.92 mL). The reaction mixture is stirred a:n additional 1.S h.
The reaction mixture is partitioned between aqueous HCl and EtOAc" The aqueous solution is separated, and is extracted further with EtOAc. The combined EtOAc extracts are dried, filtered and concentrated to a beige-colored foam. This foam is taken up in 1:1 20 MeCN/H20. This solution is frozen and lyophilized to give Example 290 as a beige-colored solid: rnp I42-144 °C; IR (diffuse reflectance) 3169, 3094, 3031, 2980, 2964, 2935, 1735,1691, 1591, 1556, 1531, 1480, 1431, 1400, 1379, 1344, 1308, 1288, 1266, 1216, 1194, 1148, 799, 782, 772 cm '; Anal. C 48.72, H 4.29, Cl 12.26, N 9.95, S 5.62 {calcd C 48.81, H 4.10, Cl 13.10, N I0.3S, S 5.92).

WO 99!67230 PCT/US99114233 BioIo;gicai Assays Jurkat-Endothelial Cell Adhesion Assay The following assay established the activity of the present compounds in inhibiting [3,-mediated cell adhesion in a representative in vitra system.
This assay measures the adhesive interactions of a T-cell line, Jurkat, known to express the a4~3, integrin, to endothelial monolayers in the presence of test compounds.
The test compounds were added in increasing concentrations to T-cells and then the T-ceIl compound mixture was added to IL-1 stimulated endothelial cell monolayers.
The plates were incubated, washed and the percentage oi' attached cells was quantitated. The present assay directly demonstrates the cell adhesion inhibitory activity and adhesion modulatory activity of the compounds.
Human umbilical vein endothelial cells were pur<:hased from Clonetics (San Diego, CA.) at passage number 2. The cells were grown on 0.5% porcine skin gelatin pre-coated flasks (Sigma, St. Louis MO.) in EGM-UV media (Clonetics, San Diego, CA) supplemented with I O% fetal bovine serum. Cells are refed every 2-3 days reaching confluence by day 4 to 6. The cells are monitored for factor VIII antigen and results show that at passage l:Z, the cells are positive for this antigen. The endothelial cells are not used following passage 6.
The T-cell line Jurkat was obtained from American Type Tissue Culture Collection {Rockville, MD) and the cells were cultured in RPMI containing 10 fetal calf serum. The cells were washed twice in Hank's :Balanced Salt Solution (HBSS) and resuspended in Dulbecco's Minimal Eagle's Media (DMEM) containing 2.5 mg/ml Human Serum Albumin (HSA). Jurkat cells ( 1 x 106 cells/ml) were stained with 10 nglml BCECF-AM (Molecular Probes, Eugene, OR)) in HBSS without phenol red. The cells were loaded with BCECF for 60 minutes in the dark at 370C, washed 2 times, and resuspended in DMEM-HSA solution.
Confluent endothelial monolayers, grown in 96-well tissue culture plates, were stimulated for 4 hr. at 37 °C with 0.1 ng/ml (~50 U/ml) recombinant IL-1 (Amgen, Thousand Oaks, CA). Following this incubation, the monolayers were washed twice with HBSS and 0.1 ml of DMEM-HSA solution was added. Jurkat WO 99167230 PCT/US99l14233 -2sI-cells (s X 105 cells} were combined with the appropriate concentration of the test compound and 0:1 ml of the Jurkat cell-compound mixture was added to the endothelial cell monolayers. Generally, 100, 20, s and I.2s p,M compound concentrations were tested. These concentrations are adjusted downward for s analogs found or thought to be more potent. The plates were placed on ice for s minutes to allow for Jurkat cell settling and the plates were incubated at 37 °C for 20 minutes. Following this incubation, the monolayers were washed twice with PBS containing 1 mM calcium chloride and I mM magnesium chloride and the plates were read using a Millipore Cytofluor 2300 (Marllboro, MA.}.
Fluorescence in each well was measured as Arbitrary Fluorescence Units and percent adhesion in the absence of compound was adjusted to 100% and the % adhesion in the presence of compound was calculated. Monolayers were also fixed in 3%
paraformaldehyde and evaluated microscopically to verify the adhesion. This procedure is a modification of a previously published method (Cardarelli et al., J.
1 s Biol. Chem. 269:18668-1$673 (1994)}.
Jurkat-CS-1 assay The CS-1 derived peptide, CLHPGEILDVPST, and the scrambled control peptide, CLHGPIELVSDPT, were synthesized on a Beckman 990 synthesizer using t-Boc methodology. The peptides were immobili2:ed onto microtiter plates using the heterobifunctional crosslinker 3-(2-pyridyldithio)propionic acid N-hydroxysuccinimide ester (SPDP) as reported by Pierschbacher et al., Proc.
Nall.
Acad. USA, 80:1224-1227 (1983). Microtiter plates were coated with 20- pg/ml HSA for 2 hr. at room temperature, washed once with Pl3S and derivatized with 2s p.g/ml SPDP for 1 hr. After washing, 100 ~1 of a 100 pg/ml cysteine containing peptide solution which had been recently dissolved was added to the wells and allowed to crosslink to the plates overnight at 4 °C. Unbound peptide was removed from plates by washing with PBS. To block non-reactecE sites, the plates are coated with 100 ~l of a 2.s mg/ml BSA solution in PBS for I hr. at 37 °C. 100 pl of Jurkat cells (2.s x 106 cells/ml) in DMEM plus BSA (2.s mg/ml) was mixed with an appropriate concentration of the compound to be tested and the mixture was added to peptide coated dishes and incubated fox 1 hr. at 37 °C.
Generally 100 20, and I.25 ~M concentrations of the compound were tested. The concentrations of the compound were adjusted downward for compounds thought or found to be 5 more potent.
Following this incubation the plates werewashed. once with PBS and the attached cells were fixed with 3% paraformaidehyde in fBS and stained with 0.5%
toluidine blue in 3.7% formaldehyde. The cells were stained overnight at room temperature and the optical density at 590 nm of toluidin.e blue stained cells was determined using a vertical pathway spectrophotometer to quantitate attachment (VMAX Kinetic Microplate Reader, Molecular Devices, Menlo Park, CA). This procedure is a modification of a previously published method (Cardarelli et al, J.
Biol. Chem., 269:18668-18673 (1994) and Cardarelli et al, Proc. Natl. Acad.
Sci.
USA, 83:2647-2651 (1986)).
I S The preferred compounds are those which have low ICS° values in the Jurkat EC assay or the Jurkat-CS-1 assay described above or which have at least moderate activity in both assays. AlI of the compounds of the present invention have an activity of less than 50 uM in the Jurkat CS-1 assay or less than 500 p,M in the 3urkat EC assay. Compounds with activity in the Jurkat CS-1 assay preferably have ICso values of less than 1 pM, more preferably less than 0.5 ACM, most preferably less than or equal to 0.08 p.M. Compounds with activity in the Jurkat EC assay preferably have ICS° values of less than 10 ~,M,, more preferably less than 5 pM, most preferably less than or equal to 0.8 ~xM.
In the Jurkat EC Assay, ICS° value ranges (p,M) are depicted by A, B, and C
and in the Jurkat CS-1 Assay, ICS° value ranges are depicted by D, E, and F. These ranges are as follows:
In vitro data:
EC: A >_ 1 1ZM; I p,M > B > 0.25 p,M; C <_ 0:25 p,M
CS-1 D >_ 0.75 pM; 0.75 p.M > E > 0.05 wM; F s 0.05 N.M.

Ex. JK/EC JK/CS-I
,.-~.

1 A ~ E

__ _ B E

C F

__ A D

C F

28 A D.

A E

B E

37 C _ F

42 ~ B ~ E

Ex. JK/EC JK/CS-1 44 A __._._ D

SS C F

61 g E

62 C _. - _ F

64 C _ F

__.-__ -79 , A D

_ _ E~. JK/EC JKICS-1 A D

90 A, 97 A _ D

100 g E

lOT B E

i03 B F

110 A _ lil B E

113 A _ E

i15 A E

ii6 A D

ill A E

_ Ex. JK/EC JK/CS-1 ~

168 A, i75 A

Ex. JKlEC JK/CS-1 _. _ ~

181 A -~ E

187 i A E

191 A _ E

_ _ 206 B g Ex. JK/EC JK/CS-3 ___ 236 A D

_ 239 __ A E

240 A _ E

243 B _ E

244 B g 246 B _ E

2SS A __. E

264 C _ F

Ex. JKIEC JK/CS-1 _ 273 D

276 . D

Bioloeicai Activity in Dextran Pleurisy Model Certain compounds of the present invention were tested in a Dextran~ pleurisy model.
Rationale for Developin an a,~i, Inte~rin Antagonist to 'Treat Inflammatory Diseases VLA-4, a member of the (31 integrin family of adhesion molecules, is thought to play a critical role in several types of inflammatory disease processes by promoting leukocyte adhesion to vascular cell adhesion molecule (VCAM-1 ) and the CS-1 domain of fibronectin in extracellular tissue matrix (Elices MJ, Osborn L, Takada Y, Crouse C, Luhowskyj S. Hemler M, Lobb RR. VCAM-1 on activated endothelium interacts with the leukocyte intesrin VLA-4 at a site distinct from the VLA-4-fibronectin binding site. Cell;
60: 577-584. 1990. Humphries MJ. Akiyama SK. Komoriya A, Olden K, Yamada KM.

Identification of an alternatively-stiIiced site in human plasma f bronectin that mediates cell type-specific adhesion. J Cell Biol; 103: 2637-2647. 1986, Wayner EA, Garcia-Pardo A, Humphries MJ, McDonald JA, Carter WG. Identification and characterization of the T
lymphocyte adhesion receptor for an alternative cell attachment domain CS-1 in plasma .
fibronectin. J Cell Biol; 109: 1321-1330, 1989, Guan J-L, Hypes RO. Lymphoid cells recognize an alternatively-spliced segment of fibronectin via the inte~rin a~(3, . Cell; 60:
53-6I, 1990) Of the cell types expressing VLA-4, the major emphasis has been on eosinophils, lymphocytes, and monocytes. Validation of the role of VLA-4 has relied predominantly on the use of anti-VLA-4 antibodies which have been shown to suppress delayed-type hypersensitivity responses {Issekutz TB. Dual inhibition of VLA-4. and LFA-1 maximally inhibits cutaneous delayed-type hyper<~ensitivitv-induced inflammation.
Am J Pathol; 143: 1286-1293, 1993, Scheynius A, Camp RL, Pure E. Reduced contact sensitivity reactions in mice treated with monoclonal antibodies to leukocyte function associated molecule-1 and intercellular adhesion molecule~l . J Immunol; 150:
655-663, 1993, Ferguson TA, Kupper TS. Antigen-independent processes in antigen-specific immuni . J Immunol; 150: 1172-1182, 1993, Chisholm PL, Williams CA, Lobb RR.
Monoclonal antibodies to the rote ~; 'ran a-4 subunit inhibit the murine contact hypersensitivity response. Eur J Immunol; 23: 682-688. 1993, Elices MJ, Tamraz S, Tollefson V, Vollger LW. The integrin VLA-4 mediates leukocyte recruitment to skin inflammatory sites in vivo. Clip Exp Rheumatol; 1 I (Suppl 8) S77-80}, 1993, experimental allergic encephalomyelitis (Yednock TA, Cannon C, F:itz LC, Sanchez-Madrid F, Steinman LM, Karin N. Prevention of exnerirr~ental autoimmune encephalomyelitis by antibodies a~ a~inst aa~3, rote rip. Nature; 356: 63-66.
1992, CaneIla B, Raine CS. The VCAM-1/VLA-4 pathway is involved in chronic lesion expression in multiple sclerosis (MSI. J Neuropathol Exp Neurol; 52: 311, 1993), HIV-induced encephalitis (Sasseville VG, Newman W, Brodie 5.1. Hesterberg P, Pauley D, Ringler DJ.
Monocvte adhesion to endothelium in simian immunodeficiencv virus-induced AIDS
encephalitis is mediated by vascular cell adhesion rrtolecule-1/a,~, integrin reactions. Am J Pathol; 144: 27-40, 1994), pulmonary inflammation and airway hyperreactvity in asthma (Abraham WM, Sielczak MW. Ahrned A, Cortes A. Lauredo IT, Kim J. Pepinsky, B, et al.

a~-inte~rms mediate antigen-induced late bronchial responses and prolonged airw~
hvperresponsiveness in sheen. J Clin Invest: 93: 776-787, 1994, Pretolani M.
Ruffle C, Roberto LapaeSilva J, Joseph D, Lobb RR. Vargaftig BB. Antibody to very late activation antigen 4 prevents antigen-induced bronchial hyperreactivitv and cellular infiltration in the rub. inea-p~rwa~. J Exp Med; I 80: 795-805; 1994), experimental models of autoimmune-mediated diabetes (Yang X-D, Karin N, Tisch R, Steinman L, McDevitt HO.
Inhibition of insulitis and prevention of diabetes in non-obese diabetic mice by blocking L-selectin and very late antigen 4n 4 adhesion receptors. Proc Natl Acad Sci USA; 90:
10494-10498, 1993, Burkly LC, Jakubowski A, Hattori Ivl. Protection aeainst adoptive transfer of autoimmune diabetes medicated through very late antigen-4 integrin. Diabetes;
43: 529-534, 1994), and experimental colitis {Podolsky I)K, Lobb R, King N, Benjamin CD, Pepinsky B, Sehgal P, et al. Attentuation of colitis in the cotton-top Tamarin by anti-4 inteirrin monoclonal antibody. 3 Clin Invest; 92: 372-380, 1993). Since eosinophils represent a major component of the inflammatory cell influx in asthmatic lung tissue we developed a simple acute inflammatory model of VLA-4 integrin-dependent eosinophil infiltration which could be used to identify VLA-4 antagonists; such compounds would be of potential value in the treatment of asthma as well as other diseases in which VLA-4 played a role.
Materials and Methods Animals, housing and viral testing:
C57BL/6 mice (Jackson, Bar Harbor, ME; ), 6-8 weeks old, weighing 20-25g were used throughout. All mice were acclimated for at least 7-14 days after arrival and maintained under controlled temperature {20-22oC) and a 12 hr daily light cycle (6.00 A.M. - 6.00 P.M.). Mice were housed in laminar flow racks and checked biweekly for viral infections (mouse hepatitis virus, minute virus of mice. rodent orphan parvovirus, Sendai) with kits obtained from Oreganon Teknika {Durham. NC) using established enzyme-linked immunoabsorbent assays. Mice testing positive for any of the above were omitted from the study. All mice were fed standard laboratory chow (Upjohn Lab Rodent Irradiated Mouse Chow. #5011-3, PMI Feeds, St. Louis. MO) and acidified drinking water (pH 5.0) ad libitum.

Induction of Inflammation by Intrapleural Injection of Dextran:
Intrapleural injections were made using a 27G needle cut to 3-4 mm and blunted by filing. Injections were made by inserting the needle between the mid-intercostaI ribs on the right side of the thoracic cavity.
Dextran (MW S-40x106, St Louis; MO.) was injected as a I0% solution in saline in a volume of 100 ul/mouse. Care was taken to avoid bleeding at the site of injection at which the intercostal muscles were cut to facilitate smooth insertion of the needle.
Ouantitation of Pleural Inflamrnatory Leukocyte Responses:
Pleural leukocytes were collected as follows: 4h post-induction, pleural inflammatory exudate was removed by washing with 2 x 1.0 mi Ca'~/Mg'~"~ free HBSS
{Gibco, Grand Island, NY) containing 45 mg EDTA/100 rnl HBSS, 4oC. Total leukocyte counts were made by hemocytometer following erythrocyte Iysis in 2% acetic acid in PBS
buffer; exudate leukocyte pellets were resuspended in serum for cytospin preparations arid stained (Diff Quik, Baxter Healthcare, McGraw Park, IL) for differential leukocyte counts {neutrophils, eosinophils, and mononuclear leukocytes}.
The pleural cavities of mice receiving either no intrapleural injection, or saline were washed and the cells counted in the same way to estimate baseline or saline-induced pleural leukocyte counts respectively.
Administration of compounds' All drugs were dissolved in PBS and the pH adjusted to 7.5 with NaOH. Each compound was administered intravenously through the retroorbital sinus at hourly intervals (0-3h) starting from time "0" as indicated. Mice were carefully monitored for side effects; none were noted for the series of compounds reported herein.
The following compounds were tested for their inhibitory effects on dextran-induced leukocyte infiltration: Examples 3, 8, 9, 10, 12, 16, 37, 62, 66, 67, 99, 100, 11 I, 113, 1 I5, 127. 131, 141, I84, 185, 192, PBS (saline} was administered iv. as a control.

WO 99/67230 PCTlUS99/14233 Inhibition of eosinophii infiltration. which was suppressed by anti-alpha-4 Mab {PS/2, s0%}, was used as a readout of VLA-4 antagonist activity of the compounds tested. Data for neutrophils are also reported.
Results:
s Dextran pleural leukocyte response. The total pleural leukocyte counts were 255x104(+/-16 SEM) cells in the normal pleural cavity; of the normail pleural leukocyte population, all cells were mononuclear (a similar response was observed following intrapleural saline injection). Four hours after intrapleuraI injection ofdextaran total pleural leukocyte counts increased to 719x104(+/-67 SEM) and comprised 36.8x104(+/-4.1 SEM}
eosinophils, 292x104(+/-2s SEM) neutrophils and 391x104(+L-48 SEM) mononuclear leukocytes.
inhibition of Eosinophil inf ltration A>40; B: 20-39; C < 19 Example Dose Eos 3 sOx2iv A

8 100 x 1 C
po 9 SOx2iv A

10 100 x I B
po 12 sOx2iv A

16 sOx2iv A

37 sOx2iv A

62 s0x2iv B

66 SOx2iv A

67 SOx2iv A

99 s0 x 2 iv A

loo soxziv B

111 sOx2iv C

113 s0 x 2 iv C

Example Dose Eos I15 SOx2iv B

127 50x2iv B

I31 50x2iv C

141 SOx2iv A

185 50 x 2 iv B

184 50 x 2 iv B

192 SOx2iv B

Claims (40)

-265- What is claimed is:
1. A compound of the formula:
wherein R1 may occur one to four times and each occurrence is independently hydrogen or C1-6 alkyl;
R2 is hydrogen, pyridyl, C1-6 alkyl, (C1-6 alkyl)-CO2-R11, or -CO2-R11;
in addition, R1 and R2 may be attached to the same carbon atom and form a carbocyclic ring of 5-8 atoms together with the carbon atom to which they are attached, or they may be attached to the same carbon atom and form a ring of 5-8 atoms of the formula:
together with the carbon atom to which they are attached:
R3 is hydrogen, phenyl, C1-6 alkyl, C3-6 alkenyl, C7-17 arylalkyl , (C1-6 alkyl)-CO2-R11, (C2-6 alkenyl)-CO2-R11, (C1-6 alkyl)-CO-C1-6 alkyl, (C1-6 alkyl)-O-C1-6 alkyl, (C1-6 alkyl)-OH, (C1-6 alkyl)-CN, adamantyl or one of the following:

in addition, R2 and R3-(Y)o- may combine with each other at the terminal thereof to form a ring of the following formula together with the carbon atom and the nitrogen atom to which they are attached:
R4 is -O-R11, NH2, NHOH, -O-(C7-10 arylalkyl), or is of the formula R5 is a formula of the following:
R6 is N or CH;
R7 is hydrogen or halogen R8 is -NH-Y1-, -OCH2- or -CONH-;
R9 may occur one to three times and is a halogen, C1-6 alkoxy, C1-6 alkyl or trifluoromethyl;
R10 is C1-6 alkyl, or (C1-6 alkyl)-OH, or hydrogen;
R11 is hydrogen or C1-6 alkyl;
R12 is C1-6 alkyl or the following formula:
R13 is N or CH;
W is (C1-6 alkyl);
X is S, O, or CH2;
Y and Y1 are independently -CO-, -C(=O)O-, -SO2-, or -C(=O)N(R10)-;
Z is O, CH2, or N-R11;
l is 1, 2, or 3;
m is 1 or 2;
n is 0 or 1;
o is 0 or 1;
p is 0 or 1;
g is 0 or 1; and r is 0, 1, 2 or 3;
with the provisos that (1) when Y is -C(=O)O-, R3 cannot be hydrogen;
(2) when R4 is equal to O-(C, alkyl), C4 alkyl is not equal to tert-butyl;
(3) in those pyrrolidine structures (l is 1; m is 2; n is 0; o is 0; p is 1; X
is CH2), W is equal to CH2; and (4) the compound is not
2. The compound according to claim 1, wherein R5 is a formula of the following:
wherein R7 is hydrogen or Cl.
3. The compound according to claim 2, wherein R2 is hydrogen or C1-6 alkyl;
in addition, R1 and R2 may be attached to the same carbon atom and may form a carbocyclic ring of 5-8 atoms together with the carbon atom to which they are attached or be attached to the same carbon atom and form a ring of 5-8 atoms of the formula:
together with the carbon atom to which they are attached;
n is 0;
m is 2; and p is 0.
4. The compound according to claim 3, wherein R1 is hydrogen or C1-3 alkyl;
R2 is hydrogen or C1-4 alkyl;
in addition, R1 and R2 may be attached to the same carbon atom and may form a carbocyclic ring of 5-8 atoms together with the carbon atom to which they are attached or be attached to the same atom and form a ring of 5-8 atoms of the formula:
together with the carbon atom to which they are attached;
R3 is hydrogen, C1-6 alkyl, C7-17 arylalkyl, (C1-6 alkyl)-OH, (C1-6 alkyl)-CO2-R11, (C1-6 alkyl)-CN, adamantyl, phenyl, or one of the following:
R4 is -O-R11, NH2, NHOH, or is of the formula R11 is hydrogen or CH3; and X is S or O.
5. The compound according to claim 3, wherein R1 is hydrogen;

R2 is hydrogen;
R3 is (C2-6 alkenyl)-CO2-R11, (C1-6 alkyl)-O-C1-3 alkyl, (C1-6 alkyl)-CO2R11, or one of the following:
R4 is O-R11;
R6 is CH;
R11 is hydrogen;
R7 is hydrogen;
X is S;
Y is -CO-; and l is 1.
6. The compound according to claim 3, wherein R1 is hydrogen;
R2 is hydrogen;
R3 is C1-6 alkyl, (C1-6 alkyl)-CO2-R11, (C2-6 alkenyl)-CO2-R11, (C1-6 alkyl)-alkyl, (C1-6 alkyl)-O-C1-3 alkyl, (C1-6 alkyl)-CN, or one of the following:

R4 is OH;
R6 is CH;
R11 is hydrogen;
R7 is hydrogen;
X is CH2; and Y is -CO- or -C(=O)NH-.
7. The compound according to claim 2, wherein W is (C1-3 alkyl);
X is CH2;
Y is -C(=O)O-;
R1 is hydrogen;
R2 is hydrogen, (C1-3 alkyl)-CO2-R11, or -CO2-R11;
R3 is hydrogen, C7-10 arylalkyl, C1-6 alkyl, or (C1-6 alkyl)-CO2-R11;
R4 is OH;
R6 is CH;
R11 is hydrogen;
R7 is hydrogen;
l is 1 or 3; and n is 0.
8. The compound according to claim 2, wherein W is C1-3 alkyl;
X is CH2;
R1 is hydrogen;
R2 is (C1-4 alkyl)-CO2-R11, or CO2-R11;
R3 is hydrogen, C1-3 alkyl, or C2-7 alkenyl;
R4 is OH, R6 is CH;
R11 is hydrogen;
R7 is hydrogen;
l is 1;
m is 1;
n is 1;
o is 0; and p is 1.
9. The compound according to claim 1, wherein said compound is
10. The compound according to claim 4, wherein R1 is hydrogen;

R2 is hydrogen;
R3 is C1-6 alkyl, (C1-6 alkyl)-CO2R11, (C2-6 alkenyl)-CO2R11, (C1-6 alkyl)-O-C1-3 alkyl, or one of the following:
R4 is O-R11;
R6 is CH;
R11 is hydrogen or C1-6 alkyl;
R7 is hydrogen;
X is S;
Y is -C(=O)O-; and l is 1.
11. The compound according to claim 1, wherein R1 is hydrogen or C1-3 alkyl;
R2 is hydrogen or C1-4 alkyl;
in addition, R1 and R2 may be attached to the same carbon atom and may form a carbocyclic ring of 5-8 atoms, or be attached to the same atom and form a ring of 5-8 atoms of the formula:
together with the carbon atom to which they are attached;
R3 is hydrogen, C1-6 alkyl, C7-17 arylalkyl, (C1-6 alkyl)-OH, (C1-6 alkyl)-CO2-R11, (C1-6 alkyl)-CN, adamantyl, phenyl, or one of the following:

R4 is -O-R11, NH2, NHOH, or is of the formula R11 is hydrogen or C1-6 alkyl; and X is S or O.
12. A compound of the formula:
wherein R1 may occur one to four times and each occurrence is independently hydrogen or C1-6 alkyl;
R2 is hydrogen, pyridyl, C1-6 alkyl, (C1-6 alkyl)-CO2-R11, or -CO2-R11;

in addition, R1 and R2 may be attached to the same carbon atom and farm a carbocyclic ring of 5-8 atoms together with the carbon atom to which they are attached, or they may be attached to the same carbon atom and form a ring of 5-8 atoms of the formula:
together with the carbon atom to which they are attached;
R3 is hydrogen, phenyl, C1-6 alkyl, C3-6 alkenyl, C7-17 arylalkyl , (C1-6 alkyl)-CO2-R11, (C2-6 alkenyl)-CO2-R11, (C1-6 alkyl)-CO-C1-6 alkyl, (C1-6 alkyl)-O-C1-6 alkyl, (C1-6alkyl)-OH, (C1-6 alkyl)-CN, adamantyl or one of the following:
in addition, R2 and R3-(Y)o- may combine with each other at the terminal thereof to form a ring of the following formula together with the carbon atom and the nitrogen atom to which they are attached:
;

R4 is -O-R11, NH2, NHOH, -O-(C7-10 arylalkyl), or is of the formula ;
R5 is a formula of the following:
;
R6 is N or CH;
R7 is hydrogen or halogen;
R8 is -NH-Y1-, -OCH2- or -CONH-;
R9 may occur one to three times and is a halogens C1-6 alkoxy, C1-6 alkyl or trifluoromethyl;
R10 is C1-6 alkyl, or (C1-6 alkyl)-OH, or hydrogen;
R11 is hydrogen or C1-6 alkyl;
R,2 is C1-6 alkyl or the following formula:
R13 is N or CH;
W is (C1-6 alkyl);
X is S, O, or CH2;
Y and Y1 are independently -CO-, -C(=O)O-, -SO2 , or -C(=O)N(R10)-;
Z is O, CH2, or N-R11;
l is 1, 2, or 3;
m is 1 or 2;
n is 0 or 1;
o is 0 or 1;
p is 0 or 1;
q is 0 or 1;and r is 0,1,2 or 3;
with the provisos that (1) when Y is -C(=O)O-, R3 cannot be hydrogen;
(2) when R4, is equal to O-(C4 alkyl), C4 alkyl is not equal to tert-butyl;
(3) in those pyrrolidine structures (l is 1; m is 2; n is 0; a is 0;p is 1; X
is CH2), W is equal to CH2;
(4) the compound has an IC50 value of less than 5µM in a Jurkat CS-1 assay and/or an IC50 value of less than 50µM in a Jurkat EC assay; and (5) the compound is not
13. A pharmaceutical composition comprising:
a therapeutically effective amount of the compound as set forth in any one of the preceding claims; and a pharmaceutically acceptable carrier or diluent.
14. A method for treating or preventing .alpha.4.beta.1 adhesion mediated conditions in a human which comprises administering to a patient an effective amount of the compound according to any one of claims 1, 2, 3. 4, 5, 6, 7, 8, 9, 10, 11, or 12.
15. The method according to claim 14, wherein said condition is selected from the group consisting of rheumatoid arthritis, asthma, allergy conditions, allograft rejection, psoriasis, eczema, contact dermatitis and other skin inflammatory diseases, inflammatory and immunoinflammatory conditions including ophthalmic inflammatory conditions, inflammatory bowel diseases, atherosclerosis, and ulcerative colitis.
16. The method according to claim 15, wherein said condition is asthma.
17. A compound of the formula:
wherein R1 may occur one to four times and each occurrence is independently hydrogen or C1-6 alkyl;
R2 is hydrogen, pyridyl, C1-6 alkyl, (C1-6 alkyl)-CO)2-R11, or -CO2-R11;
in addition, R1 and R2 may be attached to the same carbon atom and form a carbocyclic ring of 5-8 atoms together with the carbon atom to which they are attached, or they may be attached to the same carbon atom and form a ring of 5-8 atoms of the formula:
together with the carbon atom to which they are attached;
R3 is hydrogen, phenyl, C1-6 alkyl, C3-6 alkenyl, C7-17 arylalkyl , (C1-6 alkyl)-CO2-R11, (C2-6 alkenyl)-CO2-R11, (C1-6 alkyl)-CO-C1-6 alkyl, (C1-6 alkyl)-O-C1-6 alkyl,(C1-6 alkyl)-OH, (C1-6 alkyl)-CN, adamantyl or one of the following:

in addition, R2 and R3-(Y)o- may combine with each other at the terminal thereof to form a ring of the following formula together with the carbon atom and the nitrogen atom to which they are attached:
;
R4 is -O-R11, NH2, NHOH, -O-(C7-10 arylalkyl), or is of the formula ;
R5 is a formula of the following:
;
R6 is N or CH;
R7 is hydrogen or halogen;

R8 is -NHCO-;
R9 may occur one to three times and is a halogen, C1-6 alkoxy, C1-6 alkyl or trifluoromethyl;
R10 is C1-6 alkyl, or (C1-6 alkyl)-OH, or hydrogen;
R11 is hydrogen or C1-6 alkyl;
R12 is C1-6 alkyl or the following formula:
;
R13 is N or CH;
W is (C1-6 alkyl);
X is S, O, or CH2;
Y is -CO-, -C(=O)O-, or -C(=O)N(R10)-;
Z is O, CH2, or N-R11;
l is 1, 2, or 3;
m is 1 or 2;
n is 0 or 1;
o is 0 or 1;
p is 0 or 1;
q is 0 or 1;and r is 0, 1, 2 or 3;
with the provisos that (1) when Y is -C(=O)O-, R3 cannot be hydrogen;
(2) when R4 is equal to O-(C4 alkyl), C4 alkyl is not equal to tert-butyl; and (3) in those pyrrolidine structures (l is 1; m is 2; n is 0; o is 0; p is 1; X
is CH2), W is equal to CH2.
18. The compound according to claim 17, wherein R5 is a formula of the following:
wherein R7 is hydrogen or Cl.
19. The compound according to claim 18, wherein R2 is hydrogen or C1-6 alkyl;
in addition, R2 and R2 may be attached to the same carbon atom and may form a carbocyclic ring of 5-8 atoms together with the carbon atom to which they are attached or be attached to the same carbon atom and form a ring of 5-8 atoms of the formula:
together with the carbon atom to which they are attached;
n is 0;
m is 2; and p is 0.
20. The compound according to claim 19, wherein R1 is hydrogen or C1-3 alkyl;
R2 is hydrogen or C1-4 alkyl;
in addition, R1 and R2 may be attached to the same carbon atom and may form a carbocyclic ring of 5-8 atoms together with the carbon atom to which they are attached or be attached to the same atom and form a ring of 5-8 atoms of the formula:

together with the carbon atom to which they are attached;
R3 is hydrogen, C1-6 alkyl, C7-17 arylalkyl, (C1-6 alkyl)-OH, (C1-6 alkyl)-CO2-R11, (C1-6 alkyl)-CN, adamantyl, phenyl, or one of the following:
R4 is -O-R11, NH2, NHOH, or is of the formula ;
R11 is hydrogen or CH3; and X is S or O.
21. The compound according to claim 19, wherein R1 is hydrogen;
R2 is hydrogen;
R3 is (C2-6 alkenyl)-CO2-R11, (C1-6 alkyl)-O-C1-3 alkyl, (C1-6 alkyl)-CO2R11, or one of the following:

R4 is O-R11;
R6 is CH;
R11 is hydrogen;
R7 is hydrogen;
X is S;
Y is -CO-; and l is 1.
22. The compound according to claim 19, wherein R1 is hydrogen;
R2 is hydrogen;
R3 is C1-6 alkyl, (C1-6 alkyl)-CO2-R11, (C2-6 alkenyl)-CO2-R11, (C1-6 alkyl)-alkyl, (C1-6 alkyl)-O-C1-3 alkyl, (C1-6 alkyl)-CN, or one of the following:
R4 is OH;
R6 is CH;

R11 is hydrogen;
R7 is hydrogen;
X is CH2; and Y is -CO- or -C(=O)NH-.
23. The compound according to claim 18, wherein W is (C1-3 alkyl);
X is CH2;
Y is C(=O)O-;
R1 is hydrogen;
R2 is hydrogen, (C1-3 alkyl)-CO2-R11, or -CO2-R11;
R3 is hydrogen, C7-10 arylalkyl, C1-6 alkyl, or (C1-6 alkyl)-CO2-R11;
R4 is OH;
R6 is CH;
R11 is hydrogen;
R7 is hydrogen;
l is 1 or 3; and n is 0.
24. The compound according to claim 18, wherein W is C1-3 alkyl;
X is CH2;
R1 is hydrogen;
R2 is (C1-4 alkyl)-CO2-R11, or CO2-R11;
R3 is hydrogen, C1-3 alkyl, or C2-7 alkenyl;
R4 is OH, R6 is CH;
R11 is hydrogen;

R7 is hydrogen;
l is 1;
m is 1;
n is 1;
o is 0; and p is 1.
25. The compound according to claim 17; wherein said compound is .
26. The compound according to claim 20, wherein R1 is hydrogen;
R2 is hydrogen;
R3 is C1-6 alkyl, (C1-6 alkyl)-CO2R11, (C2-6 alkenyl)-CO2R11, (C1-6 alkyl)-O-C1-3 alkyl;
or one of the following:
R4 is O-R11;
R6 is CH;
R11 is hydrogen or C1-6 alkyl;
R7 is hydrogen;
X is S;

Y is -C(=O)O-; and l is 1.
27. The compound according to claim 17, wherein R1 is hydrogen or C1-3 alkyl;
R2 is hydrogen or C1-4 alkyl;
in addition, R1 and R2 may be attached to the same carbon atom and may form a carbocyclic ring of 5-8 atoms, or be attached to the same atom and form a ring of 5-8 atoms of the formula:
together with the carbon atom to which they are attached;
R3 is hydrogen, C1-6 alkyl, C1-6 arylalkyl, (C7-17 alkyl)-OH, (C1-6 alkyl)-CO2-R11, (C1-6 alkyl)-CN, adamantyl, phenyl, or one of the following:
R4, is -O-R11 , NH2, NHOH, or is of the formula ;

R11 is hydrogen or C1-6 alkyl; and X is S or O.
28. A compound of the formula:
wherein R1 may occur one to four times and each occurrence is independently hydrogen or C1-6 alkyl;
R2 is hydrogen, pyridyl, C1-6 alkyl, (C1-6 alkyl)-CO2-R11, or -CO2-R11;
in addition, R1 and R2 may be attached to the same carbon atom and form a carbocyclic ring of 5-8 atoms together with the carbon atom to which they are attached; or they may be attached to the same carbon atom and form a ring of 5-8 atoms of the formula:
together with the carbon atom to which they are attached;
R3 is hydrogen, phenyl, C1-6 alkyl, C3-6 alkenyl, C7-17 arylalkyl, (C1-6 alkyl)-CO2-R11, (C2-6 alkenyl)-CO2-R11, (C1-6 alkyl)-CO-C1-6 alkyl, (C1-6 alkyl)-O-C1-6 alkyl, (C1-6 alkyl)-OH, (C1-6 alkyl)-CN, adamantyl or one of the following:

in addition, R2 and R3-(Y)o- may combine with each other at the terminal thereof to form a ring of the following formula together with the carbon atom and the nitrogen atom to which they are attached:
;
R4 is -O-R11, NH2, NHOH, -O-(C7-10 arylalkyl), or is of the formula ;
R5 is a formula of the following:
;
R6 is N or CH;
R7 is hydrogen or halogen;

R8 is -NHCO-;
R9 may occur one to three times and is a halogen, C1-6 alkoxy, C1-6 alkyl or trifluoromethyl;
R10 is C1-6 alkyl, or (C1-6 alkyl)-OH, or hydrogen;
R11 is hydrogen or C1-6 alkyl;
R12 is C1-6 alkyl or the following formula:
;
R13 is N or CH;
W is (C1-6 alkyl);
X is S, O, or CH2;
Y is -CO-, -C(=O)O-, or -C(=O)N(R10)-;
Z is O, CH2, or N-R11;
l is 1, 2, or 3;
m is 1 or 2;
n is 0 or 1;
o is 0 or 1;
p is 0 or 1;
q is 0 or 1; and r is 0,1,2 or 3;
with the provisos that (1) when Y is -C(=O)O-, R3 cannot be hydrogen;
(2) when R4 is equal to O-(C4 alkyl), C4 alkyl is not equal to tert-butyl;
(3) in those pyrrolidine structures (l is 1; m is 2; n is 0; o is 0; p is 1; X
is CH2), W is equal to CH2; and (4) the compound has an IC50 value of less than 5µM in a Jurkat CS-1 assay andlor an IC50 value of less than 50µM in a Jurkat EC assay.
29. A compound of the formula:

wherein R1 may occur one to four times and each occurrence is independently hydrogen or C1-6 alkyl;
R2 is hydrogen, pyridyl, C1-6 alkyl, (C1-6 alkyl)-CO2-R11, or -CO2-R11;
in addition, R1 and R2 may be attached to the same carbon atom and form a carbocyclic ring of 5-8 atoms together with the carbon atom to which they are attached, or they may be attached to the same carbon atom and form a ring of 5-8 atoms of the formula:

together with the carbon atom to which they are attached;
R3 is hydrogen, phenyl, C1-6 alkyl, C3-6 alkenyl, C7-17 arylalkyl, (C1-6 alkyl)-CO2-R11, (C2-6 alkenyl)-CO2-R11, (C1-6 alkyl)-CO-C1-6 alkyl, (C1-6 alkyl)-O-C1-6 alkyl, (C1-6 alkyl)-OH, (C1-6 alkyl)-CN, adamantyl or one of the following:

in addition, R2 and R3-(Y)o may combine with each other at the terminal thereof to form a ring of the following formula together with the carbon atom and the nitrogen atom to which they are attached:

R4 is -O-R11, NH2, NHOH, -O-(C7-10 arylalkyl), or is of the formula R5 is a formula of the following:

R6 is N or CH;
R7 is hydrogen or halogen;

R8 is -OCH2-;
R9 may occur one to three times and is a halogen, C1-6 alkoxy, C1-6 alkyl or trifluoromethyl;
R10 is C1-6 alkyl, or (C1-6 alkyl)-OH, or hydrogen;
R11 is hydrogen or C1-6 alkyl;
R12 is C1-6 alkyl or the following formula:

R13 is N or CH;
W is (C1-6 alkyl);
X is S, O, or CH2;
Y is -CO-, -C(=O)O-, or -C(=O)N(R10)-;
Z is O, CH2, or N-R11;
l is 1, 2, or 3;
m is 1 or 2;
n is 0 or 1;
o is 0 or 1;
p is 0 or 1;
q is 0 or 1; and r is 0, 1, 2 or 3;
with the provisos that (1) when Y is -C(=O)O-, R3 cannot be hydrogen;
(2) when R4 is equal to O-(C4 alkyl), C, alkyl is not equal to tert-butyl;
(3) in those pyrrolidine structures (1 is l; m is 2; n is 0; o is 0; p is 1; X
is CH2), W is equal to CH2;
(4) when R3 is phenyl, C1-6 alkyl, C7-17 arylalkyl, (C1-6 alkyl)-CO2-R11, (C1-6 alkyl)-O-C1-6 alkyl, or (C1-6 alkyl)OH; o is 0; and (5) the compound is not
30. The compound according to claim 29, wherein R5 is a formula of the following:

wherein R7 is hydrogen or Cl.
31. The compound according to claim 30, wherein R2 is hydrogen or C1-6 alkyl;
in addition, R1 and R2 may be attached to the same carbon atom and may form a carbocyclic ring of 5-8 atoms together with the carbon atom to which they are attached or be attached to the same carbon atom and form a ring of 5-8 atoms of the formula:

together with the carbon atom to which they are attached;
n is 0;
m is 2; and p is 0.
32. The compound according to claim 31, wherein R1 is hydrogen or C1-3 alkyl;
R2 is hydrogen or C1-4 alkyl;
in addition, R1 and R2 may be attached to the same carbon atom and may form a carbocyclic ring of 5-8 atoms together with the carbon atom to which they are attached or be attached to the same atom and form a ring of 5-8 atoms of the formula:

together with the carbon atom to which they are attached;
R3 is hydrogen, C1-6 alkyl, C7-17 arylalkyl, (C1-6 alkyl)-OH, (C1-6 alkyl)-CO2-R11, (C1-6 alkyl)-CN, adamantyl, phenyl, or one of the following:

R4 is -O-R11, NH2, NHOH, or is of the formula R11 is hydrogen or CH3; and X is S or O.
33. The compound according to claim 31, wherein R1 is hydrogen;

R2 is hydrogen;
R3 is (C2-6 alkenyl)-CO2-R11, (C1-6 alkyl)-O-C1-3, alkyl, (C1-6 alkyl)-CO2R11, or one of the following:

R4 is O-R11;
R6 is CH;
R11 is hydrogen;
R7 is hydrogen;
X is S;
Y is -CO-; and l is 1.
34. The compound according to claim 31, wherein R1 is hydrogen;
R2 is hydrogen;
R3 is C1-6 alkyl, (C1-6 alkyl)-CO2-R11, (C2-6 alkenyl)-CO2-R11, (C1-6 alkyl)-alkyl, (C1-6 alkyl)-O-C1-3, alkyl, (C1-6 alkyl)-CN, or one of the following:

R4 is OH;
R6 is CH;
R11 is hydrogen;
R7 is hydrogen;
X is CH2; and Y is -CO- or -C(=O)NH-.
35. The compound according to claim 30, wherein W is (C1-3 alkyl);
X is CH2;
Y is -C(=O)O-;
R1 is hydrogen;
R2 is hydrogen, (C1-3 alkyl)-CO2-R11, or -CO2-R11;
R3 is hydrogen, C7-10 arylalkyl, C1-6 alkyl, or (C1-6 alkyl)-CO2-R11;
R4 is OH;
R6 is CH;
R11 is hydrogen;
R7 is hydrogen;
l is 1 or 3; and n is 0.
36. The compound according to claim 30, wherein W is C1-3 alkyl;
X is CH2;
R1 is hydrogen;
R2 is (C1-4 alkyl)-CO2-R11, or CO2-R11;
R3 is hydrogen, C1-3 alkyl, or C2-7 alkenyl;
R4 is OH, R6 is CH;
R11 is hydrogen;
R7 is hydrogen;
l is 1;
m is 1;
n is 1;
o is 0; and p is 1.
37. The compound according to claim 29, wherein said compound is
38. The compound according to claim 32, wherein R1 is hydrogen;

R2 is hydrogen;

R3 is C1-6 alkyl, (C1-6 alkyl)-CO2R11, (C2-6 alkenyl)-CO2R11, (C1-6 alkyl)-O-C1-3 alkyl, or one of the following:

R4 is O-R11;
R6 is CH;
R11 is hydrogen or C1-6 alkyl;
R7 is hydrogen;
X is S;
Y is -C(=O)O-; and l is 1.
39. The compound according to claim 29, wherein R1 is hydrogen or C1-3 alkyl;
R2 is hydrogen or C1-4 alkyl;
in addition, R1 and R2 may be attached to the same carbon atom and may form a carbocyclic ring of 5-8 atoms, or be attached to the same atom and form a ring of 5-8 atoms of the formula:

together with the carbon atom to which they are attached;
R3 is hydrogen, C1-6 alkyl, C7-17 arylalkyl, (C1-6 alkyl)-OH, (C1-6 alkyl)-CO2-R11, (C1-6 alkyl)-CN, adamantyl, phenyl, or one of the following:

R4 is -O-R11, NH2, NHOH, or is of the formula R11 is hydrogen or C1-6 alkyl; and X is S or O.
40. A compound of the formula:

wherein R1 may occur one to four times and each occurrence is independently hydrogen or C1-6 alkyl;
R2 is hydrogen, pyridyl, C1-6 alkyl, (C1-6 alkyl)-CO2-R11, or -CO2-R11;
in addition, R1 and R2 may be attached to the same carbon atom and form a carbocyclic ring of 5-8 atoms together with the carbon atom to which they are attached, or they may be attached to the same carbon atom and form a ring of 5-8 atoms of the formula:

together with the carbon atom to which they are attached;
R3 is hydrogen, phenyl, C1-6 alkyl, C3-6 alkenyl, C7-17 arylalkyl , (C1-6 alkyl)-CO2-R11, (C2-6 alkenyl)-CO2-R11, (C1-6 alkyl)-CO-C1-6 alkyl, (C1-6 alkyl)-O-C1-6 alkyl, (C1-6 alkyl)-OH, (C1-6 alkyl)-CN, adamantyl or one of the following:

in addition, R2 and R3-(Y)o- may combine with each other at the terminal thereof to form a ring of the following formula together with the carbon atom and the nitrogen atom to which they are attached:

R4 is -O-R11, NH2, NHOH, -O-(C7-10 arylalkyl), or is of the formula R5 is a formula of the following:

R6 is N or CH;
R7 is hydrogen or halogen;
R8 is -OCH2-;
R9 may occur one to three times and is a halogen, C1-6 alkoxy, C1-6 alkyl or trifluoromethyl;
R10 is C1-6 alkyl, or (C1-6 alkyl)-OH, or hydrogen;
R11 is hydrogen or C1-6 alkyl;
R12 is C1-6 alkyl or the following formula:

R13 is N or CH;
W is (C1-6 alkyl);
X is S, O, or CH2;
Y is -CO-, -C(=O)O-, or -C(=O)N(R10)-;
Z is O, CH2, or N-R11;
l is 1, 2, or 3;
m is 1 or 2;
n is 0 or 1;
o is 0 or 1;
p is 0 or 1;
q is 0 or 1; and r is 0, 1, 2 or 3;
with the provisos that (1) when Y is -C(=O)O-, R3 cannot be hydrogen;

(2) when R4 is equal to O-(C4 alkyl), C4 alkyl is not equal to tert-butyl;
(3) in those pyrrolidine structures (l is 1; m is 2; n is 0; o is 0; p is 1; X
is CH2), W is equal to CH2;

(4) the compound has an IC50 value of less than 5µM in a Jurkat CS-1 assay and/or an IC50 value of less than 50µM in a Jurkat EC assay;
(5) when R3 is phenyl, C1-6 alkyl, C7-17 arylalkyl, (C1-6 alkyl)-CO2-R11, (C1-6 alkyl)-O-C1-6 alkyl, or (C1-6 alkyl)OH, o is 0; and (6) the compound is not
CA002342778A 1998-06-23 1999-06-23 Inhibitors of .alpha.4.beta.1 mediated cell adhesion Abandoned CA2342778A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9042198P 1998-06-23 1998-06-23
US60/090,421 1998-06-23
PCT/US1999/014233 WO1999067230A1 (en) 1998-06-23 1999-06-23 INHIBITORS OF α4β1 MEDIATED CELL ADHESION

Publications (1)

Publication Number Publication Date
CA2342778A1 true CA2342778A1 (en) 1999-12-29

Family

ID=22222703

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002342778A Abandoned CA2342778A1 (en) 1998-06-23 1999-06-23 Inhibitors of .alpha.4.beta.1 mediated cell adhesion

Country Status (11)

Country Link
EP (1) EP1089989A1 (en)
JP (1) JP2002518491A (en)
KR (1) KR20010083065A (en)
CN (1) CN1313855A (en)
AU (1) AU764553B2 (en)
CA (1) CA2342778A1 (en)
ID (1) ID28226A (en)
MX (1) MXPA00012765A (en)
NZ (1) NZ509010A (en)
TW (1) TW591026B (en)
WO (1) WO1999067230A1 (en)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6559127B1 (en) 1997-07-31 2003-05-06 Athena Neurosciences, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
US6939855B2 (en) 1997-07-31 2005-09-06 Elan Pharmaceuticals, Inc. Anti-inflammatory compositions and method
MY153569A (en) 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
GB9805655D0 (en) 1998-03-16 1998-05-13 Celltech Therapeutics Ltd Chemical compounds
US6521626B1 (en) 1998-03-24 2003-02-18 Celltech R&D Limited Thiocarboxamide derivatives
GB9814414D0 (en) 1998-07-03 1998-09-02 Celltech Therapeutics Ltd Chemical compounds
GB9821061D0 (en) 1998-09-28 1998-11-18 Celltech Therapeutics Ltd Chemical compounds
GB9826174D0 (en) 1998-11-30 1999-01-20 Celltech Therapeutics Ltd Chemical compounds
ATE323102T1 (en) * 1999-01-26 2006-04-15 Elan Pharm Inc PYROGLUTAMINE ACID DERIVATIVES AND RELATED COMPOUNDS WHICH REDUCE VLA-4-MEDIATED LEUKOCYTE ADHESION
US6407066B1 (en) 1999-01-26 2002-06-18 Elan Pharmaceuticals, Inc. Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4
AU4250200A (en) * 1999-04-19 2000-11-02 Coelacanth Corporation Ppar-(gamma) agonists as agents for the treatment of type ii diabetes
US6518283B1 (en) 1999-05-28 2003-02-11 Celltech R&D Limited Squaric acid derivatives
CA2380817A1 (en) * 1999-08-13 2001-02-22 Biogen, Inc. Cell adhesion inhibitors
CN1352641A (en) 1999-09-29 2002-06-05 奥索-麦克尼尔药品公司 Isonipecotamides for the treatment of integrin mediated disorders
EP1533310A1 (en) * 1999-09-29 2005-05-25 Ortho-McNeil Pharmaceutical, Inc. Isonipecotamides for the treatment of integrin-mediated disorders
US6849639B2 (en) * 1999-12-14 2005-02-01 Amgen Inc. Integrin inhibitors and their methods of use
US6455539B2 (en) 1999-12-23 2002-09-24 Celltech R&D Limited Squaric acid derivates
DE19962936A1 (en) 1999-12-24 2001-06-28 Bayer Ag New beta-aminoacid amide derivatives, are integrin antagonists useful for treating inflammatory, autoimmune or immunological disorders e.g. asthma, diabetes or rheumatoid arthritis
AP2002002565A0 (en) 1999-12-28 2002-06-30 Pfizer Prod Inc Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases.
WO2001068586A2 (en) * 2000-03-14 2001-09-20 Novartis Ag α4β1 AND α4β7 INTEGRIN INHIBITORS
JP2003531141A (en) 2000-04-17 2003-10-21 セルテック アール アンド ディ リミテッド Enamine derivatives
MY129000A (en) 2000-08-31 2007-03-30 Tanabe Seiyaku Co INHIBITORS OF a4 MEDIATED CELL ADHESION
JP2002179660A (en) * 2000-12-11 2002-06-26 Mitsubishi Gas Chem Co Inc Method for producing 1,3-thiazolidine-4-carboxylic acid amide
US6562321B2 (en) 2000-12-20 2003-05-13 Avon Products, Inc. Compositions and methods for treating hyperpigmentation
JP2004529918A (en) 2001-04-09 2004-09-30 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド Quinazoline and quinazoline analogs for the treatment of integrin-derived diseases
WO2004007444A2 (en) 2002-07-11 2004-01-22 Vicuron Pharmaceuticals, Inc. N-hydroxyamide derivatives possessing antibacterial activity
CN1938293A (en) 2004-03-24 2007-03-28 捷瑞尼股份公司 New compounds for the inhibition of angiogenesis and use of thereof
US7838522B2 (en) 2004-11-17 2010-11-23 Ares Trading S.A. Benzothiazole formulations and use thereof
RS52193B (en) 2004-12-21 2012-10-31 Merck Serono Sa. Sulfonyl amino cyclic derivatives and use thereof as mmp inhibitors
PL1844032T3 (en) 2005-01-31 2011-09-30 Merck Serono Sa N-hydroxyamide derivatives and use thereof
KR20080044836A (en) 2005-07-15 2008-05-21 라보라뚜와르 세로노 에스. 에이. Jnk inhibitors for the treatment of endometriosis
BRPI0613042A2 (en) 2005-07-15 2010-12-14 Serono Lab jnk inhibitors for the treatment of endometriosis
KR20080050591A (en) 2005-09-01 2008-06-09 아레스 트레이딩 에스.에이. Treatment of optic neuritis
UY30117A1 (en) * 2006-01-31 2007-06-29 Tanabe Seiyaku Co AMIS TRISUSTITUDED COMPOUND
JP7214882B2 (en) 2018-10-30 2023-01-30 ギリアード サイエンシーズ， インコーポレイテッド Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
AU2019373245C1 (en) 2018-10-30 2022-10-27 Gilead Sciences, Inc. Compounds for inhibition of alpha 4β7 integrin
AU2019373242B2 (en) 2018-10-30 2023-07-13 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
CN112969687A (en) 2018-10-30 2021-06-15 吉利德科学公司 Quinoline derivatives as alpha 4 beta 7 integrin inhibitors
KR20220047323A (en) 2019-08-14 2022-04-15 길리애드 사이언시즈, 인코포레이티드 Compounds for Inhibiting Alpha 4 Beta 7 Integrin
AU2021289665A1 (en) 2020-06-10 2022-12-15 Aligos Therapeutics, Inc. Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections
US11851422B2 (en) 2021-07-09 2023-12-26 Aligos Therapeutics, Inc. Anti-viral compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995015973A1 (en) * 1993-12-06 1995-06-15 Cytel Corporation Cs-1 peptidomimetics, compositions and methods of using the same
US6306840B1 (en) * 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors

Also Published As

Publication number Publication date
ID28226A (en) 2001-05-10
AU4711699A (en) 2000-01-10
NZ509010A (en) 2002-10-25
WO1999067230A1 (en) 1999-12-29
EP1089989A1 (en) 2001-04-11
MXPA00012765A (en) 2002-04-24
JP2002518491A (en) 2002-06-25
KR20010083065A (en) 2001-08-31
TW591026B (en) 2004-06-11
AU764553B2 (en) 2003-08-21
CN1313855A (en) 2001-09-19

Similar Documents

Publication Publication Date Title
CA2342778A1 (en) Inhibitors of .alpha.4.beta.1 mediated cell adhesion
US6482849B1 (en) Inhibitors of α4β1 mediated cell adhesion
KR100637110B1 (en) Cell adhesion inhibitors
ES2257808T3 (en) BIARILALCANOIC ACIDS AS CELLULAR ADHESION INHIBITORS.
NZ511478A (en) Compounds useful in the treatment of inflammatory diseases
BG65755B1 (en) Cell adhesion inhibitors
CA2291473A1 (en) Benzyl compounds which inhibit leukocyte adhesion mediated by vla-4
CA2037153A1 (en) Acetic acid derivatives
KR19990028926A (en) Cell adhesion inhibitor
US20060030553A1 (en) Cell adhesion inhibitors
JP2003503350A (en) VLA-4 inhibitor compounds
EP1144365B1 (en) Inhibitors of alpha-4 beta-1 mediated cell adhesion
US6685617B1 (en) Inhibitors of α4β1 mediated cell adhesion
JPWO2002022563A1 (en) Urea derivative and adhesive molecule inhibitor containing the same as active ingredient
WO2001081298A2 (en) Cyclic carboxylic acids as integrin antagonists
GB2369357A (en) Aliphatic, cyclic amino carboxylic acids as integrin antagonists
WO2003030889A1 (en) Para-amino benzoic acids as integrin antagonists
GB2367817A (en) Cyclic carboxylic acids as integrin antagonists
AU3006401A (en) Vla-4 integrin antagonists
MXPA00001743A (en) N-aroylphenylalanine derivatives
AU9133001A (en) Cell adhesion inhibitors
MXPA99001773A (en) Antithrombotic azacycloalkylalkanoyl peptides and pseudopeptides

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead